

ISSN 0001-5555

ActaDV

ACTA DERMATO- VENEREOLOGICA

Volume 98 2018 **Supplement No. 219**

ADVANCES IN DERMATOLOGY AND VENEREOLOGY

A Non-profit International Journal for
Interdisciplinary Skin Research, Clinical and Experimental
Dermatology and Sexually Transmitted Diseases

Official Journal of
- European Society for Dermatology and
Psychiatry

Affiliated with
- The International Forum for the Study of Itch

Abstracts from the 5th World Psoriasis & Psoriatic Arthritis Conference 2018

June 27–30, 2018

Stockholm, Sweden

**Immediate
Open Access**

 Society for Publication of
Acta Dermato-Venereologica

www.medicaljournals.se/adv

Abstracts from the 5th World Psoriasis & Psoriatic Arthritis Conference 2018

The International Federation of Psoriasis Associations welcomes You to the

5th WORLD PSORIASIS & PSORIATIC ARTHRITIS CONFERENCE 2018

“Psoriasis – Science and Patients: Global Challenges and Future perspectives.”

June 27 - 30, 2018
Stockholm Waterfront Congress Centre, Stockholm, Sweden



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS



Ref.no Title**Biomarkers and Imaging**

001 A metagenomics study of the elbow of psoriasis subjects and their healthy relatives

Clinical phenotypes

002 Nail disorders in patients with Psoriasis vulgaris

003 Psoriasis hidden in Gottron's papules

Comorbidities

004 Characteristics of psoriasis in obese patients versus non-obese patients; a multicenter study

005 Psoriasis and comorbidity

006 Risk of periodontal disease in patients with chronic plaque psoriasis

007 Splenomegaly and Psoriasis - A case report

008 Psoriasis as predictor for cardiovascular and metabolic comorbidity in middle-aged women

009 A Case of Concurrent Psoriasis and Vitiligo

010 Successful long-term double disease control by adalimumab in a patient with psoriasis vulgaris and hidradenitis suppurativa

011 Clinical and epidemiological characterization of psoriasis and psoriatic arthritis on a multidisciplinary assesment model.

012 Alcohol and Psoriasis- a Prospective Swedish Study

013 "Psoriasis and Cancer. Retrospective study in the Psoriasis sector of the Dermatology Service at Ramos Mejia Hospital"

014 Hematological disorders in the patient with psoriatic arthritis treated with methotrexate and tumor necrosis alpha (TNFalpha) inhibitor

015 The relationship between psoriasis, comorbidities, and depression onset: A nationwide observational control study

Current and new therapeutic modalities

016 Efficacy of Adalimumab plus Methotrexate in Patients with Moderate to Severe Plaque Psoriasis

018 Attainment of remission and minimal disease activity after starting methotrexate subcutaneous therap

019 Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database

020 Ixekizumab improves impact of genital psoriasis on sexual activity: Results from a Phase 3b study

021 Dose optimization of Secukinumab in subjects with moderate to severe plaque psoriasis: OPTIMISE study

022 Inhibition of anti-TNF-alpha cytokine in the treatment of psoriasis and the analysis of infectious complications

023 Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis in Scandinavia

024 First Patient-Reported Insights From a Multinational, Retrospective, Cross-Sectional Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice (APPRECIATE)

025 Physician- and Patient-Reported Outcomes With Apremilast for Patients With Plaque Psoriasis During Routine Dermatology Care in Germany: A Second Interim Analysis

026 Improvements in Work Productivity With Up to 104 Weeks of Apremilast Monotherapy: Results From a Phase 3b, Randomized, Controlled Study in Biologic-Naive Subjects With Active Psoriatic Arthritis

027 Examining Disease Severity and Symptom Improvement With Patient and Physician Assessments: Results From a Phase IV Analysis of Apremilast in Patients With Moderate Plaque Psoriasis

028 Hemoglobin A1c and Weight Changes With Apremilast in Patients With Psoriasis and Psoriatic Arthritis: Pooled Laboratory Analysis of the Phase 3 ESTEEM and PALACE Trials

029 Canadian Humira Post-Marketing Observational Epidemiological Study Assessing the Effectiveness of Adalimumab vs Non-Biologic DMARDs in Psoriatic Arthritis (Complete-PsA): 12-Month Effectiveness Data

030 Secukinumab Efficacy in Patients with Active Psoriatic Arthritis: Meta-analysis of 4 Phase 3 Trials

031 Impact of adalimumab vs. non-biologic treatments on skin outcomes of psoriatic arthritis patients: real-world data from the COMPLETE Study

032 Ixekizumab Improves Nail and Skin Psoriasis through 52 Weeks of Treatment in Patients with Active Psoriatic Arthritis: Results from Two Randomized, Double-Blind, Phase 3, Clinical Trials (SPIRIT-P1 and SPIRIT-P2)

034 Ixekizumab Makes Therapeutic Thresholds Possible in Active Psoriatic Arthritis Patients: Results from SPIRIT Trials

035 The macrophage modulator MP1032 shows safety and efficacy in a human phase IIa study for the treatment of moderate-to-severe plaque psoriasis

036 Secukinumab Improves Signs and Symptoms of Psoriatic Arthritis: Results from a Phase 3 Study, FUTURE 5

037 Incidence of Inflammatory Bowel Disease In Patients Treated With Secukinumab: Pooled Analysis of 21 Randomised Controlled Phase 3/4 Clinical Trials of Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis

038 Analysis of the position of the fumaric acid esters in current European psoriasis guidelines

039 Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies, FUTURE 2 and FUTURE 3

041 Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-years

042 Clinical response after guselkumab treatment among adalimumab PASI 90 non- responders: Results from the VOYAGE 1 and 2 trials

043 Consistency of response by weight across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and 2 trials

044 Impact of Clinical Specialty Setting on Disease Management in Patients with Psoriatic Arthritis

045 Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: results through Week 24 from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 and VOYAGE 2 trials

046 Safety of Certolizumab Pegol over 48 Weeks in Chronic Plaque Psoriasis Phase 3 Trials

047 Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-year Results from a Phase 3 Study

- 048 Predictors of Response to Tildrakizumab for Moderate to Severe Chronic Plaque Psoriasis
- 049 Long-term efficacy of guselkumab treatment after drug withdrawal and retreatment in patients with moderate-severe plaque psoriasis: results from VOYAGE 2
- 050 Outcomes Associated with Achievement of Various Treatment Targets in Patients With Psoriatic Arthritis Receiving Adalimumab
- 051 Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: Three Year Results from a Phase 3 Study (SPIRIT-P1)
- 052 Incidence of Serious Gastrointestinal Events Among Tildrakizumab-Treated Patients With Psoriasis
- 053 Durable Reduction in Absolute PASI with Certolizumab Pegol in Patients with Chronic Plaque Psoriasis
- 054 Relationships Between Tildrakizumab Dose, Exposure, Efficacy and Safety in Psoriasis Phase 3 Studies
- 055 Long-Term Safety and Efficacy of Adalimumab from the Phase 3 Randomized, Placebo-Controlled Trial in Patients with Nail and Skin Psoriasis
- 056 Eight-Year Interim Results from the ESPRIT 10-Year Postmarketing Surveillance Registry of Adalimumab for Moderate to Severe Psoriasis
- 057 Durability of Response in Certolizumab Pegol-Treated Patients over 48 Weeks in CIMPASI-1 & 2 Trials
- 058 Primary Efficacy and Safety of Adalimumab in Nail Psoriasis From the First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled Trial With Subanalysis in Patients With and Without Psoriatic Arthritis
- 059 Certolizumab Pegol Is Effective for Chronic Plaque Psoriasis Across Patient Subgroups
- 060 Discontinuation of Biologic Therapies in Chronic Plaque Psoriasis: A Retrospective Cohort
- 061 Incidence of Infections in Clinical Trials of Tildrakizumab for Moderate to Severe Plaque Psoriasis
- 062 Efficacy and Safety of Risankizumab: Results from Two Double-Blind, Placebo- and Ustekinumab-Controlled, Phase 3 Trials in Moderate-to-Severe Plaque Psoriasis
- 063 Efficacy and safety of guselkumab administered with a novel self-injection device for the treatment of moderate-to-severe psoriasis: Results from the Phase III ORION self-dose study through Week 16
- 064 Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
- 065 Efficacy of Tildrakizumab in Moderate to Severe Psoriasis Patients With Prior Exposure to Apremilast
- 066 Risankizumab Efficacy/Safety in Moderate-to-Severe Plaque Psoriasis: 16-Week Results from IMMhance
- 067 Disease Severity and Efficacy Insights: Patient-Level PASI Scores in Tildrakizumab Psoriasis Trials
- 068 Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis
- 070 Better Skin Clearance is Associated with Improved Quality of Life in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab
- 071 Statistic review of psoriasis systematic therapies in North Greece
- 073 Pharmacovigilance of systemic antipsoriatic drugs: an update from routine care
- 074 The Impact of Patient Requests on Psoriatic Arthritis Treatment
- Epidemiology**
- 075 The Risk Of KC In Psoriasis Patients Receiving Biologics Compared To Conventional Systemic Therapies
- 076 Patient perceptions of psoriasis severity in Sweden, Norway, and Denmark
- 077 Patient expectations and satisfaction in psoriasis treatment: A survey from Europe and Canada
- 078 Socioeconomic determinants of paediatric psoriasis
- 079 Obesity and the risk of psoriasis: A Korean nationwide, population-based study
- 080 Clinical characterization of Psoriatic Arthritis in a multidisciplinary care model of patients with Psoriasis
- 081 Triggering factors in childhood psoriasis
- 082 Quality of care for psoriasis in the past 12 years – results from a series of nationwide health care studies in Germany
- 083 Global Psoriasis Atlas – Work Stream 2
- 084 Global Burden of Disease: A Systematic Literature Review on Disability Weights for Skin Diseases
- Genetics**
- 085 MIR-499 polymorphism is associated with susceptibility to psoriatic arthritis – preliminary study
- 086 Association between inflammasome-related polymorphisms and clinical phenotypes of Psoriatic arthritis
- Health Economics and Health Policies**
- 088 Frequency of Inadequate Response to Treatment among Psoriasis Patients on First-Line Biologics
- 089 Barriers of guideline-compliant care for psoriasis in Germany – Results of the European study PsoBarrier
- Interesting Clinical Cases**
- 090 Individualised Therapy for Psoriasis - Case series
- 091 A Unique Clinical Case of Psoriatic Arthritis and Relapsing Polychondritis
- 092 Spiny follicular hyperkeratosis in a psoriasis patient treated with ustekinumab
- 093 Combination therapy of apremilast and biological product in a patient with psoriasis.
- 094 Psoriasis worst-case scenarios: A series of 3 case reports
- 095 Successful switching to biosimilar in psoriatic patient with severe drug reaction to infliximab. A case report
- 096 Safety of Apremilast in the treatment of a psoriasis patient with chronic Hepatitis B
- Pathophysiology and immunobiology**
- 098 IL-22 induces keratinocytes hyperproliferation in psoriasis via miR-21 and miR-31 upregulation
- 099 Serum concentration of IFN-gamma in patients with psoriasis: correlation with clinical type and severity of disease
- 100 Immunological memory exists in the recurrent lesion and nonrecurrent skin after remission in psoriatic patients
- 101 Investigating systemic inflammation as the common link between depression, Psoriasis, and Psoriatic arthritis in US Veterans.
- 102 The Immune-phenotype of Small Plaque Psoriasis

- 104 Serum Glucocorticoid-inducible Kinase-1(SGK1) Levels in Patients with Psoriatic Arthritis
 105 Differential NH2-terminal autoantigen trimming may explain epistasis between HLA-C*06:02 and ERAP1 variants in psoriasis risk
 106 Environmental triggers of an HLA-C*06:02-restricted autoimmune response in psoriasis
 107 A skewed pool of resident T cells triggers disease-associated tissue responses in never-lesional psoriasis
- Psoriasis and Psoriatic Arthritis relationship**
- 108 Nail involvement in psoriasis; is it a predictor of psoriatic arthritis?
 109 Absolute and relative PASI improvements with ixekizumab treatment: Results at Week 12 from IXORA-P
 110 Prevalence and sex differences of psoriatic arthritis in patients with severe plaque psoriasis.
 111 Skin Lesion Severity In Early Axial and Peripheral Psoriatic Arthritis Patients
 112 Gastrointestinal symptoms are common in U.S. patients with moderate-severe psoriasis
 113 Secukinumab's Long-Term Safety Remains Favorable up to 5 Years of Treatment
 114 Impact of Improvement in Skin and Joint on Quality of Life in Active Psoriatic Arthritis Patients
 115 Secukinumab Shows High and Sustained Efficacy in Subjects with Moderate to Severe Palmoplantar Psoriasis: 2.5-Year Results From the GESTURE Study
 116 Secukinumab Shows High and Sustained Efficacy in Nail Psoriasis: 2.5-Year TRANSFIGURE Study Results
 117 The obesity and prevalence psoriatic arthritis in patients with plaque psoriasis: dermatological real-setting data.
 118 Diagnosis of Psoriatic Arthritis in Patients with Moderate to Severe Chronic Plaque Psoriasis Treated with Secukinumab vs. Other Treatments in the PURE Registry: Indication of Selection Preferences and Underdiagnosis
 119 Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks
 120 Tildrakizumab efficacy over time by week 28 response levels in two Phase 3 clinical trials in patients with chronic plaque psoriasis
 122 Potential Disconnect: Co-Management of Patients with Psoriatic Arthritis Between Rheumatologists and Dermatologists
 123 The Use of Tumor Necrosis Factor Inhibitors (TNF) in the Second-Line Biologic/Small Molecule Setting: A Cross-Specialty Comparison
 124 Impact of Guselkumab versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in VOYAGE 2
- Quality of Life**
- 125 The Dermatology Life Quality Index in Russian patients with psoriasis and psoriatic arthritis.
 126 Effects of mindfulness-based cognitive therapy on self-reported psoriasis and psychological symptoms
 127 A mixed methods study exploring the impact of mindfulness on psoriasis, anxiety, depression and QoL
 128 A link between quality of patient-physician communication and patient healthcare needs in PsA
 129 Psoriasis Patients Point of View: What are we Missing when Managing Them?
 130 The impact of psoriasis and psoriatic arthritis on quality of life and career in Scandinavia
 131 Quality of life of patients with psoriasis in Khartoum dermatology hospital, December 2017
 132 Mirikizumab Significantly Improves Self-Reported Disease Severity and General Health Status in Patients with Moderate-to-Severe Psoriasis
 133 Effect of Tildrakizumab on Personal Relationships in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
 134 Pruritus severity assessment and correlation with baseline characteristics of patients with psoriasis vulgaris: an exploratory analysis of the Phase IIIb, PSORITUS study
 135 Quality of life and psychosocial implications in patients with psoriasis
 136 Swedish psoriatic patients' perspective of their disease. Results from an observational patient survey.
 137 Ixekizumab Provides Greater Cumulative Benefits versus Ustekinumab over 24 Weeks for Patients with Moderate-to-Severe Psoriasis in a Randomized, Double-Blind Phase 3b Clinical Trial
 138 Coach@Home: A Support Program for Patients Treated With Certolizumab Pegol
 139 A Comprehensive Survey Assessing the Family Planning Needs of Women with Psoriasis
 140 The Psychosocial Impact of Psoriasis: Differential Experiences of Men and Women in Early Adulthood
 141 Certolizumab Pegol Improves Patient-Reported Outcomes in Chronic Plaque Psoriasis Over 1 Year
 142 Translating WHO resolution into the public: the German program against stigmatization of people with chronic visible skin diseases
 143 The Global Research on the Impact of Dermatological Diseases (GRIDD)
- Young scientists (born on or after January 1, 1983)**
- 144 Treatment of Nail Psoriasis with Different Pulse Durations of Pulsed Dye Laser
 145 Neutropenia in a psoriasis patient: Secukinumab or micronutrient deficiency?
 146 Establishment of a Psoriatic Skin Model for α -Irradiation
 147 The History of Psoriasis
 148 Comorbidities and treatments in patients with inverse psoriasis
- Late Breakers**
- 150 Development of the "PsO Sleepy-Q" and the "PsA Sleepy-Q": two questionnaires to characterize sleep in patients with psoriatic disease
 151 Unstable forms of psoriasis – indicator of an intermediate state of systemic disease
 152 Could biological agents foster suicide through its potential antidepressant mechanism? A Psychodermatological approach.
 153 Treating the pain, not the problem? Results from a Swedish online survey on psoriatic arthritis and psoriasis with joint pain.
 154 An International Delphi survey to define screening for psoriatic arthritis and measurement of psoriatic arthritis symptoms in psoriasis clinical trials
 155 The impact of a diagnosis on the patients' perception of treatment and care. Results from an online survey on psoriatic arthritis and psoriasis with joint pain.

POSTERS

P001

A METAGENOMICS STUDY OF THE ELBOW OF PSORIASIS SUBJECTS AND THEIR HEALTHY RELATIVES

Hailun Wang¹, Michael Ni¹, Japio Fung¹, Kang Yan¹, Xiaoxin Yao¹, Yinpeng Wang¹, Martin Krieger², Henry Chan¹, Herbert Pang¹

¹The University of Hong Kong, and ²Yale University

Introduction: Psoriasis is a multifaceted immune-mediated skin disease and has been associated with other comorbidities. Previous studies in psoriasis reported the abundance of microbial taxa above the species rank (family *Firmicutes* and genus *Staphylococcus*), or the combined abundance of multiple taxa (*Corynebacterium*, *Propionibacterium*, *Staphylococcus*, and *Streptococcus*) were associated with psoriasis [1–3]. Characterizing the skin microbiome of psoriasis subjects and family controls can further our understanding of microbiota's role in this disease.

Objectives: This study aims to reveal the difference of skin microbiome between skin lesion area and normal area of the elbow as well as family controls.

Methods: DNA samples were extracted from 21 elbow-skin. 14 of 21 were from 7 psoriasis subjects' lesion side and normal side. The rest were from a healthy family member whom the subject lives with. Shotgun metagenomic sequencing was adapted to resolve the skin microbiota. Partially overlapping t-test was used to investigate differentially abundant taxa. PERMANOVA was used to test the difference of microbial community composition influenced by psoriasis and sampling families.

Results: Bacteria phyla *Proteobacteria*, *Actinobacteria*, and *Bacteroidetes* were three most abundant microbial taxa in both lesion and normal skin. Bacteria phyla *Cyanobacteria* and *Candidatus Parcubacteria*, family *Hymenobacteraceae* were less abundant on lesion skin than normal skin ($p < 0.05$). Sampling families had significantly different elbow-skin microbial composition for bacterial genus level profile ($p = 0.001$).

Conclusions: Several bacterial taxa different from those previously discovered are more abundant on normal skin than lesion skin in the elbow.

References:

- [1] Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis. NPJ Biofilms Microbiomes. 3,14 (2017).
- [2] Statnikov, A. et al. Microbiomic signatures of psoriasis: feasibility and methodology comparison. Sci. Rep. 3, 2620 (2013).
- [3] Alekseyenko, A. V. et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome. 1, 31 (2013).

P002

NAIL DISORDERS IN PATIENTS WITH PSORIASIS VULGARIS

Jasmina Muhovic

University Clinical Centre Sarajevo

Introduction: Psoriasis vulgaris is a chronic inflammatory skin disease characterized by T-cell-mediated hyperproliferation of keratinocytes in the skin. Approximately, 10–78% of patients with psoriasis have concurrent nail psoriasis while isolated nail involvement is seen in 5–10% of patients. Affected nail plates often thicken and crumble and because they are very visible patients tend to avoid normal day-to-day activities and social interactions. Importantly, 70–80% of patients with psoriatic arthritis have nail psoriasis. In this overview, we review the clinical manifestations of psoriasis affecting the nails.

Objectives: To correlate frequency of certain nail disorders in patients with psoriasis vulgaris. The observed disorders were: onycholysis, subungual hyperkeratosis, oil spots, and pitting in both male and female patients aged 15–75 and combined with psoriatic arthritis.

Methods: A total of 60 patients who were treated in our Inpatients

Service with diagnosis of Psoriasis vulgaris from January 2017 to July 2017 at Dermatology Department, University Clinical of Sarajevo. We searched for specific nail disorders.

Results: A total number of 60 patients with Psoriasis vulgaris, both male and female aged 15–75 were examined. Out of that number, 43 patients reported to have specific nail disorders and/or psoriatic arthritis, and 17 of them were without any nail disorders or psoriatic arthritis. Among the number of 43 examined psoriasis patients with nail disorders, there were 23 female and 20 male patients, all of them aged between 45–60. Seven female and eight male patients had previously diagnosed psoriatic arthritis combined with psoriasis and nail disorders, while the rest of them, 28 patients, only had psoriasis followed by progressive changes on their nails, but without any signs of psoriatic arthritis. The presented nail disorders in all patients included in these two groups were: subungual hyperkeratosis, onycholysis and pitting all combined in 14 patients, only subungual hyperkeratosis in 10 patients, pitting in 7 patients, 7 of them showed only onycholysis on both hands and 6 patients had oil spotting and pitting together. In patients without psoriatic arthritis the prevalence of disorders in all affected groups was in male patients.

Conclusion: Nail psoriasis engenders both physical and psychological handicap, leading to significant negative repercussions in the quality of life. The presence of nail disease in a patient with psoriasis may indicate a severe form of the disease and must be taken into account when selecting a treatment option, with an aim to reduce pain, functional impairment as well as emotional distress.

P003

PSORIASIS HIDDEN IN GOTTRON'S PAPULES

Florentina Berianu, Juan J. Maya

Mayo Clinic Florida

Introduction: Patients with Dermatomyositis (DM) present with rashes in a photosensitive distribution and occasionally a scaly rash over elbows, knees and scalp can resemble psoriasis. The biopsy of such lesions shows interface dermatitis which is highly distinguishing for DM. In rare occasions, patients can suffer from both DM and psoriasis (Ps). **Objectives:** To report a case of Dermatomyositis and Psoriatic arthritis

Method: 45 years old female presented with a red, itchy rash with diffuse swelling over the entire body associated with swallowing difficulties and weakness affecting mainly the proximal muscles of upper and lower extremities. She has pain and stiffness in her hands and feet. DM was confirmed based on specific findings on skin biopsy, EMG with myopathic features and a muscle biopsy that confirmed the myopathy. Patient had insulin dependent diabetes and IVIG was the initial choice of therapy to avoid steroid use. Patient responded excellent in regards to generalized rash and had reported improvement in regards to proximal muscle weakness and swallowing difficulties but she had persistence of the scaly rash over elbows, knees and developed what resembled dactylitis along with worsened asymmetric inflammatory arthritis of ankle, hand and feet joints. Based on her presentation, Ps and psoriatic arthritis (PsA) were diagnosed. Methotrexate was added and patient had improved in skin psoriasis along with inflammatory arthritis. **Results:** Ps and PsA were associated with DM in this patient. These are distinct diseases that have parallel courses and require different therapeutic approaches.

Conclusion: Ps has been reported in association with Connective Tissue Diseases. Gottron's papules can resemble Ps in patients with DM but rare case reports have described concomitant DM and Ps. The association of DM, Ps and PsA was even more rarely described.

References:

1. Tselios K, Yap KS, Pakchotanont R et al. Psoriasis in systemic lu-

pus erythematosus: a single-center experience. Clin Rheumatol. 2017 Apr;36(4):879-884.

2. Inkeles MS, No D, Wu JJ. Clinical improvement of a patient with both amyopathic dermatomyositis and psoriasis following treatment with cyclosporine. Dermatol Online J. 2017 Aug 15;23(8)

3. Kato Y, Yamamoto T. Development of psoriasis with relapse of dermatomyositis-associated interstitial lung disease. Int J Rheum Dis. 2017 May;20(5):660-661.

4. Ueno T, Kanzaki A et al. Association of psoriasis with Hashimoto's thyroiditis, Sjögren's syndrome and dermatomyositis. J Dermatol. 2016 Jun;43(6):711-2.

P004

CHARACTERISTICS OF PSORIASIS IN OBESE PATIENTS VERSUS NON-OBESE PATIENTS; A MULTICENTER STUDY

Omid Zargari¹, Seyyede Zeinab Azimi², Tara Barat¹, Vahideh Lajevardi³, Ehsan Kazemnejad⁴, Mohamad Shahidi Dadras¹

¹Department of Dermatology, Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, ²Department of Dermatology and ⁴Department of Biostatistics, Guilan University of Medical Sciences, Rasht, and ³Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran

Introduction: Psoriasis is a common chronic inflammatory skin disease, which is gradually being recognized as a systemic inflammatory disorder. Psoriasis and obesity are strongly linked, but there is not enough data whether obese psoriatic patients present differently from non-obese psoriatic patients.

Objective: To compare the phenotype, clinical features, severity, baseline comorbidities and laboratory findings among psoriatic patients with/without obesity.

Methods: All the psoriatic patients, from three centers, who were receiving systemic therapy were included in the study. Patients were divided into two groups: those with obesity and those without obesity.

Results: We included 497 patients: 154 (31%) patients were obese and 343 (69%) were non-obese. Obese patients had more comorbidities, particularly hyperlipidemia, followed by hypertension and diabetes. Fasting blood sugar and serum lipids were significantly higher among obese subjects.

Conclusions: Given the differences between obese patients and non-obese patients, the former group should be followed and managed more closely and with specific attention.

References:

1. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008; 58(6):1031-42.
2. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol. 2011; 147(4):419-24

P005

PSORIASIS AND COMORBIDITY

Veranika Liubiankova, Sviatlana Makarava

Mogilev Regional Centre of Dermatology and Venerology

Introduction. In recent years special attention has been paid not only to the systemic nature of the process in psoriasis, but also to its association with comorbidities. Comorbidity is a regular combination of various diseases or conditions in one patient, it occurs in many inflammatory processes.

Objectives: The study of the incidence of concomitant diseases in patients with psoriasis in relation to patients with allergic contact dermatitis, analysis by age group.

Methods: A retrospective analysis of data of 804 patients, who were treated in 2016–2017 in Mogilev Regional Dermatology and Venerology Centre with different forms of psoriasis, was conducted. 492 males, 312 females. The mean age was 43.05 years. The

control group consisted of patients with allergic contact dermatitis, comparable in age and sex, in an amount of 397 people.

Results: Specific gravity and incidence of comorbidity in patients with psoriasis: cardiovascular damage 41% (331), gastrointestinal tract - 30.4% (245), endocrine system - 22.7% (183), metabolic syndrome - 28.2% (227), chronic otorhinolaryngological diseases - 11.4% (92), diseases of urinary system - 6.2% (50), respiratory system - 4.7% (38). Significant differences between the groups were obtained for all the comorbidity except respiratory diseases. Psoriatic polyarthritis were observed in 219 patients (27.3%), nail psoriasis – in 117 patients (14.6%). The average body mass index in the psoriasis group was 27.2, in the allergic contact dermatitis group - 25.3. Significant differences between the groups were obtained for all the laboratory test changes except the general bilirubin, C-reactive protein and urinalysis. The percentage of diseases changed with increasing age: diseases of the cardiovascular system from 10% to 87%, gastrointestinal diseases from 20% to 61%, endocrine system diseases - from 14.5% to 38%, metabolic syndrome - from 11% to 34%, otorhinolaryngological diseases - from 15% to 8.5%, diseases of the urinary system - from 1.8% to 8.5%, respiratory system diseases – from 1.8% to 13%.

Conclusions: The analysis showed that in patients with psoriasis the most frequent comorbidity are: cardiovascular and gastrointestinal diseases, endocrine disorders, polyarthritis, nail psoriasis and metabolic syndrome. A rather high risk of comorbidity is established, in comparison with the population, which can directly affects the severity of the course of the disease, the effectiveness of the therapy and life expectancy.

References:

1. Potekae N., Kruglova L. Psoriatic Disease. – Moscow. - 2014. - P. 94 (in Russian)
2. Cohen A.D., Sherf M., Vidavsky L., Vardy D.A. Association between psoriasis and the metabolic syndrome. A crosssectional study // Dermatology. — 2008. — Vol. 216(2). — P. 152
3. Eng S., Xing B., Caro I., Werther W. Selected cardiovascular diseases in psoriasis, nonpsoriasis, and efalizumab-treated psoriasis patients // Acad. Dermatol. — 2009. — P. 3381

P006

RISK OF PERIODONTAL DISEASE IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS

Veronica Lopez Castillo, Inmaculada Lopez Castillo, Pedro Rodriguez, Jose Maria Ricart Vaya

Introduction: Psoriasis is a common, chronic, inflammatory, multisystem disease affecting approximately 2% of population. It has been associated with certain diseases and there is a strong link between metabolic syndrome and psoriasis. Chronic periodontitis is an infectious disease resulting in inflammation within the supporting tissues of the teeth, progressive attachment loss, and bone resorption and clinically characterized by pocket formation and/or gingival recession. Psoriasis and chronic periodontitis share common risk factors and co-morbidities.

Objective: The aim of our study was to determine how frequently chronic periodontitis is associated with patients with psoriasis compared to systemic healthy subjects and if its presence is associated to severity of psoriatic lesions.

Methods: Baseline demographic data including sex, age, smoking habits, family history of psoriasis or periodontal disease was recorded in 40 psoriasis subjects and 40 healthy subjects. Information on comorbidities and pharmacological treatment, daily tooth brushing, the presence of gingival bleeding, location of skin lesions, weight and height were also evaluated. The periodontal clinical parameters probing depth, periodontal attachment level, plaque index and presence or absence of radiographic bone loss were recorded. The severity of psoriasis was assessed by Psoriasis Area and Severity Index. A complete blood test was asked for all subjects included in the study.

Results: During the study enrolment period 40 patients with psoriasis and 40 age- and gender-matched controls were included in this study. Probing depth and periodontal attachment level showed significant higher values in psoriasis group compared to healthy subjects.

Conclusions: We found evidence of a psoriasis-associated increased risk of periodontitis. Thus, dermatologists should be aware of this comorbidity because these patients should be closely followed-up by a dentist for the adequate and early treatment of periodontitis. Periodontitis may be associated with psoriasis but further studies are needed to elucidate their relationship.

References:

1. Egeberg A, Mallbris L, Gislason G et al. Risk of periodontitis in patients with psoriasis and psoriatic arthritis. *J EADV* 2017, 31: 288-293.
2. Ungprasert P, Wijampreecha K, Wetter DA. Periodontitis and risk of psoriasis: a systematic review and meta-analysis. *J EADV* 2017, 31: 857-862.

P007

SPLENOMEGALY AND PSORIASIS - A CASE REPORT

Suzana Ozanic Bulic

Department of Dermatovenereology, KBC Sestre milosrdnice, Zagreb, Croatia

Psoriasis is a chronic, systemic, inflammatory disease associated with numerous comorbidities that have been well documented in the literature. Comorbidities often become clinically evident years after the onset of psoriasis and are related to persistent low-grade inflammation with secretion of proinflammatory cytokines, as seen in metabolic syndrome (1). Nevertheless, the evidence shows new emerging comorbidities that share link with psoriasis. Hjuler et al. observed increased splenic inflammation in patients with moderate-to-severe psoriasis (2). They also showed that splenic activity was correlating with aortic wall inflammation in psoriasis patients, explaining the increased risk of heart disease (2).

A 56-year old patient with chronic plaque psoriasis (Fig 1) for more than thirty years, presented with splenomegaly, diabetes type two, arterial hypertension, chronic kidney disease stage III, obesity, with BMI > 40, and depression. Psoriasis severely flared up in 2012, and on workup up for cataract operation, enlarged lymph nodes were observed and further confirmed on CT scans in axillae, inguinal, mediastinum and upper abdomen. Patient was hospitalized at haematology department and reactive lymphadenopathy due to skin inflammation was diagnosed. Acitretin was started and stopped after a week for worsening of pancytopenia, and Methotrexate was stopped after two weeks for triple increase in liver enzymes, although the dose was of only 5 mg weekly. In August 2017, repeated blood tests were normal and abdominal US showed no progression in hepato-splenomegaly, with spleen measuring 23 cm. Psoriasis was severe, with PASI 36, BSA 31% and DLQI 19. Ustekinumab 90 mg was started in October 2017 with PASI75 achieved after 12 weeks of treatment. Patient has been closely monitored with no haematological side-effects on last assessment.

Significant splenomegaly and lymphadenopathy with no underlying haematological disease has not been described as a comorbidity of psoriasis. The treatment with biologics was delayed in our patient as underlying haematological malignancy was suspected. The untreated severe psoriasis flared up in the mean time the whole spectrum of comorbidities, led by depression. Ustekinumab has significantly improved his psoriasis (Fig 2), with improvement in depression that was best observed in patient's motivation to lose weight and be referred for gastric bypass.

Effective control of psoriasis and associated conditions requires not only appropriate treatment, but also management of comorbidities, including screening and treatment by various specialists, as disease is known for its cumulative impairment over patient's lifetime (3).

P008

PSORIASIS AS PREDICTOR FOR CARDIOVASCULAR AND METABOLIC COMORBIDITY IN MIDDLE-AGED WOMEN

Christoffer Blegvad¹, Anne-Marie Nybo Andersen², Abdulfatah Adam², Claus Zachariae¹, Lone Skov¹

¹Copenhagen Research Group for Inflammatory Skin (CORGIS), Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, ²Section of Epidemiology, Department of Public Health, University of Copenhagen, Denmark

Introduction: Cardiovascular and metabolic comorbidities such as ischemic heart disease and diabetes are known to be associated with psoriasis. However, it is less clear whether this is due to common life-style related risk factors such as overweight and smoking. **Objectives:** We wished to investigate the association between psoriasis and cardiovascular and metabolic comorbidity in a cohort of middle-aged women, and at the same time taking the effect of body mass index (BMI) and smoking into account.

Methods: The study population consisted of expectant mothers in a large nationwide birth cohort established between 1996 and 2002. During pregnancy, the women were asked whether they have ever had any skin diseases including psoriasis, and whether the disease was diagnosed by a physician. The relation to self-reported cardiovascular and metabolic comorbidity 11 years after giving birth was assessed by multiple logistic regression. Furthermore, we performed an analysis where the cohort was followed up for hospital-diagnosed comorbidity including cardiac death until 31st December 2014. Here the risk was assessed by Cox proportional hazards regression. All analyses were adjusted for age, pre-pregnant BMI, and smoking status collected at time of inclusion during pregnancy.

Results: We identified 2,435 (2.90%) women with a history of psoriasis and 81,388 women without psoriasis. The women with and without psoriasis were on average respectively 30.4 (SD 4.5) and 29.9 (SD 4.3) years old at time of inclusion in the study. Women with psoriasis had slightly higher BMI and smoked markedly more than women without psoriasis (38.1% vs. 26.4%). A history of psoriasis was significantly associated with self-reported hypercholesterolemia (adjusted odds ratio 1.31; 1.01-1.70) and hospital-diagnosed hypertension (adjusted hazard ratio 1.33; 1.08-1.65). A positive association was also found with respectively hospital-diagnosed ischaemic heart disease, type 2 diabetes, and hypercholesterolemia, however, these findings were not statistically significant. No associations were found for self-reported hypertension, thrombosis, or type 2 diabetes.

Conclusions: Women with psoriasis are at increased risk of developing cardiovascular and metabolic comorbidity in early adult life. This may suggest an importance of awareness of these comorbidities also in younger patients with early screening for hypertension, hyperglycemia, and hypercholesterolemia.

P009

A CASE OF CONCURRENT PSORIASIS AND VITILIGO

Selma Poparic

Dermatology Department University Clinical Center of Sarajevo

Introduction: Psoriasis and vitiligo are common dermatoses that affect 1-3% (psoriasis) and 0.5% (vitiligo) of the general population, respectively. Yet the pathogenesis of the association between these two dermatoses is still unknown.

Case report: We report a case of a 52-year-old patient who was admitted to our department with a 6-month history of squamous papules and plaques on his right elbow region and both right and left lower leg. He was also noticed with hypopigmented patches on his right and left wrist. Anamnestic questionnaire revealed that his mother has had similar discolorations on her skin, but never

underwent any diagnostic procedure, nor treatment. Clinical and histopathological diagnosis of erythematous areas on the patients right elbow and right and left lower leg was a plaque psoriasis, while hypopigmented patches on his wrists were diagnosed as vitiligo. Blood work up and T3, fT4, TSH, ANA laboratory tests were within normal ranges.

Conclusion: Psoriasis and vitiligo, although seemingly unrelated skin disorders, have a lot in common. Causes, incidence, and even distribution seem to strongly correlate between these two.

P010

SUCCESSFUL LONG-TERM DOUBLE DISEASE CONTROL BY ADALIMUMAB IN A PATIENT WITH PSORIASIS VULGARIS AND HIDRADENITIS SUPPURATIVA

Melita Vuksic Polic¹, Zlatica Jukic¹, Andrea Krnic¹, Renata Vukadin¹, Ivana Patrk²

¹Osiijek University Hospital: Faculty of Medicine Osiijek, ²Privat dermatovenereological clinic dr Ivana Patrk, Zadar

Introduction: Psoriasis vulgaris /PV/ is a chronic inflammatory skin disease¹. Studies have shown the role of genes important for the transcription of inflammatory cytokines, such as TNF alpha and IL-23, which play main role in the pathogenesis of psoriasis². Hidradenitis suppurativa /HS/ is chronic inflammatory skin disease³, in which pathogenesis are IL-23 and TNF alpha, supporting the theory of the immunologic disease⁴. Adalimumab is human monoclonal antibody that has a great affinity for the membrane of TNF alpha⁵. We report the case of a 44-year-old Caucasian woman with a history of PV and HS, both diseases are in remission during the therapy with adalimumab.

Case report: We report the case of a 44-year-old Caucasian woman with a history of PV and HS that started adalimumab therapy 3 years ago. PV started 14 years ago and was verified by skin biopsy. Initially, the clinical course of psoriasis was mild and later she took course to moderate psoriasis with PASI 10. Psoriasis was treated only with local therapy. HS started when she was 38-years-old in her left groin, as swelling and pain on palpation and in movement. Skin changes started to develop also on the right groin and perianal region as painful nodules, with pus draining, and fistula tracts. Skin biopsy confirmed HS. Chest X-ray and gastroenterology examination were performed to exclude any additional illnesses and she also did a psychological testing. She was treated with different antibiotics also prednisone and isotretinoin at a dose 1mg/kg/day. Topical therapy was consisting of antibiotics, antiseptics and hydrocolloid dressings. She had 3 surgical interventions. In 2015, she started adalimumab according to the scheme. On the day of the initial application of adalimumab, patient had 4 abscesses, 13 nodules and 16 fistula tracts. She had successful clinical response to the drug and is without psoriatic symptoms or HS active lesions. Both diseases are successfully controlled and quality of life has improved.

References:

1. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patient's beliefs and attitudes towards the disease. *Br J Dermatol* 1996;135:533-7.
2. Reich K, Hüffmeier U, König IR, Lasorz J, Lohman J, Wendler J, Traupe H, Mössner R, Reis A, Burhardt H. TNF polymorphisms in psoriasis association of psoriatic arthritis with the promoter polymorphism TNF-857 independent of the PSORS1 risk allele. *Arthritis Rheum* 2007;56:2056-64.
3. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). *Dermatoendocrinol* 2010;2:9-16.
4. Matusiak I, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? *Acta Derm Venereol* 2009;89:601-3.
5. Haslund P, Lee Ra, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. *Acta Derm Venereol* 2009;89:595-600.

P011

CLINICAL AND EPIDEMIOLOGICAL CHARACTERIZATION OF PSORIASIS AND PSORIATIC ARTHRITIS ON A MULTIDISCIPLINARY ASSESSMENT MODEL

Karla Del Rocio Macias-Garcia, Dalila Alejandra Lopez Rodriguez

Dermatologico Country

Introduction: Presentation and clinical course in Psoriasis are heterogeneous. A multidisciplinary assessment model was designed by five specialties: dermatology, rheumatology, internal medicine, nutrition and psychiatry, to evaluate at the same time and place, patients with psoriasis.

Objective: To ascertain frequency of comorbidities in psoriatic patients and conduct a clinical and epidemiological characterization.

Methods: Prospective study, from August 2016 to February 2018, patients attending to Multidisciplinary Clinic for psoriasis in Dermatologico Country were included.

Results: 53 patients were included. Median age was 42 years old and 62.3% were female. Family history of psoriasis was found in 26.4% patients and 19.4% had spondyloarthropathy family history. Most common comorbidities found obesity, metabolic syndrome, diabetes mellitus, dyslipidemia, hypertension and fatty liver. Affective assessment was found for 49.1% met criteria for anxiety. Psoriasis found 96.2% with psoriasis in skin and 56.6% in nails. Most common presentation of psoriasis, was plaque psoriasis in 66%. PASI score showed 50.9% with mild disease, 15.1% moderate, and 34% had severe. NAPS score was from 0 to 61, with a median of 3 (0.13). DLQI indicated that only 13.2% had no condition in life quality, meanwhile 86.8% patients had impaired quality of life. Psoriatic arthritis, and identify 58.5% patients that met CASPAR criteria, axial disease was present in 51.6%, peripheral joint disease in 71% and in 13.2% both were present. 54.8% (17) patients had enthesitis and 16.1% had dactylitis. DAS28 was performed, and showed 45.2% with severe activity. Total number of subjects with peripheral disease 100%, did not meet criteria for MDA. HAQ score to assess PsA patients quality of life, revealed a median of 1.38 (1.10, 2.25).

Conclusions: we found that more than half of the patients presented a severe form of psoriasis with significant quality of life impairment. The number of psoriatic arthritis was higher than expected with both axial and peripheral manifestations. We have found a high proportion of patients with comorbidities such as metabolic syndrome, diabetes mellitus, hypertension, dyslipidemia and obesity. We also found a high frequency of psychiatric illness. The limitations of our study are the small sample to highlight if comorbidities had an impact on the severity of skin and joint disease. This multidisciplinary model has identified psoriasis as a disease with an unpredictable course, which requires several evaluations by a multidisciplinary model, with a group of experts beyond Dermatologist and Rheumatologist.

P012

ALCOHOL AND PSORIASIS- A PROSPECTIVE SWEDISH STUDY

Caroline Svanström¹, Sol-Britt Lonne-Rahm¹, Ebru Bircan², Knut Stokkeland³, Johan Franck⁴, Klas Nordlind⁵

¹Department of Dermatology, Mälarsjukhuset, Eskilstuna, ²Department of Medicine, Solna, Dermatology and Venereology Unit, Karolinska Institutet, ³Department of Medicine, Gastroenterology and Hepatology Unit, Karolinska Institutet, ⁴Department of Clinical Neuroscience, Division of Psychiatry, Karolinska Institutet, Stockholm, and ⁵Department of Medicine, Visby Hospital, Visby, ⁶Department of Medicine, Solna, Dermatology and Venereology Unit, Karolinska Institutet, Stockholm, Sweden

Background: We have earlier in a limited cross-sectional study shown a correlation in females for alcohol consumption and extent

of psoriasis. There are few prospective studies on the relation of alcohol with the extent of psoriasis.

Objectives: The purpose of this prospective study was to further investigate how alcohol affects psoriasis in female patients.

Methods: Twenty-two female psoriasis patients with light to moderate psoriasis, with only local treatment and with a regular alcohol intake, were recruited. The study was run for three years, starting in 2014. We used Christmas and New Year, as intervention period, when the amount of alcohol is expected to exceed normal consumption. The total study period was 8 weeks. During the study period, the alcohol intake was measured by the patients filling a calendar, specifying the alcohol intake per day, moreover, the degree of severity of psoriasis, degree of pruritus, and of perceived stress, using a visual analog scale. In addition, the patients once a week determined Self-Administered Psoriasis Area and Severity Index (SAPASI).

Results: The alcohol intake, which was generally low to moderate, increased during Christmas and New Year, reaching its maximum during week 52 (Christmas week). There was a marginal increase in the extent of psoriasis, determined by SAPASI, during week 52. There was no correlation with alcohol intake nor pruritus. The level of perceived stress decreased shortly after week 52, and reached its lowest value during week 1, after that increasing.

Conclusion: Even if there is an increased alcohol consumption during Christmas and New Year, there is no evident worsening of psoriasis.

P013

PSORIASIS AND CANCER. RETROSPECTIVE STUDY IN THE PSORIASIS SECTOR OF THE DERMATOLOGY SERVICE AT RAMOS MEJIA HOSPITAL

Jennifer Kreimer, Alejandra Crespo, Elena Chaparro, Daniela Gonzalez, Veira Rosana, Kogan Nora

Introduction: Psoriasis is a chronic, systemic, immune-mediated inflammatory disease that compromises the skin, attachments, semi-mucosal, mucous membranes and joints. There are different clinical forms that can vary in the same patient at different times of life. It is accompanied by comorbidities that affect the quality and survival of patients. Within the comorbidities associated with psoriasis, malignancies constitute a prominent and controversial group. In the review of the current literature, there would be evidence of a relationship between psoriasis and cancer, given the existence of structural and molecular similarities between the two pathologies. **Objectives:** To assess the prevalence of cancer development in patients with psoriasis in our population.

Methods: A retrospective epidemiological analysis of the total population of 1969 patients with psoriasis is carried out, attended in the psoriasis sector of the dermatology service of Ramos Mejía Hospital in the period between January 2008 and January 2018.

Results: We identified 56 patients who presented coexistence of oncological pathology and psoriasis of different severity: 38 severe, 14 moderate and 4 mild. The population was divided equally between both sexes. Of these 56 patients, 61 tumors were detected (non-melanoma skin cancer, solid tumors and lymphomas). The oncological manifestations are the following: table 1.

Table 1. Oncological manifestations

| Oncological manifestations | Oncological manifestations |
|-----------------------------------|----------------------------|
| Tumor quantification | Total % |
| Cutaneous Squamous Cell Carcinoma | 4 7% |
| Basal Cell Carcinoma | 12 20% |
| Breast Cancer | 9 15% |
| Prostate Cancer | 12 20% |
| Thyroid Cancer | 6 10% |
| Endometrial Cancer | 3 5% |
| Lung Cancer | 1 2% |
| Colon Cancer | 4 7% |
| Lymphoma | No Hodgkin 1 2% |
| Cervical Cancer | 2 3% |
| Kidney Cancer | 1 2% |
| Multiple Myeloma | 1 2% |
| Testicular Cancer | 2 3% |
| Tumoral Mucositis | Fungoid 1 2% |
| Acute Myeloid Leukemia | 1 2% |
| Bladder Cancer | 1 2% |
| TOTAL | 61 100% |

The epidemiological analysis of this group of patients showed an incidence for all types of malignancies of 3.098% in this population. The diagnosis of psoriasis preceded the oncological diagnosis in 50 of the patients studied.

Conclusions: The incidence of cancer in the general population in Argentina, according to the Ministry of Health is 172.3–242.9 per 100,000 inhabitants. In our study population, we found an incidence of 3.098%, which would support the hypothesis of an increased risk of developing cancer in patients with psoriasis. The risk was identical in both sexes and directly proportional to the degree of severity of the psoriasis.

Reference:

Pouplard C, Brenaut E, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. JEADV 27 (Suppl. 3), 36–46, 2013 Ramos Mejia, Service of Dermatology

P014

HEMATOLOGICAL DISORDERS IN THE PATIENT WITH PSORIATIC ARTHRITIS TREATED WITH METHOTREXATE AND TUMOR NECROSIS ALPHA (TNFALPHA) INHIBITOR

Renata Sokolik¹, Aleksandra Butrym², Grzegorz Mazur², Piotr Wiland¹

¹Department and Clinic of Rheumatology and Internal Medicine, ²Department and Clinic of Internal and Occupational Diseases and Hypertension, Wrocław Medical University, Wrocław Poland

Introduction: Non-Hodgkin lymphomas are a heterogeneous group of neoplastic disorders characterized by clonal lymphoid cell proliferation. They rank sixth among the cancers in terms of the frequency of occurrence in adults. Waldenström macroglobulinemia is lymphoplasmic hyperplasia with excessive production of monoclonal M-protein. According to literature data, patients with psoriasis have more frequent lymphomas than healthy population. The real risk of lymphoproliferative disease in psoriatic arthritis patients has not yet been defined.

Objectives: The aim of the study was to describe a case of a patient with psoriatic arthritis and concurrent monoclonal gammopathy, who did not respond to treatment with TNFalpha inhibitor in combination with methotrexate.

Methods: A 57 year old woman with psoriasis and psoriatic arthritis diagnosed in 2012 (presence of HLA B27 antigen, arthritis of the sacroiliac joints, peripheral arthritis) with monoclonal gammopathy of undetermined significance, was treated with non-steroid anti-inflammatory drugs, methotrexate (20 mg once a week), folic acid 15 mg and inhibitor of TNFalpha.

At the beginning of biological therapy she presented with laboratory results: ESR 126, total protein 8 g/dl, abnormal IgM 11.6 g/l (normal range 0.4–2.3 g/l), IgG 2.25 g/l (normal range 7–16g/l), IgA 0.32 g/l (normal range 0.7–4 g/l). Immunofixation test revealed positivity for IgM kappa monoclonal protein. There were no abnormalities in the bone marrow aspiration biopsy, no lymphadenopathy was observed. She complained of general weakness and polyneuropathy. Analysis of spino-cerebral fluid showed type V of oligoclonal band.

Results: In 2017, after 2 years of TNFalpha inhibitor combined with methotrexate therapy, the diagnosis of Waldenström macroglobulinemia has been done. The patient presented with high ESR 103 and monoclonal IgM 33 g/l. Repeated aspiration bone marrow biopsy showed 3% of plasmacytes and 21% of lymphocytes.

Conclusions: The patient started standard RCD chemotherapy regimen (rituximab, cyclophosphamide, dexamethason) with good clinical response to therapy.

P015

THE RELATIONSHIP BETWEEN PSORIASIS, COMORBIDITIES, AND DEPRESSION ONSET: A NATIONWIDE OBSERVATIONAL CONTROL STUDY

Kirk Geale¹, Martin Henriksson², Jussi Jokinen³, Marcus Schmitt-Egenolf¹

¹Dermatology, Department of Public Health and Clinical Medicine, Umeå

University, Umeå, ²Department of Medical and Health Sciences, Linköping University, Linköping, ³Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

Introduction: Psoriasis is a complex, systemic disease associated with comorbidities extending beyond the skin, often affecting psychological well-being which may manifest as clinical depression. Psoriasis can be viewed narrowly by focusing on the skin, or holistically to include associated comorbidities. To date, the complex interplay between psoriasis, comorbidities, and depression has not been adequately described, and an innovative approach is necessary to understand interrelationship between them.

Objectives: Calculate incidence rates of depression in psoriasis patients compared to the general population and subsequently explore the risk factors associated with depression onset. Determine the contributions of comorbidities compared to narrowly defined, psoriasis-only symptoms.

Methods: 96,666 psoriasis patients were matched to 15 controls and followed from psoriasis onset until incident depression diagnosis or censoring using population-based routine care data. Incidence of depression was calculated using Poisson regression models. Risk of depression onset using a narrow definition of psoriasis was compared to a holistic definition including all comorbidities using a Cox proportional hazards model, with additional adjustment for sociodemographic factors. Comorbidities were represented by ICD chapters with more than 5% correlation with psoriasis. Sensitivity analysis examined the role of psoriatic arthropathy, alternative depression definitions, and searched for unobserved confounding.

Results: Patients with psoriasis have a higher incidence of clinical depression than those without the disease. Holistically, psoriasis was associated with an increased risk of depression onset of 40% (HR = 1.404, $p < 0.001$), compared to 12% increase (HR = 1.115, $p < 0.001$) when narrowly defined. The proportional hazards assumption appeared to hold in each survival analysis. A substantial portion, but not all, of psoriasis patients' risk of depression onset was attributable to comorbidities, and sociodemographic factors did not appear to affect the estimates of association between depression and psoriasis. Major differences were found between antidepressant- and diagnosis-based definitions of depression, while inclusion of psoriatic arthropathy did not affect the results. No unmeasured confounding was identified.

Conclusions: Due to the elevated risk of depression in psoriasis patients, treating physicians should ensure patients' psychological well-being is addressed, especially in those presenting with additional risk factors, to break the cyclical relationship between depression and psoriasis and improve patients' quality of life. Contemporary, holistic management of psoriasis patients should encourage routine screening for depression.

P016

EFFICACY OF ADALIMUMAB PLUS METHOTREXATE IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Ghasem Rahmatpour Rokni, Mohamad Goldust
Mazandaran University of Medical Sciences

Background: Adalimumab, a high-affinity monoclonal antibody that selectively targets tumor necrosis factor alpha, is efficacious in treating moderate-to-severe plaque psoriasis. Currently there are some reports regarding drug resistance to adalimumab (1,2). **Objective:** This study aimed at evaluating the efficacy of adalimumab plus methotrexate in patients with moderate to severe plaque psoriasis.

Methods: In this cross sectional study, 23 patients suffering from moderate to severe psoriasis were recruited. Patients received adalimumab 80 mg week 0, 1 and then 40 mg every 2 weeks and methotrexate up to 25 mg/week. The primary outcome measure was the difference in Psoriasis area and severity index (PASI-

75) response after 12 weeks. The secondary outcomes included PASI 75 at week 6 (onset of action) and week 12, Investigator's Global Assessment (IGA), Patient Global Assessment, impact on quality of life (Skindex-17 and SF-36), Treatment Satisfaction Questionnaire of Medication, duration of remission, maintenance treatment and safety.

Results: In the study group, 86.9% (20 out of 23 patients) reached PASI-75 at week 12. The longitudinal analysis showed a PASI reduction of 6.42% per week. The onset of action was achieved in 65.2%. At week 12, IGA 'clear or almost clear' was observed in 91.3% ($p < 0.01$). Skindex-17 symptom score was significant with combination therapy ($p < 0.01$). Maintenance treatment achieved PASI 75 for 82.6% ($p < 0.01$). Mild adverse events were reported in 79.5%.

Conclusion: Combination therapy of adalimumab plus methotrexate is a highly effective, well-tolerated, maintenance therapy in patients with moderate to severe plaque psoriasis.

References:

1. Mease P, Hall S, FitzGerald O et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. *N Engl J Med* 2017 Oct 19. 377;1537-1550.
2. Papp K, Bachelez H, Costanzo A et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. *J Am Acad Dermatol* 2017 Jun. 1976;1093-1102.

P018

ATTAINMENT OF REMISSION AND MINIMAL DISEASE ACTIVITY AFTER STARTING METHOTREXATE SUBCUTANEOUS THERAPY

Elena Loginova, Tatiana Korotaeva, Elena Gubar, Svetlana Glukhova, Eugeny Nasonov

Nasonova Research Institute of Rheumatology, Moscow

Introduction: Methotrexate (MTX) is the first-choice therapy in psoriatic arthritis (PsA). There is limited data concerning efficacy of early administration and rapidly dose escalation of MTX subcutaneous (s/c) in early (E) PsA patients (pts).

Objective: to study attainment of remission (REM) or minimal disease activity (MDA) after starting MTX s/c therapy in EPsA pts treated according to treat-to-target (T2T) strategy.

Methods: 77 (M-37/F-40) pts with active EPsA, according to the CASPAR criteria were included. Mean age 37.4 ± 10.8 years (yrs.), PsA duration 11 ± 10 months (mon.), psoriasis duration 86 ± 96.1 mon., DAPSA 32.45 ± 12.7 . At baseline all pts started MTX s/c therapy. The dose of MTX s/c was escalated by 5 mg every 2 weeks from 10 mg/wk to appropriate dose 20–25 mg/wk according to the drug intolerance. If the patient did not achieve remission or MDA on MTX mono-therapy, biological (b)DMARDs was added. At baseline and every 3 mon. of study (till 24 mon.) all pts underwent assessment of PsA activity by DAPSA and MDA criteria (tender joint count ≤ 1 , swollen joint count ≤ 1 , PASI ≤ 1 or BSA ≤ 3 , patient pain global assessment VAS ≤ 15 , patient's global disease activity VAS ≤ 20 , HAQ ≤ 0.5 , enthesitis count ≤ 1). The proportion of pts who achieved REM by DAPSA ≤ 4 and MDA (5 of 7 cutpoints), the timing of REM/MDA, the mean dose of MTX during the study were performed. $M \pm SD$, Me [Q75; Q50], (%), W-test were calculated. All $p < 0.05$ were considered to indicate statistical significance.

Results: 36 out of 77 pts (46.75%) did not achieve REM or MDA in MTX therapy within 7 \pm 5 mon. and bDMARDs were added. 5 out of 77 pts (6.5%) stopped MTX therapy due to intolerance within 6 \pm 2 mon. 36 out of 77 pts (46.75%) went on taking MTX-mono-therapy. In 22 out of 36 pts, who had mean DAPSA 27.7 ± 10.0 at baseline, data was available by the 24 mon. of study. At baseline median dose of MTX s/c was 15 [10;20], Min 10–Max 20 mg/wk. At the third mon. of study median dose of MTX s/c was escalated to 20 [20;20], Min 0–Max 25 mg/wk. After attainment of REM/MDA the dose of MTX was decreased. At the end of the study median dose of MTX s/c was 7.5 [0;15], Min 0–Max 20

mg/wk (fig.1). After starting MTX disease activity by DAPSA significantly decreased by the third mon. and maintained till the end of the study (fig.2). DAPSA-REM and MDA was reached within 9.7 ± 7.7 and 13.7 ± 7.6 mon. accordingly. By the 24 mon. of therapy stable REM by DAPSA and MDA was seen in 10 out of 22 pts (45.5%) and in 16 out of 22 pts (72.7%) accordingly. **Conclusions:** In half of EPSA pts early administration of MTX s/c and rapidly dose escalation is effective and well tolerated. After achieving REM or MDA, a decrease of the dose of MTX is possible in most cases.

P019

SECUKINUMAB IN PREGNANCY: OUTCOMES IN PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS FROM THE GLOBAL SAFETY DATABASE

Richard Warren¹, Kristian Reich², Richard Langley³, Bruce Strober⁴, Dafna Gladman⁵, Atul Deodhar⁶, Teresa Bachhuber⁷, Weibin Bao⁸, Evelyn Altemeyer⁹, Samina Hussain¹⁰, Jorge Saff⁸

¹The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, UK, ²Dermatologikum Berlin and Georg-August-University Göttingen, Germany, ³Dalhousie University, Halifax NS, Canada, ⁴University of Connecticut Health Center, Farmington, CT, USA and Probit Medical Research, Canada, ⁵Toronto Western Hospital, Toronto, Canada, ⁶Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, USA, ⁷Novartis Pharma GmbH, Nuremberg, Germany, ⁸Novartis Pharmaceuticals Corporation, East Hanover, USA, ⁹Novartis Ireland Ltd, Dublin, Ireland, ¹⁰Novartis Healthcare Pvt. Ltd, Hyderabad, India

Introduction: Secukinumab, a fully human monoclonal antibody selectively targeting IL-17A, is highly efficacious in the treatment of moderate to severe psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with sustained efficacy and favorable safety profile. Long term treatment with targeted therapies such as secukinumab may be necessary in women of childbearing age. Pre-clinical animal studies with secukinumab, which can cross the placenta, do not indicate harmful effects with respect to pregnancy, embryonic/fetal development, parturition or postnatal development, however only limited data has been reported on human pregnancies.

Objectives: Using the Novartis global safety database, we analyzed the outcome of pregnancies where there was maternal or paternal exposure to secukinumab.

Methods: The Novartis global safety database (covering all secukinumab indications and including clinical trial and post-marketing data) was searched for cases reporting pregnancy and neonatal topics. All pregnancies where there was either maternal or paternal exposure to secukinumab were included in the systematic, independently validated analysis. The cut-off date was 25th June, 2017.

Results: Of 292 pregnancies reported, 141 (48.3%) came from clinical trials, 79 (27.1%) were spontaneous reports and 72 (24.7%) were from post-marketing surveillance, with 238 cases of maternal and 54 cases of paternal exposure. 175 patients received secukinumab for psoriasis, 38 for PsA, 15 for AS and 62 for other/unknown indications. The majority of patients discontinued secukinumab in the first trimester of pregnancy; 18 did not discontinue. Of 153 cases where the outcome was known, there were 73 full term normal neonates and 37 elective terminations. Rates of spontaneous abortions were 30/292, 10.3% overall (30/153 known outcomes, 19.6%). These are in line with previously reported rates (15–20%) for the general population with maternal age of 30.6 (study mean). No still births (> 20 weeks) were reported. Three congenital abnormalities were reported following maternal and 1 paternal exposure, with no repeated pattern of abnormality. At data cut-off, 32 pregnancies were ongoing.

Conclusions: There was no evidence for increased rates of adverse pregnancy outcomes across indications with secukinumab in this

review of the safety database. Given the limited exposure reported to date, the safe continuous use of secukinumab throughout pregnancy requires further research.

P020

IXEKIZUMAB IMPROVES IMPACT OF GENITAL PSORIASIS ON SEXUAL ACTIVITY: RESULTS FROM A PHASE 3B STUDY

Jennifer Clay Cather¹, Kim Meeuwis², Russel Burge³, Alison Potts Bleakman³, Chen-Yen Lin³, Alice Gottlieb⁴, Catriona Ryan⁵

¹Modern Dermatology and Modern Research Associates, Dallas, TX, USA, ²Radboud University Medical Center, Nijmegen, The Netherlands, ³Eli Lilly and Company, Indianapolis, IN, USA, ⁴Department of Dermatology, New York Medical College at Metropolitan Hospital, New York, NY, USA, ⁵St. Vincent's University Hospital, Dublin, Ireland

Introduction: Genital psoriasis (GP) is often associated with impaired sexual health. Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A.

Objective: To evaluate the effect of IXE on the impact of GP on sexual activity during 12 weeks of treatment compared to placebo (PBO) in patients with moderate-to-severe GP.

Methods: In this double-blind, placebo-controlled study, patients ($n = 149$) with moderate-to-severe GP were randomized (1:1) to receive PBO or 80 mg IXE every 2 weeks following an initial dose of PBO or 160 mg IXE. The impact of GP on sexual activity was measured by pre-specified patient-reported outcomes including the Genital Psoriasis Sexual Impact Scale (GPSIS), which is composed of the Sexual Activity Avoidance (Avoidance) and Impact of Sexual Activity on Genital Psoriasis Symptoms (Impact) subscales, the Sexual Frequency Questionnaire (SFQ) item 2, and the Dermatology Life Quality Index (DLQI) item 9. Of patients with a baseline SFQ item 2 score ≥ 2 , the percentage of patients whose frequency of sexual activity was never (0) or rarely (1) limited by GP (SFQ item 2 0/1) was examined. Among patients with respective GPSIS subscale scores ≥ 3 at baseline, response was measured as the percentage of patients whose frequency of avoiding sexual activity was never (1) or rarely (2) impacted by GP (GPSIS-Avoidance 1/2) and whose GP symptom worsening after sexual activity was very low/none at all (1) or low (2) (GPSIS-Impact 1/2). DLQI item 9 response was measured as the percentage of patients with no (0) or a little (1) impairment of sexual activity. Treatment comparisons were made using a logistic regression model with missing values imputed by non-responder imputation. **Results:** IXE treatment reduced the impact of GP on sexual activity at Week 12 versus PBO as assessed by SFQ item 2 0/1 (IXE 78.4%, PBO 21.4%; $p < 0.001$), GPSIS-Avoidance 1/2 (IXE 76.7%, PBO 25.7%; $p < 0.001$), and DLQI item 9 0/1 (IXE 92.0%, PBO 56.8%; $p < 0.001$). IXE was superior to PBO as early as Week 1 for SFQ item 2 0/1 ($p < 0.05$), Week 2 for DLQI item 9 0/1 ($p < 0.001$), and Week 4 for GPSIS-Avoidance 1/2 ($p < 0.01$). GPSIS-Impact 1/2 response rates suggested a trend of reduced impact of sexual activity on GP symptoms (IXE 85.7%, PBO 52.9%; $p = 0.062$).

Conclusions: During 12 weeks of treatment, IXE resulted in a rapid and significant decrease in the impact of GP on sexual activity, including how often GP limited sexual frequency among patients with moderate-to-severe GP.

Cather J, Meeuwis K, Burge R, Bleakman AP, Lin C-Y, Ryan C. Ixekizumab Provides Greater Improvement Versus Placebo on the Impact of Genital Psoriasis on Sexual Activity for Patients with Moderate-to-Severe Genital Psoriasis in a Randomized, Double-Blind Phase 3b Clinical Trial. American Academy of Dermatology-76th Annual Meeting 2018.

P021

DOSE OPTIMIZATION OF SECUKINUMAB IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: OPTIMISE STUDY

Kristian Reich¹, Lluís Puig², Jacek Szepletowski³, Carle Paul⁴,

Michael Rissler⁵, Christian Sieder⁶, Roberto Orsenigo⁷, Kamel Chaouche-Teyara⁵

¹SCIderm Research Institute Hamburg and Dermatologikum Berlin, Germany, ²Department of Dermatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ³Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland, ⁴Department of Dermatology, Larrey University Hospital, Toulouse, France, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharma GmbH, Nuernberg, Germany, ⁷Novartis Farma S.p.A, Origgio, Italy

Introduction: Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A, a key cytokine involved in the development of psoriasis. Heterogeneity in clinical response to targeted therapies such as secukinumab may be addressed by flexible dosing.

Objectives: To compare downtitration of PASI90 responders to 6-weekly and uptitration of PASI \geq 75 to <90 responders to two-weekly secukinumab dosing with standard 4-weekly dosing.

Methods: OPTIMISE was a randomized, multicenter, open-label, rater blinded Phase 3b study. 1647 subjects received secukinumab 300 mg at baseline, Weeks 1, 2, 3 and 4 then 4-weekly to Week 24. At Week 24, PASI90 responders were randomized to secukinumab 300 mg q4w ($n=644$) or q6w ($n=662$) to Week 52; PASI \geq 75 to <90 responders were randomized to secukinumab 300 mg q4w ($n=114$) or 2-weekly (q2w) ($n=92$) to Week 52. Groups were stratified by body weight (<90kg, \geq 90kg).

Results: PASI90 response was maintained at Week 52 by 85.7% subjects with q4w dosing vs 74.9% with q6w dosing; OR 1.91 (95% CI 1.44, 2.55). The primary endpoint, non-inferiority of q6w vs q4w dosing in PASI90 responders, was not met. In PASI \geq 75 to <90 responders, 46.5% of subjects achieved PASI90 response by Week 52 with q4w dosing. PASI90 response at Week 52 was numerically higher for q2w compared to q4w dosing (56.5% vs. 46.5%), but this difference did not reach statistical significance ($p=0.1013$). This numerical benefit of q2w dosing was even higher in subjects weighing ≥ 90 kg ($n=49$; 57.1% vs. 39.6%; $p=0.1053$). No new or unexpected safety signals were observed. **Conclusions:** Non-inferiority of q6w vs. q4w dosing cannot be claimed in maintaining PASI90 response achieved at Week 24. Around half of PASI \geq 75 to <90 responders at 24 weeks, can achieve PASI90 response with continued q4w dosing. Subjects with higher body weight may benefit from the q2w dosing.

P022

INHIBITION OF ANTI-TNF-ALPHA CYTOKINE IN THE TREATMENT OF PSORIASIS AND THE ANALYSIS OF INFECTIOUS COMPLICATIONS

Tatiana Pěčová¹, Karolína Vorčáková¹, Marián Grendár², Juraj Pěč¹

¹Department of Dermatovenereology, ²Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia

Introduction: TNF-alpha cytokine plays an important role in the regulation of activation, proliferation, differentiation and apoptosis of the immune cells. It is an important therapeutic target in the treatment of chronic plaque psoriasis. From its other roles, it plays key part in formation and maintenance of granuloma through the increased fagocytic capacity of macrophages and eradication of intracellular pathogens, therefore its inhibitors pose a risk for granulomatous infections and reactivation of latent tuberculosis. **Objectives:** The main focus was to assess the infectious complications of biologic anti-TNF-alpha treatment of chronic plaque psoriasis with focus on the tuberculosis and reactivation of its latent form. Moreover, the authors tried to establish possible risk factors on the reactivation of latent tuberculosis.

Methods: The authors analyzed the group of 190 patients from Middle-European population treated with TNF-alpha inhibitors, as compared to other biologics, for the occurrence of infectious

complications. Interferon-gamma release assay (IGRA) test was performed before the start of the treatment and then every year, in accordance with The Tuberculosis Network European Trials Group (TBNET) consensus. Statistical analysis was performed on the results.

Results: 3% of patients had permanently positive IGRA test (before and after beginning of the treatment) and in 28% of patients treated by TNF inhibitors, conversion of IGRA test appeared with negative test before treatment and positive test after administration of biologics. No active tuberculosis was detected. The average time of IGRA conversion was 3 years after beginning of treatment. The only statistically significant predictor was age, with an increase of age by one year associated with the 5.8% increase of risk of IGRA conversion. Regarding other infectious complications, the most common infections in patients treated with biologics were respiratory and HPV infections. No severe infection leading to the permanent discontinuation of treatment was observed.

Conclusions: Treatment with TNF-alpha inhibitors was associated with statistically significant risk of IGRA test conversion. The only established predictor of risk was age of patient, with no influence of previous or concomitant systemic treatment. However, the limitation was size of group of patients. The most common infections were common respiratory infections and viral HPV infections.

References:

- Andersen P, Munk ME, Pollock JM et al. Specific immune-based diagnosis of tuberculosis. *Lancet* 2000; 356:1099-1104.
- Bieber J, Kavanaugh A. Tuberculosis and opportunistic infections: relevance to biologic agents. *Clin Exp Rheumatol*. 2004; 22:126-133.
- Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. *J Am Acad Dermatol* 2008; 59:209-217.
- Drago L, Nicola L, Signori V et al. Dynamic QuantiFERON response in psoriasis patients taking long-term biologic therapy. *Dermatol Ther* 2013; 3:73-81.
- Hernandez C, Cetner AS, Jordan JE, et al. Tuberculosis in the age of biologic therapy. *J Am Acad Dermatol* 2008; 9:363-380.
- Solovič I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. *Eur Respir J* 2010; 36:1185-1206.

P023

TREATMENT USE AND SATISFACTION AMONG PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS IN SCANDINAVIA

Kåre Steinar Tveit¹, Albert Duvetorp², Mikkel Østergaard³, Lone Skov⁴, Kjersti Danielsen⁵, Lars Iversen⁶, Oliver Seifert⁷

¹Haukeland University Hospital, Bergen, Norway, ²Linköping University, Linköping, Sweden; ³Skånes Universitetssjukhus, Malmö, Sweden, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, University of Copenhagen, Copenhagen, Denmark, ⁵Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark, ⁶UiT The Arctic University of Norway, Tromsø, Norway; ⁷University Hospital of North Norway, Tromsø, Norway, ⁸Aarhus University Hospital, Aarhus, Denmark, ⁹Linköping University, Linköping, Sweden; ¹⁰Ryhov Hospital, Jönköping, Sweden

Introduction: Patients' perspectives on psoriasis (PsO) and psoriatic arthritis (PsA) treatment are important in establishing better approaches to their care.

Objectives: To assess treatment use and satisfaction among patients with PsO/PsA in Scandinavia.

Methods: NORPAPP was an on-line survey carried out in Nov/Dec 2015 using YouGov panels in Sweden, Denmark, and Norway. Adults with physician-diagnosed PsO or PsA ($n=1221$), answered questions about contact with the healthcare system, and treatment experience and satisfaction. Self-perceived disease severity was dichotomised to severe (responses of "quite severe", "very severe" or "extremely severe") and non-severe ("not particularly severe" or "not severe at all").

Results: Among respondents with PsO alone 38.9% had seen a dermatologist in the past year, and 10.7% had never seen a dermatologist; 60.9% of those with PsA±PsO had seen a rheumatologist in the past year; 14.3% had never seen a rheumatologist. Systemic treatments had been used by 14.6% of respondents with PsO alone and 58.5% with PsA±PsO. Respondents with self-perceived severe symptoms and patient organization members (POMs) were more likely than those with non-severe symptoms or non-members, to have discussed systemic treatments with their physician and to have used the treatments; however, 35.2% of respondents with self-perceived severe symptoms had never discussed systemic treatment with their physician. Asked about long-term health risks of systemic treatments, 18–44 year-olds and POMs were less likely to answer “don’t know” than 45–74 year-olds (47.7%–49.1% vs 66.7%–72.9%) or non-members (26.1%–30.7% vs 66.8%–70.4%). Biologics had been used by 40.7% of POMs vs 6.9% of non-members, and 21.5% of 18–44 year-olds vs 8.1% of 45–74 year-olds. Among respondents using oral/injectable methotrexate 30.5% were dissatisfied, 60.2% citing side-effects as the reason; 22.9% of biologics users were dissatisfied, 28.9% citing lack of effect and 28.1% citing side-effects.

Conclusion: In Scandinavia POMs and young patients are more likely to receive systemic treatment. A high proportion of patients are dissatisfied with their treatment because of side effects.

P024

FIRST PATIENT-REPORTED INSIGHTS FROM A MULTINATIONAL, RETROSPECTIVE, CROSS-SECTIONAL STUDY OF REAL-WORLD EXPERIENCE OF PSORIASIS PATIENTS TREATED WITH APREMILAST IN CLINICAL DERMATOLOGY PRACTICE (APPRECIATE)

Matthias Augustin¹, Marc Alexander Radtke¹, Kilian Eyerich², Mona Stähle³, Christine Bundy⁴, Myriam Cordey⁵, Volker Koscielnny⁵, C. Elise Kleyn⁶, Christopher EM Griffiths⁶

¹Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, ²Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany, ³Department of Medicine, Karolinska Institute, Solna, Sweden, ⁴School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK, ⁵Celgene International, Boudry, Switzerland, ⁶Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

Introduction: Patient (pt)-centered care is gaining traction in long-term disease management. We report on a multinational, retrospective, cross-sectional study in psoriasis pts treated with apremilast (APR), an oral phosphodiesterase 4 inhibitor, in a real-world clinical setting.

Objectives: The study aims to identify important pt needs and therapeutic benefits of APR.

Methods: Consecutive pts with chronic plaque psoriasis treated according to routine clinical practice who could be contacted 6±1 mo after APR initiation were enrolled. Medical chart review, standardized pt-reported outcome tools (PBI, TSQM-9), and pt/physician questionnaires were used. An interim analysis of the first 104 pts from 40 sites in Germany (42), UK (31), and Sweden (31) was performed using predefined descriptive statistics.

Results: 102 pt questionnaires were analyzed (98%). At 6±1 mo, 74 pts (71%) continued APR; 30 (29%) had discontinued APR (lack of efficacy [14%], safety/tolerability [11%], other [4%]). Assessment of pts' main needs from a therapy (quite/very important on the PBI) revealed the importance pts attributed to skin involvement (93% of responders), confidence in healing (92%), being itch free (85%), fewer side effects (84%), being able to lead

a normal everyday life (83%), and needing less time for daily treatment (80%). Based on a clinically meaningful PBI score ≥1, 78% of pts achieved a benefit with APR after 6 mo. Mean (SD) PBI score was 2.2 (1.3) and increased to 2.5 (1.2) for pts on continued APR at 6 mo vs 1.6 (1.3) for pts who discontinued APR. Pts achieved benefit related to skin involvement (60%), confidence in healing (70%), itch (69%), side effects (60%), being able to lead a normal everyday life (72%), and needing less time for daily treatment (65%). Consistent with phase 3 studies, most frequently reported AEs were diarrhea (19.2%), nausea (16.4%), and headache (11.5%); 25% of pts reported weight loss (no change, 71%; gain, 4%).

Conclusions: This interim analysis indicates main pt needs from a therapy extend beyond skin improvement. Findings indicate APR may address diverse pt needs.

Prior Presentation: EADV 2017

P025

PHYSICIAN- AND PATIENT-REPORTED OUTCOMES WITH APREMILAST FOR PATIENTS WITH PLAQUE PSORIASIS DURING ROUTINE DERMATOLOGY CARE IN GERMANY: A SECOND INTERIM ANALYSIS

Kristian Reich¹, Stefanie Bomas², Bernhard Korge³, Uwe Schwichtenberg⁴, Hannah Mentz⁵, Kathrin Groegel⁵, Natalie Núñez Gómez⁵

¹Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, ²Praxis Dr. med. S. Rotterdam, Gelsenkirchen-Feldmark, ³Priv. Doz. Dr. med. Korge, Düren, ⁴Derma Nord Hautarztpraxen Dr. med. Schwichtenberg, Bremen, ⁵Celgene GmbH, Munich, Germany

Introduction: LAPIS-PSO is an ongoing, 52-week, prospective, multicenter, observational cohort study in real-world dermatology clinical settings in Germany.

Objectives: To present a 4-month interim analysis of patient (pt)-reported outcomes and efficacy assessments of apremilast (APR) among pts ($n = 294$; full analysis set [FAS], $n = 196$) who were continuing APR at 4 mo.

Methods: Physician- and pt-reported outcomes for QOL, treatment effectiveness, and treatment satisfaction were evaluated in pts with psoriasis vulgaris during long-term APR treatment. The primary endpoint at Visit 2 (~4 mo after baseline [BL]) is the proportion of pts who achieve DLQI score ≤5 or improvement from BL in DLQI score ≥5 points.

Results: At BL, mean (SD) age was 51.7 (13.20) years in the FAS; 90 pts (45.9%) were female. At APR initiation, 171 pts (87.3%) had Physician's Global Assessment of disease severity (PGA) ≥3 and 174 (89.2%) had Patient's Global Assessment of disease severity (PaGA) ≥3; mean psoriasis-involved BSA was 22.2%, mean pruritus VAS score was 56.6 mm, and mean DLQI score was 14.1. In all, 62.7% of pts had scalp PGA (ScPGA) ≥3; 42.5% had palmoplantar PGA (PPPGA) ≥3. Among pts continuing APR at 4 mo, 120/181 (66.3%) achieved DLQI score ≤5 or reduction by ≥5 points. Mean (SD) improvement in BSA was -9.5% (14.91) and mean (SD) percentage improvement in pruritus VAS score was -47.3% (32.29). A total of 32.1% of pts achieved PGA 0 (clear) or 1 (minimal); 32.6% achieved PaGA 0 or 1. NAPS-50 was achieved by 62.4% (53/85) of pts. In all, 58.4% (87/149) of pts achieved ScPGA 0 or 1 and 69.0% (29/42) had PPPGA 0 or 1. AEs were consistent with the known safety profile of APR. Eighty pts (27.8%) reported ≥1 AE; 1 AE occurred in ≥5% of pts (diarrhea, $n = 21$ [7.3%]).

Conclusion: In routine clinical care in Germany, APR treatment outcomes for pts with psoriasis vulgaris, including difficult-to-treat locations such as the nails, scalp, palms, and soles, confirm the broad efficacy of APR observed in clinical trials.

Prior Presentation: AAD 2018

P026**IMPROVEMENTS IN WORK PRODUCTIVITY WITH UP TO 104 WEEKS OF APREMILAST MONOTHERAPY: RESULTS FROM A PHASE 3B, RANDOMIZED, CONTROLLED STUDY IN BIOLOGIC-NAIVE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS**

Philip J. Mease¹, Dafna D. Gladman², Eric K. Davenport³, Xiaolei Zhou³, Benoit Guerette⁴, Lichen Teng⁴, Satyin Kaura⁴, Peter Nash⁵
¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³RTI Health Solutions, Research Triangle Park, NC, USA, ⁴Celgene Corporation, Summit, NJ, USA, ⁵University of Queensland, Brisbane, Australia

Introduction: PsA patients may have impaired functioning in home or work activities. The phase 3b ACTIVE study assessed efficacy of apremilast (APR) monotherapy in biologic-naïve subjects with active PsA who may have had exposure to 1 conventional DMARD.

Objectives: Assess work productivity through Wk104.

Methods: Subjects were randomized (1:1) to APR 30 mg BID or placebo (PBO). Subjects whose SJC/TJC did not improve $\geq 10\%$ at Wk16 were eligible for early escape. At Wk24, remaining PBO subjects switched to APR. Work productivity and activity impairment were assessed at baseline (BL) and Wk16 using the WPAI:PsA; WPAI:PsA Absenteeism, Presenteeism, Work Productivity Loss, and Activity Impairment subscale scores range from 0% to 100%; higher scores indicate greater impairment. Work-related subscales were assessed in employed subjects; activity impairment was assessed in all subjects. Correlations were examined at Wk16 between WPAI:PsA subscale and SF-36v2 domain scores (Physical Functioning [PF], Bodily Pain [Pain], and Vitality [VIT]) associations with ACR20 response. Work productivity improvement was assessed to Wk104.

Results: BL characteristics were similar between groups. At Wk16, APR improved work productivity and ability to carry out daily activities vs PBO, with greater mean improvements in overall Work Productivity Loss ($p=0.001$) and Activity Impairment ($p<0.001$). Estimated mean change in Absenteeism score was similar with APR vs PBO ($p=0.679$). The Presenteeism score showed significant improvement with APR vs worsening with PBO (-10.8% vs 4.1% ; $P=0.002$). At Wk16, statistically significant correlations were observed between WPAI:PsA subscale (except Absenteeism) and SF-36v2 domain scores, as were associations with ACR20 response. In subjects randomized to APR at BL, Wk16 improvements were generally maintained to Wk104 in those continuing APR.

Conclusions: In biologic-naïve subjects with PsA, APR contributed to overall improvement in work productivity at Wk16, which correlated with SF-36v2 PF, Pain, and VIT scores and was associated with ACR20 response; improvements in WPAI:PsA subscale scores were generally maintained to Wk104.

Prior Presentation: EULAR 2018

P027**EXAMINING DISEASE SEVERITY AND SYMPTOM IMPROVEMENT WITH PATIENT AND PHYSICIAN ASSESSMENTS: RESULTS FROM A PHASE IV ANALYSIS OF APREMILAST IN PATIENTS WITH MODERATE PLAQUE PSORIASIS**

Mark Lebwohl¹, J. Mark Jackson², Jerry Bagel³, Eugenia Levi⁴, Jerry Weaver⁴, Linda Stein Gold⁵, Ali Alikhan⁶, Seth Forman⁷, Benjamin Lockshin⁸, Kristina Callis Duffin⁹

¹Icahn School of Medicine at Mount Sinai, New York, NY, ²University of Louisville, Forefront Dermatology, Louisville, KY, ³Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, ⁴Celgene Corporation, Summit, NJ, ⁵Henry Ford Health System, West Bloomfield, MI, ⁶Univer-

sity of Cincinnati, Department of Dermatology, Cincinnati, OH, ⁷Forward Clinical Trials, Tampa, FL, ⁸DermAssociates, Rockville, MD, ⁹University of Utah, Salt Lake City, UT, USA

Introduction: UNVEIL is the first study of apremilast in patients (pts) with moderate psoriasis (BSA 5%-10%) naïve to biologic and systemic therapy.

Objectives: Improvements on physician and pt assessments over 52wks are described.

Methods: Pts with chronic moderate plaque psoriasis (BSA 5%-10%; sPGA = 3 [0-5 scale]) were randomized (2:1) to apremilast 30 mg BID (APR) or placebo (PBO) for 16wks. Pts continued APR (APR/APR) or switched from PBO to APR (PBO/APR) through Wk52 (open-label treatment). Physician assessments were product of sPGA and BSA (PGAxBSA), proportion of pts who achieved sPGA score 0 (clear) or 1 (almost clear) and PGAxBSA-75 ($\geq 75\%$ improvement from baseline [BL]). Pt assessments were Dermatology Life Quality Index (DLQI), pruritus VAS (0-100 mm), Treatment Satisfaction Questionnaire for Medication (TSQM), and Pt's Global Assessment (PtGA [0-4 scale]).

Results: In randomized pts (PBO $n=73$; APR $n=148$), mean BL BSA was 7.2%, PGAxBSA was 21.8, DLQI was 11.0, and pruritus VAS was 56.6mm. At Wk16, mean improvement in PGAxBSA was greater with APR vs PBO (-48.1% vs -10.2% ; $P<0.0001$); more pts achieved sPGA 0 or 1 and PGAxBSA-75 with APR vs PBO (30.4% vs 9.6% and 35.1% vs 12.3%). At Wk16 achievement of DLQI response (≥ 5 -point decrease in pts with BL DLQI > 5) was greater with APR vs PBO (63.8% vs 34.5%), as were pruritus VAS response (improvement $\geq 20\%$: 62.8% vs 45.2%) and TSQM global satisfaction (63.2 vs 48.7) and effectiveness (57.3 vs 38.8). More pts had PtGA ≤ 1 with APR vs PBO (33.8% vs 20.5%). At Wk52, PGAxBSA changes were -42.2% (PBO/APR) and -55.5% (APR/APR); 45.3% (PBO/APR) and 42.1% (APR/APR) of pts achieved PGAxBSA-75, 35.9% (PBO/APR) and 33.1% (APR/APR) achieved sPGA response, 55.6% (PBO/APR) and 59.4% (APR/APR) achieved DLQI response, and 68.8% (PBO/APR) and 66.9% (APR/APR) achieved pruritus VAS response. TSQM global satisfaction (PBO/APR 59.2; APR/APR 59.9) and effectiveness (PBO/APR 57.7; APR/APR 54.1) were similar between groups at Wk52; 42.2% (PBO/APR) vs 37.2% (APR/APR) had PtGA ≤ 1 .

Conclusion: Physician and pt assessments improved with APR up to 52wks in biologic- and systemic-naïve pts with moderate psoriasis.

Prior Presentation: AAD 2018

P028**HEMOGLOBIN A1C AND WEIGHT CHANGES WITH APREMILAST IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS: POOLED LABORATORY ANALYSIS OF THE PHASE 3 ESTEEM AND PALACE TRIALS**

Luis Puig¹, Neil Korman², Chiara Greggio³, Joshua Cirulli³, Lichen Teng³, Vinod Chandran⁴, Majed Khraishi⁵, Nehal N. Mehta⁶

¹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²Case Western University and University Hospitals Cleveland Medical Center, Cleveland, OH, ³Celgene Corporation, Summit, NJ, ⁴University of Toronto and Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Memorial University of Newfoundland, St. Johns, NL, Canada, ⁶National Heart, Lung and Blood Institute, Bethesda, MD

Introduction: Psoriasis and psoriatic arthritis (PsA) are associated with high prevalence of obesity and metabolic syndrome. In phase 3 trials, apremilast, an oral PDE4 inhibitor, was efficacious in patients (pts) with moderate to severe plaque psoriasis (ESTEEM 1 and 2 [EST]) and active PsA (PALACE 1-3 [PAL]).

Objectives: To explore potential effects of apremilast on metabolic parameters, we assessed weight change and A1c in pts receiving placebo (PBO) or apremilast 30 mg twice daily (APR) in a pooled analysis of EST and PAL.

Methods: Mean A1c change and mean percent weight change at Wk16 were compared among pts with baseline (BL) A1c < 5.7%, 5.7% to 6.4% (prediabetes), and $\geq 6.5\%$ (diabetes) and between pts reporting/not reporting concomitant insulin use. Spearman rank correlations between percent change from BL in weight and change in A1c at Wk16 were calculated; $p < 0.05$ was considered significant. **Results:** In the pooled EST-PAL population, 2,242 pts (PBO $n = 913$; APR $n = 1,329$) received study medication at BL. In all, 230 pts had BL A1c $\geq 6.5\%$. At Wk16, A1c change in pts with BL A1c < 5.7% was 0.02 with PBO and 0.04 with APR. In pts with BL A1c 5.7% to 6.4%, small changes were observed (PBO -0.07; APR -0.12). Greatest A1c changes were in pts with BL A1c $\geq 6.5\%$ (PBO -0.08; APR -0.31). At Wk16, mean weight change was 0.11% (PBO) and -1.32% (APR). In pts reporting and not reporting concomitant insulin use, mean weight change was 0.05% and 0.12% with PBO, respectively, and -1.83% and -1.31% with APR. Weight change in pts with BL A1c < 5.7%, 5.7% to 6.4%, and $\geq 6.5\%$ was 0.02%, 0.26%, and 0.11% with PBO, respectively, and -1.24%, -1.35%, and -1.68% with APR. Correlations between changes in weight and A1c were generally low, with greater correlation in APR pts with higher BL A1c. Correlation was statistically significant in APR pts with BL A1c $\geq 6.5\%$. **Conclusion:** With APR, decreases in weight and A1c were greater in pts with higher BL A1c. Pts receiving APR and insulin had weight loss despite the association between insulin use and weight gain. Future studies may be warranted to determine whether reductions in A1c with APR are independent of weight loss. Prior presentation: AAD 2018

P029

CANADIAN HUMIRA POST-MARKETING OBSERVATIONAL EPIDEMIOLOGICAL STUDY ASSESSING THE EFFECTIVENESS OF ADALIMUMAB VS NON-BIOLOGIC DMARDS IN PSORIATIC ARTHRITIS (COMPLETE-PSA): 12-MONTH EFFECTIVENESS DATA

Majed Khraishi¹, Louis Bessette², Andrew Chow³, Boulos Harraoui⁴, Viktoriya Pavlova⁵, Jacqueline Stewart⁶, Valencia Remple⁷

¹Memorial University of Newfoundland, St. John's NL, ²Laval University, Centre Hospitalier de l'Université Laval, Quebec QC, ³University of Toronto ON, ⁴Centre hospitalier de l'Université de Montréal, Montreal QC, ⁵McMaster University, Hamilton ON, ⁶University of British Columbia, Penticton BC, ⁷AbbVie Corporation, Montreal QC, Canada

Background: Observational studies comparing the effectiveness of adalimumab (ADA) to non-biologic DMARDs (nbDMARD) in PsA patients failing prior treatment are scarce. COMPLETE-PSA is a Canadian observational study which assessed effectiveness of ADA and non-biological therapies (NSAIDs and DMARDs) among PsA patients failing previous therapy.

Objectives: To describe the baseline (BL) demographic and disease parameters and to compare 12-month real-life effectiveness of patients initiating nbDMARD or ADA.

Methods: Eligible patients eligible are anti-TNF α naïve adults, with active PsA requiring a treatment regimen change, per the treating physician's judgment. This analysis included patients enrolled during Jul/2011–Jun/2016. Outcome measures analyzed were: DAS28, SF-12, DLQI, presence of extra-articular manifestations (EAMs; enthesitis & dactylitis), psoriasis BSA, achievement of modified MDA (achievement of [i] 4/6 (MDA 1) and [ii] 5/6 following criteria (MDA 2): TJC ≤ 1 , SJC ≤ 1 , BSA $\leq 3\%$, pain VAS ≤ 15 mm, PtGA ≤ 20 and HAQ ≤ 0.5), modified remission (SJC = 0, TJC = 0, absence of enthesitis and dactylitis, BSA $\leq 3\%$ and HAQ ≤ 0.5), DAPSA LDA (≤ 14), and DAPSA remission (REM; ≤ 4). Analyses were conducted by initial group assignment (intent-to-treat approach).

Results: 406 patients were included (nbDMARD $n = 146$, ADA $n = 260$). BL demographics were comparable between treatment

groups. However, patients initiating ADA were more likely to be unemployed (47.3% ADA vs 34.9% nbDMARD, $p = 0.015$), had higher DAS28 (4.8 vs 4.4, $p = 0.002$) and total DLQI score (6.1 vs 4.3, $p = 0.007$), and were more likely to have BSA $\geq 3\%$ (44.6% vs 35.0%, $p = 0.063$) and high DAPSA disease activity (50.8% vs 32.3%, $p = 0.015$). A higher proportion of nbDMARD patients had dactylitis (36.1% vs 25.3%, $p = 0.023$). No differences were observed between groups in enthesitis, overall EAMs, or QoL at BL. Following 12 months, mean adjusted DAS28 (2.6 vs 3.4, $p < 0.001$) and DLQI (2.2 vs 2.9, $p = 0.530$) scores, but not SF-12, were lower in the ADA group. Furthermore, even though statistical significance was not always met, ADA patients had lower DAPSA score ($p = 0.025$) (LDA/REM: 64.9% vs 58.6%; REM: 37.7% vs 17.1%), were more likely to be in modified remission (14.7% vs 9.7%, $p = 0.311$), and to have mMDA (mMDA 1: 15.6% vs 12.6%, $p = 0.529$; mMDA 2: 17% vs 11.5%, $p = 0.253$) and BSA < 3% (89.3% vs 83.9%, $p = 0.207$). Also, EAM prevalence decreased in both groups but was significantly lower in the ADA group (17.4% vs 35.8%, $p < 0.001$). Over time, 9.6% of ADA patients initiated another biologic and 32.2% of patients in the nbDMARD group initiated biologic treatment ($p < 0.001$).

Conclusions: PsA patients initiating ADA in Canadian routine clinical care have significantly greater BL disease severity compared with those initiating nbDMARDs. However, 12-month ADA treatment resulted in improved disease control and EAMs. DAPSA-REM evaluation seems more sensitive than mMDA in differentiating both populations.

P030

SECUKINUMAB EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF 4 PHASE 3 TRIALS

Philip Mease¹, Bruce Kirkham², Peter Nash³, Alejandro Balsa⁴, Bernard Combe⁵, Jürgen Rech⁶, Ruvie Martin⁷, Gregory Ligozio⁷, Ken Abrams⁷, Luminita Pricop⁷

¹Swedish Medical Centre and University of Washington, Seattle, USA, ²Guy's & St Thomas' NHS Foundation Trust, London, UK, ³Department of Medicine, University of Queensland, Brisbane, Australia, ⁴Hospital Universitario La Paz, Instituto de Investigación Sanitaria (IdiPAZ), Madrid, Spain, ⁵Hôpital Lapeyronie, Université Montpellier I, Montpellier, France, ⁶Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Monash University, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, USA

Introduction: Secukinumab (SEC) has exhibited rapid, significant and sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) in 4 Phase 3 studies.1–4

Objective: To report meta-analyzed efficacy results for SEC versus placebo at Week (Wk) 16 in PsA patients (pts) by prior TNF inhibitor (TNFi) use and with/without concomitant methotrexate (MTX) use from 4 Phase 3 studies: FUTURE 2,3,4,5.

Methods: A total of 2148 pts with active PsA were randomised in FUTURE 2, 3, 4 and 5 studies (397, 414, 341 and 996, respectively). Study designs were described elsewhere.1–4 Assessments included ACR20/50 by prior TNFi use (naïve/inadequate response or intolerance [-IR]) and with/without MTX use.

Results: Out of 2049 pts in analysis, 461, 572, 335, and 681 pts received SEC 300mg, 150mg, 150mg without load (NL) and placebo (PBO), respectively. ACR 20/50 responses were improved with SEC vs PBO at Wk 16 in both TNFi-naïve/-IR pts and pts with/without concomitant MTX use (Table); improvements were also observed with SEC vs PBO for all other secondary endpoints.

Conclusions: SEC provided improvement in the signs and symptoms of active PsA regardless of previous TNFi therapy or concomitant MTX use. Higher response rates were observed in TNFi-naïve pts compared to TNFi-IR pts. SEC 300mg was associated with higher responses compared to 150mg in pts with TNFi-IR and no concomitant MTX use.

References:

- 1) J Rheumatol. 2017; 56(11):1993-03. 2) Rheumatology 2017;56:1993-03; 3) Arthritis Rheumatol. 2017;69 (s10); 4) PANLAR 2018, A718

Table: ACR20/50 responses at Week 16 by TNFi status and concomitant MTX use

| Pts subgroup | ACR20/50 Response [Treatment Effect vs. PBO at Week 16 (%)] | | |
|--------------|---|-----------|----------------|
| | SEC 300mg | SEC 150mg | SEC 150mg (NL) |
| TNFi naïve | 34.6/30.1 | 31.6/25.1 | 34.5/22.6 |
| TNFi-IR | 29.3/18.1 | 24.5/14.7 | 17.8/8.3 |
| With MTX | 23.1/20.1 | 28.1/20.1 | 23.5/11.3 |
| Without MTX | 41.6/29.1 | 29.7/20.6 | 34.5/22.6 |

P031

IMPACT OF ADALIMUMAB VS. NON-BIOLOGIC TREATMENTS ON SKIN OUTCOMES OF PSORIATIC ARTHRITIS PATIENTS: REAL-WORLD DATA FROM THE COMPLETE STUDY

Majed Khraishi¹, Louis Bessette², Boulos Haraoui³, Valencia Remple⁴

¹Memorial University of Newfoundland, St. John's NL, ²Laval University, Centre Hospitalier de l'Université Laval, Quebec, ³Centre hospitalier de l'Université de Montréal, ⁴AbbVie Corporation, Montreal, QC, Canada

Background: Previous studies have shown the efficacy of anti-TNF α agents in improving nail, skin and joint manifestations of psoriatic arthritis (PsA). However, real-world data on the comparative effectiveness of switching to or adding these agents vs. continuing non-biologic treatments in patients having failed prior non-biologic treatment are necessary to support the integration of treatment algorithms into routine care.

Objectives: The aim of this analysis was to compare the effect of adalimumab (ADA) vs. non-biologic treatments (nbDMARD: NSAIDs and DMARDs) on skin outcomes and patient reported outcomes following initial treatment failure. In addition, the impact of the extent of baseline skin disease on treatment outcomes was examined.

Methods: Patients eligible for COMPLETE PsA are anti-TNF α naïve adults, with active PsA who require change in their treatment regimen, per the judgment of the treating physician. In the current analysis patients enrolled between July/2011 – Jun/2016 who had available information on baseline psoriasis body surface area (BSA) were included. Outcome measures analyzed were: BSA, Dermatology Life Quality Index (DLQI), Short Form Health Survey (SF-12), and the Beck Depression Inventory (BDI). Analyses were conducted by initial group assignment (intent-to-treat approach). **Results:** A total of 392 patients were included (ADA $n=249$, nbDMARD $n=143$). Baseline demographics and disease duration were comparable between treatment groups. However, patients initiating ADA were more likely to have BSA $\geq 3\%$ (44.6% vs. 35%, $p=0.063$) and had higher DLQI (6.2 vs. 4.3, $p=0.006$) scores. No differences were observed in SF-12 physical (PCS) and mental (MCS) component scores at baseline.

During treatment, BSA levels significantly improved in both groups but more patients achieved a BSA $< 3\%$ when treated with ADA vs. nbDMARD both at 6 months (89.7% vs. 80.2%, $p=0.027$) and 12 months (89.0% vs. 83.7%, $p=0.222$). Furthermore, upon adjusting for baseline scores, patients in the ADA group experienced greater improvements in DLQI (Δ LSM = -1.62, $p=0.004$), particularly in the daily activities, leisure, and work/school domains, and SF-12 PCS (Δ LSM = 0.36, $p<0.001$). These differences between groups in BSA levels and DLQI improvement were more profound among patients with BSA $\geq 3\%$ at baseline. During follow-up, 9.2% of ADA patients initiated another biologic and 32.2% of patients in the nbDMARD group initiated biologic treatment ($p<0.001$).

Conclusions: PsA patients starting ADA following initial failure of non-biologic treatment in Canadian routine clinical care experience greater benefits in skin outcomes and quality of life compared to switching to different non-biologic treatment. These benefits are particularly evident among patients with more severe skin disease at baseline.

P032

IXEKIZUMAB IMPROVES NAIL AND SKIN PSORIASIS THROUGH 52 WEEKS OF TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO RANDOMIZED, DOUBLE-BLIND, PHASE 3, CLINICAL TRIALS (SPIRIT-P1 AND SPIRIT-P2)

Joseph F. Merola¹, Mitsumasa Kishimoto², David Adams³, So Young Park³, Diamant Thaçi⁴

¹Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA, ²Immuno-Rheumatology Center, St. Luke's International University, St. Luke's International Hospital, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, USA, ⁴Comprehensive Center for Inflammation Medicine, University Hospital, Schleswig-Holstein Campus Luebeck, Luebeck, Germany

Introduction: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for treatment of patients (pts) with active psoriatic arthritis (PsA) and provides persistent efficacy through 52 weeks (wks) of treatment.

Objective: To evaluate the efficacy of IXE treatment over 52 wks on nail and skin psoriasis in biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve and -experienced pts with active PsA. **Methods:** Adult pts with active PsA were bDMARD-naïve (SPIRIT-P1) or -experienced (SPIRIT-P2, TNF inhibitor inadequate responders [TNFi-IR] or intolerant). Pts were randomized to IXE 80 mg every 2 (Q2W) or 4 wks (Q4W), placebo, or (in SPIRIT-P1) 40 mg adalimumab Q2W. Efficacy of IXE on nail and skin psoriasis in patients randomized to IXE was measured by the Nail Psoriasis Severity Index (NAPSI), Psoriasis Area and Severity Index (PASI), and static Physician Global Assessment (sPGA). Missing data were imputed using nonresponder imputation for categorical variables and modified baseline observation carried forward for continuous variables.

Results: IXE provided high clinical response in skin and nail psoriasis that persisted through 52 wks of treatment, regardless of IXE dosing or prior bDMARD use (Table).

| | SPIRIT-P1 (bDMARD Naïve) | | SPIRIT-P2 (TNFi-IR or Intolerant) | |
|--------------------------------------|-----------------------------|--------------------|--------------------------------------|--------------------|
| | IXE Q4W $n=107$ | IXE Q2W $n=103$ | IXE Q4W $n=122$ | IXE Q2W $n=123$ |
| PASI 75 ^a | 52/73 (71.2) | 45/59 (76.3) | 41/68 (60.3) | 37/68 (54.4) |
| PASI 90 ^a | 44/73 (60.3) | 43/59 (72.9) | 34/68 (50.0) | 27/68 (39.7) |
| PASI 100 ^a | 37/73 (50.7) | 37/59 (62.7) | 27/68 (39.7) | 24/68 (35.3) |
| sPGA 0/1 ^b | 39/52 (75.0) | 29/41 (70.7) | 37/60 (61.7) | 41/62 (66.1) |
| sPGA 0 ^b | 29/52 (55.8) | 23/41 (56.1) | 26/60 (43.3) | 27/62 (43.5) |
| NAPSI = 0 ^c | 30/69 (43.5) | 28/74 (37.8) | 41/89 (46.1) | 24/74 (32.4) |
| NAPSI mean (SD) change from baseline | -15.9 (18.3) | -20.0 (20.8) | -15.2 (19.7) | -14.4 (19.0) |

Unless otherwise indicated, values are presented as: n/Nx (%), where Nx is *pts with baseline BSA $\geq 3\%$, *pts with baseline sPGA ≥ 3 , or *pts with baseline fingernail psoriasis

Conclusions: In these two phase 3 clinical trials in patients with active PsA, ixekizumab provided persistent high clinical response for improvement or clearance of nail and skin psoriasis through 52 wks of treatment.

P034

IXEKIZUMAB MAKES THERAPEUTIC THRESHOLDS POSSIBLE IN ACTIVE PSORIATIC ARTHRITIS PATIENTS: RESULTS FROM SPIRIT TRIALS

Laura C Coates¹, M. Elaine Husni², Eric Lespessailles³, Lisa Kerr⁴, Gaia Gallo⁴

¹University of Oxford, Leeds, UK, ²Cleveland Clinic, Cleveland, OH, USA,

³Université d'Orléans, Orléans, EA, France, ⁴Eli Lilly and Company, Indianapolis, IN, USA

Introduction: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement.

Objective: To explore the effect of ixekizumab (IXE), an anti-IL-17A monoclonal antibody, as assessed by composite endpoints, up to 52 weeks (wks) for the SPIRIT-P1 and SPIRIT-P2 trials.

Methods: Data were analyzed from 2 double-blind, phase 3 trials investigating the efficacy and safety of IXE in active PsA patients (pts). For SPIRIT-1 [1] biologic disease-modifying antirheumatic drug-naïve pts were randomized to placebo (PBO, $n = 106$) or 80 mg IXE every 4 wks (Q4W, $n = 107$) or every 2 wks (Q2W, $n = 103$) post 160 mg starting dose. For SPIRIT-2 [2] (inadequate responders to tumor necrosis factor inhibitors [TNFi]) pts were randomized to PBO ($n = 118$) or 80 mg IXE Q4W ($n = 122$) or Q2W ($n = 123$) post 160 mg starting dose. Minimal disease activity (MDA), MDA very low disease activity (VLDA), Disease Activity in Psoriatic Arthritis (DAPSA) LDA, DAPSA remission, Psoriatic Arthritis Disease Activity Score (PASDAS) LDA, and PASDAS VLDA composite endpoints were evaluated. Imputation for categorical responses was non-responder imputation. Treatment comparisons (with placebo up to Wk 24) based on the intent-to-treat population were made using a logistic regression model. Data up to Wk52 are summarized.

Results: At Wk 24, percentage of pts achieving MDA (SPIRIT-P1 Q4W: 29.9; Q2W: 40.8; PBO: 15.1; SPIRIT-P2 Q4W: 27.9; Q2W: 31.9; PBO: 3.4), MDA VLDA (SPIRIT-P1 Q4W: 10.3; Q2W: 11.7; PBO: 0.9; SPIRIT-P2 Q4W: 12.3; IXEQ2W: 3.3; PBO: 0.8), DAPSA LDA (SPIRIT-P1 Q4W: 31.8; Q2W: 34.0; PBO: 17.9; SPIRIT-P2 Q4W: 25.4; Q2W: 27.6; PBO: 11.1), DAPSA remission (SPIRIT-P1 Q4W: 15.9; Q2W: 24.3; PBO: 4.7; SPIRIT-P2 Q4W: 14.8; Q2W: 7.3; PBO: 0.8), PASDAS LDA (SPIRIT-P1 Q4W: 42.1; Q2W: 50.5; PBO: 18.9; SPIRIT-P2 Q4W: 39.3; Q2W: 35.0; PBO: 6.8), and PASDAS VLDA (SPIRIT-P1 Q4W: 11.2; Q2W: 20.4; PBO: 1.9; SPIRIT-P2 Q4W: 13.1; Q2W: 7.3; PBO: 0.0) was greater with Q4W and Q2W versus placebo.

Similarly, at Wk 52 the response rates were either sustained or improved: MDA (SPIRIT-P1 Q4W: 39.3; Q2W: 36.9; SPIRIT-P2 Q4W: 34.4; Q2W: 23.6), MDA VLDA (SPIRIT-P1 Q4W: 14.0; Q2W: 15.5; SPIRIT-P2 Q4W: 12.3; Q2W: 6.5), DAPSA LDA (SPIRIT-P1 Q4W: 30.8; Q2W: 29.1; SPIRIT-P2 Q4W: 34.4; Q2W: 26.0), DAPSA remission (SPIRIT-P1 Q4W: 22.4; Q2W: 29.1; SPIRIT-P2 Q4W: 18.9; Q2W: 11.4), PASDAS LDA (SPIRIT-P1 Q4W: 43.0; Q2W: 50.5; SPIRIT-P2 Q4W: 45.1; Q2W: 30.9), and PASDAS VLDA (SPIRIT-P1 Q4W: 17.8; Q2W: 26.2; SPIRIT-P2 Q4W: 17.2; Q2W: 11.4).

Conclusions: Regardless of previous TNFi exposure, a higher proportion of IXE-treated pts achieved MDA and MDA VLDA, DAPSA LDA and DAPSA remission, and PASDAS LDA and PASDAS VLDA at Wk 24 versus placebo. At Wk 52, the extent of IXE clinical response sustained or further improved.

Reference:

1. Mease PJ et al. *Ann Rheum Dis*. 2017;76(1):79-87. 2. Nash P et al. *Lancet*. 2017;389(10086):2317-2327.

P035

THE MACROPHAGE MODULATOR MP1032 SHOWS SAFETY AND EFFICACY IN A HUMAN PHASE IIA STUDY FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS

Petra Schulz, Astrid Kaiser, David Kosel, Sara Schumann, Wolfgang Brysch

MetrioPharm GmbH, Berlin, Germany

Introduction: MP1032 belongs to a new class of anti-inflammatory drugs that modulate the redox state of activated macrophages. MP1032 attenuates pro-inflammatory cytokine secretion *in vivo* and *in vitro* and has pronounced disease-modifying effects in various preclinical models.

Objectives: This randomized, double-blind, parallel, and placebo-controlled trial aimed to evaluate pharmacokinetics, safety, and efficacy of orally administered MP1032 in patients with moderate-to-severe plaque psoriasis.

Methods: Forty-six patients with chronic plaque psoriasis (PASI > 10; disease duration ≥ 6 months) were equally randomized to

receive either 100 mg MP1032 or placebo by twice daily oral administration. The study design consisted of a 42 day treatment period with a follow-up of 28 days. Pharmacokinetic sampling occurred on day 1 at 15, 30, 60, and 120 min post-dose. Adverse events were coded according to the Medical Dictionary for Regulatory Activities. Efficacy parameters were assessed at screening and on day 1, 15, 29, 43, 57, and 71.

Results: Enrolled patients had an average age of 40 years (21–65 years) and a median baseline PASI of 13.6 (ranging from 10.1 to 40.8). Pharmacokinetic evaluation demonstrated that MP1032 was rapidly absorbed, reaching maximum plasma concentrations within 15 min after administration. Then, MP1032 plasma levels were quickly declining, indicating a fast elimination. Safety analysis did not reveal any clinically important safety issues. No serious adverse events or deaths were reported and the incidence of treatment emergent adverse events (TEAEs) between placebo and the MP1032 treatment group was comparable. The majority of TEAEs were mild to moderate in nature (mostly common cold, headache, and itching). Analysis of clinical laboratory data and vital signs did also not reveal any adverse effects of MP1032. After only six weeks of treatment, MP1032 led to a PASI reduction of about 25% in patients who entered the study with a PASI of 10–15. In contrast, placebo administration reduced the respective PASI only about 12%. During the four-week follow-up period, median PASI scores in the MP1032 group trended back upward while the placebo group remained unchanged, suggesting a positive therapeutic effect of MP1032. Since, patients with a lower basal PASI had greater improvements during therapy than those with higher scores, MP1032 seems to be a treatment option for patients with mainly moderate psoriasis.

Conclusion: After six weeks of treatment, there was a clinically relevant response in patients who entered the study with PASI scores of 10–15. Overall, MP1032 demonstrated an excellent safety profile and was well tolerated. Hence, redox modulation targeted at the innate immune response represents a promising new therapeutic mechanism for psoriasis and other chronic inflammatory diseases.

P036

SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 STUDY, FUTURE 5

Philip J. Mease¹, D van der Heijde², R Landewé³, S Mpfu⁴, P Rahman⁵, H Tahir⁶, A Singhal⁷, S Navarra⁸, E Boettcher⁸, X Zhu¹⁰, A Readie¹⁰, L Pricop¹⁰, K Abrams¹⁰

¹Swedish Medical Center and University of Washington, Seattle, WA, USA,

²Leiden University Medical Center, Leiden, ³University of Amsterdam and Atrium Medical Center, Amsterdam, the Netherlands, ⁴Novartis, Pharma AG, Basel, Switzerland, ⁵Memorial University, Newfoundland and Labrador, Canada, ⁶Whipps, Cross Hospital, London, UK, ⁷Southwest Rheumatology, Dallas, TX, USA, ⁸Rheumazentrum Favoriten, Vienna, Austria, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Introduction/Objectives: Secukinumab (SEC), a fully human mAb to IL-17A, has shown efficacy in psoriatic arthritis (PsA). Here we present the primary results of FUTURE 5, assessing efficacy, including inhibition of radiographic progression of subcutaneous (sc) SEC 300 and 150mg in patients (pts) with PsA (1).

Methods: Pts ($n = 996$) with active PsA, were randomized (2:2:2:3) to sc SEC 300mg with loading dosage (LD; $n = 222$), 150mg with LD ($n = 220$), 150mg without LD ($n = 222$), or placebo (PBO; $n = 332$). All groups received SEC or PBO at baseline (BL). Weeks (Wks) 1, 2, 3, and 4, and then every 4 wks. Primary endpoint was ACR20 at Wk16. Key secondary endpoint was radiographic structural progression, as measured by modified total van der Heijde Sharp score (mTSS).

Results: SEC significantly improved ACR20 at Wk16 vs PBO

(Table). Radiographic progression (mTSS) was significantly inhibited at Wk24 in all SEC arms vs PBO (Table). A greater proportion of pts had no radiographic progression (change from BL in mTSS ≤ 0.5) with SEC vs PBO: 88% (300mg), 79% (150mg), 83% (150mg without LD), and 73% (PBO). Results for other secondary endpoints are shown in Table. No unexpected safety signals were reported.

Conclusions: Subcutaneous SEC 300 mg with LD and 150 mg with and without LD provided rapid and clinically significant improvements in the signs and symptoms of PsA and inhibited radiographic progression. Safety profile was consistent with that previously reported.

Reference:

1. Mease PJ, et al. *Arthritis Rheumatol.* 2017;69(suppl 10).

Table

| Wk 16 data(a) | 300 mg | 150 mg | 150 mg without LD | PBO |
|----------------------------|---------------|-------------------|-------------------|----------|
| ACR20(b) | 62.6*** | 55.5*** | 59.5*** | 27.4 |
| mTSS(c) | 0.08* | 0.17 [^] | -0.09* | 0.5 |
| PASI 75/90(b,d) | 70***/53.6*** | 60***/36.8*** | 58.1***/31.6*** | 12.3/9.3 |
| HAQ-DI(c) | -0.6*** | -0.4*** | -0.5*** | -0.2 |
| Enthesitis resolution(b,e) | 55.7** | 54.6** | 41.9 | 35.4 |
| Dactylitis resolution(b,e) | 65.9*** | 57.5** | 56.3 | 32.3 |
| DLQI(c,d) | -8.5*** | -7.4*** | -7.0*** | -2.4 |
| mNAPSI(c,f) | -9.2*** | -9.3*** | -7.7*** | -2.5 |

*** $P < 0.0001$; ** $P < 0.001$; * $P < 0.01$; [^] $P < 0.05$ un-adjusted P -values vs PBO. (a)Wk24 data for mTSS; (b)% responders; (c)mean change from BL; (d)Data from pts with BL psoriasis $\geq 3\%$ body surface area; (e)Data from pts with dactylitis or enthesitis at BL; (f)Data from pts with nail psoriasis at BL.

P037

INCIDENCE OF INFLAMMATORY BOWEL DISEASE IN PATIENTS TREATED WITH SECUKINUMAB: POOLED ANALYSIS OF 21 RANDOMISED CONTROLLED PHASE 3/4 CLINICAL TRIALS OF PSORIASIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS

Stefan Schreiber¹, Jean-Frederic Colombel², Brian G Feagan³, Kristian Reich⁴, Atul Deodhar⁵, Iain B McInnes⁶, Brian Porter⁷, Ayan Das Gupta⁸, Luminita Pricop⁷, Todd Fox⁹

¹Department of Internal Medicine, University Hospital Schleswig-Holstein, Kiel, Germany, ²Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA, ³Robarts Clinical Trials Inc., Department of Epidemiology and Biostatistics, Department of Medicine, Division of Gastroenterology, University of Western Ontario, London, Ontario, Canada, ⁴Dermatologikum Hamburg and Georg-August-University, Göttingen, Germany, ⁵Oregon Health & Science University, Portland, OR, USA, ⁶Institute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ⁸Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁹Novartis Pharma AG, Basel, Switzerland

Introduction: Inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) are common comorbidities associated with psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Compared with the general population, epidemiological studies have shown that patients (pts) with psoriasis or PsA are at a 2–4-fold increased risk of developing CD and a 2–3-fold increased risk of developing UC. 1–5 Additionally, in pts with AS, there is a 3–5-fold increased risk of IBD compared with the general population. 6 Secukinumab is a fully human monoclonal antibody that neutralizes interleukin-17A and is approved for the treatment of psoriasis, PsA, and AS.

Objectives: To evaluate the incidence of IBD, CD, and UC in pts with psoriasis, PsA, or AS who received IL-17A-inhibition with secukinumab from 21 phase 3/4 clinical trials of secukinumab for psoriasis, PsA, or AS.

Methods: This analysis evaluated pooled data from fourteen phase 3 and one phase 4 psoriasis trials, three phase 3 PsA trials, and three phase 3 AS trials. Pts with a history of IBD, but not active ongoing IBD, were eligible for enrollment in these trials. Data from all pts that received at least one dose of secukinumab were included in this analysis. IBD reporting includes cases of CD, UC, and IBD not otherwise specified (NOS).

Results: A total of 7355 pts receiving secukinumab were assessed for the presence of IBD: 5181 with psoriasis, 1380 with PsA, and 794 with AS. Over the entire treatment period, the mean total exposure to secukinumab was 10,416.9 patient-years (pt-yrs) in pts with psoriasis, 3866.9 pt-yrs in pts with PsA, and 1943.1 pt-yrs in pts with AS. The exposure-adjusted incidence rate (EAIR) per 100 pt-yrs (95% confidence interval) of CD, UC, and IBD NOS in secukinumab-treated pts were 0.05 [0.02, 0.11], 0.13 [0.07, 0.23], and 0.01 [0.00, 0.05], respectively in the psoriasis studies; 0.08 [0.02, 0.23], 0.08 [0.02, 0.23], and 0.05 [0.01, 0.19], respectively in the PsA studies; and 0.4 [0.2, 0.8], 0.2 [0.1, 0.5], and 0.1 [0.0, 0.3], respectively in the AS studies. Additionally, the incidence of IBD, CD, and UC did not increase over time.

Conclusion: Pooled data from 21 studies indicated that the observed exposure-adjusted incidence rates of IBD, CD, and UC with secukinumab were low and did not increase over time in pts with moderate to severe plaque psoriasis, PsA, or AS.

References:

1. Augustin M, et al. *Acta Derm Venereol.* 2010;90(2):147-51
2. Cohen AD, et al. *J Eur Acad Dermatol Venereol* 2009;23:561-5.
3. Egeberg A, et al. *Br J Dermatol.* 2016;175(3):487-92. 4. Li WQ, et al. *Ann Rheum Dis.* 2013;72(7):1200-5.
5. Makredes M, et al. *J Am Acad Dermatol.* 2009;61(3):405-10.
6. Stolwijk C, et al. *Ann Rheum Dis.* 2015;74(7):1373-8; 6. Stolwijk C, et al. *Ann Rheum Dis.* 2015;74(7):1373-8.

P038

ANALYSIS OF THE POSITION OF THE FUMARIC ACID ESTERS IN CURRENT EUROPEAN PSORIASIS GUIDELINES

Cecilia Dietrich¹, Adria Gual², Laura Padulles²

¹Dermatologikum Hamburg, Germany, ²Almirall S.A., Barcelona, Spain

Introduction: Since 1994 a combination of fumaric acid esters (FAEs) (dimethylfumarate [DMF] plus three salts of monoethylfumarate [MEF]) has been approved in Germany for moderate-to-severe psoriasis, however is not widely licensed elsewhere. While a new formulation of DMF has been recently approved by the European Commission (June 2017) as monotherapy for adults with moderate-to-severe psoriasis, only UK (NICE) guidelines mention DMF to date.[1]

Method: Current treatment guidelines for plaque psoriasis in several European countries are reviewed to determine if these guidelines include therapy with FAEs and how these may guide the use of DMF monotherapy in the future.

Results: FAE status varies across Europe. Current European guidelines recommend FAEs for the initial and long-term treatment of psoriasis. These guidelines (based on consensus/expert opinion) also recommend a gradual increase in dose.[2] Country-specific guidelines vary in their individual recommendations. German guidelines endorse FAEs as 1st-line treatment for moderate-to-severe psoriasis, based on BSA $> 10\%$ or a PASI score of > 10 , and recommend clinical assessments after 16–24 weeks of treatment.[3] UK guidelines approve FAEs only as a 2nd-line option for severe plaque psoriasis (PASI ≥ 10 or DLQI ≥ 10),[1] whilst in the Netherlands FAEs are indicated only for initial treatment of moderate-to-severe disease.[4] Swiss guidelines also recommend the use of FAEs for moderate-to-severe psoriasis, but only in patients who are unresponsive to topical therapy.[5] In Sweden, FAEs can be considered as a 2nd-line treatment option.[6] Other country-specific guidelines are less clear. While Spanish guidelines discuss FAEs as a slower-acting therapy requiring treatment goals to be set at week 16, no specific guidance on the use of FAEs is given.[7] Likewise, while Italian guidelines mention FAEs, they are not included in treatment recommendations as they are currently not licensed in Italy.[8] In contrast, there is no mention of FAEs in guidelines in Denmark, Portugal and Norway. **Conclusion:** European guidelines recommend FAEs for both the

initial and long-term treatment of moderate-to-severe psoriasis. In Germany, FAEs have been licensed for > 20 years and are commonly used as 1st-line therapy. In the rest of Europe, there is growing acceptance of FAEs as a systemic therapy option in moderate-to-severe disease. Guidelines continue to evolve as experience grows outside Germany, and will need to be updated to guide the use of the newly approved DMF monotherapy in future.

References:

1. NICE 2017. <https://www.nice.org.uk/guidance/TA475>
2. Nast A, et al. JEADV 2015;29:2277-94
3. Nast A, et al. 2017 <https://bit.ly/2ESJhv3>
4. Zwegers J, et al. 2014 <https://bit.ly/2GtvwA2>
5. Kolios AG, et al. Dermatol 2016. 232:385-406
6. Krogstad A. Psoriasis 2017 <https://bit.ly/2F05vbh>
7. Dauden E, et al. JEADV 2016;30 Suppl 2:1-18
8. Gisondi P, et al. JEADV 2017;31(5):774-790

P039

SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3

Laura C Coates¹, Dennis McGonagle², Georg Schett³, Philip J Mease⁴, Erhard Quebe-Fehling⁵, Darren L Asquith⁶, Lawrence Rasouliyan⁷, Shephard Mpofu⁵, Corine Gaillez⁵

¹University of Oxford, Oxford, UK, ²University of Leeds, Leeds, UK, ³University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Swedish Medical Centre and University of Washington, Seattle, USA, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals UK Ltd., Camberley, UK, ⁷RTI Health Solutions, Barcelona, Spain

Introduction: Enthesitis, one of the key features of psoriatic arthritis (PsA), shows chronicity in 50–70% of affected patients (pts). 1 Secukinumab (SEC), a fully human monoclonal antibody that selectively neutralises IL-17A, provided significant and sustained improvement in the signs and symptoms of active PsA, with sustained resolution of enthesitis in Phase 3 studies. 2,3

Objectives: To evaluate the effect of SEC on resolution of enthesitis count (EC; defined by Leeds Enthesitis Index) in PsA pts using pooled data from two Phase 3 studies, FUTURE 2 (NCT01752634) and FUTURE 3 (NCT01989468).

Methods: SEC and placebo (PBO) were administered weekly during the first 4 weeks (wks) followed by subcutaneous maintenance dosing every 4 weeks thereafter (PBO until Wk 16/24). The results are reported only for SEC 300 and 150 mg (approved doses). Pts with baseline (BL) enthesitis (BLE) or without BLE (No BLE) were included. Evaluation through Wk 104 included: time to first resolution of enthesitis (i.e. EC = 0); shift analysis of BL EC (1, 2 or 3–6) to full resolution (FR) and partial resolution (PR; reduction of EC) at Wks 24 and 104; and number of new enthesitis sites developed in No BLE pts. Data are as observed in the overall population; time to first resolution of enthesitis was analysed in the overall population and by prior use of tumour necrosis factor inhibitor (TNFi-naïve and -inadequate responders [IR]).

Results: A total of 466 pts had BLE with a mean EC of 3.1±1.6, and 246 pts had no BLE. Median days to resolution of EC in BLE pts for SEC 300, 150 mg and PBO groups were 57, 85 and 167 in overall population; 57, 85 and 120 in TNFi-naïve pts; and 92, 82 and 169 in TNFi-IR pts, respectively. In pts with BL EC = 1/2, 72%/61% (SEC 300 mg), 71%/66% (SEC 150 mg) and 45%/44% (PBO), respectively, achieved FR at Wk 24, with FR in SEC groups sustained or increased to 77%/81% (SEC 300 mg) and 75%/88% (SEC 150 mg) at Wk 104. In BL EC = 3–6, 81% (SEC 300 mg), 73% (SEC 150 mg) and 71% (PBO) of pts achieved FR and PR at Wk 24, with an increase of FR and PR to 88% (in both SEC 300 and 150 mg) at Wk 104. A total of 89% of pts with No BLE did not develop enthesitis by Wk 104.

Conclusions: Time to resolution of enthesitis was earlier with SEC than PBO in the overall population, with faster resolution observed

in TNFi-naïve than TNFi-IR pts. Majority of SEC-treated pts with BL EC = 1/2 had FR by Wk 24, with further an improvement by Wk 104. In pts with BL EC = 3–6, greater improvement was observed with SEC 300 mg vs PBO in the proportion of pts with FR and PR of enthesitis at Wk 24; further improvements were observed in both SEC groups at Wk 104.

References:

1. Schett G, et al. Nat Rev Rheumatol. 2017;13:731–41.
2. Mease PJ, et al. N Engl J Med. 2015;373:1329–39.
3. McInnes IB, et al. Lancet 2015;386:1137–46.

P041

LONG-TERM SAFETY OF ADALIMUMAB (HUMIRA) IN ADULT PATIENTS FROM GLOBAL CLINICAL TRIALS ACROSS MULTIPLE INDICATIONS: AN UPDATED ANALYSIS IN 29,987 PATIENTS REPRESENTING 56,951 PATIENT-YEARS

Gerd R. Burmester¹, Remo Panaccione², Kenneth B. Gordon³, James Rosenbaum⁴, Dilek Arikan⁵, Winnie L. Lau⁵, Rita Tarzynski-Potempa²

¹Charité - University Medicine Berlin, Berlin, Germany, ²University of Calgary, Calgary, AB, Canada, ³Medical College of Wisconsin, Milwaukee, WI, USA, ⁴Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR, USA, ⁵AbbVie Inc., North Chicago, IL, USA

Introduction: Adalimumab is an anti-tumour necrosis factor- α (TNF- α) agent indicated for the treatment of immune-mediated diseases. The long-term safety of adalimumab was previously reported in 23,458 patients representing up to 12 years of clinical trial exposure in rheumatoid arthritis (RA), juvenile idiopathic arthritis, ankylosing spondylitis (AS), psoriatic arthritis (PsA), plaque psoriasis (Ps), and Crohn's disease (CD).

Objectives: Here we report an updated analysis examining the long-term safety of adalimumab in adult patients with RA, AS, non-radiographic axial spondyloarthritis (nr-axSpA), peripheral SpA (pSpA), PsA, Ps, hidradenitis suppurativa (HS), CD, ulcerative colitis (UC), and non-infectious uveitis (UV).

Methods: Safety data from 78 clinical trials of adalimumab (RA, 33; AS, 5; nr-axSpA, 2; pSpA, 1; PsA, 3; Ps, 13; HS, 3; CD, 11; UC, 4; UV, 2; other, 1) were included in these analyses, including randomized controlled, open-label, and long-term extension studies conducted in Europe, North America, South America, Asia, Australia, New Zealand, and South Africa through December 31, 2016. Adalimumab postmarketing surveillance data were not included in this analysis. Safety assessments included all adverse events (AEs) and serious AEs (SAEs) that occurred after the first adalimumab study dose and up to 70 days (5 half-lives) after the last study dose.

Results: This analysis included 29,987 patients, representing 56,951 patient-years of exposure. The majority of adalimumab exposure was in RA studies (37,106 PYs). The most frequently reported SAE of interest was infection (highest incidences in CD: 6.9, UV: 4.1, RA: 3.9, and UC: 3.5). The overall standardized mortality ratio was 0.65, 95% CI [0.5, 0.74]. For most of the adalimumab populations (AS, PsA, Ps, UC, CD, and RA), the observed number of deaths was below what would be expected in an age- and sex-adjusted population. For HS, nr-axSpA, pSpA, and UV studies, the small size of these trials precluded accurate assessment of the standardized mortality ratio, and the 95% CIs all included 1.0.

Conclusion: This analysis of data from clinical trials of adalimumab demonstrated an overall safety profile consistent with previous findings and with the TNF inhibitor class. No new safety signals or tolerability issues with adalimumab treatment were identified and, for most indications, the mortality rate was below what would be expected in an age- and sex-adjusted population. Efficacy and safety data continue to support the well-established benefits of adalimumab for the approved indications.

Previously Published Arthritis Rheumatol. 2017; 69 (suppl 10).

P042**CLINICAL RESPONSE AFTER GUSELKUMAB TREATMENT AMONG ADALIMUMAB PASI 90 NON-RESPONDERS: RESULTS FROM THE VOYAGE 1 AND 2 TRIALS**

Christopher Griffith¹, Marc Alexander Radtke², Sang Woong Youn³, Robert Bissonnette⁴, Michael Song⁵, Yasmine Wasfi⁵, Bruce Randazzo⁵, Yin You⁵, Yaung-Kaung Shen⁵, Bruce Strober⁶

¹Dermatology Centre, Salford Royal Hospital, University of Manchester, UK, ²Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany, ³Seoul National University College of Medicine, Bundang Hospital, Seongnam City, South Korea, ⁴Innovaderm Research, Montreal, QC, Canada, ⁵Janssen Research & Development, LLC, Spring House, PA, USA, ⁶University of Connecticut Health Center, Farmington, Connecticut and Probit Medical Research, Waterloo, Ontario, Canada

Objective: To evaluate the levels of response to guselkumab (GUS) among adalimumab (ADA) PASI 90 non-responders in the VOYAGE 1 and VOYAGE 2 trials.

Materials/Methods: In VOYAGE 1 ($n=837$), patients were randomized to GUS 100 mg at Weeks (Wks) 0/4/12, then every 8 wks; placebo (PBO) at Wks 0/4/12 followed by GUS 100 mg at Wks 16/20 and then every 8 wks; or ADA 80 mg at Wk 0, 40 mg at Wk 1, and 40 mg every 2 wks through Wk 47. In VOYAGE 2 ($n=992$), patients were randomized to GUS 100 mg at Wks 0/4/12/20; PBO at Wks 0/4/12 then GUS 100 mg at Wks 16/20; or ADA 80 mg at Wk 0, 40 mg at Wk 1, and then every 2 wks through Wk 23. ADA PASI 90 non-responders initiated GUS at Wk 52 (VOYAGE 1) or at Wk 28 (VOYAGE 2) and continued GUS treatment through Wk 100. Here we report PASI 100, PASI 90, IGA 0 (cleared) and IGA 0/1 (cleared/minimal disease), Dermatology Quality of Life Index (DLQI), and Psoriasis Symptom and Sign Diary (PSSD) outcomes among these ADA PASI 90 non-responders after initiating GUS treatment through Wk 100.

Results: In VOYAGE 1, among 138 ADA-treated PASI 90 non-responders who initiated GUS treatment at Wk 52, a PASI 90 response was achieved by 75.0% of patients at Wk 76, and 72.6% of patients at Wk 100. At Wk 100, 78.5% of patients achieved an IGA 0/1 response, 74.8% of patients reported a DLQI 0/1 score, 33.3% of patients reported a PSSD symptom score of 0, and 18.9% reported a PSSD sign score of 0. In VOYAGE 2, among 112 ADA-treated PASI 90 non-responders who initiated GUS at Wk 28, a PASI 90 response was achieved by 66.1% of patients at Wk 48 and 75.5% of patients at Wk 100. At Wk 100, 81.0% of patients achieved an IGA 0/1 response, 65.3% of patients reported a DLQI 0/1 score, 32.6% of patients reported a PSSD symptom score of 0, and patients 18.0% reported a PSSD sign score of 0.

Conclusions: Among ADA PASI 90 non-responders, GUS treatment provided robust levels of efficacy, which were maintained through Wk 100.

P043**CONSISTENCY OF RESPONSE BY WEIGHT ACROSS SUBGROUPS OF PATIENTS WITH PSORIASIS TREATED WITH GUSELKUMAB: RESULTS FROM THE VOYAGE 1 AND 2 TRIALS**

Kim Papp¹, Jeffrey Crowley², Diana Rubel³, Ian Landells⁴, Michael Song⁵, Yasmine Wasfi⁵, Yin You⁵, Yaung-Kaung Shen⁵, Diamant Thaci⁶

¹Clinical Research and Probit Research, Inc., Waterloo, Ontario, Canada, ²Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA, USA, ³Woden Dermatology, Phillip ACT 2606, Australia, ⁴Nexus Clinical Research, St. John's Newfoundland, CA, ⁵Janssen Research & Development, LLC, Spring House, PA, USA, ⁶Universitätsklinikum Schleswig-Holstein-Lubeck, Germany

Objective: To evaluate the consistency of response of guselkumab (GUS) across predetermined weight quartile subgroups of psoriasis patients.

Materials/Methods: In VOYAGE 1 ($n=837$) and VOYAGE 2 ($n=992$), patients were randomized to GUS 100 mg at Weeks 0/4/12/20; placebo (PBO) at Weeks 0/4/12 followed by GUS 100 mg at Weeks 16/20; or ADA 80 mg at Week 0, 40 mg at Week 1, and 40 mg every 2 weeks through Week 23. The co-primary endpoints were the proportions of GUS vs PBO patients achieving: 1) $\geq 90\%$ improvement in PASI score (PASI 90), and 2) cleared/minimal disease (IGA 0/1) responses at Week 16. Response rates across endpoints were evaluated for predetermined subgroups by baseline weight quartiles.

Results: Pooled data from the two studies at Week 16 and Week 24 demonstrated that patients in the guselkumab group achieved substantially higher clinical responses compared with placebo at Week 16 and ADA at Week 24 across all quartiles of weight as cutoffs. At Week 16, for each quartile, defined by <74.6 , ≥ 74.6 – <86.4 , ≥ 86.4 – <100 , and ≥ 100 kg, the proportions of GUS patients with a PASI 90 response were 76.0%, 78.6%, 66.2%, and 65.2%, respectively and the proportions with an IGA 0/1 response were 89.1%, 88.6%, 78.7%, and 82.6%, respectively. The proportions of PBO patients with a PASI 90 response by these quartiles were 5.0%, 2.9%, 1.2%, and 0.9%, respectively and the proportions with an IGA 0/1 response were 11.6%, 10.5%, 4.9%, and 3.5%, respectively.

At Week 24, the proportions of GUS patients with a PASI 90 response by weight quartile were 79.7%, 81.1%, 75.1%, and 73.4%, respectively and the proportions with an IGA 0/1 response were 85.9%, 88.1%, 83.1%, and 78.3%, respectively. The proportions of ADA patients with a PASI 90 response by these quartiles were 62.4%, 66.0%, 52.7%, and 35.5%, respectively and the proportions with an IGA 0/1 response were 70.9%, 76.5%, 61.1%, and 45.2%, respectively.

Conclusions: The efficacy of GUS treatment was demonstrated across all predefined weight quartiles and high efficacy responses were observed in psoriasis patients without regard to weight.

P044**IMPACT OF CLINICAL SPECIALTY SETTING ON DISEASE MANAGEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS**

Wolf-Henning Boehncke¹, Rudolf Horváth², Ediz Dalkılıç³, Sónia A. L. Lima⁴, Masato Okada⁵, Maja Hojnik⁶, Fabiana Ganz⁷, Ennio Lubrano⁸

¹Geneva Univ. Hospitals and Univ. of Geneva, Geneva, Switzerland, ²Univ. Hospital Motol, Prague, Czech Republic, ³Uludağ Univ. Sch. of Med., Gorukle, Bursa, Turkey, ⁴ABC Med. Sch., Santo André, Brazil, ⁵St. Luke's International Hospital, Tokyo, Japan, ⁶AbbVie, Ljubljana, Slovenia, ⁷AbbVie AG, Baar, Switzerland, ⁸Univ. of Molise, Campobasso, Italy

Introduction: Evidence suggests that timely and effective management can improve long-term outcomes in patients (pts) with psoriatic arthritis (PsA); however factors influencing treatment management decisions are not well understood.

Objective: To evaluate the association between the clinical specialty setting and time from inflammatory musculoskeletal symptom onset to PsA diagnosis and to different management steps in pts with a diagnosis of PsA.

Methods: LOOP is a large cross-sectional, multi-center, observational study conducted in 17 countries across Western and Eastern Europe, Latin America, and Asia. Adult pts (≥ 18 years) with a suspected or an established diagnosis of PsA routinely visiting a rheumatologist (rheum), dermatologist (derm) or non-rheum/non-derm site were eligible to participate in this study. Each enrolled patient in the study was assessed by both rheum and derm. Main endpoints assessed were time from inflammatory musculoskeletal symptom onset to PsA diagnosis, time from PsA diagnosis to first csDMARD and to first bDMARD, and time from first csDMARD to first bDMARD.

Results: Of the 1483 pts enrolled in this study, 1273 pts with a confirmed diagnosis of PsA were included in this analysis. A ma-

jority of pts were recruited by rheums (671, 52.7%), followed by derms (541, 42.5%), psychiatrists (36, 2.8%), and other specialties (25, 2.0%). PsA was first suspected by a rheum in 726 (57.0%) pts and by a derm in 541 pts (42.5%). Pt demographics and disease characteristics were mostly comparable between rheum and derm settings. Disease activity was higher in PsA pts in derm setting compared with rheum setting. The mean time from symptom onset to PsA diagnosis was 24 months (mo) in rheum setting and 1 mo longer for derms. In rheum and derm settings, the mean time from PsA diagnosis to first csDMARD were 11 and 25 mo, respectively; whereas the mean time to first bDMARD were 52 and 55 mo, respectively. The mean time from first csDMARD to first bDMARD was 42 mo for rheums; while it was 3 months shorter for derms. **Conclusion:** Although the duration from symptom onset to PsA diagnosis was similar between rheum and derm setting, there were differences in the timing of introduction of different DMARD classes. Notably, mean time to first csDMARD was significantly shorter in rheum setting. PsA pts in derm setting had significantly higher disease activity. These data lend further support to the need for rheum-derm collaborative approach to optimize management of pts with PsA.

P045

SPEED OF RESPONSE OF GUSELKUMAB COMPARED WITH ADALIMUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: RESULTS THROUGH WEEK 24 FROM THE PHASE 3, DOUBLE-BLINDED, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED VOYAGE 1 AND VOYAGE 2 TRIALS

Andrew Blauvelt¹, Stephen Tyring², Sandra Philipp³, David Adam⁴, Michael Song⁵, Yasmine Wasfi⁶, Yin You⁶, Yaung-Kaung Shen², Jerry Bagel⁶

¹Oregon Medical Research Center, Portland, OR, ²Center for Clinical Studies, Webster, TX, USA, ³Dermatology, Charité, Universitätsmedizin Berlin, Berlin, Germany, ⁴CCA Medical Research Corp. Ajax, ON, and Probit Medical Research, Waterloo, ON, Canada, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Psoriasis Treatment Center of Central NJ, East Windsor, NJ, USA

Background: VOYAGE 1 and 2 were two phase 3 double-blinded, placebo/active comparator-controlled trials evaluating guselkumab (GUS), a fully human monoclonal antibody targeting interleukin (IL)-23, compared with adalimumab (ADA) in the treatment of patients with moderate-to-severe plaque psoriasis. Here, we report speed of response results based on Psoriasis Area and Severity Index (PASI) outcomes through Week 24 from pooled VOYAGE 1 and 2 data.

Methods: In VOYAGE 1 and 2, patients with plaque psoriasis were randomized at baseline to GUS 100 mg (Weeks 0 and 4, then every 8 weeks [q8w]; pooled $n = 825$), ADA (80 mg Week 0, 40 mg Week 1, then 40 mg every 2 weeks [q2w]; pooled $n = 582$), or placebo (Weeks 0, 4, and 12, then GUS 100 mg at Weeks 16 and 20; pooled $n = 422$). Efficacy was evaluated using PASI 75, PASI 90, and PASI 100 responses (patients achieving $\geq 75\%$, $\geq 90\%$, and 100% PASI improvement from baseline, respectively) through Week 24. Median time to achieve a response was defined as the time taken for $\geq 50\%$ of the patients to ever achieve a response.

Results: Based on the pooled VOYAGE 1 and 2 data, median time to achieve a PASI 75 response was ≤ 8 weeks for both the GUS and ADA groups. However, median time to achieve a PASI 90 response was ≤ 12 weeks for GUS and ≤ 16 weeks for ADA. Median time to achieve a PASI 100 response was ≤ 24 weeks for GUS, but was not achieved for ADA. Median time to achieve any defined endpoint was not achieved for the placebo group.

Conclusions: Taken together, these results demonstrate that patients with moderate-to-severe psoriasis treated with GUS rapidly achieved high levels of response, and more efficiently and more quickly than with ADA.

P046

SAFETY OF CERTOLIZUMAB PEGOL OVER 48 WEEKS IN CHRONIC PLAQUE PSORIASIS PHASE 3 TRIALS

Andrew Blauvelt¹, Bruce Strober², Richard Langley³, Daniel Burge³, Lisa Pisenti⁵, Mohamed Yassine⁵, Sarah Kavanagh⁶, Catherine Arendt⁷, Robert Roller⁶, Mark Lebwohl⁸, Kristian Reich⁹

¹Oregon Medical Research Center, Portland, OR, ²University of Connecticut Health Center, Farmington, CT, USA, ³Dalhousie University, Nova Scotia, Canada, ⁴Demira, Inc., Menlo Park, CA, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Raleigh, NC, USA, ⁷UCB Pharma, Brussels, Belgium, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, USA, ⁹SCIderm Research Institute, Hamburg, and Dermatologikum Berlin, Germany

Introduction: The Fc-free, PEGylated, anti-tumor necrosis factor certolizumab pegol (CZP) has shown efficacy in chronic plaque psoriasis (PSO) over 48 weeks' treatment.[1,2]

Objectives: To report 48-week safety data for CZP in PSO.

Methods: Data were pooled from ongoing phase 3 trials of CZP in adults with PSO ($n = 962$): CIMPASI-1 (NCT02326298), CIMPASI-2 (NCT02326272), CIMPACT (NCT02346240). Patients (pts) had PSO ≥ 6 months (Psoriasis Area Severity Index ≥ 12 , $\geq 10\%$ body surface area affected, physician's global assessment $\geq 3/5$) and were randomized to CZP 400 mg every 2 weeks (Q2W) or 200 mg Q2W (400 mg loading dose at Weeks 0/2/4), placebo (PBO) for 16 weeks, or etanercept for 12 weeks (CIMPACT only). We present data for pts receiving ≥ 1 CZP dose during initial and/or maintenance periods with up to 48 weeks' exposure as of 20Oct2016 (CIMPASI-1), 16Aug2016 (CIMPASI-2), 05Dec2016 (CIMPACT). Adverse events (AEs) were classified using MedDRA v18.1. Incidence rates (IR) are the incidence of new cases per 100 patient-years (PY).

Results: Total CZP exposure was 730PY. 709 pts (73.7%) experienced ≥ 1 AE; IRs were similar between pts receiving CZP 200 mg Q2W and 400 mg Q2W (Table 1). Rates of serious AEs were low, including infections and infestations (Table 1). There were 4 malignancies (1 anaplastic oligodendroglioma, 2 basal cell carcinoma, 1 keratoacanthoma), 1 congestive heart failure, 1 death (motor vehicle accident) and 1 case of primary progressive multiple sclerosis, all reported in patients receiving CZP 400 mg Q2W. AE IR did not increase with exposure duration, and at Week 16 was comparable for CZP and PBO pts (Table 2).

Conclusion: CZP safety was as expected for this therapeutic class in PSO and there were no new safety signals.

References:

1. Reich K, (2017). *Skin*,1;24; 2. Augustin M, (2017). *Skin*,1;s24

Table 1 AEs and Serious AEs to Week 48

| IR/100 PY (95% CI) | | | |
|-------------------------------------|--------------------------|---------------------------------|---------------------------------|
| | All CZP ($n = 962$) | CZP 400 mg Q2W ($n = 627$) | CZP 200 mg Q2W ($n = 460$) |
| AEs | 219.6 (203.7–236.4) | 228.6 (207.8–250.9) | 221.2 (197.6–246.7) |
| Serious AEs | 9.1 (7.0–11.6) | 10.1 (7.3–13.8) | 7.6 (4.8–11.4) |
| Serious infections and infestations | 1.5 (0.8–2.7) | 1.9 (0.8–3.8) | 1.0 (0.2–2.8) |
| Active tuberculosis | 0.1 (0.0–0.8) | 0.2 (0.0–1.3) | 0 |

Table 2 AEs to Week 16

| IR/100 PY (95% CI) | | | |
|--------------------|----------------------|--------------------------|---------------------------------|
| | PBO ($n = 157$) | All CZP ($n = 692$) | CZP 400 mg Q2W ($n = 342$) |
| AEs | 342.6 (277.8–417.9) | 319.1 (289.1–351.4) | 348.3 (303.5–397.9) |
| | | | CZP 200 mg Q2W ($n = 350$) |
| | | | 292.1 (252.8–335.9) |

P047

SECUKINUMAB PROVIDES SUSTAINED MINIMAL DISEASE ACTIVITY (MDA) AND REMISSION RELATED TO DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS (DAPSA): 2-YEAR RESULTS FROM A PHASE 3 STUDY

Laura C Coates¹, Peter Nash², Tore Kristian Kvien³, Laure Gossec⁴, Philip J Mease⁵, Lawrence Rasouliyan⁶, Luminita Pricop⁷, Corine Gaillez⁸, Josef S Smolen⁹

¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, ²University of Queens-

land, Brisbane, Australia, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Pitié Salpêtrière Hospital, AP-HP, Paris, France, ⁵Swedish Medical Centre and University of Washington, Seattle, USA, ⁶RTI Health Solutions, Barcelona, Spain, ⁷Novartis Pharmaceuticals Corp., East Hanover, USA, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Medical University of Vienna, Vienna, Austria

Introduction: DAPSA and MDA are validated composite indices used in psoriatic arthritis (PsA) to measure disease activity states (1). **Objectives:** To assess the proportion of pts treated with secukinumab (SEC) reaching DAPSA remission (REM) or low disease activity (LDA) and those who reached either MDA or very low disease activity (VLDA) at Weeks (wks) 16 and 104 in the FUTURE 2 study (2).

Methods: DAPSA-REM, DAPSA-REM/LDA, MDA, and VLDA and their core components were assessed in the overall population and in pts stratified by prior anti-TNF use (TNF-Naïve/IR) and time since first PsA diagnosis (≤ 2 / > 2 years) using as observed data. **Results:** At Wk16, in the overall population, the proportion of pts treated with SEC 300/150 mg achieving remission was 14%/10% (DAPSA-REM) and 8%/6% (VLDA) and achieving LDA was 42%/44% (DAPSA-REM/LDA) and 28%/23% (MDA). A higher proportion of anti-TNF-naïve pts and pts with early diagnosis (≤ 2 years) treated with SEC achieved and sustained DAPSA-REM/LDA and MDA than in the overall population (Table). DAPSA-REM/LDA and MDA responses with SEC were sustained through Wk104.

Conclusions: In the overall population, a higher proportion of SEC treated pts at Wk16 achieved DAPSA-REM, VLDA, DAPSA-REM/LDA, and MDA than those treated with placebo with a greater number of pts achieving DAPSA-REM or LDA than VLDA or MDA, respectively. These responses were sustained through Wk104.

References:

1. Coates, Helliwell. Ann Rheum Dis 2016;75:640-43.
2. McInnes et al. Rheumatol. 2017;56:1993-2003.

Table.

| % Response | DAPSA-REM/ LDA | | DAPSA-REM/ MDA | |
|--------------|-------------------|--------------|------------------------|-------|
| | TNF-Naïve/IR | TNF-Naïve/IR | ≤ 2 / > 2 years | years |
| Wk16 300 mg | 52/22 | 34/15 | 52/40 | 43/23 |
| Wk104 150 mg | 54/27 | 32/8 | 42/45 | 21/24 |
| Placebo | 23/10 | 14/3 | 17/19 | 7/12 |
| 300 mg | 75/46 | 49/25 | 63/66 | 33/43 |
| 150 mg | 62/33 | 37/10 | 46/57 | 20/33 |

Total number of pts providing data to the analysis: secukinumab 300 mg ($n=100$), 150 mg ($n=100$) and placebo ($n=98$).

P048

PREDICTORS OF RESPONSE TO TILDRAKIZUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS

Andrew Blauvelt¹, Kristian Reich², Kim A Papp³, Stephen K Tyring⁴, Rodney Sinclair⁵, Diamant Thaci⁶, Melinda Gooderham⁷, Qing Li⁸, Nicole Cichanowitz, Carmen La Rosa⁸

¹Oregon Medical Research Center, Portland, OR, USA, ²SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, ³Probit Medical Research, Waterloo, ON, Canada, ⁴Department of Dermatology, University of Texas, Houston, TX, USA, ⁵University of Melbourne, Melbourne, VIC, Australia, ⁶University of Lübeck, Lübeck, Germany, ⁷Queens University, SKiN Centre for Dermatology and Probit Medical Research, Peterborough, and ⁸Merck & Co., Inc., Kenilworth, NJ, USA

Introduction: Efficacy of tildrakizumab (TIL), a high affinity, humanized, immunoglobulin G1κ monoclonal antibody against interleukin-23p19, has been evaluated for chronic plaque psoriasis (PsO) in 2 phase 3 randomized controlled trials.

Objective: The aim of our analysis was to determine predictors of response to TIL treatment in the 2 trials.

Methods: Patients (pts) with moderate to severe PsO were randomized in reSURFACE 1 (phase 3; NCT01722331) and

reSURFACE 2 (phase 3; NCT01729754) [1]. In Part 1 (Week [W]1–W12), pts received subcutaneous TIL 200 mg, TIL 100 mg, or placebo (PBO) at W0 and W4. Pts receiving PBO in Part 1 were rerandomized to TIL 200 mg or 100 mg in Part 2 (W12–W28). For each trial, continuous variables of mean baseline Psoriasis Area and Severity Index (PASI), body mass index (BMI), Physician's Global Assessment (PGA), and PASI component for head region as well as dichotomous variables of baseline PASI > 20 or ≤ 20 and PASI 50 response or nonresponse at W8 were evaluated as predictors of response. Response was defined in this analysis as PASI 50 or PASI 90 at W12 and W28.

Results: None of the continuous variables appeared to be consistently predictive of PASI 50 or PASI 90 response, nor were baseline PASI > 20 or ≤ 20 definitive predictors of response. PASI 50 response vs nonresponse at W8 with TIL 200 mg appeared to be predictive of a PASI 50 response at W12 (percentage of patients \pm SD: 98% \pm 0.9% vs 59% \pm 6.1%, respectively, in reSURFACE 1, and 99% \pm 0.8% vs 57% \pm 5.7%, respectively, in reSURFACE 2) and of a PASI 90 response at W12 (47% \pm 3.3% vs 0% \pm 0%, respectively, in reSURFACE 1, and 50% \pm 3.3% vs 5% \pm 2.6%, respectively, in reSURFACE 2). The percentage of patients with PASI 50 response vs nonresponse at W8 with TIL 200 mg who achieved PASI 50 by W28 was 99% \pm 0.6% vs 90% \pm 3.8%, respectively, in reSURFACE 1, and 99% \pm 0.8% vs 86% \pm 4.0%, respectively, in reSURFACE 2; the percentage who achieved PASI 90 by W28 was 70% \pm 3.1% vs 23% \pm 5.4%, respectively, in reSURFACE 1, and 70% \pm 3.1% vs 21% \pm 4.7%, respectively, in reSURFACE 2. Similar trends in predictive responses were observed with TIL 100-mg treatment.

Conclusions: Achievement of PASI 50 by W8 was predictive of a PASI 50 and PASI 90 response at W12 and W28. Most of the patients who had not achieved PASI 50 by W8 were able to achieve a PASI 50 response by W28. Baseline PASI score, PGA, and BMI were not predictive of PASI 50 or PASI 90 response.

Reference:

1. Reich K, et al. Lancet. 2017;390:276–288.

Acknowledgements: The studies were funded by Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Analyses were presented at the American Academy of Dermatology Annual Meeting, February 16–20, 2018, San Diego, CA, USA.

P049

LONG-TERM EFFICACY OF GUSELKUMAB TREATMENT AFTER DRUG WITHDRAWAL AND RETREATMENT IN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS: RESULTS FROM VOYAGE 2

Kenneth Gordon¹, April Armstrong², Peter Foley³, Yasmine Wasfi⁴, Michael Song⁴, Yaung-Kaung Shen⁴, Shu Li⁴, Ernesto J Muñoz-Ellías⁴, Bruce Randazzo⁴, Kristian Reich⁵

¹Medical College of Wisconsin, Milwaukee, WI, ²University of Southern California, Los Angeles, CA, USA, ³The University of Melbourne, St. Vincent's Hospital, Melbourne and Skin & Cancer Foundation Inc., Carlton, VIC, Australia, ⁴Janssen Research & Development, LLC, ⁵Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany

Objective: To report long-term efficacy of guselkumab (GUS) after drug withdrawal and retreatment in patients with moderate-severe psoriasis (PsO) in the Phase 3 VOYAGE 2 study.

Methods: At Wk28, patients initially randomized to GUS who achieved a PASI90 response were re-randomized to either PBO/withdrawal (with retreatment upon loss of $\geq 50\%$ PASI improvement achieved at Wk28 or at Wk72 if retreatment criteria were not met) or continued GUS treatment through Wk72.

Results: Among 375 patients initially randomized to GUS who achieved a PASI90 response at Wk28, 182 were re-randomized to PBO/withdrawal and 193 to GUS/maintenance treatment. Efficacy for the continued GUS treatment group was maintained through Wk72, while responses for the withdrawal group diminished, with PASI90 responses of 86.0% vs 11.5% respectively at

Wk72. Among the 182 patients in the withdrawal arm, 117 were retreated with GUS prior to Wk72; 56 did not meet retreatment criteria and initiated retreatment at Wk72 per protocol. Of 173 patients retreated, 87.6% achieved PASI90 within 6 months of commencing retreatment. No new safety signals were observed with GUS withdrawal and retreatment through Wk100. Maintenance of PASI90 response after drug withdrawal was associated with continued suppression of IL-17A, IL-17F, & IL-22, while loss of response was associated with increased levels of these circulating cytokines.

Conclusion: Superior maintenance of high efficacy response rates was achieved with continuous GUS treatment vs withdrawal, and the majority of retreated patients achieved PASI90. Maintenance of PASI90 after drug withdrawal was associated with continued suppression of IL-17A, IL-17F, and IL-22.

P050

OUTCOMES ASSOCIATED WITH ACHIEVEMENT OF VARIOUS TREATMENT TARGETS IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING ADALIMUMAB

Josef S. Smolen¹, Daniel Aletaha¹, Dafna D. Gladman², Ying Zhang³, Fabiana Ganz⁴

¹Medical University of Vienna, Vienna, Austria, ²University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada, ³AbbVie, Inc., North Chicago, IL, USA, ⁴AbbVie, Inc., Baar, Switzerland

Background: Various instruments are currently used for disease activity and outcome assessment in psoriatic arthritis (PsA). Some measures attempt to incorporate the total spectrum of psoriatic disease manifestations [eg, minimal disease activity (MDA)] while others focus on arthritis assessments [eg, disease activity index for PsA (DAPSA)]. Whether in patients (pts) with PsA it is sufficient to primarily consider joint disease aspects remains unclear. **Objective:** To compare DAPSA remission and low disease activity (LDA) with MDA and very low disease activity (VLDA) for the presence of residual abnormalities of the respective composing variables.

Methods: This post hoc analysis included pts with PsA receiving adalimumab (ADA) in one of two multicenter studies: ADEPT was a 24-week (wk), randomized, double-blind, placebo-controlled trial; ACCLAIM was a 12-wk, open-label study conducted in Canada in care settings that reflected usual practice. Frequencies of DAPSA remission/LDA and MDA/VLDA were summarized, and the individual PsA manifestations within these states were assessed. DAPSA was summed from the following continuous variables: swollen (66) and tender (68) joints, pt global assessment (PtGA, cm), pt pain (PP, cm), and C-reactive protein (CRP, mg/dL). DAPSA remission was defined as ≤ 4 and DAPSA LDA as > 4 and ≤ 14 . MDA criteria were as follows: ≤ 1 tender, ≤ 1 swollen joint, ≤ 1 enthesal point, PP ≤ 15 mm, PtGA ≤ 20 mm, HAQ ≤ 0.5 , and PASI ≤ 3 . MDA was calculated as fulfilling 5 of the 7 criteria, and VLDA calculated as fulfilling all 7 criteria. Data were as observed.

Results: Among 151 pts receiving ADA in ADEPT, 33 (22%) each achieved DAPSA remission and LDA at wk 24, and 20 (14%) and 11 (7%) achieved MDA and VLDA, respectively. Pts achieving DAPSA LDA appeared to mirror those in MDA, with the exception of experiencing numerically higher PP, PtGA, and PASI scores at wk 24. Pts in DAPSA LDA did experience numerically lower SJC when compared with the MDA achievers, and, like MDA achievers, displayed little residual enthesitis. Only VLDA, but not MDA, could match the stringency of DAPSA remission, a finding that was confirmed through analysis of the ACCLAIM cohort. However, VLDA allowed for numerically higher residual PP and PtGA levels when compared with DAPSA remission. Importantly, residual enthesitis did not differ among pts achieving DAPSA remission or VLDA. Irrespective of disease activity assessment, pts receiving ADA displayed little to no radiographic progression.

Conclusions: In the ADEPT and ACCLAIM cohorts, pts who achieved DAPSA remission or VLDA demonstrated similar outcomes with respect to the individual components of both scores, despite the omission of several of these within the DAPSA. Given the DAPSA's continuous nature, its use may offer a good alternative to fulfillment of the VLDA criteria, but these results require confirmation in different pt populations.

Previously published Ann Rheum Dis 2017.

P051

EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)

Vinod Chandran¹, Roy Fleischmann², Eric Lespessailles³, Philip Helliwell⁴, Olivier Benichou⁵, Janelle Erickson⁶, Catherine Shuler⁵

¹Krembil Research Institute, University of Toronto, Toronto, Canada, ²Metroplex Clinical Research Center, Dallas, USA, ³University Orléans, Orléans, France, ⁴University of Leeds, UK, ⁵Eli Lilly and Company, Indianapolis, USA

Introduction: Ixekizumab (IXE), an interleukin-17A antagonist, was superior to placebo (PBO) in improving the signs and symptoms of psoriatic arthritis (PsA) at Week 24 in biologic-naïve patients (pts).

Objective: To determine the efficacy and safety of IXE treatment up to 3 years in biologic-naïve pts with PsA. **Methods:** In the SPIRIT-P1 Phase 3 trial (NCT01695239), 210 pts were randomized to IXE (80 mg every 4 [Q4W] or 2 [Q2W] weeks), 101 pts to adalimumab (active reference arm), and 106 pts to PBO at Week 0. ADA and PBO patients were re-randomized to IXE at the end of the double-blind treatment period. Ad-hoc efficacy for all pts initially randomized to IXE (intent-to-treat [ITT]) is presented. Modified non-responder imputation (missing data considered non-response for pts discontinued due to lack of efficacy or adverse events [AEs]; multiple imputation for all other missing data) was applied to efficacy response outcomes. Ad hoc safety data, for all pts who received at least one IXE dose during the trial ($n = 386$), are presented as exposure-adjusted incidence rates (IRs; number of pts with events*100 /total pt years [PY]).

Results: Efficacy results are summarized for ITT IXE-treated pts (Table 1). Improvements in ACR (American College of Rheumatology) responses, enthesitis, dactylitis, PASI (Psoriasis Area and Severity Index), and NAPS (Nail Psoriasis Severity Index) persisted up to 3 years. Safety assessments for all pts initially randomized to IXE or re-randomized to IXE during SPIRIT-P1 are summarized (Table 2). IRs of treatment-emergent AEs (TEAEs) were similar between IXE Q4W and Q2W treatment groups.

Table 1. Efficacy Outcome Measures at Week 156 (ITT IXE-Treated Population)

| | IXE Q4W (n = 107) | IXE Q2W (n = 103) |
|------------|-------------------|-------------------|
| ACR20 | 69% | 62% |
| ACR50 | 51% | 56% |
| ACR70 | 33% | 44% |
| LEI = 0a | 47% | 40% |
| LDI-B = 0b | 62% | 69% |
| PASI75c | 63% | 69% |
| PASI90c | 51% | 65% |
| PASI100c | 44% | 61% |
| NAPSI = 0d | 54% | 57% |

^aPts with Leeds Enthesitis Index (LEI) > 0 at baseline. ^bPts with Leeds Dactylitis Index-Basic (LDI-B) > 0 at baseline. ^cPts with psoriatic lesions $\geq 3\%$ of body surface area at baseline. ^dPts with fingernail psoriasis at baseline.

Table 2.

| | Total IXE Q4W (n = 195; Total PY = 450.4) | Total IXE Q2W (n = 191; Total PY = 442.1) |
|--------------------------|--|--|
| TEAEs | 169 (37.5) | 168 (38.0) |
| Serious AEs | 38 (8.4) | 23 (5.2) |
| Serious Infections | 8 (1.8) | 2 (0.5) |
| Discontinued due to AE | 17 (3.8) | 23 (5.2) |
| Death | 1a (0.2) | 0 |
| Infections | 111 (24.6) | 112 (25.3) |
| Injection-Site Reactions | 40 (8.9) | 43 (9.7) |
| Hypersensitivities | 10 (2.2) | 21 (4.7) |

^an = pts with ≥ 1 designated AE. Data presented as n (IR). For safety analyses, baseline was defined as the time of the first IXE injection. Total PYs is the total time pts were in the treatment period following the first IXE injection. aPt experienced a cerebrocardiovascular accident.

Conclusion: In pts treated with IXE, improvements in the signs and symptoms of PsA persisted up to 3 years. The safety profile was consistent with previous studies of IXE. Previously presented as Chandran et al. 2018 EULAR Congress. June 13-16th

P052

INCIDENCE OF SERIOUS GASTROINTESTINAL EVENTS AMONG TILDRAKIZUMAB-TREATED PATIENTS WITH PSORIASIS

Melinda Gooderham¹, Boni E Elewski², David M Pariser³, Howard Sofen⁴, Alan M Mendelsohn⁵, Nicole Cichanowitz⁶, Qing Li⁶, Carmen La Rosa⁶

¹Probit Medical Research, Waterloo, and Skin Centre for Dermatology, Peterborough, Canada, ²Department of Dermatology, University of Alabama at Birmingham School of Medicine, Birmingham, ³Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, ⁴Department of Medicine (Dermatology) UCLA, Los Angeles, ⁵Sun Pharmaceutical Industries, Inc., Princeton, ⁶Merck & Co., Inc., Kenilworth, USA

Introduction: Tildrakizumab is a high-affinity, humanized, immunoglobulin G1κ monoclonal antibody against interleukin-23p19 for the treatment of chronic plaque psoriasis.

Objectives: We evaluated gastrointestinal (GI) adverse events (AE) and, specifically, cases of inflammatory bowel disease (IBD; ie, Crohn's disease or ulcerative colitis) in the clinical development program for tildrakizumab.

Methods: Patients with moderate to severe plaque psoriasis were randomized in 3 large clinical trials: P05495 (phase 2; NCT01225731), reSURFACE 1 (phase 3; NCT01722331), and reSURFACE 2 (phase 3; NCT01729754) [1,2]. In this post hoc analysis, we sought to identify serious GI AEs and new-onset or exacerbation of pre-existing IBD from a pooled dataset of tildrakizumab-treated patients from these 3 trials, which followed patients up to 52 (reSURFACE 2) or 64 (reSURFACE 1) weeks. This analysis evaluated patients who received tildrakizumab 100 mg and 200 mg in P05495 and the reSURFACE trials.

Results: In this analysis, we pooled 1911 patients from the 3 trials who received either tildrakizumab 100 or 200 mg. There were no new cases of IBD reported; among 6 patients with a history of IBD randomized to tildrakizumab, none experienced an exacerbation. The numbers (rate per 100 patient-years) of patients with serious GI AEs in the pooled dataset were 8 (0.80) for tildrakizumab 100 mg and 4 (0.43) for tildrakizumab 200 mg. These serious GI AEs included abdominal pain, constipation, diverticulum, dyspepsia, gastritis, thrombosed hemorrhoids, esophageal polyp, pancreatitis (1 patient each) among patients treated with tildrakizumab 100 mg, and abdominal hernia, upper abdominal pain, acute pancreatitis, and salivary gland enlargement (1 patient each) among patients treated with tildrakizumab 200 mg.

Conclusion: In this post hoc analysis of patients from 3 large, randomized clinical trials, serious GI AEs were infrequent and there were no new cases of IBD or exacerbations of IBD.

Acknowledgements: The studies were funded by Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Reference:

1. Papp K, et al. Br J Dermatol. 2015;173:930-939. 2. Reich K, et al. Lancet. 2017;390:276-288.

P053

DURABLE REDUCTION IN ABSOLUTE PASI WITH CERTOLIZUMAB PEGOL IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS

Alice B Gottlieb¹, Andrew Blauvelt², Diamant Thaci³, Craig Leonard⁴, Yves Poulin⁵, Luke Peterson⁶, Catherine Arendt⁷, Marion Boehnlein⁸, Kristian Reich⁹

¹Department of Dermatology, New York Medical College at Metropolitan Hospital, NY, NY, ²Oregon Medical Research Center, Portland, OR, ³University

Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany, ⁴Central Dermatology and Saint Louis University School of Medicine, St. Louis, MO, ⁵Centre de Recherche Dermatologique du Québec Métropolitain, Québec, Canada, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Monheim, ⁹SCIderm Research Institute, Hamburg, and Dermatologikum Berlin, Germany

Introduction: Certolizumab pegol (CZP), an Fc-free, PEGylated, anti-tumor necrosis factor, has shown efficacy in chronic plaque psoriasis (PSO). [1,2]

Objectives: To assess the proportions of patients (pts) achieving selected PASI thresholds over 48 weeks of CZP treatment.

Methods: Data were pooled from CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272), ongoing phase 3 trials in adults with moderate to severe PSO ≥6 months (Psoriasis Area Severity Index [PASI] ≥12, ≥10% body surface area affected, physician's global assessment ≥3/5). Pts were randomized 2:2:1 to CZP 400 mg every 2 weeks (Q2W), 200 mg Q2W (400 mg loading dose [LD] at Weeks 0/2/4), or placebo (PBO). Week 16 PASI 50 responders receiving CZP continued the same dose to Week 48. We present the proportions of patients reaching PASI ≤1, 2, 3 and 5 at Weeks 16 and 48. Responder rate estimates were calculated using a logistic regression model. Pts not achieving PASI 50 at Weeks 16/32/40/48 were subsequently classed as non-responders. Other missing data were imputed using multiple imputation (Markov Chain Monte Carlo method).

Results: At Week 0, 175, 186 and 100 pts were randomized to CZP 400 mg Q2W, CZP 200 mg Q2W, and PBO. Baseline mean PASI was comparable across CZP 400 mg Q2W/CZP 200 mg Q2W/PBO pts: 19.6 (SD:7.3)/19.2 (7.2)/18.6 (6.6). At Week 16, PASI ≤1 was achieved by 39.9% pts receiving CZP 400 mg Q2W and 36.2% CZP 200 mg pts, vs 2.6% PBO pts. Similarly, a higher proportion of CZP vs PBO pts achieved PASI ≤2, PASI ≤3 and PASI ≤5 (Table). In CZP-treated pts, PASI was maintained or further reduced to Week 48, with 48.2% CZP 400 mg Q2W pts and 39.9% CZP 200 mg Q2W pts achieving PASI ≤1 after 48 weeks' treatment (Table).

Conclusions: Higher proportions of CZP vs PBO pts met absolute PASI cut-offs over 16 weeks and response was maintained or further improved to Week 48. Although durability of response was observed with both doses, higher proportions of pts treated with CZP 400 mg Q2W than 200 mg Q2W were able to reach the most stringent cut-offs at Week 48.

Reference:

1. Reich K, (2017). Skin,1;s23; 2. Augustin M, (2017). Skin,1;s24

Table. Pts achieving absolute PASI cut-offs at Weeks 16 and 48

| PASI | Week | PBO (n = 100) % (95% CI) | CZP 400 mg Q2W (n = 175) % (95% CI) | CZP 200 mg Q2W (n = 186) % (95% CI) |
|------|------|--------------------------------|---|---|
| ≤1 | 16 | 2.6% (0.0-6.2) | 39.9% (29.3-50.4) | 36.2% (26.5-45.9) |
| | 48 | - | 48.2% (37.4-59.0) | 39.9% (29.8-50.0) |
| ≤2 | 16 | 3.3% (0.0-7.0) | 54.5% (43.9-65.1) | 46.7% (36.5-56.8) |
| | 48 | - | 70.5% (60.2-80.8) | 55.9% (44.6-67.3) |
| ≤3 | 16 | 6.8% (1.0-12.5) | 70.5% (59.3-81.6) | 65.1% (53.4-76.7) |
| | 48 | - | 75.2% (65.5-85.0) | 63.7% (52.6-74.8) |
| ≤5 | 16 | 12.2% (4.3-20.1) | 83.0% (74.9-91.1) | 77.6% (68.4-86.9) |
| | 48 | - | 82.3% (74.4-90.3) | 73.1% (63.4-82.7) |

aPts received CZP 400 mg Q2W LD at Weeks 0/2/4. CI: Confidence interval.

P054

RELATIONSHIPS BETWEEN TILDRAKIZUMAB DOSE, EXPOSURE, EFFICACY AND SAFETY IN PSORIASIS PHASE 3 STUDIES

Bruce Strober¹, Howard Sofen², Paul Yamauchi³, Alan Mendelsohn⁴, Jeff Parno⁴, Simon Lowry⁴, Stephen Rozzo⁴, Boni Elewski⁵

¹UConn Health, University of Connecticut, Farmington, CT, USA; ²Probit Medical Research, Waterloo, ON, Canada, ³Ronald Reagan UCLA Medical Center, Los Angeles, CA, ⁴University of California at Los Angeles Medical Center, Santa Monica, CA, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶University of Alabama at Birmingham Hospital, Birmingham, AL, USA

Introduction: Tildrakizumab (TIL) is a high-affinity, humanized,

anti-interleukin-23p19 monoclonal antibody that demonstrated efficacy in phase 3 trials in moderate to severe chronic plaque psoriasis (reSURFACE 1 [NCT01722331] and 2 [NCT01729754]) [1]. **Objective:** Here we investigated the relationship between TIL serum concentration, and efficacy and safety outcomes, in reSURFACE 1 and 2.

Methods: Placebo or TIL 100 mg or 200 mg was administered at Weeks 0 and 4, then every 12 weeks. Endpoints included proportion of patients achieving 75% Psoriasis Area and Severity Index (PASI 75) improvement from baseline (PASI 75 responders). Pooled efficacy data for each dose from reSURFACE 1 and 2 were grouped into quartiles based on average (mean) serum TIL concentration during Weeks 0–12 (Cav12). Associations between median Cav12 for each quartile (Q) and TIL dose were analyzed for PASI 75 response at Week 12 and adverse events (AEs).

Results: TIL steady-state concentrations were achieved by Week 16 and were proportional to the dose administered. Median Cav12 (range) for TIL Q1–Q4, respectively, were 4.4 (2.1–5.2), 5.7 (5.2–6.4), 7.0 (6.4–7.8), and 8.7 (7.8–16.1) µg/mL for TIL 100 mg ($n = 616$) and 8.7 (4.2–10.4), 11.5 (10.4–12.5), 14.1 (12.5–15.5), and 17.3 (15.5–30.6) µg/mL for TIL 200 mg ($n = 622$). PASI responses were similar for corresponding quartiles across doses, with no relationship between serum concentration and patient response for Q1–Q3. Greater PASI 75 responses were associated with the highest Cav12 (Q4), particularly for TIL 100 mg where PASI 75 response rates (95% confidence intervals [CI]) were 58.4% (54.6, 62.3), 62.3% (58.4, 66.1), 59.2% (55.3, 63.1), and 73.7% (70.1, 77.0) for Q1–Q4, respectively. Corresponding PASI 75 rates (95% CIs) for patients receiving 200 mg were 52.9% (49.0, 56.8), 68.6% (64.9, 72.2), 64.5% (60.6, 68.1), and 74.8% (71.2, 78.0) over Q1–Q4. There were no associations between AE rates and serum concentrations, and incidence rates of any AE, any infections, serious infections, upper respiratory tract infections, malignancies, non-melanoma skin cancer, confirmed extended major cardiovascular events, and drug-related hypersensitivity for TIL-treated patients were similar to, or less than, for placebo-treated patients.

Conclusions: No relationship was apparent between TIL dose or Cav12 and PASI response, although the greatest response was seen for the highest serum concentration. Importantly, there were no associations between serum concentration and AE incidence. Study sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; analyses funded by Sun Pharmaceutical Industries, Inc.

Reference:

1. Reich K, et al. *Lancet*. 2017;390:276–288.

P055

LONG-TERM SAFETY AND EFFICACY OF ADALIMUMAB FROM THE PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH NAIL AND SKIN PSORIASIS

Jeff Crowley¹, Paolo Gisondi², Ziqian Geng³, Ofelia Reyes Servin³
¹Bakersfield Dermatology, Bakersfield, CA, USA, ²University of Verona, Verona, Italy, ³AbbVie Inc, North Chicago, IL, USA

Introduction: We evaluated long-term (up to 52 weeks) safety and efficacy of originator adalimumab every-other-week treatment (ADA eow) for fingernail psoriasis (Ps) in patients (pts) with moderate-to-severe Ps with substantial, clinically impactful, moderate-to-severe fingernail Ps.

Methods: In 26-week Period A, pts were randomized 1:1 to 40 mg ADA after initial 80 mg dose, or matching placebo (pbo). Period B (open-label, 26 weeks) entry criteria: completion of Period A, or $\geq 25\%$ increase from baseline in affected body surface area (BSA) at week 16. At Period B entry (week 26), Period-A pbo pts received an initial blinded dose of 80 mg ADA; all received ADA eow from weeks 27 through 51. We analyzed all pts who received

ADA throughout the 52 weeks. Efficacy is reported using multiple imputation (MI) for missing data, and as observed results.

Results: Of the 217 randomized pts, 203 received at ≥ 1 dose of ADA, 188 entered Period B, and 168 completed the trial. Of those receiving continuous ADA treatment through 52 weeks ($n = 109$), response rates (MI) for key efficacy outcomes at weeks 26 and 52, respectively, were as follows. $\geq 75\%$ improvement from baseline in modified Nail Ps Severity Index (mNAPSI 75): 47.4% and 54.5%. Physician's Global Assessment of fingernail Ps of 0 (clear) or 1 (minimal) with ≥ 2 grades improvement from baseline (PGA-F 0/1): 51.1% and 55.6%. Mean change (improvement) from baseline in nail Ps pain (numerical rating scale [NRS]): 3.6 and 3.8. Mean change (improvement) from baseline in Nail Ps Physical Functioning Severity score (NPPFS): 3.4 and 3.9. Mean change (improvement) from baseline in Dermatology Life Quality Index score (DLQI): 9.1 and 9.0 ($n = 94$).

As observed response rates at weeks 26 and 52 respectively, were as follows. mNAPSI 75: 47/88 (53.4%) and 52/80 (65.0%). PGA-F 0/1: 48/88 (54.5%) and 49/80 (61.3%). Mean change (improvement) from baseline in nail Ps pain (NRS): 3.8 ($n = 92$) and 4.4 ($n = 80$). Mean change (improvement) from baseline in NPPFS: 3.9 ($n = 92$) and 4.4 ($n = 80$). Mean change (improvement) from baseline in DLQI: 9.3 ($n = 69$) and 9.7 ($n = 65$).

Adverse events (AEs) per 100 pt years (E/100PYs; in 140.3 PYs) were: any event, 352 (250.9), serious AEs, 21 (15.0); and serious infections, 9 (6.4). AE's were similar to those observed in phase 3 clinical trials of ADA for Ps.

Conclusion: ADA treatment of nail Ps across 52 weeks demonstrated short- and long-term efficacy. No new safety signals were identified in these pts receiving ≥ 1 dose of ADA.

P056

EIGHT-YEAR INTERIM RESULTS FROM THE ESPRIT 10-YEAR POSTMARKETING SURVEILLANCE REGISTRY OF ADALIMUMAB FOR MODERATE TO SEVERE PSORIASIS

Jashin J. Wu¹, William Abramovits², Francisco Kerdel³, Dilek Arikan⁴, Dianlin Guo⁴, Hartmut Kupper⁵, Vera Kuehn⁵, Rakesh Singh⁴, Alan Fleischer⁴

¹Kaiser Permanente Los Angeles Medical Center, Los Angeles, ²Division of Dermatology, Baylor University Medical Center, Dallas, ³Florida Academic Dermatology Centers, Miami, ⁴AbbVie Inc., North Chicago, USA, ⁵AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany

Introduction: ESPRIT is a 10-year (y) international prospective observational registry evaluating the long-term safety and effectiveness of originator adalimumab (ADA) in adult patients (pts) with moderate to severe chronic plaque psoriasis.

Objectives: To determine safety, effectiveness, and pt-reported outcomes (PROs) over an 8-y period from an interim analysis of data collected from the ESPRIT registry.

Methods: ESPRIT enrolled pts who were continuing ADA treatment from a current prescription or previous study participation, or initiating ADA ≤ 4 weeks of entering the registry. The All-Treated pt population (All-Rx) received at least 1 ADA dose in this registry. Pts were evaluated at 3 and 6 months (mos) post-enrollment, and then every 6 mos for up to 10 ys. This interim analysis includes data collected from 26 Sep 2008 through 30 Nov 2016. Incidence rates (IR) for all treatment-emergent adverse events (All-TEAEs) in All-Rx pts are reported as events per 100 pt-ys (E/100PY) of overall exposure to ADA. Physician's Global Assessment (PGA) and PROs (US only) were evaluated in as-observed population (pt numbers were small at 96 mos).

Results: For the 6045 All-Rx pts enrolled and dosed in ESPRIT, median duration of overall exposure to ADA was 3.9 ys. Registry discontinuation rate in All-Rx pts was 39.4%; with the most common reason being lost to follow up (18.2%). IR (E/100PY) for All-TEAEs was: overall 22.0; serious AEs 4.5; malignancies

1.1, serious infections 1.0; non-melanoma skin cancer 0.7; active TB <0.1; and All-TEAEs leading to death 0.2. Standardized mortality ratio was 0.34 (95% CI, 0.25–0.46), indicating the observed number of deaths was below expected in an age-, sex- and country-matched population. PGA clear/minimal was achieved by 57.0%, 58.7%, 59.1%, 62.6%, 61.9%, 63.8%, 65.5%, and 45.0% of pts at 12, 24, 36, 48, 60, 72, 84, and 96 mos, respectively. In 4202 US pts, mean change from baseline in Dermatology Quality of Life Index, total work productivity impairment, and total activity impairment at 12-mo intervals were -3.1/-5.5/-8.3, -3.2/-5.4/-9.1, -3.3/-5.3/-8.4, -3.5/-5.6/-8.7, -3.9/-5.8/-9.3, -3.7/-6.3/-8.7, -5.1/-9.1/-11.4, and -5.9/-7.5/-13.8.

Conclusions: In this 8-y interim analysis, no new safety signals were observed and safety was consistent with the known safety profile of ADA. The number of TE deaths in the registry was below the expected rate. As-observed effectiveness of ADA and improvement from baseline in PROs were maintained through 96 mos.

P057

DURABILITY OF RESPONSE IN CERTOLIZUMAB PEGOL-TREATED PATIENTS OVER 48 WEEKS IN CIMPASI-1 & 2 TRIALS

Kristian Reich¹, Andrew Blauvelt², Diamant Thaçi³, Craig Leonard⁴, Yves Poulin⁵, Luke Peterson⁶, Catherine Arendt⁷, Alice B Gottlieb⁸

¹SCIderm Research Institute, Hamburg, and Dermatologikum Berlin, Germany, ²Oregon Medical Research Center, Portland, USA, ³University Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany, ⁴Central Dermatology and Saint Louis University School of Medicine, St. Louis, USA, ⁵Centre de Recherche Dermatologique du Québec Métropolitain, Québec, Canada, ⁶UCB Pharma, Raleigh, USA, ⁷UCB Pharma, Brussels, Belgium, ⁸Department of Dermatology, New York Medical College at Metropolitan Hospital, NY, USA

Introduction: Certolizumab pegol (CZP), the only Fc-free, PE-Gylated, anti-tumor necrosis factor biologic, has shown clinical improvements and a safety profile consistent with the class in adults with chronic plaque psoriasis (PSO).[1,2,3]

Objectives: To assess durability to Week 48 of the initial Week 16 clinical response with CZP in PSO patients (pts) in two identical phase 3 trials.

Methods: Data were pooled from CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272), ongoing CZP phase 3 trials in adults with PSO ≥6 months (Psoriasis Area Severity Index [PASI] ≥12, ≥10% body surface area affected, physician's global assessment [PGA] ≥3/5). Pts were randomized 2:2:1 to CZP 400 mg every two weeks (Q2W), 200 mg Q2W (400 mg loading dose [LD] at Weeks 0/2/4), or placebo (PBO). At Week 16, PASI 50 responders receiving CZP continued the same dose through the maintenance period to Week 48. PASI 50 non-responders at Weeks 32/40/48 were classed as non-responders at subsequent time points. These analyses do not include PBO pts or Week 16 PASI 50 non-responders. We report number needed to treat (NNT) to achieve PASI 75 at Week 16, and PASI 75 at Week 48 in pts who achieved PASI 75 at Week 16. Week 16 NNT, 95% confidence intervals (95% CI) and Week 48 PASI 75 responder rates were estimated using logistic regression in which missing data and patients withdrawn due to relapse (< PASI 50 during the maintenance period) were imputed using multiple imputation (Markov Chain Monte Carlo [MCMC] method). Sensitivity analyses on PASI 75 were conducted using non-responder imputation (NRI).

Results: At Week 16, NNT to achieve a PASI 75 response was 1.41 (95% CI: 1.26–1.60) for the CZP 400 mg Q2W dose group and 1.53 (1.35–1.77) for the CZP 200 mg Q2W dose group.

Of the pts randomized to CZP 400 mg Q2W and CZP 200 mg Q2W

at Week 0 who entered the blinded maintenance phase, 132/149 and 130/150 achieved PASI 75, respectively. Out of Week 16 PASI 75 responders, 98.0% of patients treated with CZP 400 mg Q2W and 87.5% of patients treated with CZP 200 mg Q2W also reported a PASI 75 response at Week 48 (Table). Sensitivity analyses using NRI showed similar trends with both doses, and similar trends were seen in PASI 90 response rates.

Conclusions: These analyses show that patients in both CZP dose groups demonstrate durability of their initial Week 16 high-level response to Week 48, with greatest durability seen in the CZP 400 mg Q2W dose group (98.0% maintenance between Weeks 16 and 48).

Reference:

1. Blauvelt A (2018). Skin, 2:s16; 2. Reich K (2017). Skin, 1;s23; 3. Augustin M (2017). Skin, 1;s24

Table: Pts achieving PASI 75 at Week 48 among Week 16 PASI 75 responders pooled for CIMPASI-1 and CIMPASI-2

| | CZP 400 mg Q2W | CZP 200 mg Q2W |
|-----------------------|------------------|-------------------|
| Week 16 responders, n | 132 | 130 |
| Week 48 responders | | |
| MCMC, % (95% CI) | 98.0% (95.6–100) | 87.5% (79.7–95.4) |
| NRI, % of Week 16 (n) | 88.6% (117) | 78.5% (102) |

aPts received 400 mg CZP LD at Weeks 0/2/4.

P058

PRIMARY EFFICACY AND SAFETY OF ADALIMUMAB IN NAIL PSORIASIS FROM THE FIRST 26 WEEKS OF A PHASE-3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH SUBANALYSIS IN PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS

Boni E. Elewski¹, Pheobe A. Rich², Frank Behrens³, Gérard Guillet⁴, Ziqian Geng⁵, Ofelia Reyes Servin⁵

¹University of Alabama at Birmingham, School of Medicine, Birmingham, AL, USA, ²Oregon Health and Science University Hospital, Portland, OR, USA, ³Goethe University Medical Center, Frankfurt, Germany, ⁴Hopital La Miletrie, Service de Dermatologie, CHU Poitiers, France, ⁵AbbVie Inc, North Chicago, IL, USA

Introduction: Psoriasis (Ps) disease burden for patients with psoriasis (Ps) and concomitant fingernail Ps plus psoriatic arthritis (PsA) is higher compared with patients with Ps alone.

Objective: We report safety and efficacy of originator adalimumab (ADA) in patients with fingernail Ps, and also for patients with or without concomitant PsA.

Methods: Results are reported from the double-blind PBO-controlled, Period A in which 217 patients with moderate to severe plaque Ps and fingernail Ps were included and randomized 1:1 to receive 40 mg ADA every other week (eow) from week 1 (initial 80mg dose at week 0), or matching PBO, for 26 weeks. The primary endpoints were the proportion of patients with ≥75% improvement in modified Nail Ps Severity Index (mNAPSI 75) and the proportion of patients with Physician's Global Assessment of Fingernail Psoriasis (PGA-F) of clear (0) or minimal (1) with ≥2-grade reduction from baseline (primary in US only; for regulatory purposes). Missing data were handled by multiple imputation. Safety was assessed using treatment-emergent adverse events (AEs).

Results: Of the 217 randomized patients (108 PBO, 109 ADA), 84.3% were male; mean age was 46.7 years; 188 (86.6%) completed 26 weeks of treatment or early escaped to Period B according to protocol. At baseline, 28.6% had PsA (29.6% PBO, 27.5% ADA) with mean duration 7.91 years [SD 8.314]. Total fingernail mNAPSI 75 was achieved by 0.5% PBO vs 61.5% ADA of patients with PsA and 4.6% PBO vs 40.9% ADA without PsA ($p < 0.001$ for both groups). PGA-F 0 or 1 with ≥2-grade reduction was achieved by 4.4% PBO vs 59.3% ADA with PsA and 7.9% PBO vs 44.9% ADA without PsA ($p < 0.001$ for both groups). Adverse

events (AEs) in Period A were reported by 55.6% PBO vs 56.9% ADA (with PsA: 56.3% PBO vs 56.7% ADA; without PsA: 55.3% PBO vs 57.0% ADA without PsA); serious AEs by 4.6% PBO vs 7.3% ADA (with PsA: 9.4% PBO vs 10.0% ADA; without PsA: 2.6% PBO vs 6.3% ADA).

Conclusions: The results demonstrated that in this population, ADA was more effective than PBO for the treatment of fingernail Ps, and significantly improved signs and symptoms, both overall and regardless of the presence or absence of PsA; no new safety risks were identified with ADA eow treatment for 26 weeks.

Previously published J Am Acad Derm. 2017. 76(6 suppl 1): AB204.

P059

CERTOLIZUMAB PEGOL IS EFFECTIVE FOR CHRONIC PLAQUE PSORIASIS ACROSS PATIENT SUBGROUPS

Kristian Reich¹, Andrew Blauvelt², Diamant Thaçi³, Craig Leonard⁴, Yves Poulin⁵, Daniel Burge⁶, Luke Peterson⁷, Catherine Arendt⁸, Alice B Gottlieb⁹

¹SCIderm Research Institute, Hamburg, and Dermatologikum Berlin, Germany, ²Oregon Medical Research Center, Portland, OR, USA, ³University Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany, ⁴Central Dermatology and Saint Louis University School of Medicine, St. Louis, MO, USA, ⁵Centre de Recherche Dermatologique du Québec Métropolitain, Québec, Canada, ⁶Demira, Inc., Menlo Park, CA, ⁷UCB Pharma, Raleigh, NC, USA, ⁸UCB Pharma, Brussels, Belgium, ⁹Department of Dermatology, New York Medical College at Metropolitan Hospital, New York, NY, USA

Introduction: The Fc-free, PEGylated, anti-tumor necrosis factor certolizumab pegol (CZP) has shown efficacy in chronic plaque psoriasis (PSO). [1,2]

Objectives: To assess the efficacy of CZP to 48 weeks across patient (pt) demographic and baseline disease characteristic subgroups in phase 3 trials.

Methods: In this prespecified, pooled subgroup analysis, data were pooled from CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272), ongoing phase 3 trials in adults with moderate to severe PSO ≥6 months (psoriasis area and severity index [PASI] ≥12, affected body surface area [BSA] ≥10%, physician's global assessment [PGA] ≥3/5). Pts were randomized 2:2:1 to CZP 400 mg every 2 weeks (Q2W), 200 mg Q2W (400 mg loading dose at Weeks 0/2/4), or placebo (PBO). At Week 16, PASI 50 responders receiving CZP continued the same dose through the maintenance period to Week 48. PASI 50 nonresponders at Weeks 32/40/48 were classed as nonresponders at subsequent time points. Subgroups included age, weight, body mass index (BMI), baseline PASI, BSA and PSO duration. PASI 75, PGA 0/1, and PASI 90 responder rates were summarized at Week 16 using a logistic regression model with multiple imputation (overall population) and descriptively at Week 48 based on nonresponse imputation (subgroups).

Results: 175/186/100 pts received CZP 400 mg Q2W/CZP 200 mg Q2W/PBO. Efficacy was observed across all subgroups for both CZP 400 mg Q2W and 200 mg Q2W, with higher Week 48 PASI 75 responder rates in CZP 400 mg Q2W vs CZP 200 mg Q2W treated pts (Table). Similar trends were observed for PGA 0/1 and PASI 90.

Conclusions: Treatment with either dose of CZP resulted in clinically meaningful improvements in signs and symptoms of PSO at Week 16 maintained at Week 48. Similar to the overall population, PASI 75, PGA 0/1, and PASI 90 responder rates were greater for CZP 400 mg Q2W versus 200 mg Q2W across most subgroups at Week 48.

References:

1. Reich K (2017). Skin,1;s23; 2. Augustin M (2017). Skin,1;s24

Table: Week 48 PASI 75 subgroup responder rates

| | CZP 400 mg Q2W (n = 175) | | CZP 200 mg Q2W (n = 186) | |
|----------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| | N | PASI 75 responders n (%) | N | PASI 75 responders n (%) |
| Baseline demographics | | | | |
| Weight (kg) | | | | |
| ≤74.00 | 40 | 32 (80.0) | 32 | 23 (71.9) |
| >74.00–≤85.00 | 36 | 28 (77.8) | 35 | 24 (68.6) |
| >85.00–≤95.40 | 36 | 26 (72.2) | 34 | 23 (67.6) |
| >95.40–≤109.00 | 28 | 18 (64.3) | 45 | 26 (57.8) |
| >109.00 | 35 | 24 (68.6) | 40 | 21 (52.5) |
| BMI (kg/m ²) | | | | |
| ≤25.44 | 37 | 30 (81.1) | 35 | 25 (71.4) |
| >25.44–≤28.68 | 39 | 36 (92.3) | 33 | 25 (75.8) |
| >28.68–≤31.92 | 39 | 26 (66.7) | 32 | 20 (62.5) |
| >31.92–≤37.16 | 25 | 16 (64.0) | 48 | 30 (62.5) |
| >37.16 | 35 | 20 (57.1) | 38 | 17 (44.7) |
| Age (years) | | | | |
| <40 | 65 | 54 (83.1) | 67 | 45 (67.2) |
| ≥40–<64 | 97 | 66 (68.0) | 107 | 65 (60.7) |
| ≥65 | 13 | 8 (61.5) | 12 | 7 (58.3) |
| Baseline disease characteristics | | | | |
| PSO duration (years, median) | | | | |
| ≤15.00 | 84 | 61 (72.6) | 96 | 64 (66.7) |
| >15.00 | 91 | 67 (73.6) | 90 | 53 (58.9) |
| PASI (median) | | | | |
| ≤17.00 | 79 | 55 (69.6) | 97 | 59 (60.8) |
| >17.00 | 96 | 73 (76.0) | 89 | 58 (65.2) |
| BSA (% , median) | | | | |
| ≤19.0 | 88 | 67 (76.1) | 97 | 60 (61.9) |
| >19.0 | 87 | 61 (70.1) | 89 | 57 (64.0) |

P060

DISCONTINUATION OF BIOLOGIC THERAPIES IN CHRONIC PLAQUE PSORIASIS: A RETROSPECTIVE COHORT

Susanne Gulliver, Wayne Gulliver, Shane Randell

NewLab Clinical Research

Introduction: Psoriasis is a chronic debilitating autoimmune disease which manifests on the skin through red scaly plaques. Biologic treatment have been very successful in controlling moderate to severe psoriasis, however they are quite expensive and not all treatments work for all patients. This study looks to understand the demographics, treatment patterns, treatment failures, number of therapies and time to switching. A cohort of 459 patients treated with biologics was examined

Objectives: 1. To understand the demographics, treatment patterns, treatment failures, number of therapies and time to switching.

2. To decipher patterns in biologic use in order to prescribe more efficiently and optimize health care resources.

Methods: This was a retrospective cohort of all patients exposed to biologic or PD-4 inhibitors within a single Dermatologist's private practice. A simple summary of patient demographics including gender, treatment patterns, reasons and length of time before discontinuation was compiled. Reasons for discontinuation included lack of efficacy (primary or secondary), adverse events (AEs), patient choice or other.

Results: There were 189 females (41.2%) and 270 males (58.8%) with 914 incidences of biologic or PD-4 inhibitor treatment. The mean age was 53.48±12.6 and the mean treatment duration was 37.3 months±39.5 (approx. 3000 treatment years).

39.2% of patients (180) remained on the first biologic (range 0.5 to 15 years). The mean number of therapies was 1.99 (range 1–8), but increased to 2.63 if patients were not biologic naive.

More male patients stayed on their first biologic (74.2% in ustekinumab-treated patients and in the Apremilast group 32.3%).

Reasons for discontinuation: AEs (14.69%) and non-response (30%); highest rates were in etanercept (78.0%), and infliximab (75.4%); lowest rates was in etanercept 12.8% (14 of 109 patients), highest in infliximab 34.9%, (44 of 126 patients).

Conclusions: The most common cause for discontinuation of biologics was an AE and non-responsiveness (45.69%). Women

were more likely to discontinue therapy than men. Males were more likely to remain on the first biologic therapy. Adalimumab and ustekinumab had lowest rates of discontinuation. Etanercept, infliximab and apremilast had the highest.

References:

1. M. Esposito, et al. Survival rate of antitumour necrosis factor α treatments for psoriasis in routine dermatological practice: a multicentre observational study. *Br J Dermatol* (2013). [Online] <http://onlinelibrary.wiley.com/doi/10.1111/bjd.12422/full>.
2. R. Gniadecki et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. *Br J Dermatology* (2014). [Online] <http://onlinelibrary.wiley.com/doi/10.1111/bjd.13343/full>
3. A.A. Levin, A.B. Gottlieb, S.C. Au. A comparison of drug failure rates and reasons for discontinuation in biologics versus systemic therapies. *Journal of Drugs in Dermatology* (2014) [Online] <http://europepmc.org/abstract/med/25007369>
4. R.B. Warren, et al. Differential Drug Survival of Biologic therapies for the treatment of psoriasis a prospective Observational cohort Study from the British association of Dermatologists Biologic interventions register (BADBIR). *J Invest Dermatol* (2015). [Online] <http://www.sciencedirect.com/science/article/pii/S0022202X15418494>
5. J. Zweegers, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. *Br J Dermatol* (2016) 175: 340–347. doi:10.1111/bjd.14552.

P061

INCIDENCE OF INFECTIONS IN CLINICAL TRIALS OF TILDRAKIZUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS

Jeffrey Crowley¹, Craig Leonardi², Sheila Sturgill-Koszycki³, Alan Menter⁴, Alan Mendelsohn³, Qing Li⁴, Nicole Cichanowitz⁵, Carmen La Rosa⁵

¹Bakersfield Dermatology, Bakersfield, CA, ²Central Dermatology, St Louis, MO, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁴Division of Dermatology, Baylor Scott & White and Texas A&M College of Medicine, Dallas, TX, ⁵Merck & Co., Inc., Kenilworth, NJ, USA

Introduction: Risk of infections is a concern with cytokine inhibitor treatments.

Objectives: This analysis assessed infections during phase 2 and 3 trials of tildrakizumab (TIL), a high-affinity, humanized, IgG1k monoclonal antibody against IL-23p19 under development for moderate to severe chronic plaque psoriasis.

Methods: Patients (Pts) were randomized in P05495 (phase 2; NCT01225731), reSURFACE 1 (phase 3; NCT01722331), and reSURFACE 2 (phase 3; NCT01729754) [1,2]. In Part 1 (Week (W)1–16) of P05495, pts received subcutaneous (SC) TIL 5, 25, 100, or 200 mg or placebo (PBO) at W0 and W4 and were rerandomized to various TIL doses in Part 2 (W16–52). In Part 1 (W1–12) of reSURFACE 1 and 2, pts received SC TIL 200 mg, TIL 100 mg, or PBO at W0 and W4. Pts were rerandomized in Part 2 (W12–28) and Part 3 (W28–64 or W28–52 in reSURFACE 1 and 2, respectively). Etanercept (ETN) 50 mg was an active control in Parts 1–2 of reSURFACE 2. Treatment-emergent adverse event data pools ($n = 2081$) for the PBO-controlled and full trial periods (52 weeks for P05495/reSURFACE 2; 64 weeks for reSURFACE 1) were analyzed. Severe infections met the regulatory definition of a serious adverse event or required intravenous antibiotics.

Results: In the PBO-controlled period, incidences of infections were comparable for TIL 100 mg and 200 mg (23% and 22%, respectively) and PBO (23%); all were comparable with ETN (24%). Incidences of severe infections were low for all treatment groups (range, 0.0%–0.3%; TIL ≥ 0.6 vs PBO). In the full trial period, exposure-adjusted rates (pts/100 pt-years) for infections with TIL 100 mg and 200 mg (48.9 and 52.6, respectively) were lower than with PBO and ETN (79.5 and 86.0, respectively). Exposure-adjusted rates for severe infections were 1.10, 1.61, 1.96, and 0.91

for TIL 100 mg, TIL 200 mg, ETN, and PBO, respectively. In all, 33 severe infections were identified (respiratory: TIL 100 mg, 4 events; TIL 200 mg, 2 events; ETN and PBO, 0 events; skin: TIL 100 mg, 3 events; TIL 200 mg, 6 events; ETN, 2 events; PBO, 3 events; gastrointestinal: TIL 100 mg, 4 events; TIL 200 mg, 5 events; ETN and PBO, 0 events; urinary tract: TIL 200 mg, 1 event; ETN, 1 event; TIL 100 mg and PBO, 0 events). One pt had bone tuberculosis (TIL 200 mg; original purified protein derivative test was negative); 1 sepsis event (TIL 200 mg) occurred months after ending TIL treatment.

Conclusion: Infection rates with TIL treatment were low and comparable to PBO and ETN during the PBO-controlled period. By W52/64, exposure-adjusted rates remained low for all groups.

Reference:

1. Papp K, et al. *Br J Dermatol*. 2015;173:930-939. 2. Reich K, et al. *Lancet*. 2017;390:276-288.

Acknowledgements: The studies were funded by Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Analyses were presented at the American Academy of Dermatology Annual Meeting, February 16–20, 2018, San Diego, CA, USA.

P062

EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

Kenneth B. Gordon¹, Bruce Strober², Mark Lebwohl³, Matthias Augustin⁴, Andrew Blauvelt⁵, Yves Poulin⁶, Kim A. Papp⁷, Howard Sosen⁸, Lluís Puig⁹, Peter Foley¹⁰, Mamitaro Ohtsuki¹¹, Mary Flack¹², Ziqian Geng¹³, Yihua Gu¹³, Joaquin M. Valdes¹³, Elizabeth H.Z. Thompson¹⁴, Hervé Bachelez¹⁵

¹Medical College of Wisconsin, Milwaukee, Wisconsin, ²University of Connecticut Health Center and Probiity Medical Research, Farmington, CT, ³Icahn School of Medicine at Mount Sinai, New York, NY, USA, ⁴University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, ⁵Oregon Medical Research Center, Portland, OR, USA, ⁶Centre Dermatologique du Québec Métropolitain, Québec, QC, Canada, ⁷K Papp Clinical Research and Probiity Medical Research, Waterloo, ON, Canada, ⁸University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA, ⁹Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁰The University of Melbourne, Parkville, Skin & Cancer Foundation Inc, Carlton, and Probiity Medical Research, Carlton, VIC, Australia, ¹¹Jichi Medical University, Shimotsuke, Japan, ¹²Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ¹³AbbVie Inc., North Chicago, IL, USA, ¹⁴AbbVie Inc., Redwood City, CA, USA, ¹⁵Saint-Louis Hospital, Sorbonne Paris Cité University Paris Diderot, Paris, France

Introduction: Interleukin-23 is a key cytokine in the development and maintenance of psoriatic lesions. Risankizumab is a humanized IgG1 monoclonal antibody that binds to IL-23's p19 subunit, selectively inhibiting this critical cytokine and its role in psoriatic inflammation.

Methods: UltIMMa-1 ($n = 506$) and UltIMMa-2 ($n = 491$) were replicate, randomized, double-blind, placebo- and active comparator-controlled studies that evaluated efficacy and safety of risankizumab in adult patients with moderate-to-severe plaque psoriasis. Patients were stratified by weight and prior TNFi-exposure and randomized 3:1:1 to receive 150 mg risankizumab, 45/90 mg ustekinumab (weight-based per label) or matching placebo. Patients were dosed at weeks 0, 4, 16, 28, and 40, with placebo crossover to risankizumab at week 16. Co-primary endpoints were PASI 90 and sPGA0/1 at week 16 versus placebo with comparisons between risankizumab and ustekinumab as ranked secondary endpoints. Missing data were imputed as non-response.

Results: All primary and ranked secondary endpoints were met for both trials ($p < 0.001$). At week 16 of UltIMMa-1&2 trials, risankizumab-treated patients achieved significantly higher PASI 90 (75.3%/74.8%) and sPGA0/1 (87.8%/83.7%) response rates versus placebo- (4.9%/2.0%; 7.8%/5.1%) or ustekinumab-treated

patients (42.0%/47.5%; 63.0%/61.6%). At week 52, risankizumab-treated patients achieved significantly higher response rates versus ustekinumab. In both trials, treatment-emergent adverse event (TEAE) rates were comparable across treatment groups throughout the study duration. The most frequently reported TEAE was upper respiratory tract infection.

Conclusion: Risankizumab was consistently superior to both placebo and ustekinumab in the treatment of moderate-to-severe plaque psoriasis. TEAE profiles were similar between risankizumab and ustekinumab, and there were no unexpected safety findings.

P063

EFFICACY AND SAFETY OF GUSELKUMAB ADMINISTERED WITH A NOVEL SELF-INJECTION DEVICE FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: RESULTS FROM THE PHASE III ORION SELF-DOSE STUDY THROUGH WEEK 16

Laura Ferris¹, Elyssa Ott², Gigi Jiang², H. Chih-Ho Hong³, Wojciech Baran⁴

¹University of Pittsburgh, Pittsburgh, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³UBC Department of Dermatology and Skin Science, Vancouver, BC and Probit Medical Research, Surrey, ⁴Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland

Objective: To evaluate the efficacy and safety of guselkumab (GUS) administered using a novel, self-injection device in adult patients with moderate-severe plaque psoriasis (PsO).

Methods: ORION is a Phase 3, multicenter, randomized, double-blind, PBO-controlled study evaluating GUS administered using a self-SC injection device that delivers the contents of a pre-filled syringe. Patients of age ≥ 18 years with moderate-severe PsO for at least 6 months, IGA score ≥ 3 , PASI score ≥ 12 , and BSA $\geq 10\%$, and were candidates for/or may have previously received systemic therapy or phototherapy, were eligible for the study. At baseline, 78 patients were randomized to PBO ($n=16$) at wks 0, 4, and 12 with crossover to GUS 100mg at wks 16, 20, and 28 or GUS ($n=62$) at wks 0, 4, 12, 20, and 28. The co-primary endpoints were the proportions of patients achieving 1) an IGA score of cleared (0) or minimal (1) and 2) a PASI 90 response at wk16 (GUS vs PBO). Major secondary endpoints were the proportions of patients achieving an IGA score of 0 and a PASI 100 response at wk16. Results through wk16 are presented.

Results: Baseline demographics and PsO disease characteristics were generally similar between the PBO and GUS-treatment groups. At wk16, significantly higher proportions of GUS vs PBO patients achieved an IGA score of 0/1 (80.6% vs. 0.0%, $p < 0.001$) and a PASI 90 response (75.8% vs. 0.0%, $p < 0.001$). In addition, significantly higher proportions of GUS vs PBO patients achieved an IGA score of 0 (56.5% vs 0.0, $p < 0.001$) and a PASI 100 response (50.0% vs 0.0, $p < 0.001$) at wk16.

Through wk16, the proportions of patients with ≥ 1 AE were comparable between the treatment groups (GUS: 62.9%, PBO: 68.8%; respectively). Discontinuation rates due to AEs were 1.6% for GUS patients and 6.3% for PBO patients. Two patients in the GUS group had SAEs (1 chest discomfort and 1 atypical chest pain). There were no serious infections, malignancies, or deaths.

Conclusion: GUS administered using a novel self-injection device was efficacious and well-tolerated in patients with moderate-severe PsO. The efficacy and safety profile of GUS administered with this device was consistent with previously reported findings from the pivotal phase 3 studies in which GUS was administered using a different self-injection device.

P064

EFFICACY OF TILDRAKIZUMAB IN ETANERCEPT PARTIAL RESPONDERS OR NONRESPONDERS

Jeffrey Crowley¹, Kim A Papp², Chih-ho Hong³, Jeff Parno⁴, Alan M Mendelsohn⁴, Qing Li⁵, Nicole Cichanowitz², Carmen La Rosa⁵
¹Bakersfield Dermatology, Bakersfield, CA, USA, ²Probit Medical Research, Waterloo, ON, Canada, ³University of British Columbia, Department of Dermatology and Skin Science and Probit Medical Research, Surrey, BC, Canada, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, ⁵Merck & Co., Inc., Kenilworth, NJ, USA

Introduction: Etanercept (ETN) is an anti-tumor necrosis factor medication that was among the first biologics approved for psoriasis. Additional medications have been developed or are in development for psoriasis, and patients who do not adequately respond to ETN may benefit from these more recent biologics.

Objectives: To evaluate the efficacy of tildrakizumab (TIL), a high-affinity, humanized, anti-interleukin-23p19 antibody in patients (pts) with moderate to severe chronic plaque psoriasis who were partial responders (Psoriasis Area and Severity Index [PASI] ≥ 50 – < 75) or nonresponders (PASI < 50) to ETN and were subsequently rerandomized to TIL in a phase 3 trial.

Methods: Pts with psoriasis ($\geq 10\%$ body surface area, Physician's Global Assessment [PGA] ≥ 3 , and PASI score ≥ 12) participated in a 3-part, 52-week, randomized controlled trial (reSURFACE 2; NCT01729754) [1]. In Part 1 (Week [W]0–W12), pts were randomized to subcutaneous TIL 200 mg, TIL 100 mg, or placebo (PBO) administered at W0 and W4, or ETN 50 mg administered 2x/week. In Part 2 (W12–W28), TIL- and ETN-treated pts remained on the same treatment (TIL administered at W16; ETN 1x/week), whereas PBO-treated pts were rerandomized to TIL 100 or 200 mg. In Part 3 (W28–W52), ETN responders (PASI ≥ 75) were discontinued, partial and nonresponders were switched to TIL 200 mg (administered at W32, W36, W48). For this post hoc analysis, the percentages of pts (\pm SD) with PASI responses and PGA response (score of 0 [clear] or 1 [minimal] with at least a 2-grade score reduction from baseline) were determined at W52. Primary results from the trial have been previously reported.

Results: In all, 1090 pts were randomized. Of the 313 pts randomized to ETN, by W28 there were 83 partial responders and 39 nonresponders. At W52 (after 20 weeks of TIL treatment) for ETN partial responders, 75% \pm 5%, 34% \pm 5%, 15% \pm 4%, and 58% \pm 5% had achieved PASI 75, 90, 100, and PGA responses, respectively, with TIL 200-mg treatment. At W52 for ETN nonresponders, 54% \pm 6%, 31% \pm 5%, 10% \pm 3%, and 56% \pm 5% had achieved PASI 75, 90, 100, and PGA responses, respectively, with TIL 200-mg treatment. Adverse events were similar in pts switched from ETN to TIL at W28, compared with the pts who were maintained on TIL through W52.

Conclusions: A substantial portion of patients with moderate to severe chronic plaque psoriasis who were partial responders or nonresponders to ETN may respond after switching to treatment with TIL 200 mg. TIL may be a reasonable option for those who do not achieve adequate response to ETN.

Reference:

1. Reich K, et al. Lancet. 2017;390:276-288.

Acknowledgments: This study was funded by Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Analyses were presented at the American Academy of Dermatology Annual Meeting, February 16–20, 2018, San Diego, CA, USA.

P065

EFFICACY OF TILDRAKIZUMAB IN MODERATE TO SEVERE PSORIASIS PATIENTS WITH PRIOR EXPOSURE TO APREMILAST

Kenneth Gordon¹, Kristian Reich², David Pariser³, Alan Menter⁴, Stephen Tyring⁵, Howard Sofen⁶, Stephen Rozzo⁷, Jeffrey Parno⁷, Qing Li⁸, Carmen La Rosa⁸

¹Medical College of Wisconsin, Milwaukee, WI, USA, ²SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, ³Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, ⁴Division of Dermatology, Baylor University Medical Center, Dallas, TX,

⁵Department of Dermatology, University of Texas, Houston, TX, ⁶Department of Medicine (Dermatology) UCLA, Los Angeles, CA, ⁷Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁸Merck & Co., Inc., Kenilworth, NJ, USA

Introduction: Tildrakizumab (TIL) is a high-affinity, anti-interleukin-23p19 monoclonal antibody for the treatment of chronic plaque psoriasis.

Objectives: We assessed a subgroup of patients with chronic plaque psoriasis who reported prior treatment with apremilast (APT), a phosphodiesterase 4 inhibitor, to evaluate its potential influence on efficacy in 2 large phase 3 clinical studies of tildrakizumab.

Methods: The reSURFACE studies were 3-part, double-blind, randomized controlled studies in patients (≥ 18 years of age) with moderate to severe chronic plaque psoriasis [1]. TIL 100 and 200 mg were evaluated for 64 weeks (reSURFACE 1; NCT01722331) and 52 weeks (reSURFACE 2; NCT01729754). Part 1 (0–12 weeks) was placebo (PBO)-controlled, whereas Part 2 (12–28 weeks) rerandomized PBO patients to TIL. The washout period for discontinuation of APT before randomization in these studies was 4 weeks. In this post hoc analysis, we analyzed the efficacy responses to TIL in patients who reported prior exposure to APT. Physicians' Global Assessment (PGA) (0 or 1) and Psoriasis Area and Severity Index (PASI) 75, 90, and 100 responses were assessed at Weeks 12 and 28 in this cohort. One patient with missing data at Weeks 12 and 28 was considered to be a nonresponder at these visits. The TIL groups were pooled owing to the small numbers reporting prior APT exposure.

Results: The pooled reSURFACE 1 and 2 dataset includes 1238 patients randomized to TIL; of these, prior APT exposure was reported by 35 patients ($n = 21$ for 100 mg and $n = 14$ for 200 mg). In the overall pooled population of TIL-treated patients, PASI 75, PASI 90, PASI 100, and PGA (0.1) responses were achieved by 783 (63%), 450 (36%), 161 (13%), and 715 (58%) at Week 12 and 898 (73%), 647 (52%), 303 (25%), and 784 (63%) at Week 28, respectively. In the population of TIL-treated patients with prior APT exposure, PASI 75, PASI 90, PASI 100, and PGA (0.1) responses were achieved by 21 (60%), 9 (26%), 5 (14%), and 22 (63%) at Week 12 and 27 (77%), 16 (46%), 7 (20%), and 22 (63%) at Week 28, respectively. There were no discontinuations due to adverse events (AEs) among patients with prior APT exposure.

Conclusions: Efficacy responses with TIL were similar for the small sample of patients with prior exposure to APT and the overall pooled population from reSURFACE 1 and reSURFACE 2. These results were consistent with the notion that no adverse effect on efficacy or discontinuations due to AEs are expected when initiating treatment with TIL among patients with prior exposure to APT.

Reference:

1. Reich K, et al. Lancet. 2017;390:276–288.

Acknowledgements: The studies were funded by Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Analyses were presented at the American Academy of Dermatology Annual Meeting, February 16–20, 2018, San Diego, CA, USA.

P066

RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMANCE

Andrew Blauvelt¹, Kim A. Papp², Melinda Gooderham³, Richard G. Langley⁴, Craig Leonardi⁵, Jean-Philippe Lacour⁶, Sandra Philipp⁷, Stephen Tying⁸, Michael Bukhalo⁹, Jashin J. Wu¹⁰, Jerry Bagel¹¹, Ellen H. Frankel¹², David Pariser¹³, Mary Flack¹⁴, Joseph Scherer¹⁴, Ziqian Geng¹⁵, Yihua Gu¹⁵, Anne Camez¹⁶, Elizabeth H.Z. Thompson¹⁷

¹Oregon Medical Research Center, Portland, OR, ²K Papp Clinical Research and Probiy Medical Research, Waterloo, ³School of Medicine, Queen's University, Kingston, and Centre for Dermatology and Probiy Medical Research, Peterborough, ON, ⁴Dalhousie University, Halifax, NS, Canada, ⁵St. Louis University, St. Louis, MO, USA, ⁶Hôpital de l'Archev,

University of Nice–Sophia Antipolis, Nice, France, ⁷Charité Universitätsmedizin Berlin, Berlin, Germany, ⁸University of Texas Health Science Center and Center for Clinical Studies, Houston, TX, ⁹Altman Dermatology Associates, Arlington Heights, IL, ¹⁰Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, ¹¹Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, ¹²RISkinDoc, Cranston, RI, ¹³Eastern Virginia Medical School and Virginia Clinical Research Inc, Norfolk, VA, ¹⁴Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ¹⁵AbbVie Inc., North Chicago, IL, USA, ¹⁶AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ¹⁷AbbVie Inc., Redwood City, CA, USA

Introduction: Interleukin-23 (IL-23), a key regulator of multiple effector cytokines (including IL-17, IL-22, and TNF), is thought to drive the development and maintenance of psoriatic lesions. Risankizumab is a potent humanized IgG1 monoclonal antibody that inhibits IL-23 by specifically binding its p19 subunit.

Objectives: To report efficacy and safety results of risankizumab from initial 16-week (wk) placebo (PBO)-controlled period of IMMANCE trial in patients (pts) with moderate-to-severe chronic plaque psoriasis (PsO).

Methods: IMMANCE (NCT02672852) is a phase 3 multicenter, randomized, double-blind, PBO-controlled trial, evaluating the efficacy and safety of risankizumab versus PBO in pts with moderate-to-severe chronic plaque PsO. The initial 16-wk PBO-controlled period (507 pts, stratified by weight and prior TNFi-exposure, randomized 4:1 to receive either risankizumab [150 mg at wks 0 and 4] or PBO) was followed by randomized withdrawal and subsequent re-treatment with risankizumab. Co-primary endpoints were PASI 90 and sPGA 0/1 responses at wk 16; missing data were imputed as non-responders.

Results: At baseline, the mean age and weight were 49.2 years and 92.0 kg, respectively; 70.2% of pts were male. A history of diagnosed or suspected psoriatic arthritis was reported in 34.7% of pts and prior TNFi therapy was reported in 36.5% of pts. Mean baseline PASI and BSA were 20.2 and 26.1%, respectively. At wk 16, all primary and ranked secondary endpoints were met ($p < 0.001$). At Wk 16, risankizumab -treated pts achieved significantly higher PASI 90 (73.2%) and sPGA 0/1 (83.5%) response rates versus PBO-treated pts (2.0%; 7.0%). Treatment-emergent adverse events (TEAEs) and serious AEs were reported in 45.5% and 2.0% of risankizumab-treated pts, respectively. Through 16 wks, there were no deaths, major adverse cardiovascular events, or cases of tuberculosis in risankizumab-treated pts.

Conclusions: Risankizumab was superior to PBO in the treatment of adult pts with moderate-to-severe plaque PsO. The safety profile was consistent with previously reported risankizumab trials with no new or unexpected safety findings.

P067

DISEASE SEVERITY AND EFFICACY INSIGHTS: PATIENT-LEVEL PASI SCORES IN TILDRAKIZUMAB PSORIASIS TRIALS

Kenneth Gordon¹, Jeffrey Crowley³, Yves Poulin³, Alan Mendelsohn⁴, Jeff Parno⁴, Stephen Rozzo⁴, Charles Ellis⁵

¹Medical College of Wisconsin, Milwaukee, WI, ²Bakersfield Dermatology & Skin Cancer Medical Group, Bakersfield, USA, ³Centre hospitalier de l'université Laval, Hôpital Hôtel-Dieu de Québec, Québec City, Canada, ⁴Sun Pharmaceutical Industries, Inc., Princeton, ⁵Department of Dermatology, University of Michigan Medical School, Ann Arbor, USA

Introduction: Tildrakizumab (TIL) is a high-affinity anti-IL-23p19 antibody that showed efficacy in 2 phase 3 chronic plaque psoriasis studies (reSURFACE 1 [NCT01722331] and 2 [NCT01729754]) [1]. Some dichotomous efficacy measures, eg, proportions of patients achieving a 75% Psoriasis Area and Severity Index (PASI) response, provide limited efficacy and disease severity information at a patient level. Analysis of patient-level PASI data could address these limitations.

Objective: To identify potential insights into efficacy assessment

and disease severity using a post hoc analysis of patient-level PASI data.

Methods: ReSURFACE 1 and 2 methods have been described previously [1]. Patients who participated in either TIL phase 3 study received TIL 100 mg or TIL 200 mg at Week (W)0 and W4, and every 12 weeks thereafter, or placebo (PBO) at W0 and W4 then TIL 100 mg or 200 mg at W12 and W16. PASI score distributions were analyzed using descriptive statistics.

Results: Numbers of patients and mean and median PASI scores are shown in the Table. By W4 (1 dose), 55% of patients in both TIL arms had PASI < 12, and would no longer meet clinical trial entry criteria. The percentage of patients with PASI < 12 increased during TIL treatment: 87% at W12, 93% at W28 (100 mg); 90% at W12, 97% at W28 (200 mg). At W12, 32% (TIL 100 mg), 29% (TIL 200 mg), and 2% (PBO) of patients had PASI ≤ 1.0. By W28, 48% (TIL 100 mg) and 52% (TIL 200 mg) of patients had PASI ≤ 1.0. Median PASI scores at W28 were 2.0 (TIL 100 mg) and 1.0 (TIL 200 mg).

Conclusions: These results suggest that PASI scores may provide additional information about disease severity, and resolution with treatment, that might not otherwise be available using dichotomous PASI assessments. Most TIL-treated patients had clinical improvement by W4, and ≈50% had nominal disease severity (PASI ≤ 1.0) by W28.

Reference:

1. Reich K, et al. Lancet. 2017;390:276–288.

Study sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; analyses funded by Sun Pharmaceutical Industries, Inc.

Table. PASI Scores

| | TIL 100 mg (n = 616) | TIL 200 mg (n = 622) | PBO (n = 309) |
|----------------------------|-------------------------|-------------------------|-------------------|
| W0 | | | |
| Patients with PASI data, n | 616 | 622 | 309 |
| Mean (95% CI) | 20.2 (19.6, 20.9) | 20.3 (19.7, 20.9) | 19.7 (18.8, 20.5) |
| Median (range) | 18.0 (8.0–59.0) | 18.0 (5.0–66.0) | 18.0 (12.0–56.0) |
| W4 | | | |
| Patients with PASI data, n | 610 | 611 | 302 |
| Mean (95% CI) | 12.1 (11.5, 12.8) | 12.0 (11.4, 12.6) | 18.0 (17.0, 19.0) |
| Median (range) | 11.0 (0.0–53.0) | 11.0 (0.0–54.0) | 16.0 (2.0–59.0) |
| PASI < 12, n (%) | 337 (55) | 335 (55) | 60 (20) |
| PASI ≤ 1.0, n (%) | 8 (1) | 11 (2) | 0 (0) |
| W12 | | | |
| Patients with PASI data, n | 598 | 602 | 288 |
| Mean (95% CI) | 5.2 (4.7, 5.7) | 4.6 (4.2, 5.1) | 16.6 (15.6, 17.7) |
| Median (range) | 3.0 (0.0–38.0) | 3.0 (0.0–36.0) | 15.5 (0.0–57.0) |
| PASI < 12, n (%) | 521 (87) | 539 (90) | 73 (25) |
| PASI ≤ 1.0, n (%) | 189 (32) | 175 (29) | 5 (2) |
| W28 | | | |
| Patients with PASI data, n | 575 | 581 | - |
| Mean (95% CI) | 3.4 (3.0, 3.8) | 2.7 (2.4, 3.0) | - |
| Median (range) | 2.0 (0.0–26.0) | 1.0 (0.0–24.0) | - |
| PASI < 12, n (%) | 533 (93) | 561 (97) | - |
| PASI ≤ 1.0, n (%) | 278 (48) | 303 (52) | - |

P068

SUSTAINED AND IMPROVED EFFICACY OF TILDRAKIZUMAB FROM WEEK 28 TO WEEK 52 IN TREATING MODERATE-TO-SEVERE PLAQUE PSORIASIS

Boni Elewski¹, Alan Menter², Jeffrey Crowley³, Stephen Tying⁴, Yang Zhao⁵, Simon Lowry⁵, Stephen Rozzo⁵, Alan Mendelsohn⁵, Jeffrey Parno⁵, Kenneth Gordon⁶

¹Department of Dermatology, The University of Alabama at Birmingham, Birmingham, Alabama, ²Division of Dermatology, Baylor University Medical Center, Dallas, TX, ³Bakersfield Dermatology, Bakersfield, CA, ⁴Department of Dermatology, University of Texas Health Science Center, Houston, TX, ⁵Sun Pharmaceuticals, Princeton, NJ, ⁶Medical College of Wisconsin, Milwaukee, WI, USA

Introduction: Two phase-3, double-blind, randomized controlled trials (reSURFACE 1: NCT01722331; reSURFACE 2: NCT01729754) have demonstrated the efficacy and safety of tildrakizumab, a high affinity, humanized, IgG1 κ, anti-interleukin-23

monoclonal antibody, in the treatment of adult patients with moderate-to-severe plaque psoriasis over 28 weeks¹.

Objective: This analysis evaluated whether the efficacy is sustained or improved from week 28 through week 52.

Methods: Both trials randomized adult patients with moderate-to-severe plaque psoriasis to receive tildrakizumab 100 mg or 200 mg at weeks 0, 4, then every 12 weeks. At week 28, patients with Psoriasis Area and Severity Index (PASI) response ≥50% were re-randomized, based on their week-28 PASI response, to receive the same, a higher or a lower dose of tildrakizumab or placebo (randomized withdrawal in reSURFACE 1 per the trial designs). The current analysis evaluated only patients treated with the same dose of tildrakizumab (100 mg or 200 mg) throughout the first 52 weeks. Four mutually exclusive groups were created based on week-28 PASI response: PASI 100, PASI 90–99, PASI 75–89 and PASI 50–74. PASI responses at week 52 (observed data) were analyzed for each week-28 PASI-response group.

Results: This analysis included 352 patients on tildrakizumab 100 mg (male: 69.9%; mean baseline age: 44.9 years) and 313 on tildrakizumab 200 mg (male: 67.1%; mean baseline age: 46.4 years). The proportions of patients achieving PASI 100, PASI 90–99, PASI 75–89 and PASI 50–74 at week 28 were 25.9%, 38.4%, 25.3% and 10.5% respectively for those on the 100 mg dose, and 24.6%, 24.3%, 19.5% and 31.6% respectively for those on the 200 mg dose. Among patients who achieved week-28 PASI ≥90 with either dose of tildrakizumab, 88.9–89.4% maintained PASI ≥90 at week 52. Overall, 91.1% patients on the 100 mg dose and 93.9% on the 200 mg dose with week-28 PASI ≥75 maintained PASI ≥75 at week 52. In addition, 39.3–40.4% of patients with week-28 PASI 75–89 remained PASI 75–89 at week 52 and 33.7%–41.0% improved to PASI ≥90. Among patients with week-28 PASI 50–74, 20.2–29.7% achieved PASI ≥90 and 52.5–64.9% achieved PASI ≥75 at week 52. Overall, only 2.6% of patients on the 100 mg (9 out of 352) or 200 mg (8 out of 313) dose had week-52 PASI < 50.

Conclusions: Among patients with moderate-to-severe plaque psoriasis treated with tildrakizumab 100 or 200 mg at weeks 0, 4, then every 12 weeks, those who achieved week-28 PASI ≥50 and continued on the same dose had sustained or improved efficacy from week 28 through week 52. The majority patients who achieved week-28 PASI ≥75 or PASI ≥90 maintained PASI ≥75 or PASI ≥90 at week 52. More than half of partial responders (PASI 50–74) at week 28 eventually achieved PASI ≥75 and at least 1 in 5 achieved PASI ≥90 at week 52.

Reference:

1. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288.

This abstract was presented at 2018 Winter Clinical Dermatology Conference-Hawaii.

P070

BETTER SKIN CLEARANCE IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN MODERATE-TO-SEVERE PSORIASIS PATIENTS TREATED WITH TILDRAKIZUMAB

Andrew Blauvelt¹, Stephen Tying², Melinda Gooderham³, John Koo⁴, Yang Zhao⁵, Simon Lowry⁵, Stephen Rozzo⁵, Alan Mendelsohn⁵, Jeffrey Parno⁵, Kristian Reich⁶

¹Oregon Medical Research Center, Portland, OR, ²Department of Dermatology, University of Texas Health Science Center, Houston, TX, ³Skin Centre for Dermatology, Peterborough, ON, Canada, ⁴Department of Dermatology, University of California at San Francisco, CA, ⁵Sun Pharmaceuticals, Princeton, NJ, USA, ⁶SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany

Introduction: Tildrakizumab, a high affinity, humanized, IgG1 κ, anti-interleukin-23 monoclonal antibody, has demonstrated effica-

cy and safety in patients with moderate-to-severe plaque psoriasis in two phase 3, double-blinded, randomized controlled trials (reSURFACE 1: NCT01722331; reSURFACE 2: NCT01729754)1. **Objective:** The analysis examined the association between quality-of-life improvements and the degree of skin clearance in patients enrolled in the two phase 3 trials and treated with tildrakizumab 100 mg or 200 mg at weeks 0, 4, then every 12 weeks.

Methods: Both trials used a three-part design: Part 1 (weeks 0–12) was placebo-controlled; Part 2 (weeks 12–28) re-randomized placebo patients to receive tildrakizumab 100 or 200 mg; Part 3 (weeks 28–64, reSURFACE 1; weeks 28–52, reSURFACE 2) re-randomized patients from the tildrakizumab arms with Psoriasis Area and Severity Index (PASI) response ≥ 50 at week 28 to receive the same, a higher, or a lower dose of tildrakizumab, or placebo (randomized withdrawal in reSURFACE 1). The Dermatology Life Quality Index (DLQI) questionnaire was administered at weeks 0, 12, 28, 40, and 52. Tildrakizumab-treated patients were pooled from the two trials and classified into 5 mutually exclusive groups based on their week-28 PASI response: PASI < 50, PASI 50–74, PASI 75–89, PASI 90–99, and PASI 100. Baseline characteristics, the proportion of patients with DLQI 0/1, and mean DLQI changes from baseline were examined for each PASI response group. **Results:** Overall, 575 patients on tildrakizumab 100 mg (male: 69.6%; mean baseline age: 45.6 years) and 581 on tildrakizumab 200 mg (male: 73.0%; mean baseline age: 45.9 years) were included. At week 28, 8.3%, 22.0%, 40.9%, 66.3%, and 86.5% (8.7%, 35.2%, 43.9%, 70.4%, and 85.9%) of patients with PASI < 50, 50–74, 75–89, 90–99, and 100 achieved DLQI 0/1 for those on 100 mg (200 mg), respectively. Patients with higher week-28 PASI response also had greater mean DLQI reductions from baseline at week 28 (100 mg: 5.7–13.4; 200 mg: 5.4–12.9). Similar patterns were observed among patients continuously treated with tildrakizumab 100 mg or 200 mg from baseline to week 52, with better PASI-response patients having greater proportions achieving DLQI 0/1 and greater DLQI reductions sustained from week 28 through week 52.

Conclusion: Tildrakizumab-treated patients with higher levels of PASI response also demonstrated better quality-of-life improvements. Achieving PASI 100 was not necessarily associated with achieving DLQI 0/1, therefore both efficacy and quality-of-life improvements need to be evaluated separately to provide a complete picture of treatment success.

Reference:

1. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. *Lancet*. 2017;390(10091):276–288.

This abstract has been accepted by 2018 EADV Spring Symposium.

P071

STATISTIC REVIEW OF PSORIASIS SYSTEMATIC THERAPIES IN NORTH GREECE

Konstantinos Efstimiadis, Florentina-Silvia Delli

State Clinical for Skin and Venereal Diseases Thessaloniki, Greece

Introduction: Psoriasis is a chronic disease that can have a significant effect on quality of life. Therefore, management of psoriasis involves both psychosocial and physical aspects of this disease, lately generally admitted as systemic. Numerous topical and systemic therapies are available for the treatment of the cutaneous manifestations of psoriasis. In our daily clinical practice, treatment modalities are chosen on the basis of disease severity estimated with PASI and DLQI, relevant comorbidities, and patient preference.

Objective: To assess the frequencies of each systemic drug, classical or biological, used for the treatment of mild, moderate to severe psoriasis in our hospital care unit from January 2016 since December 2016.

Methods: Moderate to severe psoriasis was defined by PASI > 10 and/or DLQI > 10 and/or any PASI in a patient with psoriatic arthritis.

Results: Most of our patients with mild to moderate psoriasis are using topical and classical therapies. A significant number of patients with severe psoriasis are using biological therapies and about a half of them were already used a classical or other biologic drug.

Conclusion: Despite the fact that new biological drugs are available for psoriasis treatment, it seems that the patients with mild psoriasis are still treating with topical products. At least as far as it concerns our Mediterranean country, it seems that our patients difficult accept the biological therapies as first choice line treatment.

P073

PHARMAKOVIGILANCE OF SYSTEMIC ANTIPSORITIC DRUGS: AN UPDATE FROM ROUTINE CARE

Christina Sorbe¹, Laura Kühl¹, Stephan Jeff Rustenbach¹, Ralph von Kiedrowski², Marc Alexander Radtke¹, Matthias Augustin¹

¹University Medical Center Hamburg-Eppendorf, ²Dermatological office, Selters

Introduction & Objectives: The spectrum of antipsoriatic systemic therapies is constantly changing. The short-term efficacy and safety of the various therapies are demonstrated in controlled clinical studies. The German Psoriasis Registry PsoBest aims to gain long-term evidence of safety and effectiveness in routine care. Updated interim data of long-term safety of biological and non-biological treatment of psoriasis is presented.

Materials & Methods: The non-interventional German Psoriasis Registry PsoBest observes adult patients with moderate to severe psoriasis and/or psoriatic arthritis. Patients are registered at naïve systemic treatment start and are observed for 10 years in routine care. The registry aims to gain long-term evidence of safety and effectiveness of systemic antipsoriatic drugs. Data is collected in dermatological practices and walk-in clinics. Presented are standardised patient rates per 100 patient years (py) of exposure classified by system organ classes of MedDRA® (SOC, Medical Dictionary for Regulatory Activities).

Results: Until June 2017, 5,825 patients were registered and sufficient for analyses. They were predominantly male (58.8%), had a mean age of 47.7 years (SD 14.5) and 30.0% of patients suffered psoriatic arthritis. 4,729 patient years (py) were observed on biologic treatments and 6,583 py on other systemic treatments. For all cause death, malignancies and other serious adverse events (SAE), there were no significant differences between the treatment cohorts. Highest SAE rates were observed in the SOCs Surgical and medical procedures (3.5 and 2.6 patients/ 100 py on biologics and non-biologics, respectively), General disorders and administration site conditions (2.0 and 1.8 patients/ 100 py), Infections and infestations (1.6 and 1.1 patients/ 100 py) and Neoplasms (1.4 and 1.3 patients/ 100 py). Events from other SOCs were observed for less than 1 patient/ 100 py.

Non-serious adverse events (AE) within the SOCs Skin and subcutaneous tissue disorders, Renal and urinary disorders, Blood and lymphatic system disorders, Gastrointestinal disorders, Nervous system disorders, Vascular disorders as well as Investigations were less frequent in biologic treatment compared to non-biologics (2.2 vs. 5.3, 0.3 vs. 0.7, 0.4 vs. 2.3, 2.4 vs. 11.3, 1.3 vs. 2.7, 1.2 vs. 2.1 and 2.0 vs. 3.4 patients/ 100 py, respectively, $p \leq 0.05$). Non-serious infections were observed more often in biologics (7.0 vs. 4.8 0 patients/ 100 py, $p \leq 0.05$). For the lately authorized treatments secukinumab and apremilast 253 and 111 py were observed, for biosimilar treatment 5 py. They showed no deviations from the previously observed safety profile of other systemic therapies.

Conclusions: In the general, no increased risk of biological or non-biological treatments was observed. The specific differences in non-serious events will be evaluated in more detail in future

analyses. For robust data on recently authorised therapeutics, more observation time is needed, especially with a constantly changing spectrum of treatments.

P074

THE IMPACT OF PATIENT REQUESTS ON PSORIATIC ARTHRITIS TREATMENT

*Lynn Price, Jennifer Robinson, Gianna Melendez
Spherix Global Insights*

Introduction: As a result of direct to consumer advertising, patients frequently request well-known brands for the treatment of psoriatic arthritis, and these patients tend to be highly involved in their therapy decisions. Patient requests commonly relate to formulation preferences, and in an indication dominated by biologics administered either subcutaneously or intravenously, oral small molecules are in high demand.

Objectives: One of the objectives of this study was to gain further insight into patient requests as a main driver for switching to and from biologics/apremilast.

Methods: An independent market analytics firm collaborated with US rheumatologists ($n=200$) to conduct a retrospective chart review of patients diagnosed with psoriatic arthritis (PsA) ($n=1,008$), who had switched from one biologic therapy or apremilast to another in the prior twelve weeks. Rheumatologists were able to submit up to seven PsA patient charts. Data were collected in April 2017 and included clinical and non-clinical patient demographics, as well as physician demographics and attitudinal survey responses.

Results: PsA patients tend to be very involved when it comes to treatment decisions as 60 percent of patients had significant input or were the primary driver behind the recent decision to switch agents. Of those patient driven switches, only 36 percent of treating rheumatologists felt there was strong clinical rationale behind the switch; despite this, nearly half of rheumatologists state they tend to approve specific patient requests.

Two-thirds of collaborating rheumatologists believe patients would choose an oral agent over one that administered subcutaneously, thus switching to apremilast is particularly common when patients are involved in the decision. Patient requests were the primary driver behind 24 percent of all switches to apremilast, compared to just 12 percent when switching to a biologic. Furthermore, for rheumatologists who are not in favor of an “apremilast before biologics” treatment approach, patient requests are significantly more of a driver for the brand than those who have adopted an “apremilast before biologics” approach.

Conclusion: PsA patients are highly involved in the decision to initiate and switch biologic/apremilast therapies, and treating rheumatologists tend to be open to granting such requests, regardless of clinical rationale. When patient requests are a primary driver for switching, apremilast benefits the most; largely due to the oral formulation. With the new approval of the first JAK inhibitor and second oral option in the PsA market, tofacitinib will likely fill a gap for both physicians and patients by introducing a high efficacy oral option, warranting follow-up analysis on the evolution and impact of patient requests in PsA.

P075

THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES

Kayleigh Mason

The University of Manchester, Manchester, UK

Introduction: Whether psoriasis patients exposed to biologic therapies have an elevated risk of keratinocyte carcinoma (KC), including basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) remains uncertain.

Objective: The aim of the present study was to determine whether such patients were at higher risk of developing a KC compared to those on conventional therapy.

Methods: The British Association of Dermatologists Biologic Interventions Register (BADBIR), a pharmacovigilance register of psoriasis patients, explores the long-term safety of systemic therapies. Patients with chronic plaque psoriasis registering to BADBIR on their first biologic or a conventional therapy, who had at least one follow-up completed were included in analyses if they were of white ethnicity, Fitzpatrick skin types 1–4 and reported no previous cancers. Confounding factors included: age; sex; smoking; and previous exposure to acitretin, psoralen ultraviolet-A (PUVA), ciclosporin, and/or PUVA and ciclosporin. Propensity score-weighted Cox-proportional hazard models estimated the hazard ratio (HR) for developing a first KC or separately, first BCC or cSCC.

Results: In total, 5672 patients initiating biologic therapy and 3188 patients on conventional therapy who met the entry criteria were identified with 20558 and 7829 person-years of follow-up, respectively. During follow-up, 74 (1.3%) patients initiating a biologic therapy were diagnosed with their first KC (43 BCC; 34 cSCC first) and 22 (0.7%) patients receiving conventional therapy with their first KC (15 BCC; 10 cSCC first). No significant difference in risk was observed for developing a KC (adjusted HR 1.05; 95% CI 0.64, 1.73), BCC (0.84; 95% CI 0.45, 1.54) or cSCC (1.20; 95% CI 0.57, 2.50) on biologic compared to conventional therapy.

Conclusion: Biologic therapy does not appear to confer a higher risk of developing a first KC as compared to conventional therapy in psoriasis patients. These data will help inform clinical decision making in psoriasis patients at risk of KC in whom biologic or conventional therapy is being considered.

On behalf of the BADBIR Study Group, British Association of Dermatologists, London, UK

P076

PATIENT PERCEPTIONS OF PSORIASIS SEVERITY IN SWEDEN, NORWAY, AND DENMARK

Kjersti Danielsen¹, Albert Duvetorp², Lars Iversen³, Mikkel Østergaard⁴, Oliver Seifert⁵, Kåre Steinar Tveit⁶, Lone Skov⁷

¹UiT The Arctic University of Norway, Tromsø, Norway; ²University Hospital of North Norway, Tromsø, Norway; ³Linköping University, Linköping, Sweden; ⁴Skånes Universitetssjukhus, Malmö, Sweden; ⁵Aarhus University Hospital, Aarhus, Denmark; ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, University of Copenhagen, Copenhagen, Denmark; ⁷Linköping University, Linköping, Sweden; ⁸Ryhov Hospital, Jönköping, Sweden; ⁹Haukeland University Hospital, Bergen, Norway; ¹⁰Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark

Introduction: Optimal clinical management of psoriasis (PsO) and psoriatic arthritis (PsA) requires understanding of their impact on patients.

Objectives: NORPAPP aimed to evaluate disease prevalence and patient perceptions of severity in Sweden, Denmark, and Norway.

Methods: NORPAPP was an on-line survey carried out during November and December 2015 using YouGov panels in Sweden, Denmark, and Norway. The survey included 44 questions covering self-perceived disease severity/symptoms, quality of life, contact with the healthcare system, and treatment. The initial survey population was randomly selected using framing quotas based on population census data to ensure inclusion of a representative sample of adults (aged 18–74 years) from each country. Participants were asked if they had PsO or PsA and if it was physician diagnosed: those diagnosed by a physician were invited to participate in the full survey. Final survey data were weighted to match national sex and age distributions. Self-perceived disease severity was expressed by a 5-level score. Severity of PsO based on the % body surface area (BSA, mild $\leq 3\%$; moderate 4–9%; and severe

≥10%) was based on the respondent's estimate of palms of affected skin (1 palm = 1% BSA).

Results: Among 22,050 individuals questioned, reported prevalence of PsO and/or PsA was 9.7% (9.4% in Sweden, 9.2% in Denmark, and 11.9% in Norway); 1264 (5.7%) individuals reported physician diagnosis and 1221 of these completed the full survey. Among survey participants, 74.6% reported PsO alone, 10.3% PsA alone, and 15.1% both. There was a limited correlation between self-perceived disease severity and estimates of % BSA for PsO (Spearman's rho 0.42). Self-perceived PsO severity was related to the most common symptoms (itching and flaking/scales) but % BSA-based clinical severity was not. Respondents with PsA+PsO reported significantly worse self-perceived severity and % BSA of PsO than those with PsO alone. Overall, PsA symptoms were self-perceived to be more severe than PsO symptoms.

Conclusion: Patient perceptions of PsO severity differ from their estimates of %BSA and should be considered in the assessment and management of PsO.

P077

PATIENT EXPECTATIONS AND SATISFACTION IN PSORIASIS TREATMENT: A SURVEY FROM EUROPE AND CANADA

Jonathan Barker¹, Robert McKenzie², Daniel Saure², Stefan Wilhelm², Kunal Gulati², Ronald Vender³

¹Guy's Hospital, St. John's Institute of Dermatology, London, UK, ²Eli Lilly and Company, ³Dermatological Research INC, Hamilton, Ontario, Canada

Introduction: Psoriasis is a chronic immune-mediated disease that negatively affects the quality of life of patients.¹ Despite recent advancements in treatment, patient expectations may differ from the treatment outcome, potentially leading to dissatisfaction.

Objective: To evaluate patient expectations on psoriasis treatment outcomes and to what extent these were met by the treatment.

Methods: Data were collected from patients with moderate-to-severe psoriasis with ≥ 3% skin involvement. Patients were included from 17 European countries and Canada through a structured, web-based interview in their local language. Patients were on topical, PUVA/phototherapy, conventional systemic or biological treatment. Descriptive statistical analyses were conducted.

Results: Overall, 1946 patients (mean [SD] age: 42 [13] years, 43% male) with psoriasis were surveyed between 6 July 2016 and 5 May 2017. The vast majority of patients currently on treatment reported reduced itchiness (69%), reduced flaking (62%), and clearer skin/skin that looked better generally (61%) as the main expectations of their treatment. In addition, these patients reported duration of effect (41%), extent of overall skin clearance (36%), and speed of onset (34%) as the main influences for changing their current treatment. Furthermore, patients were asked whether their achieved results matched with their initial treatment expectations. Patients reported that the convenience of dosing (68%) and administration method (68%) completely met, or even exceeded their initial expectations for the treatment. Conversely, expectations for reduced itchiness (62%), reduced flaking (62%), clearer skin/skin that looked better generally (63%) were only partially met or not met at all. Approximately, two-third of patients were dissatisfied or only partially satisfied with the extent of their skin clearance and improvement in at least one specific area. Specifically, scalp (48%), legs (42%), and arms (41%) were the highest rated areas if asked for insufficient satisfaction for clearance.

Conclusion: Data from this international survey indicate that efficacy and maintenance of response are the patients' primary expectations of psoriasis treatment whereas, insufficient response to therapy in difficult-to-treat areas appears to be a major reason for patient dissatisfaction.

Reference:

1. Paul C, Bang B, Lebwohl M. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris:

rationale for development and clinical profile. Expert Opin Pharmacother. 2017 Jan;18(1):115-121.

This survey was sponsored by Eli Lilly and Company, Indianapolis, USA.

P078

SOCIOECONOMIC DETERMINANTS OF PAEDIATRIC PSORIASIS

Jonathan Groot¹, Anne-Marie Nybo Andersen², Abdulfatah Adam², Tilde Elkjær Tind Nielsen^{2,3}, Christoffer Blegvad³, Lone Skov³

¹Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, ²Section for Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, ³Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Introduction: Psoriatic comorbidities have been shown to be inversely associated with socioeconomic position (SEP). We hypothesized that the social patterning of paediatric psoriasis would be similar to that observed for several psoriatic comorbidities, such as cardiovascular disease and type 2 diabetes mellitus.

Objectives: Our aim was to investigate whether maternal SEP is a determinant of paediatric psoriasis.

Methods: Data on paediatric psoriasis from 36,003 offspring of a national birth cohort were cross-linked with nation-wide registry data on maternal educational attainment, maternal labour market attachment and equivalised household income. We performed logistic regression analyses to test for associations between measures of maternal SEP and paediatric psoriasis. Cohort analyses were conducted, estimating the odds ratios (OR) and 95% confidence intervals (CI) of offspring psoriasis. We included maternal age at birth and maternal psoriasis as covariates in adjusted analyses.

Results: Maternal educational attainment and equivalised household income were inversely associated with offspring psoriasis. Offspring of mothers with a low educational attainment had an OR 1.62 (95% CI: 1.20–2.18; $p < 0.01$) of paediatric psoriasis, after adjusting for maternal psoriasis and age, compared to offspring of mothers with a medium educational attainment. Offspring of mothers in the highest quartile compared to mothers in the lowest quartile of equivalised maternal household income had an OR 0.59 (95% CI: 0.44–0.80; $p < 0.001$) of paediatric psoriasis, after adjusting for maternal psoriasis and age.

Conclusion: Lifetime prevalence of paediatric psoriasis was inversely associated with maternal SEP in our study population. Early life exposure to modifiable risk factors associated with SEP may play an important role in the development of paediatric psoriasis. Future studies are warranted to clarify the role of mediating factors.

P079

OBESITY AND THE RISK OF PSORIASIS: A KOREAN NATIONWIDE, POPULATION-BASED STUDY

Ju Hee Han¹, Kyung Do Han², Chul Hwan Bang¹, Young Min Park¹, Jun Young Lee¹, Yong Gyu Park², Ji Hyun Lee¹

¹Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, ²Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Korea

Introduction: Psoriasis is a T-helper-1 and -17 cell-mediated, chronic, inflammatory skin disease affecting approximately 1–3% of the general population. Psoriasis is currently considered as a chronic low-grade inflammatory condition that plays an active role in the development of the pathophysiologic phenomena responsible for metabolic syndrome and cardiovascular disease. Obesity, as a component of the metabolic syndrome, represents a major comorbidity and possibly contributes to reduced treatment response.

Objective: This nationwide, population-based study investigated the impact of body mass index (BMI) and waist circumference (WC) on the psoriasis in the Korean population.

Methods: We used the health check-up database, which is sub-

dataset of the Korean National Health Insurance Service database. Study population includes subjects who had undergone health screenings between January 2009 and December 2012. Patients who were diagnosed with psoriasis prior to the health screening or who were less than 20 years of age were excluded. This study investigated newly diagnosed patients with psoriasis (ICD-10 code, L40) by dermatologists among subjects during the follow-up period through the claim data.

Result: Total 22,633,536 subjects were included and psoriasis newly developed in 399,461 subjects. Mean BMI among newly developed psoriasis group (23.9 ± 3.25) was higher than non-psoriasis group (23.68 ± 3.27) ($p < 0.0001$). Mean WC of newly developed psoriasis group (81.21 ± 9.27) was higher than non-psoriasis group (79.99 ± 9.26) ($p < 0.0001$). BMI showed J-shaped association with the risk of psoriasis. Subjects with BMI over 30 had higher risk of psoriasis (HR 1.118, 95% CI 1.1–1.137). The risk of psoriasis increased in proportion to WC. Subjects with WC over 105 cm showed highest risk of psoriasis (HR 1.305, 95% CI 1.261–1.349) after adjusting confounding factors including BMI. The risk of psoriasis increased most in the male group with normal weight, abdominal obesity (HR 1.175, 95% CI 1.15–1.2).

Conclusion: According to our study, the WC is more likely to affect the risk of psoriasis than obesity. Our study supports the association between abdominal obesity and psoriasis, which increases awareness of the role of abdominal obesity in the pathogenesis and comorbidities of psoriasis.

P080

CLINICAL CHARACTERIZATION OF PSORIATIC ARTHRITIS IN A MULTIDISCIPLINARY CARE MODEL OF PATIENTS WITH PSORIASIS

Dalila Alejandra Lopez-Rodriguez
Dermatologico Country

Introduction: Psoriatic arthritis (PsA) is an inflammatory arthropathy that occurs in patients with Psoriasis (PsO). The frequency of PsA in patients with PsO has been estimated between 10–40%. The presentation and clinical course are variable, therefore, it is necessary to understand the clinical behavior, severity and associated factors that condition functional impairment, disability and lost quality of life.

Objective: To describe the clinical features of the ApS, in a multidisciplinary PsO clinic.

Methods: Prospective study, August 2016–february 2018, patients attending to Multidisciplinary Clinic for psoriasis in Dermatologico Country were included.

Results: A total of 53 participants were included, finding a prevalence of psoriatic arthropathy of 58.5%.

The median age was 42 years and 71% were female. Patients with ApS have higher frequency of DM2, metabolic syndrome and hepatic steatosis. However, the differences are not statistically significant, which could be a result of the sample size. According to the activity of PsO the most frequent presentation was plaque psoriasis in 67.7%. Median PASI was 5.4 (1.5, 16.4). Axial presentation of ApS was observed in 51.6% and peripheral disease in 71%, enthesitis was found in 54.8% and dactylitis 16.1%. To determine the severity of PsA according DAS 28 score, we found 45.2% of patients presented severe activity. One hundred percent of the subjects with peripheral disease did not achieve low activity criteria of the disease measured by MDA. When calculating the tertiles of the HAQ instrument, it is possible to observe that 51.6% of patients presented severe deterioration in the quality of life. In the logistic regression model without adjustment, the presence of a severe DAS 28 is associated with an increase in the risk of deterioration in quality of life, with OR of 6.24 (1.74, 22.2). The presence of BMI > 27 is associated with an increase in the risk of deterioration in quality of life with OR of 6.53 (1.59, 26.8). When performing the adjusted multivariate

model, the only variables that were associated with severe deterioration of quality of life were the presence of BMI > 27 and on the other side, pain, with BMI > 27 is the factor that mostly impairs the quality of life.

Conclusions: Prevalence of PsA in this series of patients with skin or nail psoriasis was 58.3%. The 45.2% of patients showed severe activity and 51.6% severe deterioration in their quality of life, that leads to disability and limitation performing daily activities. An early diagnosis provides the possibility of appropriate treatment to improve function, quality of life and decrease the progression and complications of the disease.

P081

TRIGGERING FACTORS IN CHILDHOOD PSORIASIS

Iveta Dencheva¹, Ivan Botev², Lyubka Miteva¹

¹Dermatology clinic "Persenk", ²Department of Dermatology and Venereology, Medical University, Sofia, Bulgaria; Dermatology clinic "Persenk", Sofia, Bulgaria

Introduction: Psoriasis is a chronic multisystem, inflammatory disease that occurs at any age. It represents about 4% of all dermatosis observed in children. Approximately one third of all patients have onset of the disease under the age of 16. The most common triggering factors in children are stress, Koebner phenomenon, infections and seasonal change.

Objectives: The aim of this study was to assess the most common triggering and precipitating factors of psoriasis among Bulgarian children.

Materials and Methods: This study included 42 consecutively diagnosed children with psoriasis who presented in the Department of Dermatology and Venereology at Alexandrovska University Hospital, in Sofia, Bulgaria. The inclusion criteria were a clinical diagnosis of psoriasis and age under 18 years.

Results: A total of 42 children with psoriasis were examined, 18 (42.85%) males and 24 (57.15%) females. The most frequent factors precipitating psoriasis in our group of children were psychosocial stress in 16 (38.09%) cases. Koebner's phenomenon was observed in 3 (7.14%) patients. In only two (4.76%) children triggering factors associated with psoriasis were infections. In 17 (40.47%) cases aggravating factors could not be identified. The influence of the season on disease activity could be determined in 25 (59.52%) patients. All of them showed worsening in winter and improvement in summer.

Conclusion: The most frequent factors precipitating psoriasis in children revealed in this study, were stressful life events, Koebner phenomenon and infectious disease. Among patients who reported triggering factors, stress was the most common cause. The study showed that psoriasis in children relapses and worsens mainly in winter season.

P082

QUALITY OF CARE FOR PSORIASIS IN THE PAST 12 YEARS – RESULTS FROM A SERIES OF NATIONWIDE HEALTH CARE STUDIES IN GERMANY

Matthias Augustin

Institute for Health Services Research in Dermatology

Introduction: In Germany, the quality of health care for psoriasis was very critical in 2005. Most patients lacked of sufficient care and there was only a minor proportion receiving systemic drugs. In the mean time, there has been conducted a national psoriasis program in order to improve the quality of psoriasis care, including development of an evidence-based guideline, a consensus of treatment goals, the invention of a "culture of measurement" and consented national goals for psoriasis care. These measures were supported by the establishment of 30 regional psoriasis networks involving more than 800 dermatologists.

Objectives: (1) Presentation of the very recent results on the health care situation of patients with psoriasis vulgaris in dermatological

treatment in Germany 2016/17 (2) Comparison of health care quality indicators between the surveys 2004/05, 2007, 2013/14 and 2016/17.

Methods: Nationwide, non-interventional, cross-sectional studies. In each survey between 71 and 130 centers included patients and data from patients and dermatologists were obtained from a minimum of 1500 patients per survey. Quality of care indicators were severity of the psoriasis (PASI and proportion of patients with PASI > 20, indicating high severity), quality of life (DLQI and proportion of patients with DLQI > 10, indicating strong impairments in quality of life), previous systemic therapy and inpatient treatment in the last five years.

Results: Between January 2016 and December 2017 $n = 1827$ patients from 93 dermatological centers were included in the recent survey (mean age 51 years, 45.2% female). 7.5% had severe psoriasis (PASI > 20) compared to 9.2% in 2013/14, 11.6% in 2007 and 17.8% in 2004/05. The mean PASI was 7.3 compared to 8.1 in 2013/14, 10.1 in 2007 and 11.4 in 2005. The mean DLQI was 6.1 compared to 5.9 in 2013/14, 7.5 in 2007 and 8.6 in 2005. 21.4% reported a strongly impaired quality of life (DLQI > 10) compared to 21.3% in 2013/14, 28.2% in 2007 and 34.0% in 2005. 59.5% of all participants stated that they had received systemic therapy at least once within the last five years compared to 59.5% in 2013/14, 47.3% in 2007 and 32.9% in 2005. 18% received inpatient hospital treatment within the last five years at least once, compared to 20.1% in 2013/14, 20.1% in 2007 and 26.9% in 2005.

Conclusions: It can be assumed that health care quality for psoriasis patients in Germany has improved within the last 12 years.

P083

GLOBAL PSORIASIS ATLAS – WORK STREAM 2

Matthias Augustin, Nirohshah Suthakharan

University Medical Center Hamburg, Institute for Health Services Research in Dermatology and Nursing (IVDP)

Introduction: Psoriasis is a common, chronic and non-communicable skin disease with an immensely negative impact on people's lives. There is a lack of standardized case-definition or methodology leading to a wide variation in the prevalence estimate between 0.09% and 11.43%. To tackle this knowledge deficit and in response to the WHO Global report on Psoriasis (2016), the Global Psoriasis Atlas (GPA) will be a first-ever online leading epidemiological database on psoriasis. It will inform research, policy and health care provision worldwide. GPA provides a detailed disease prevalence and incidence as well as information on access to treatment, comorbidities and cost to society which will enable extensive comparisons between countries over time. Furthermore, it will provide accurate health data for decision makers, stakeholders and patients worldwide.

Objectives: The GPA includes two Work Streams (WS) Teams. WS1 is conducting extensive literature review on psoriasis. In this paper the WS2 is explaining the development of methodology to serve the framework for compiling the GPA data. **Methods:** Currently, data sources are being collected in two phases and for the selection of data sources an in-/exclusion criteria were developed and followed. Firstly, a global online survey on data source identification is being conducted in > 150 countries worldwide addressed to dermatologists and non-dermatologists. The questionnaire identifies local, regional and national data sources including registries, research institutes, projects, publications and other relevant sources supporting the GPA project. Secondly, Desk research on the same data sources is being conducted. Discussion on the following aspects: identification of non-published sources, integration of different sources, solving interpolation issues of hard-to-reach areas and creating database.

Results: Desk research has identified potential data sources from 199 countries which includes 194 ministries of health, 97 registries, 84 patient associations, 32 statistic institutes, 25 Public Health

organizations, 230 research institutes (general/psoriasis specific), 13 claim data sources and 261 publications on psoriasis. The internal pilot for the global online surveys has been completed by an international expert team for further improvement. Currently, the surveys are being sent out to dermatologists and non-dermatologists. On a monthly base, both work streams are updating each other about their achievements and issues.

Conclusion: In the next steps of Work Stream 2, a database will be created in order to insert all identified data sources. Information from identified data sources will be used to contact (via email) the responsible persons to access this data. Additionally, survey responses will be analyzed and added in the database. This database will be updated regularly and extended to include comorbidities in future.

P084

GLOBAL BURDEN OF DISEASE: A SYSTEMATIC LITERATURE REVIEW ON DISABILITY WEIGHTS FOR SKIN DISEASES

Nirohshah Suthakharan, Matthias Augustin

University Medical Center Hamburg, Institute for Health Services Research in Dermatology and Nursing (IVDP)

Introduction: Skin diseases account for one of the most common human illnesses globally but in the recent Global Burden of Disease (GBD) study, psoriasis, for example, ranked 144 out of 174 conditions in the DALY rankings. Two components of DALY calculation are prevalence of the disease and disability weight factor. The derivation of disability weight (DW) factor depends on many factors which can lead to wide range of results. GBD methodology can significantly underestimate the skin disease burden.

Objective: To understand the currently used DWs of skin diseases in-depth and if these current records of DWs can be solely based on a survey that was conducted on the general population.

Methodology: A systematic literature review was performed to answer the research questions. Comprehensive search of eligible scientific and grey publication in English, from 2007 to 2017, were conducted in PubMed and EMBASE (Ovid). The studies included were based on 16 skin condition and other diseases indicating a re-estimation, alternative approach (also besides DALY) to DWs. 20 relevant studies were included and have been elaborated in the review based on a 'conceptual model of assessing DWs and its design choices' by Haagsma et al., 2014. The health state descriptions, panel composition, and valuation methods used to derive DWs in these studies is discussed in detail.

Results: There was scarce literature available for skin diseases in particular. DW value depends on and can vary with the panel composition: general public, health experts or patients. The health state description whether disease specific or generic, with or without label, describing the course of condition over a period or only temporarily, can all influence the panel members' decision. The valuation methods paired comparison, population health equivalence, visual analogue scale, standard gambling or person/time trade-off can alter the results to a great extent. The contextual differences across the countries can also make a difference in the calculation. The inclusion of certain skin conditions/health states under other medical specialties can be a major factor leading to underestimation of overall skin disease burden worldwide.

P085

MIR-499 POLYMORPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO PSORIATIC ARTHRITIS – PRELIMINARY STUDY

Renata Sokolik¹, Jerzy Świerkot¹, Milena Iwaszko², Mikołaj Kozłowski¹, Lucyna Korman¹, Piotr Wiland¹, Katarzyna Bogunia-Kubik²

¹Department and Clinic of Rheumatology and Internal Medicine of Wrocław Medical University, ²Laboratory of Clinical Immunogenetics and

Pharmacogenetics, Hirsfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

Introduction: Polymorphism within the miR-499 has been reported to be associated with susceptibility to rheumatoid arthritis (RA) in various populations.

Objectives: Our study aimed to find out whether similar association could be observed also in Polish population in both RA and psoriatic arthritis (PsA) patients.

Methods: For this purpose 359 individuals were studied, including 111 RA patients, 86 patients with PsA and 162 healthy blood donors that served as a control group. Genotyping for miR-499 rs3746444 T/C was performed using a LightSNiP assay.

Results: Distribution of the miRNA-499 alleles and genotypes was similar in RA patients and controls. Among RA patients those carrying the CC homozygous genotype presented with lower DAS28 at diagnosis (0.027) but higher CRP levels after 12 weeks of anti-TNF treatment ($p=0.042$). Interestingly, the TT genotype (rs3746444) was overexpressed in patients with PsA as compared to controls (OR = 1.85, $p=0.034$) but its frequency was not significantly different when compared to RA cases. This polymorphism was also not found to be associated with clinical parameters in PsA patients.

Conclusions: These results show that miR-499 rs3746444 T/C polymorphism may constitute a risk factor for psoriatic arthritis development.

P086

ASSOCIATION BETWEEN INFLAMMASOME-RELATED POLYMORPHISMS AND CLINICAL PHENOTYPES OF PSORIATIC ARTHRITIS

Kristina Juneblad, Gerd-Marie Alenius

Department of Public Health and Clinical Medicine, Rheumatology, University Hospital, Umeå

Introduction: Psoriatic Arthritis (PsA) disease expression can vary from mild mono-/oligoarthritis to severe erosive polyarthritis comparable with Rheumatoid Arthritis (RA), with or without axial involvement, and manifestations such as dactylitis and enthesitis are common. Markers of systemic inflammation (ESR or CRP) are generally unhelpful as markers of disease severity since elevated in only 50% of cases.

In recent years, research on the interleukin 1 β (IL1 β)-regulating protein complex, called the inflammasome, has shown interesting associations with various inflammatory diseases. E.g. for RA (1) and psoriasis (Pso) (2,3) associations with genetic polymorphisms in genes related to the inflammasome has been discovered. So far, no studies investigating genetic polymorphisms in inflammasome genes in patients with Psoriatic Arthritis (PsA) have been published.

Aim: To analyse different single nucleotide polymorphisms (SNP:s) in genes related to the inflammasome in relation to different disease phenotypes of Psoriatic Arthritis (PsA).

Methods: DNA from 771 PsA patients from Northern Sweden were analyzed for different single nucleotide polymorphisms (SNPs) in *NLRP3* (rs35829419 (*NLRP3*-Q750K), rs10733113, rs4353135), *CARD8* (*CARD8*-C10X, rs 2043211) and *NLRP1* (rs8079034, rs878329) in relation to different phenotypes of PsA.

Results: A significant association was seen with *NLRP1* rs878329C and patients with axial involvement of disease. When different genotypes were compared, significantly higher frequency of genotype CC were detected in the subgroup with axial involvement of disease. In addition, *NLRP1* rs8079034T was significantly associated with prescription of a csDMARD. Also, the *NLRP3* rs10733113 showed association with the G-allele in patients with a skin disease with an early onset (Pso type1, onset <40 years) and in the subgroup of PsA with destructive-/deforming disease significant association was found with the major allele, C, of *NLRP3* Q705K rs35829419. (Table 1)

Conclusions: In the study, we found association with different phenotypes of PsA and different polymorphisms in inflammasome genes. The results could indicate a possible role of inflammasomes in different disease phenotypes of PsA and make further studies in the area of interest.

References:

1. Kastbom A, Verma D, Eriksson P et al. Rheumatol 2008;47:415-7.
2. Carlström M, Ekman AK, Petersson S et al. Exp Dermatol 2012;21:932-7.
3. Ekman AK, Verma D, Fredrikson M, Bivik C and Enerbäck C. Br J Dermatol 2014;171:1517-20.

Table 1. Genotype and allele frequencies in different PsA disease expressions[#]

| | Genotype | | | | C allele | χ^2 | OR (95% CI)* | p-value |
|------------------------|----------|-----------|-----------|-----------|----------|----------|--------------|---------|
| | n | G/G n (%) | G/C n (%) | C/C n (%) | | | | |
| NLRP1 rs878329 | | | | | | | | |
| Axial disease | 107 | 30 (28) | 51 (48) | 26 (24) | 48% | 4.44 | 1.37 | 0.035 |
| | | | | | | | (1.02–1.84) | |
| Peripheral disease | 539 | 184 (34) | 275 (51) | 80 (15) | 41% | | | |
| NLRP3 Q705K | | C/C | C/A | A/A | C allele | | | |
| rs35829419 | | | | | | | | |
| Destructive disease | 314 | 282 (90) | 32 (10) | 0 (0) | 95% | 4.7 | 1.61 | 0.03 |
| | | | | | | | (1.05–2.57) | |
| No destructive disease | 360 | 304 (84) | 54 (15) | 2 (0.6) | 92% | | | |
| NLRP3 rs10733113 | | G/G | G/A | A/A | G allele | | | |
| Pso type1 | 439 | 347 (79) | 87 (20) | 5 (1) | 89% | 7.4 | 1.58 | 0.007 |
| | | | | | | | (1.13–2.21) | |
| Not Pso type1 | 210 | 149 (71) | 53 (25) | 8 (4) | 84% | | | |
| NLRP1 rs8079034 | | C/C | C/T | T/T | T allele | | | |
| csDMARD ever | 499 | 320 (64) | 169 (32) | 19 (4) | 20% | 9.1 | 1.63 | 0.003 |
| | | | | | | | (1.19–2.25) | |
| Never csDMARD | 216 | 164 (76) | 47 (22) | 5 (2) | 13% | | | |

*Calculated with χ^2 test comparing variant allele frequencies between patients and controls.

[#]Only significant association are shown.

P088

FREQUENCY OF INADEQUATE RESPONSE TO TREATMENT AMONG PSORIASIS PATIENTS ON FIRST-LINE BIOLOGICS

Anna Sheahan¹, Edward Lee², Lisa Pisenti², Mohamed Yassine², Robert Suruki³

¹UCB Pharma, Raleigh, NC, ²UCB Pharma, Smyrna, GA, ³UCB Pharma, Raleigh, NC

Introduction: Studies describing the occurrence of inadequate response (IR) to biologic treatments in psoriasis (PSO) in the real-world setting are currently lacking. Thus an understanding of IR, due to the lack of treatment durability, persistence, or access, to 1st line biologics in PSO may help to identify and address unmet treatment needs.

Objectives: To assess the frequency of IR in the year after initiation of 1st line biologic treatment for PSO. IR was defined as biologic dose increase, biologic discontinuation, or add-on treatment.

Methods: Retrospective analysis of commercial US healthcare claims (2012–2016) was conducted. Patients initiating a biologic (PSO approved anti-TNF, secukinumab, ustekinumab, apremilast) with ≥ 1 year of database enrolment before and after biologic initiation (index date) who had a qualifying PSO ICD 9/10 code and no previous biologic exposure in the year prior to the index date were included. Patients experiencing any of the following were classified as experiencing an IR event: 1) ≥ 1 claim with a biologic dose > 110% of the label-recommended dose for ≥ 30 days, 2) cessation of 1st line biologic (> 2 months with no treatment) ('non-switch discontinuation'), 3) cessation of first line biologic followed by initiation of a new biologic within 2 months, or 4) addition of a corticosteroid, immunosuppressant, or biologic ('add-on treatment') with any days' supply overlap.

Results: Of the 13,995 patients meeting inclusion criteria, 9,520 (68.0%) experienced an IR event in the 12-month follow-up period (53.2% female; mean age: 46.2 yrs) and 4,475 (32.0%) did not experience an IR event (45.2% female; mean age: 46.9 yrs). The most frequently used 1st line biologics were adalimumab (42.5%) and etanercept (26.5%); the proportion of IR patients was 60.4% in adalimumab and 75.8% in etanercept. Among all IR patients,

non-switch discontinuation was experienced by 63.8% of patients, switch to another biologic by 15.1%, above label dosing by 11.5%, and add-on treatment by 9.7%. Overall, the mean time from initiation of 1st line treatment to IR event was 4.7 months, ranging from 4.3 months to add-on therapy and 5.7 months for patients switching to another biologic. Among patients switching to another biologic, 70.3% of patients were persistent on the new biologic after three months versus 54.0% after 6 months. The most frequent add-on therapies were immunosuppressive drugs (63.8%) followed by systemic corticosteroids (20.6%), and biologics (15.5%).

Conclusions: IR in 1st line PSO biologic treatment is common with non-switch discontinuation being the most frequent. This highlights an opportunity to optimize treatment options currently available and better understand patients' needs for successful therapy. Therapeutic options with improved durability may provide a clinically meaningful path to optimizing psoriasis management. Further analysis is necessary to identify underlying causes of IR and to guide more effective approaches to treatment.

Acknowledgements: This study was supported by UCB Pharma.

P089

BARRIERS OF GUIDELINE-COMPLIANT CARE FOR PSORIASIS IN GERMANY – RESULTS OF THE EUROPEAN STUDY PSOBARRIER

Matthias Augustin, Anna Langenbruch, Marc Radtke, Nicole Zander
University Medical Center Hamburg-Eppendorf

Introduction & Objectives: A series of nation-wide studies in Germany over the last years has focused on the quality of psoriasis care. It was found that a significant proportion of psoriasis patients is not treated according to the national guideline¹. Similar underprovision of care has been identified in other countries as well, reflected by patients' dissatisfaction with the management of their disease². This study aims to identify these barriers of guideline-compliant healthcare for psoriasis in Europe.

Materials & Methods: The study assesses barriers and quality of health care in a multi-centre, cross-sectional study design. Participating centres in five European countries (Denmark, Poland, Spain, United Kingdom, and Germany) aim to represent the range of dermatological health care-providing outpatient facilities of the respective country. The current analysis includes the data collected in Germany from January 2016 to May 2017.

Results: Data of $n = 497$ patients were analysed. Mean age was 49.7 years, 41.4% were female. Mean PASI was 7.2 ± 9.2 , 20.9% had a PASI > 10. The mean DLQI was 6.2 ± 6.7 . 27.0% were currently treated with systemics (excluding biologics), 22.3% with biologics. Since the diagnosis of psoriasis, the participants consulted on average 3.0 ± 2.3 different dermatologists (min 0/max 27) and had 3.5 ± 3.7 therapy changes. For 32.0% of the patients the time between the first skin changes and the first diagnosis of psoriasis was one year or longer. 7.6% stated that their health insurance turned down a therapy, treatment or referral that was recommended by a physician at least once.

Conclusions: The quite high numbers of consultations of different dermatologists, therapy changes and therapies turned down indicate that there might be barriers in psoriasis care. The generated data facilitate measures for an improved patient access to systemic drugs and biologics. The European comparison will allow for the first time the direct description of psoriasis care in a wide variety of European countries. The matching of patient-reported outcomes with data of the health care system and barriers from the physician's perspective is a novelty worldwide and the results will contribute to developing strategies to overcome these barriers.

References:

- 1 Augustin M, Schäfer I, Reich K, Glaeske G, Radtke MA. Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines. *J Dtsch Dermatol Ges.* 2011;9:833–38.
- 2 Dubertret L, Mrowietz U, Ranki A, van de Kerkhof, P C M, Chimenti S,

Lotti T, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. *Br J Dermatol.* 2006;155:729–36.

P090

INDIVIDUALISED THERAPY FOR PSORIASIS - CASE SERIES

Seema Mahesh¹, Viraj Shah², Mahesh Mallappa¹, George Vithoulkas³

¹Centre For Classical Homeopathy, ²Shah Homeopathic Clinic, ³International Academy of Classical Homeopathy

Introduction: Psoriasis and its complications are still a challenge to clinicians. The autoimmune disorder though targeting the skin, involves the immune system as a whole. The inflammatory component in the pathogenesis of psoriasis has further established the role of aberrant immune system in the process [1, 2, 3].

Homeopathy addresses every individual's peculiar combination of genetic and epigenetic causative factors in the development of such auto immune diseases [4, 5]. Therefore it may be considered as a therapy where integrated approach is indicated.

Case series: 5 cases of psoriasis are presented, two of which were in erythrodermic state [one also with sepsis superimposed]. Through monitoring of blood markers and documenting on photos and videos the effect of individualised homeopathic therapy on psoriasis and its complications is demonstrated.

The theory of Levels of Health can explain the variety in the presentation of psoriasis and response to treatment in terms of the time taken and number of remedies required. The same theory also helps to assess the prognosis and comprehend the response to treatment [LOH]. With the help of the evidence of these cases we may formulate a larger study to ascertain the extent to which classical homeopathy may be employed in psoriasis.

Conclusions: These cases depict the potential for homeopathy in alleviating the suffering of patients with psoriasis if applied as individualised therapy and give grounds to further conduct controlled studies to confirm the role of homeopathy in psoriatic therapy.

References:

1. Boyd A, Menter A. Erythrodermic psoriasis. *Journal of the American Academy of Dermatology.* 1989;21(5):985-991.
2. Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis of psoriasis pathogenesis. *Molecular Immunology.* 2015;64(2):313-323.
3. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. *Journal of the European Academy of Dermatology and Venereology.* 2012;26:3-11.
4. Vithoulkas G, Tiller W. The science of homeopathy. Athens: International Academy of Classical Homeopathy; 2009.
5. Vithoulkas G. Levels of health. Alonissos: International Academy of Classical Homeopathy; 2017.

P091

A UNIQUE CLINICAL CASE OF PSORIATIC ARTHRITIS AND RELAPSING POLYCHONDROITIS

Elena Gubar, Alla Godzenko, Tatiana Korotaeva
Nasonova Research Institute of Rheumatology, Moscow

Introduction: Relapsing polychondritis (RP) is a rare systemic autoimmune disorder affecting the cartilaginous structures of the body and resulting in their destruction. In the literature available we didn't find any references to RP occurring together with psoriatic arthritis (PsA).

Objective: to demonstrate a rare clinical case of RP and PsA.

Methods: Patient (pt) (female), 29 y.o., complained of pain, swelling, and hyperemia of both ears, pain in the joints, in heels and toes and pain in cervical spine. Scalp psoriasis (Ps) and Ps in the external ear canal occurred in April, 2017, nail Ps and dactylitis in October, 2017; in November, asymmetrical polyarthritis, pain in heels, pain and limitation of movement in cervical spine developed. Besides the pt noticed redness, swelling and pain in pinnae of both ears and impairment of hearing; conjunctivitis, stomatitis and subfebrile temperature developed.

At presentation: plaque Ps on the face and scalp, nail Ps, palmo-plantar feet pustulosis (BSA=4%, PASI =2.1); both pinnae of the ears were swollen, painful and red; ear lobes were not involved. The pt suffered from conjunctivitis. The pt had asymmetrical polyarthritis, dactylitis, achillobursitis. Painful movements at cervical spine, rotation 30°-35°. ESR 54 mm/h, CRP 99 mg/l, RF negative, positive HLA B27, HLA B5 not detected. PET-CT imaging did not reveal any pathological changes besides bilateral auricular inflammation.

Results: PsA diagnosis was determined according to CASPAR criteria. RP diagnosis was based on the McAdams criteria. The diagnosis is definite when no less than three out of six criteria are present: bilateral auricular chondritis, nonerosive seronegative arthritis, nasal septum chondritis, ocular inflammation, respiratory tract chondritis, and cochlear disorder. Our pt had bilateral auricular chondritis, conjunctivitis, cochlear disorder. The diagnosis was confirmed by ear-auricles biopsy which showed perichondrial inflammation and granulocyte infiltration. The therapy delivered: methotrexate s/c 10 mg pw; Solu-Medrol i/v (750 mg cumulatively); methylprednisolone per os 16 mg per day. Within days, there was normalization of temperature, ear-auricle swelling, redness and pain had regressed; hearing was restored, conjunctivitis passed, the intensity of arthritides, dactylitis and spondylitis had decreased; the reduction in ESR, CRP was to 14 mm/h, to 7.0 mg/l accordingly.

Conclusion: As is known, when a pt has PsO, he is twice as likely to develop additional autoimmune diseases. It is of great importance to properly diagnose and treat cross autoimmune diseases. Early diagnosis (within 3 months) and adequate treatment resulted in rapidly decreased inflammatory process and in escaping nonreversible changes in cartilage tissues.

P092

SPINY FOLLICULAR HYPERKERATOSIS IN A PSORIASIS PATIENT TREATED WITH USTEKINUMAB

Antoanela Carija, Adela Markota Cagalj, Neira Puizina Ivic
University Hospital Centre Split

Introduction: We present a psoriasis patient developing asymptomatic white spiny follicular hyperkeratoses (SFH) after being treated with ustekinumab for 3 months.

Objectives: This type of eruption has been described under several names including spiny follicular keratoderma, hyperkeratotic spicules, filiform hyperkeratoses, parakeratotic horns, and follicular hyperkeratoses (1). Facial hyperkeratotic spicule eruption was reported in association with monoclonal gammopathy. Drug-induced filiform hyperkeratosis has been reported with cyclosporine, with BRAF inhibitors (vemurafenib), with acitretin and with vismodegib and sorafenib.

Methods: Our patient started ustekinumab treatment in June 2015. At the same time he was treated with methotrexate, folic acid, metformin and lisinopril/hydrochlorothiazide. Three months after ustekinumab introduction patient noticed growth of tiny skin projections located on the face, scalp, upper trunk and upper arms. Each spiny lesion was approximately 0.5 to 1 mm in diameter and up to 5 mm high. A biopsy of a white spiny keratotic projection showed orthokeratosis, acanthosis and mild spongiosis in epidermis, inflammatory infiltrate in chorion and dilated acrotrichiums. Condition resolved in several weeks without any treatment and without ustekinumab cessation.

Results: A similar condition viral-associated trichodysplasia (TS) was originally described in 1999 as a folliculocentric viral infection in a patient who was receiving cyclosporine after kidney and pancreas transplantation. Trichodysplasia spinulosa associated polyomavirus (TSPyV) was identified in TS lesions and shown to be the probable cause of this disease (2). Pathogenesis both of viral-associated TS and BRAF inhibitor-induced SFH is based on the paradoxical activation of MAPK (mitogen-activated protein

kinase) pathway, which regulates a variety of cellular processes including cell division, differentiation and apoptosis.

Conclusions: Our patient developed SFH possibly due to use of ustekinumab, IL-12 and IL-23 inhibitor. The latter has a role in differentiation process of the skin (12), suggesting that inhibition of IL-23 might explain the imperfect keratinization process observed in SFH. Considering that in our patient drug was not stopped and the condition resolved in several weeks without any treatment, possible cause could be ustekinumab-induced immunosuppression and consequent viral infection.

References:

1. Yanik ME, Erfan G, Albayrak H, et al. Acitretine-induced spiny follicular hyperkeratosis. *Cutan Ocul Toxicol.* 2016;35:165-167.
2. DeCrescenzo AJ, Philips EC, Wilkerson MG, et al. Trichodysplasia spinulosa: A rare complication of immunosuppression. *JAAD Case Reports.* 2016;2:307-309.

P093

COMBINATION THERAPY OF APREMILAST AND BIOLOGICAL PRODUCT IN A PATIENT WITH PSORIASIS

Koji Masuda, Fuminao Kanehisa, Norito Katoh
Department of dermatology, Kyoto Prefectural University of Medicine

Apremilast was approved in March 2017 in Japan for the treatment of psoriasis and psoriatic arthritis. Apremilast appears to have lower efficacy than biological product. However, its ease of administration as an oral agent coupled with a mild side effect profile makes it an attractive option for psoriasis treatment. While monotherapy with biological products is effective for many patients with psoriasis, some patients are not satisfied by the outcome. There are few data or reports about the safety and efficacy of apremilast in combination of biological product in the treatment of psoriasis.

We report a 46-year-old man with about a twenty-year history of plaque psoriasis and psoriatic arthritis who failed several therapies including topical therapy, phototherapy and etretinate. At the time of presentation, the patient was using secukinumab for 9 months, which had controlled his arthritis. However, the patient noted plaque remained mainly on his lower legs. Apremilast was added and up-titrated to 30 mg twice per day along with his secukinumab therapy. After two months of combination therapy, the patient's disease has improved and stabilized with only a few scattered erythematous mildly scaly plaques on his lower legs. The patient denied side effects of nausea, diarrhea or headache. Laboratory work was within normal limits.

However, we also experienced two other cases who failed apremilast add on therapy to biological product because of efficacy or side effects. So, this method may be useful for uncontrolled patient for psoriasis, more studies are needed to determine the safety and efficacy of using these drugs together.

P094

PSORIASIS WORST-CASE SCENARIOS: A SERIES OF 3 CASE REPORTS

Elena Popa¹, Persa Ghitulescu², Patricia Cristodor¹, Caius Solovan¹

¹Department of Dermatology and Venereology, Clinical Emergency Municipal Hospital Timisoara; University of Medicine and Pharmacy "Victor Babes" Timisoara, Romania, ²Department of Dermatology and Venereology, Clinical Emergency Municipal Hospital Timisoara

Introduction: Psoriasis is a chronic, immune, inflammatory disease, that can occur at any time and it is most common in the age group 50-69. The reported prevalence of psoriasis in countries ranges between 0.09% and 11.4%, making psoriasis a serious global problem.

Objectives: We present a series of 3 case reports that stand for some of the worst-case scenarios a Psoriasis patient could end up in.

We won't be insisting on the treatment nor the outcomes of these patients whereas the aim of this presentation is to emphasize the importance of patient's education, prevention, but also of an early and correct treatment.

Materials And Methods:

Case report no.1:

- Patient characteristics: 49-years-old white Caucasian male;
- Clinical presentation: widespread, confluent erythema of the skin, large scales, malaise, intense joint pain, shivers, oliguria, marked onychodystrophy of fingernails and toenails with an evolution of about 1 week;
- Physical examination: fever, tachycardia, generalized nontender adenopathy;
- Patients history: Psoriasis vulgaris and Psoriatic arthritis since 2003 treated with 8 months Methotrexate switched (due to digestive symptoms) to oral Acitretinum for about 2 months prior the current presentation;
- Possible cause of the flare-up: lack of compliance to treatment, but mostly because of disorderly lifestyle.

Case report no.2:

- Patient characteristics: 64-years-old white Caucasian male;
- Clinical presentation: widespread, confluent erythema of the skin, large scales, malaise, loss of appetite, marked onychodystrophy of fingernails and toenails with an evolution of about 2 weeks;
- Physical examination: fever, tachycardia;
- Patients history: Psoriasis vulgaris since 1992 treated with Adalimumab (discontinued after 2 years) and Methotrexate;
- Possible cause of the flare-up: voluntarily discontinuation of the treatment (Methotrexate) 3 weeks prior to current presentation.

Case report no.3:

- Patient characteristics: 38-years-old white Caucasian female;
- Clinical presentation: pustular lesions spread throughout an erythematous background intercalated with skin atrophies and subepidermal pseudocysts disseminated throughout the body, erythematous, scaly plaque on the scalp;
- Physical examination: vital signs within normal limits;
- Patients history: Pustular Psoriasis from the age of 7 treated with Prednisone, Acitretinum and topical steroids;
- Possible cause of the flare-up: voluntarily discontinuation of the treatment (Acitretinum) 7 months prior to current presentation (the patient wishes to conceive) and long-term use of potent topical steroids.

Results: All three cases were treated considering the Psoriasis type, clinical presentation and symptoms, each of them having a positive evolution during the hospitalization and follow-up visits.

P095

SUCCESSFUL SWITCHING TO BIOSIMILAR IN PSORIATIC PATIENT WITH SEVERE DRUG REACTION TO INFLIXIMAB. A CASE REPORT

Maria Politou¹, Maria Pompou¹, Dimitrios Rigopoulos¹, Nikolaos Fekkas², Anastasios Giannoukos¹

¹1st Department of Dermatology-Venereology "Andreas Syggros" Hospital, UOA, ²Department of Dermatology-venereology, 401 Military Hospital, Greece

Introduction: Biosimilar medicines are drugs which are highly similar to other biological medicines already licensed and that do not have any clinically meaningful difference to the originator drug in structure, pharmacokinetics, quality, safety or efficacy.

Objectives: Many clinical and observational studies involving a switch between reference infliximab and its biosimilars have been conducted or are ongoing. Switching between reference biologics and biosimilars should be performed by the prescriber for clinical reasons such as optimizing efficacy or minimizing AES. Efficacy and clinical measures of safety were similar in the switched and not switched groups at studies end. Differences in the type of AES upon switching must also be considered. Because biosimilars are

structurally distinct from innovator biologic, they may produce significantly different side effects. Although, data in the literature suggest that if a patient experience a severe allergic reaction to the originator drug it is most possible the same reaction to happen with the biosimilar this may not always be the case.

Methods/Results: We present a case of a 60 years old female patient with severe plaque psoriasis from 25 years treated with infliximab every eight weeks for the last five years with great therapeutic efficacy. During the last five infusions she presented mild reaction with itching and facial redness which was treated successfully with antihistamines without the need of interrupting the infusion. Patient was also administered pretreatment therapy with a three day course of corticosteroids to minimize these reactions. During the last infusion patient presented severe body rash and hypotension which led to the discontinuation of the infusion. Due to the great therapeutic response and because patient had undergone several therapies in the past which either hadn't tolerated or hadn't responded to, she was reluctant to change therapy so we decided to switch to a biosimilar. Patient is currently through the eight month of treatment with the biosimilar with no sign of reaction and with maintenance of the therapeutic response.

Conclusion: Biologics are much more complex than conventional chemical drugs because they are larger and have more complicated structures, so it is impossible to produce biosimilars that are identical to the originator drug. As a result, the therapeutic efficacy and safety of a biosimilar could vary from the originator because the end product is highly dependent on a proprietary manufacturing process that differs for each manufacturer. Our case suggests that we may try a switch between reference biologic and its biosimilar even when an allergic reaction to the originator drug had occurred, especially when we have a great therapeutic efficacy. However, more data is needed.

P096

SAFETY OF APREMILAST IN THE TREATMENT OF A PSORIASIS PATIENT WITH CHRONIC HEPATITIS B

Christina Fotiadou, Myrto Trakatelli, Despina Papatthemeli, Elizabeth Lazaridou

Second Department of Dermatology-Venereology, Aristotle University Medical School

Introduction: The treatment of patients with moderate-to-severe psoriasis in an everyday clinical setting, sometimes, poses serious challenges. The presence of hepatitis B Virus Infection (HBV) in these patients complicates the therapeutic choices.

Objectives: We report the case of a female patient, 52 years old, suffering from moderate-to- severe plaque psoriasis and chronic hepatitis B.

Methods: She was referred to our outpatient psoriasis clinic with a Psoriasis Area and Severity Index (PASI) score of 13.2. The patient's condition has deteriorated the past year but she had not received any kind of systemic treatment. During our pre-treatment screening tests she was found HBsAg positive although the liver function tests were within normal rates. The HBV serological status of the patient (HBsAg, HBeAg, anti-HBc, anti-HBs and anti-HBe) was estimated. HBV DNA load was measured with the Polymerase Chain Reaction (PCR) method, in order to confirm that the disease was not active, and it was undetectable.

Results: At that point it was decided to treat the patient with Apremilast using the standard titration dosing schedule (10mg on day one and increasing the dose by 10 mg daily) until reaching the maintenance dose of 30mg twice daily on day 6. Antiviral treatment was not given to the patient but liver function tests were performed at a monthly basis and HBV load every three months during treatment. All these test from the baseline until last observation (12 months after) were within normal rates. The patient exhibited an amelioration of her condition from the beginning which was confirmed by the significant reduction of her PASI score

which reached PSI75 at week 12 and PASI90 at week 24. At the time of this writing, one year after the initiation of treatment, the patient remains almost clear from her psoriatic lesions. Apremilast was well-tolerated by the patient.

Conclusions: The treatment of moderate-to-severe psoriasis in the background of chronic HBV limits the therapeutic options due to the possibility of HBV reactivation when the psoriasis patient is treated with immunosuppressive or even immunomodulatory drugs. Apremilast is an oral small-molecule PDE-inhibitor, approved by the Food and Drug Administration for the treatment of moderate-to-severe plaque psoriasis in 2014. It does not target any one cytokine but restores a balance of pro-inflammatory and anti-inflammatory mediators. The pharmacokinetics of Apremilast is not affected by hepatic impairment and the drug is not hepatotoxic. Moreover, it is not contraindicated in patients with active infection. To our knowledge, this is the first reported case of Apremilast psoriasis patient with chronic inactive Hepatitis B. It proved to be both safe and efficacious but large, well-organized studies are needed in order to confirm this conclusion.

P098

IL-22 INDUCES KERATINOCYTES HYPERPROLIFERATION IN PSORIASIS VIA MIR-21 AND MIR-31 UPREGULATION

Florence Abdallah

Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France

Psoriasis is a chronic inflammatory skin disease that affects people of all ages with an estimated 3% prevalence worldwide. It manifests as thick red irritated skin lesions due to imbalanced keratinocytes hyperproliferation and differentiation caused mainly by increased activation of IL-22 pathway in keratinocytes. Emerging studies showed a specific psoriatic miRs signature where miR-21 and miR-31 are one of the most upregulated miRs. The latter act by favoring cellular proliferation and inflammation. Hence, re-conciliating the microRNAs and the immunopathogenic occasions responsible for psoriasis development can be a new approach for developing effective mechanism and target-based agents to treat psoriasis.

The common hyper-proliferation effect of IL-22, miR-21 and miR-31 prompted us to look after a potential interaction between these actors. The expression levels of those 2 microRNAs and that of their targets were evaluated both *in vitro* and *in vivo* studies in presence or absence of IL-22.

We first exploited different skin models to investigate a potential connection between IL-22 and miR-21 or miR-31. The qPCR analysis showed a significant increase in the relative expression (RE) of both miRs in the different models upon IL-22 stimulation during 24h compared to untreated cells. These observations indicate the implication of miR-21 and miR-31 in proliferation-differentiation processes in the different layers of the epidermis. We also examined the miR-21 target RE PTEN involved in cell growth and apoptosis control and the miR-31 target RE ppp6c involved in G1 to S phase transition restriction. In line with the upregulation of miR-21 and miR-31, IL-22 stimulation resulted in significant downregulation of both targets at the genomic and proteomic levels.

We next investigated the *in vivo* correlation between IL-22 and miR-21 or miR-31 respectively in the development of psoriatic lesion. We used the imiquimod-induced psoriasiform skin inflammation in Wild type and IL-22 deficient mice (known to be almost protected from IMQ). Mice displaying a less severe disease form had less miR-21 expression. By contrast, WT mice treated with IMQ exhibited significantly higher miR-21 RE than IL-22^{-/-} mice. Furthermore, miR-31 expression in IL-22^{-/-} mice was identical to miR-31 expression in WT control mice. These results suggest a

direct correlation between IL-22 pathway and miR-31 epidermal expression. In line with these observations, the miR targets (PTEN and ppp6c) were contrariwise proportional to miRs expression confirming by that the specificity of the IL-22/miR-21 and IL-22/miR-31 correlation.

These findings identify IL-22 as a key regulator of miRs implicated in multiple signaling pathways that coordinate keratinocytes proliferation activity

P099

SERUM CONCENTRACION OF IFN-GAMMA IN PATIENTS WITH PSORIASIS: CORRELATION WITH CLINICAL TYPE AND SEVERITY OF DISEASE

Nermina Ovećina-Kurtović, Emina Kasumagić-Halilović, Jasmina Muhović

Dermatovenerology Department Clinical center University of Sarajevo, Bosnia and Herzegovina

Introduction: Psoriasis is a multifactorial chronic inflammatory disease. The etiopathogenesis of the disease is still unclear but there is evidence that many of cytokines released by keratinocytes and inflammatory leukocytes may contribute to the induction or persistence of the inflammatory process in psoriasis.

Objectives: The aim of the study was to evaluate serum concentrations of INF-gamma in patients with psoriasis and the healthy subjects and also to assess a possible association between IFN-gamma, clinical type and severity of disease.

Methods: The study included a total of 60 patients with psoriasis, both genders and all of ages. There were 20 healthy subjects in the control group. According to the clinical type of disease, patients with psoriasis were divided into four groups: psoriasis vulgaris, psoriasis pustulosa, psoriasis erythrodermica and psoriasis arthropatica. Blood samples were collected from all psoriasis patients and from healthy control subjects. Serum IFN-gamma levels were measured by an enzyme-linked immunosorbent assay (ELISA) technique. The severity of psoriasis vulgaris was assessed by Psoriasis Area and Severity Index (PASI) score.

Results: Of the total number of patients suffering from psoriasis 42 (70%) had psoriasis vulgaris. The second most frequent was psoriasis erythrodermica 9 (15%), while 6 (10%) patients had psoriasis pustulosa and 3 (5%) psoriasis arthropatica. The serum concentration of IFN-gamma in patients with psoriasis was significantly higher than that in the control group (1.91±1.79 pg/ml vs 0.91±0.38 pg/ml, respectively). Significantly elevated serum IFN-gamma concentrations were noticed in patients with psoriasis vulgaris (2.15±0.30 pg/ml), compared with patients suffering from psoriasis erythrodermica (1.57±0.68 pg/ml), psoriasis arthropatica (1.33±0.53 pg/ml), and in particular patients suffering from psoriasis pustulosa (1.08±0.21 pg/ml) who had the lowest mean serum concentration of IFN-gamma. There was no statistically significant difference between the mean values of IFN-gamma compared to the clinical type of psoriasis ($p > 0.05$). In the group of patients with psoriasis vulgaris 36 (85.71%) patients had mild form of disease with PASI < 50, and 6 (14.29%) patients had severe disease with PASI > 50. It was not found statistically significant correlation between IFN-gamma and PASI score.

Conclusions: The results of this study showed that psoriasis is associated with significant changes in serum concentration of IFN-gamma. There was no statistically significant correlation between serum IFN-gamma concentrations, clinical type of psoriasis, and also severity of psoriasis vulgaris evaluated by PASI score.

References:

Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. *Cytokine* 2015; 73 (2):342-350.
Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H Serum cytokines and growth factor levels in Japanese patients with psoriasis, *Clin Exp Dermatol* 2010; 35:645-649.

P100**IMMUNOLOGICAL MEMORY EXISTS IN THE RECURRENT LESION AND NONRECURRENT SKIN AFTER REMISSION IN PSORIATIC PATIENTS**

Zhu Shen

Institute of Dermatology and Venereology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

Introduction: Psoriasis usually recurs in previously affected areas, so a pathogenic memory has been proposed, but the nature of such site-specific recurrent memory is not completely known. Tissue-resident memory T (TRM) cells are non-recirculating memory T cells that persist long-term in epithelial tissues, including the skin. Because they can localize in the skin for many months, we speculate that TRM may contribute to recurrent pathology of psoriasis.

Objectives: The aim of the present study is to compare the differences of quantity proportion and secretion ability of cytokines of the TRM cells between recurrent and nonrecurrent lesions following remission, as well as to explicit the possible survival signal for these TRM cells in psoriatic lesion.

Methods: RNA-Seq, Gene Ontology and KEGG analysis, real-time PCR, flow cytometer analysis/sorting, cell stimulation assay, and western blot were used to explore the immunological memory.

Results: Compared with normal skin, there are common shared genes significantly upregulated (> 2 folds, $p < 0.001$) by recurrent and nonrecurrent lesions, including CD69. CD69 mRNA transcription level in nonrecurrent lesions after remission remains as high as in neighboring recurrent lesions. CD8+CD69+ TRM cells exist in both lesions, and they can secrete almost same amount of IL-17A and IL-22 after stimulation. Levels of IL-15, secreted by keratinocytes in psoriasis epidermis, in nonrecurrent lesions remain as high as in neighboring recurrent lesions, and recombinant human IL-15 can induce CD69 on TRM cells.

Conclusions: Our preliminary study shows that CD8+CD69+ TRM cells persist in clinically resolved psoriatic lesions whether it recurs or not, and they can produce IL-17A and IL-22 with critical effect on psoriatic recurrence and development. Furthermore, we have indicated the IL-15 may play crucial role in the survival of CD8+CD69+ TRM cells in psoriatic lesions.

References:

1. Mueller SN, Mackay LK. Tissue-resident memory T cells: local specialists in immune defence. *Nat Rev Immunol.* 2016 Feb;16(2):79-89.
2. Clark RA. Resident memory T cells in human health and disease. *Sci Transl Med.* 2015 Jan 7;7(269):269rv1.
3. Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. *Nat Med.* 2015 Jul;21(7):688-97.
4. Cheuk S, Wikén M, Blomqvist L, Nylén S, Talme T, Ståhle M, Eidsmo L. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. *J Immunol.* 2014 Apr 1;192(7):3111-20.

P101**INVESTIGATING SYSTEMIC INFLAMMATION AS THE COMMON LINK BETWEEN DEPRESSION, PSORIASIS, AND PSORIATIC ARTHRITIS IN US VETERANS***Samar Gupta¹, Alicja Wasilewski²**University of Michigan¹, MI State²*

Introduction: Psychosocial factors are important in the onset and/or exacerbation of psoriasis in 40% to 80% of cases. Psoriasis has been associated with suicide, and an increased prevalence of alcoholism and a range of personality characteristics.

A recent systematic meta-analysis of 98 eligible studies with a total of 401,703 psoriasis patients showed that patients with psoriasis were approximately one and a half times more likely to exhibit signs of depression compared with healthy controls. [1].

Emerging evidence suggests that depression, like psoriasis, is associated with systemic inflammation, and the systemic inflammatory profile of the two conditions show similar traits. Depression

is considered to have a strong inflammatory component, similar to psoriasis, e.g. interleukin (IL)-2, IL-6, IL-12, and tumour necrosis factor (TNF)- α [2-5].

US Veteran population has increased incidence of mental health issue as compared to general population, making Veteran group a unique population that warrants investigation.

Objectives: Hypotheses - 1/ Veterans with concomitant depression and psoriasis/PsA may have elevated inflammatory markers like CRP, ESR, and SPEP. 2/ Depression may improve with the treatment of psoriasis/psoriatic arthritis without antidepressant use.

Methods: A 36-month retrospective chart review of 100 veterans with diagnosis of depression and psoriasis/psoriatic arthritis. Elevated inflammatory markers, including sedimentation rate, C-reactive protein (CRP) and serum protein electrophoresis (SPEP), as well as longitudinal disease course of depression (PHQ-8) and psoriasis/psoriatic arthritis (HAQ-DI); specifically disease activity, and depression symptoms will be assessed. We then aim to draw a correlation between disease activity and active depressive symptoms.

Results: to be available

Conclusions: to be available

References:

1. Dowlatsahi EA, et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. *J Invest Dermatol* 2014; 134: 1542-1551.
2. Allison DJ, Ditor DS. The common inflammatory etiology of depression and cognitive impairment: a therapeutic target. *J Neuroinflammation* 2014; 11: 151.
3. Dantzer R, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008; 9: 46-56.
4. Han Q-Q, Yu J. Inflammation: a mechanism of depression? *Neurosci Bull* 2014; 30: 515-523.
5. Dowlati Y, et al. A meta-analysis of cytokines in major depression. *Biol Psychiatry [Internet]* 2010; 67: 446-457.

P102**THE IMMUNE-PHENOTYPE OF SMALL PLAQUE PSORIASIS***Touraj Khosravi-Hafshejani¹, Mehran Ghoreishi², Cristian Vera Ketter³, Magdalena Martinka⁴, Jan Dutz¹**¹Department of Undergraduate Medical Program, Faculty of Medicine,**²Department of Dermatology, and Skin Science and ⁴Department of Pathology and Laboratory Medicine, University of British Columbia, ³Department of Dermatology, Pontifical Catholic University of Chile*

Introduction: Small plaque psoriasis (SPP) is a subtype of psoriasis first described by Griffiths et al (2007). It resembles guttate psoriasis but lesions are larger, are chronic, and are not associated with streptococcal infection. We have observed SPP develop in four different population groups; patients under TNF α -inhibitor therapy, patients under immune checkpoint inhibitor (ICI) therapy, and patients with concurrent SLE or ANA positivity and psoriasis. Subtypes of psoriasis develop on a spectrum between autoimmune and auto-inflammatory responses and an interplay between three signalling pathways are involved in their distinct pathogenesis. Chronic plaque psoriasis lesions are on the autoimmune spectrum, dominated by a T-cell mediated TNF α /IL-23/IL-17/IL-22 axis. Pustular psoriasis is a neutrophilic infiltrative inflammatory skin disease resulting from dysregulation of the IL-36/IL-1 axis. Lastly, TNF α -inhibitor (TNFi) induced lesions have a SPP morphology and demonstrate increased expression of LL37 by keratinocytes, activated plasmacytoid dendritic cells and upregulated type-1 interferons (IFN). These lesions express fewer epidermal CD8 T cells.

Objectives: Our aim is to characterize the immune-phenotype of SPP in multiple clinical scenarios. We hypothesize that SPP develops as a result of increased expression of cytokines and antimicrobial peptides involved in the type-1 IFN pathway.

Methods: Skin biopsies were obtained from three patients with

TNFi-induced psoriasis, three patients with SLE and psoriasis, three patients with positive ANA and psoriasis, two patients with ICI-induced psoriasis and two patients with chronic plaque psoriasis as control. Immunohistochemistry was performed using antibodies against type-1 IFN induced MXA, LL37, IL-36 and CD8 T cells. The intensity and the area of positively stained samples were each graded from 0–4 and then multiplied to provide a final score. **Results:** Small plaque lesions in various clinical scenarios had histologic changes consistent with psoriasis. Immunohistochemical evaluation revealed an increased expression of MXA (TNFi = 14, SLE = 13.3, ANA = 11.3, ICI = 16 vs. control = 6, t-test $p < 0.05$), LL37 (TNFi = 10.8, SLE = 6, ANA = 9.7, ICI = 12 vs. control = 2, t-test $p < 0.05$) and IL-36 (TNFi = 10.5, SLE = 13.3, ANA = 11, ICI = 7, control = 0.25, t-test $p < 0.05$) in the keratinocytes of SPP patients. There was decreased CD8 T cell migration to the epidermis in SPP compared to control.

Conclusion: This is the first study to describe the immune-phenotype of SPP and to extend the phenotype observed in TNFi induced psoriasis to varying clinical scenarios. There was an increased expression of MXA, LL-37 and IL-36 as well as fewer epidermal CD8 T cells than in chronic plaque psoriasis consistent with the type-1 IFN pathway of psoriasis pathogenesis. This immune-phenotypic analysis may suggest tailored therapy for this form of psoriasis.

P104

SERUM GLUCOCORTICOID-INDUCIBLE KINASE-1 (SGK1) LEVELS IN PATIENTS WITH PSORIATIC ARTHRITIS

Göksal Keskin¹, Ali Inal², Esra Dilek Keskin³, Umit Olmez¹

¹Department of Immunology, Medical School of Ankara University, ²Department of Immunology, Medical School of Baskent University, ³Department of FTR, Medical School of Kırıkkale University

Introduction: Psoriatic arthritis (PsA) is an inflammatory rheumatic disorder that occurs in patients with psoriasis. The etiology of PsA is not well understood but evidence supports an interplay of genetic, immunologic, and environmental factors which promote pathological bone remodeling and joint damage in PsA. The glucocorticoid-inducible kinase-1 (SGK1) is genomically upregulated by cell stress. However, excessive SGK1 expression and activity participates in the pathophysiology of several disorders, such as inflammation, autoimmune disease, fibrosis, hypertension, thrombosis and tumor growth.

Objectives: In this study, we analyzed the possible role of serum SGK-1 levels in the pathogenesis of psoriatic arthritis.

Methods: 56 patients with psoriasis (40 patients with psoriatic arthritis; 16 female, 24 male, mean age; 46.7 ± 6.5 years, mean disease duration 17.7 ± 4.3 years and 16 patients without arthritis; 8 female, 8 male, mean age; 43.2 ± 1.9 years, mean disease duration; 14.1 ± 3.9 years) and 19 healthy controls (11 female, 8 male; mean age 41.3 ± 4.7 years) were enrolled in this study. Oligoarthritis was the commonest clinical presentation (76.4 %). Dactylitis (73.4%) and enthesitis (48.1%) were frequent extra-articular features. All patients were negative for rheumatoid factor. HLA-B27 was negative in 14 patients. Serum SGK-1 levels were determined by ELISA.

Results: The mean serum SGK-1 levels were 58.4 ± 18.1 pg/ml in healthy controls, 163.7 ± 27.8 pg/ml in patients without arthritis and 443.9 ± 32.1 pg/ml in patients with arthritis. Serum SGK-1 levels were significantly high in patients with psoriasis compared with healthy controls ($p < 0.001$). Serum SGK-1 levels were significantly high in patients with psoriatic arthritis compared with in patients without psoriatic arthritis ($p < 0.001$).

Conclusions: The evidence is strong that immunological mechanisms are involved in the pathogenesis of psoriasis. In this study, we demonstrated that serum SGK-1 levels were significantly elevated in patients with psoriasis and psoriatic arthritis.

P105

DIFFERENTIAL NH2-TERMINAL AUTOANTIGEN TRIMMING MAY EXPLAIN EPISTASIS BETWEEN HLA-C*06:02 AND ERAP1 VARIANTS IN PSORIASIS RISK

Akiko Arakawa¹, Emma Reeves², Sigrid Vollmer¹, Yukiyasu Arakawa¹, Edd James², Jörg Prinz¹

¹Ludwig-Maximilian-University, ²Southampton General Hospital

Introduction: NH2-terminal trimming by endoplasmic reticulum aminopeptidase 1 (ERAP1) generates the appropriate length of antigenic peptides for binding to and presentation by HLA-class I molecules. Genetic interaction between ERAP1 variants and HLA-class I alleles determines the genetic risk for various HLA-class I-associated inflammatory diseases. Epistasis between HLA-C*06:02 and ERAP1 variants affects also psoriasis risk but the mechanisms of these gene interactions remained unknown. Using a pathogenic V α 3S1/V β 13S1-TCR from a psoriatic CD8⁺ T-cell clone we had shown that in psoriasis, HLA-C*06:02 mediates an autoimmune response against melanocytes through autoantigen presentation and we had identified a peptide from ADAMTS-like protein 5 (ADAMTSL5) as HLA-C*06:02-presented melanocyte autoantigen.

Objectives: To determine the role of ERAP1 variants in psoriasis pathogenesis.

Methods: We established ERAP1 knockout cells using CRISPR/Cas9 system. ERAP1 knockout cells transfected with plasmids coding for HLA-C*06:02, ERAP1 variants, and antigenic peptides were co-cultured with the TCR hybridoma to determine the levels of TCR ligation which reflect the generation of the antigenic ADAMTSL5 peptide and other V α 3S1/V β 13S1-TCR ligands from precursors.

Results: Our data show that NH2-terminal trimming by ERAP1 is required to generate the actual antigenic ADAMTSL5 peptide from NH2-terminally elongated precursors. An ERAP1 variant protecting from psoriasis reduced the immunogenicity of the antigenic ADAMTSL5 peptide presumably through overtrimming and peptide destruction, whereas a psoriasis risk variant of ERAP1 highly kept the antigenicity of the autoantigen. This effect was specific for ADAMTSL5. Precursors of other V α 3S1/V β 13S1-TCR self-ligands were not substrates of ERAP1.

Conclusions: Using a proven psoriatic autoantigen and a cognate psoriatic TCR, these experiments provide direct evidence that gene-gene interaction between ERAP1 and HLA-C*06:02 affects the risk for psoriasis through differential autoantigen trimming from precursors. These data furthermore propose a model where ERAP1 function essentially controls the autoantigenic potential of self-peptides in HLA-class I associated CD8⁺ T-cell mediated autoimmune diseases.

P106

ENVIRONMENTAL TRIGGERS OF AN HLA-C*06:02-RESTRICTED AUTOIMMUNE RESPONSE IN PSORIASIS

Secil Vural, Yukiyasu Arakawa, Adrian Galinski, Sigrid Vollmer, Akiko Arakawa, Jörg Prinz

Ludwig Maximilian University

Introduction: Psoriasis vulgaris is a multifactorial disease. While the major psoriasis risk gene HLA-C*06:02 accounts for up to 50% of disease onset, environmental factors are considered to contribute to approximately 30% of disease risk. Psoriatic skin inflammation is driven by an HLA-C*06:02-mediated autoimmune response against melanocytes. A pathogenic V α 3S1/V β 13S1 T-cell receptor (TCR), which we had reconstituted from a lesional epidermal CD8⁺ T-cell clone of an HLA-C*06:02-positive psoriasis patient in a mouse reporter hybridoma cell line, specifically reacts against melanocytes through HLA-C*06:02 restricted recognition of a psoriatic melanocyte autoantigen, ADAMTS-like protein 5 (ADAMTSL5). However, it is unknown whether and how environ-

mental factors may contribute to autoimmunity in psoriasis. TCRs are known to be polyspecific, recognizing multiple peptide ligands which share a conserved amino acid pattern specific for each TCR. **Objectives:** To examine the potential role of environmental factors in the psoriatic autoimmune response.

Methods: We first determined the particular amino acid motif which is recognized by the psoriatic Vα3S1/Vβ13S1 TCR in the context of HLA-C*06:02. By homology searches using this conserved amino acid pattern, we selected 57 peptides from food, bacterial, fungal and viral pathogens and from the skin and intestinal microbiomes as candidate environmental antigens that may trigger the psoriatic autoimmune response. We cloned the peptides into expression plasmids, co-transfected them with HLA-C*06:02 into Cos7 cells and used them to stimulate the Vα3S1/Vβ13S1 TCR. TCR ligation was determined by GFP induction of TCR hybridoma in FACS analysis. We then stimulated blood lymphocytes with the candidate peptides that had ligated the Vα3S1/Vβ13S1 TCR. Lymphocyte activation was assessed by induction of activation markers and proliferation assays using thymidine incorporation.

Results: We identified a variety of peptides contained in proteins from food (wheat, coffee, apple, and spinach), microbiota of human skin or gut, and infectious pathogens including *Chlamydia trachomatis*, which ligated the psoriatic TCR in a polyspecific manner. Stimulation of blood lymphocytes with particular candidate antigens resulted in significant activation in psoriasis patients, as compared to healthy individuals. Interindividual-correlation analyses demonstrated cross-reactive immune responses between environmental antigens and the melanocyte autoantigen presented by HLA-C*06:02 in psoriasis patients. Among the candidate antigens, wheat peptides induced most robust lymphocyte activations in psoriasis patients. Moreover, psoriasis was significantly improved by wheat-free diet in several patients with lymphocytes responding to wheat, indicating potential pathogenic contribution of wheat antigens in psoriasis.

Conclusions: Our results provide unbiased evidence that several environmental antigens may trigger the melanocyte-specific autoimmune response in psoriasis. By identifying and avoiding those triggers at the molecular level which translate the genetic predisposition into disease manifestation, we may develop strategies to prevent disease onset and exacerbation.

P107

A SKEWED POOL OF RESIDENT T CELLS TRIGGERS DISEASE-ASSOCIATED TISSUE RESPONSES IN NEVER-LESIONAL PSORIASIS

Irène Gallais Séréal¹, Elena Hoffer¹, Borislav Ignatov¹, Elisa Martini¹, Beatrice Zitti², Marcus Ehrström³, Liv Eidsmo¹

¹Department of Medicine Solna, Karolinska Institutet, ²Centre for Haematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, ³Department of Reconstructive Plastic Surgery, Karolinska University Hospital Solna, Stockholm, Sweden

Background: Psoriasis lesions evolve as a result of cytokine driven interactions between intralesional immune cells and keratinocytes in genetically predisposed individuals. Skin resident T cells are implicated in maintenance and recurrence of psoriasis plaques but their composition and function in never-lesional psoriasis skin is less known.

Objective: Characterisation of T cell driven tissue responses and subsets of resident T cells in never-lesional psoriasis.

Methods: T cell driven tissue responses were assessed in explanted skin biopsies using Nanostring and Multiplex analysis. Epidermal and dermal T cells were characterised using flow cytometry in never-lesional skin from patients with mild disease.

Results: T cell activation induced epidermal psoriasiform- and type-1 interferon tissue responses in explants from never-lesional skin.

Skin resident T cells were skewed with enrichment of epidermal IL-17 and IL-22 producing CD4+CCR6+ and CD8+CD103+CD49a- T cells and IFN-γ producing CD4 T cells in never-lesional skin compared to healthy skin. Keratinocytes from never-lesional psoriasis responded to IFN-γ activation with IFN-α secretion and MX1 upregulation and skin explants exposed to common fungal antigens produced the CCR6-attractant CCL20. **Conclusion:** Resident T cells poised to induce psoriasiform tissue responses accumulate in never-lesional skin of psoriasis-afflicted individuals. Additionally our data suggest that microbial interplay with genetically predisposed keratinocytes may shape the local pool of resident T cells.

References:

- Verma, D., Ekman, A.-K., Bivik Eding, C. & Enerbäck, C. Genome-Wide DNA Methylation Profiling Identifies Differential Methylation in Uninvolved Psoriatic Epidermis. *J. Invest. Dermatol.* (2017). doi:10.1016/j.jid.2017.11.036
- Gudjonsson, J. E. et al. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. *J. Invest. Dermatol.* 129, 2795–2804 (2009).
- Cheuk, S. et al. Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis. *J. Immunol.* 192, 3111–3120 (2014).

P108

NAIL INVOLVEMENT IN PSORIASIS; IS IT A PREDICTOR OF PSORIATIC ARTHRITIS?

Omid Zargari¹, Ehsan Kazemnejad², Seyyede Zeinab Azimi³

¹Department of Dermatology, Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, ²Department of Biostatistics, ³Department of Dermatology, Guilan University of Medical Sciences, Rasht, Iran

Introduction: Psoriatic Arthritis (PsA) arises in an increased burden of psoriasis and impairments in both quality of life and functional capacity. The relationship between nail involvement and PsA in psoriasis is not fully characterized.

Objective: To evaluate the frequency and characteristics of nail involvement in psoriatic patients and to assess the relationship with joint involvement.

Methods: A total of 197 patients with moderate-to-severe psoriasis, were consecutively selected to participate in this cross-sectional study. The patients divided into two groups; with and without psoriatic arthritis.

Results: 69.5% of psoriatic (137 out of 197) patients had nail involvement. The most common nail abnormality was onycholysis, followed by pitting and oil drop. Nail changes were more common in patients with psoriatic arthritis (82.1% vs. 57.8%).

Limitations: Our study had certain limitations. One of them was lack of information about the subtypes of PsA. Also, we have not recorded the severity of nail involvements. Furthermore, previous medications may have interfered with the degree of nail changes in our patients.

Conclusion: Nail involvement is associated with PsA. Onycholysis, splinter hemorrhage, and oil drop were significantly more common in PsA group. In general, psoriatic patients with arthritis had the more severe disease.

References:

- Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a questionnaire-based survey. *Br J Dermatol.* 2013;169(2):314–319.
- Langenbruch A, Radtke MA, Krenske M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. *Br J Dermatol.* 2014;171(5):1123–1128.

P109

ABSOLUTE AND RELATIVE PASI IMPROVEMENTS WITH IXEKIZUMAB TREATMENT: RESULTS AT WEEK 12 FROM IXORA-P

Kim Papp¹, Remus Ioan Orasan², Paula Polzer³, Carsten Hennege³, Radu Dumitru Nica³, Stefan Wilhelm³, Ulrich Mrowietz⁴

¹Probit Medical Research, Waterloo, Ontario, Canada, ²Human Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, Romania, ³Eli Lilly and Company, Indianapolis, Indiana, USA, ⁴Department of Dermatology, University Medical Centre Schleswig-Holstein, Campus Kiel, Germany

Introduction and Objectives: Ixekizumab (IXE), an interleukin-17A antagonist, has shown superior efficacy in psoriasis compared to placebo, etanercept, and ustekinumab. This post hoc analysis intended to evaluate absolute and relative Psoriasis Area and Severity Index (PASI) improvements with IXE treatment in a phase 3 trial (IXORAP).

Methods: In IXORA-P, patients with moderate-to-severe psoriasis were randomized (2:1:1) to receive any of the 3 dosing regimens of IXE 80 mg: every 2 weeks (Q2W; $n=611$), every 4 weeks (Q4W; $n=310$), or Q4W/Q2W step-up ($n=306$), for 52 weeks. Randomization was stratified by country and weight (<80 kg, ≥ 80 to <100 kg, or ≥ 100 kg). The percentage of patients achieving a 75%, 90% or 100% improvement from baseline in PASI (PASI 75, 90, and 100) was evaluated using logistic regression with dosing regimen, country, and baseline weight as factors. Fisher's exact test with nonresponder imputation was used to compare the response rates between treatment groups. Here, we present results at 12 weeks for Q2W (label dose) and Q4W groups; results from Q4W/Q2W group will be discussed separately.

Results: Mean (standard deviation) PASI score at baseline was 20.3 (8.25). Response rates were significantly higher ($p < 0.001$) for Q2W group compared to Q4W group across all cut-off points for absolute PASI: absolute PASI ≤ 1 , 2, 3, and 5 response rates at Week 12 were 61.4%, 76.1%, 84.5%, and 89.4%, respectively, for Q2W group, and 49.7%, 64.5%, 72.6%, and 83.9%, respectively, for Q4W group. At Week 12, PASI 75 response rates in Q2W and Q4W groups were 89.2% and 83.2%, respectively ($p = 0.012$). For Q2W and Q4W groups, PASI 90 response rates were 75.3% and 63.2%, respectively ($p < 0.001$), and PASI 100 response rates were 46.0% and 32.6%, respectively ($p < 0.001$).

Conclusion: As reported in psoriasis registration trials, induction with IXE Q2W, the labeled dosing regimen, provides better clinical outcomes at Week 12.

References:

- [1] Griffiths CE, Reich K, Lebwohl M, et al. Lancet 2015;386:541-51.
- [2] Reich K, Pinter A, Lacour JP, et al. Br J Dermatol 2017;177(4):1014-23.

P110

PREVALENCE AND SEX DIFFERENCES OF PSORIATIC ARTHRITIS IN PATIENTS WITH SEVERE PLAQUE PSORIASIS.

Nadezhda Batkaeva¹, Tatiana Korotaeva², Edgem Batkaev¹

¹Peoples' Friendship University of Russia (RUDN University), ²Research Institute of Rheumatology n. a. V. A. Nasonova

Background: Prevalence of psoriatic arthritis in patients with psoriasis has conflicting data in different population. But no study has been performed in Russian population of prevalence and sex differences of psoriatic arthritis in patients with severe plaque psoriasis.

Objectives: to evaluate the prevalence PsA in patients (pts) with PsO in a dermatological hospital cohort.

Methods: 890 pts (Male-516/Female-374) with severe plaque PsO, mean age 50.4 ± 17.6 years, mean PsO duration 21.5 ± 14.7 , mean PASI 49.4 ± 0.5 were included. 374 female were divided into groups by age. 113 young F. pts with age less than 49 years (mean age 36.1 ± 11.0 years), 261 old F. pts with age more than 50 years (mean age 63.7 ± 9.6 years). 516 male were divided into groups by age. 304 young M. pts with age less than 54 years (mean age 38.5 ± 11.3 years), 212 old M. pts with age more than 55 years (mean age 38.5 ± 11.3 years) were included. PsO and PsA pts were identify in hospital Database reporting and coding by International

Statistical Classification of Disease and Related Health Problems (ICD-10) between 2010 - 2015 years. PSA was diagnosed after appointment with a rheumatologist and an X-ray examination. Diagnosis was carried out according to the criteria of CASPAR. $M \pm m$, t-test, χ^2 , (%) were calculated. All $p < 0.05$ were considered to indicate statistical significance.

Results: 303 out of 890 pts (34.0%) had psoriatic arthritis (PsA). PsA pts were older than PsO pts without arthritis – 55.3 ± 13.7 years and 50.4 ± 17.6 years accordingly ($p < 0.001$). PsA was found significantly often in F. pts compare to M. pts – in 143 out of 374 pts (38.2%) and in 129 out of 516 pts (25.0%) accordingly ($p < 0.05$). PsA was found significantly often in F. pts over 50 years old (y.o.) compare to F. pts under 50 y.o. – in 134 out of 261 pts (51.3%) and in 9 out of 113 pts (7.9%) accordingly ($p < 0.05$). In old M. and young M. PsA was found in the same cases - in 58 out of 212 pts (27.3%) and in 71 out of 304 pts (23.3%) accordingly ($p > 0.05$).

Conclusions: PsA was detected in more than a third of patients with severe plaque psoriasis. PSA was found predominantly often in F. pts over 50 years of age with severe plaque psoriasis. Future investigation in this field is needed to determine the causes of high risks PSA in this age group.

P111

SKIN LESION SEVERITY IN EARLY AXIAL AND PERIPHERAL PSORIATIC ARTHRITIS PATIENTS

Elena Gubar, Elena Loginova, Svetlana Glukhova, Tatiana Korotaeva

Nasonova Research Institute of Rheumatology, Moscow

Introduction: Comparative analysis of skin lesion severity in early PsA patients with and without axial involvement hadn't been sufficiently studied.

Objective: to compare skin lesion severity of two early peripheral PsA patient populations – with and without axial involvement.

Methods: 95 patients (pts) (M/F=47/48) with early PsA according to CASPAR criteria were included; all pts had peripheral arthritis for ≤ 2 years; no inflammatory back pain (IBP) pts were specially selected. Mean age 36.5 ± 10.7 yrs, disease duration 12.2 ± 10.3 mo, disease activity indexes DAS = 4.0 ± 1.4 , DAS28 = 4.2 ± 1.1 , BASDAI = 4.5 ± 1.6 . Skin lesion severity was evaluated in terms of body surface area (BSA) affected and Psoriasis Area Severity Index (PASI). When BSA was $\geq 3\%$, PASI was calculated. PASI ≥ 11 indicates moderate and severe psoriasis.

All pts were evaluated for the presence of inflammatory back pain (IBP) by ASAS criteria. IBP was observed in 63 (66.3%) cases. Magnetic resonance imaging (MRI) of SIJs was performed in 79 pts, regardless of the presence of IBP, on Signa Ovation 0,35T. MRI results were evaluated by an independent reader. Bone marrow edema on MRI (STIR) was considered as active MRI sacroiliitis (MRI-SI). MRI-SI was detected in 28 of 79 (35.4%) examined cases. The examination also included X-ray of sacroiliac joints (SIJs) (pelvic radiographs). Radiographic sacroiliitis (R-SI) was considered according to New York criteria (unilateral grade ≥ 3 or bilateral grade ≥ 2). R-SI was found in 29 (30.5%) cases. Pts were split into two groups: those with axial involvement (axPsA), that is with IBP and/or MRI-SI and/or R-SI; and those without axial involvement (having only peripheral PsA [pPsA]). The axPsA group included 65 (68.4%) cases, the pPsA one 30 (31.6%) cases. **Results:** skin lesions' severity was higher in the axPsA group than in the pPsA group: in axPsA pts BSA median was 3.0 [1.0 – 9.0] and in pPsA pts it was 1.0 [0.2 – 3.0] ($p = 0.007$); in the axPsA group PASI median was 15.6 [6.6 – 55.2] and in the pPsA group it was 6.0 [0.0 – 7.2] ($p = 0.006$).

Conclusion: Axial involvement in early PsA patients is associated with skin lesions' severity. These findings may have a positive impact on the selection of the best therapeutic strategy.

P112**GASTROINTESTINAL SYMPTOMS ARE COMMON IN U.S. PATIENTS WITH MODERATE-SEVERE PSORIASIS**

Steven Feldman¹, Steve Fakharzadeh², Jill Abell², Timothy Hoops², Bhaskar Srivastava², Erik Muser², Danielle Dungee², Sean Quinn², Megan Leone Perkins³, Michael Kappelman⁴

¹Wake Forest School of Medicine, Winston-Salem, NC, ²Janssen Scientific Affairs, LLC, Horsham PA, ³HealthVibe, LLC, Arlington, VA, ⁴University of North Carolina, Chapel Hill, NC, USA

Background/Objective: Patients with moderate-to-severe plaque psoriasis (PsO) are at increased risk of developing inflammatory bowel disease (IBD). A survey was conducted to evaluate the prevalence of gastrointestinal symptoms in PsO patients.

Methods: An electronic survey was available to U.S. PsO patients with data collected from Jan-Feb. 2017. Patients with moderate-to-severe plaque PsO and healthy controls (HC), with common co-morbidities allowed in both groups qualified for inclusion in the survey. Psoriasis patients were further categorized as those without recent exposure to biologic therapy (PsO-) vs those with recent (within 4 months) biologic exposure (PsO+). GI symptoms and signs, including frequency and severity, were compared across groups. CalproQuest (CPQ) scores, which have recently been proposed as a tool to identify patients with elevated fecal calprotectin levels and increased risk for IBD, were also calculated. Patients with inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), or other gastrointestinal (GI) diagnoses with symptoms that overlap with IBD were excluded.

Results: Overall, 915 patients with self-reported moderate-severe PsO and 1,411 healthy controls participated. Demographics were generally comparable between groups. GI symptoms and signs were significantly more prevalent in the PsO- and PsO+ groups vs the HC group, respectively: pain- 20.6% and 36.9% vs 10.5%; fullness/bloating- 37.2% and 48.4% vs 25.3%; and diarrhea (16.3% and 29.3% vs 12.2% (all p-values = 0.002 except diarrhea for PsO- vs HC, $p = 0.023$). Mucous and blood in the stool followed a similar pattern. A significantly greater percentage of PsO- and PsO+ patients had positive CPQ scores vs HCs, with the greatest percentage of positive CPQ scores in the PsO+ group.

Conclusion: GI symptoms and signs are common in patients with moderate-to-severe PsO, more so than in healthy controls. This suggests that physicians caring for patients with PsO may consider assessing for GI symptoms and signs, and monitoring for their progression with treatment of PsO to identify patients potentially at risk for developing IBD.

P113**SECUKINUMAB'S LONG-TERM SAFETY REMAINS FAVORABLE UP TO 5 YEARS OF TREATMENT**

Christopher Griffiths¹, A. Blauvelt², K. Reich³, C. Leonardi⁴, N. Mehta⁵, T. Tsai⁶, R. You⁷, P. Papanastasiou⁸, M. Milutinovic⁸, P. van de Kerkhof⁹

¹Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, ²Oregon Medical Research Center, Portland, Oregon, USA, ³Dermatologikum Berlin and Georg-August-University, Göttingen, Germany, ⁴Saint Louis University Health Sciences Center, St. Louis, Missouri, ⁵National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA, ⁶National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan, ⁷China Novartis Institutes for BioMedical Research, Shanghai, China, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Introduction and Objectives: Psoriasis is a condition typically requiring long-term treatment, thus longitudinal data establishing the safety of approved therapies are required. We report exposure adjusted incidence rates (IRs per 100 patient years) for treatment-emergent adverse events (AEs) per year of treatment from a pooled analysis of all secukinumab psoriasis trials to date (19 studies,

4,674 patients, 10,061 patient-years exposure; secukinumab exposure up to 5 years).

Methods: AE IRs were examined per year for subjects receiving secukinumab, and for 52 weeks only for those receiving etanercept (ETN), ustekinumab (UST), or placebo (PBO).

Results: Duration of exposure through 52 weeks of secukinumab treatment 300 mg, ETN 50 mg, UST 45/90 mg, and PBO was 1467.4, 296.9, 318.1, and 301 patient-years, respectively. Exposure duration through 2, 3, 4, and 5 years of secukinumab 300 mg treatment was 859.6, 423, 377.5, and 90 patient-years.

Over 52 weeks for secukinumab, ETN, UST, and PBO, respectively, exposure adjusted IRs were overall comparable across treatments: total AEs (275.6, 245.7, 252.2, 355.8); nasopharyngitis (28.4, 35.9, 31.2, 35.9); headache (12.6, 15, 14.6, 23.7); upper respiratory infections [URI] (9.1, 5.9, 9.9, 8.8); opportunistic infections (0.2, 0.3, 0.3, 0.3); *Candida* infections (4.7, 1.4, 1.6, 1.7); neutropenia (0.5, 1.4, 0, 0); major adverse cardiovascular events [MACE] (0.5, 0.3, 0.3, 1.3); Crohn's disease (0.1, 0, 0, 0); ulcerative colitis (0.1, 0.3, 0, 0); and malignant or unspecified tumors [excluding non-melanoma skin cancer [NMSC]] (0.4, 0.3, 0.3, 0.3).

Secukinumab 300 mg pooled safety remained favorable over time with no increases in AEs (exposure adjusted IRs for up to Year 1 to Year 5, respectively): total AEs (275.6, 168.1, 160.2, 111.9, 13.9); nasopharyngitis (28.4, 21.2, 24.1, 11.8, 3.4); headache (12.6, 5.4, 4.3, 4.9, 0); URI (9.1, 7.3, 6.1, 5.5, 0); opportunistic infections (0.2, 0.1, 0, 0, 0); *Candida* infections (4.7, 3.6, 1.9, 1.3, 1.1); neutropenia (0.5, 0.1, 0, 0, 0); MACE (0.5, 0.1, 0.5, 0, 0); Crohn's disease (0.1, 0, 0, 0, 0); ulcerative colitis (0.1, 0.4, 0.2, 0.3, 0); and malignant or unspecified tumors [excluding NMSC] (0.4, 0.4, 0.2, 0, 0).

Conclusions: This comprehensive pooled analysis supports the favorable long-term safety profile of secukinumab in patients with psoriasis; no new safety signals were identified for up to 5 years of treatment and secukinumab's safety profile was consistent with that established in a large phase 3 program.

Findings previously published at the AAD Annual Meeting, February 16–20, 2018, San-Diego, California.

P114**IMPACT OF IMPROVEMENT IN SKIN AND JOINT ON QUALITY OF LIFE IN ACTIVE PSORIATIC ARTHRITIS PATIENTS**

Arthur Kavanaugh¹, Alice Gottlieb², Akimichi Morita³, Joseph F Merola⁴, Julie Birt⁵, Chen-Yen Lin⁵, Catherine L Shuler⁵, Diamant Thaci⁶

¹University of California, San Diego, CA, ²Department of Dermatology, New York Medical College at Metropolitan Hospital, New York, NY, USA, ³Nagoya City University Medical School, Nagoya, Japan, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁵Eli Lilly and Company, Indianapolis, IN, USA, ⁶University Hospital Schleswig Holstein Campus Luebeck, Ratzeburger Allee, Germany

Introduction: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease affecting peripheral and axial joints. For patients with active psoriasis, the added burden of skin disease can further reduce health-related quality of life (HRQoL) of patients with joint disease.

Objective: To determine the contribution of joint and skin improvements in HRQoL of patients with active PsA during Phase 3 clinical trials investigating ixekizumab (IXE) treatment.

Methods: The double-blind Phase 3 trials (SPIRIT) investigated the treatment of IXE, a high-affinity monoclonal antibody selectively targeting interleukin-17A, for patients with active PsA. The integrated database of 2 SPIRIT trials consisted of biologic disease-modifying antirheumatic drug (DMARD)-naïve patients (SPIRIT-P1, NCT01695239) or inadequate responders to tumor necrosis factor (TNF)-inhibitors (SPIRIT-P2, NCT02349295). Patients were randomized to 80mg IXE every 4 weeks (Q4W,

$n = 229$) or 2 weeks (Q2W, $n = 226$) after a 160mg starting dose or placebo (PBO, $n = 224$). At baseline and Week 24, joint and skin diseases were measured by the Disease Activity index for Psoriatic Arthritis (DAPSA; calculated post-hoc) and Psoriasis Area and Severity Index (PASI), respectively. HRQoL was measured by EuroQoL 5 Dimensions Visual Analog Scale (EQ-5D VAS), Short Form-36 Health Survey (SF-36), and Work Productivity and Activity Impairment-Specific Health Problem (WPAI). The synergistic contribution of skin and joint improvements to HRQoL was modeled using smoothing spline method and depicted with response surface. Missing data were imputed using last observation carried forward.

Results: Of 679 PBO- and IXE-treated patients in the SPIRIT trials, 402 (65%) and 224 (36%) patients had $\geq 3\%$ body surface area (BSA) and $\geq 10\%$ BSA psoriasis at baseline, respectively. In these patients, we applied response surface modeling to investigate the relationship among DAPSA, PASI, and change from baseline in EQ-5D VAS at Week 24. The greatest improvement in EQ-5D VAS was associated with the largest percent improvements in both DAPSA and PASI together, rather than DAPSA or PASI alone. Similar observations, regardless of $\geq 3\%$ or $\geq 10\%$ BSA baseline psoriasis, were made in domains of SF-36 (General Health, Physical Functioning, Social Functioning, and Vitality; data not shown) and WPAI (Activity Impairment; data not shown).

Conclusion: For PsA patients with psoriasis, optimal improvements in patients' HRQoL, as measured by select domains of patient-reported outcomes, were dependent on successful treatment of both joint and skin symptoms.

Kavanaugh A, Gottlieb A, Morita A, Merola J, Birt J, Lin C-Y, Shuler CL, Thaci D. The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis. *Arthritis Rheumatol.* 2017;69(Suppl 10).

P115

SECUKINUMAB SHOWS HIGH AND SUSTAINED EFFICACY IN SUBJECTS WITH MODERATE TO SEVERE PALMOPLANTAR PSORIASIS: 2.5-YEAR RESULTS FROM THE GESTURE STUDY

Alice B Gottlieb¹, John Sullivan², Alexey Kubanov³, Ruquan You⁴, Pascaline Regnault⁵, Jennifer Frueh⁶

¹Department of Dermatology, New York Medical College, Metropolitan Hospital, NY, USA, ²Holdsworth House Medical Practice, Darlington, Australia, ³State Scientific Center of Dermatology, Venereology and Cosmetology, Moscow, Russia, ⁴China Novartis Institutes for BioMedical Research, Shanghai, China, ⁵Novartis Pharma AG, Basel, Switzerland

Introduction: Palmoplantar psoriasis (ppPsO) occurs in up to 40% of plaque psoriasis subjects and is often resistant to treatment. It is associated with pain, functional limitations, and greater impairment of health related quality of life compared with plaque psoriasis on other parts of the body (1). Secukinumab, a fully human monoclonal antibody which selectively neutralises IL-17A, has shown long lasting efficacy and safety in the complete spectrum of psoriasis manifestations, including nails, scalp, palms and soles and psoriatic arthritis.

Objectives: Here we report, the long-term follow-up efficacy and safety results from the GESTURE study, the first robust (2.5-year) data reported in subjects with moderate to severe ppPsO treated with secukinumab.

Methods: GESTURE is a double blind, randomised, placebo-controlled, parallel-group, multicentre phase 3b study to investigate safety and efficacy of secukinumab 150 and 300 mg s.c. in 205 subjects with moderate to severe ppPsO.

Results: As previously reported, after 16 weeks placebo-controlled treatment, the primary endpoint palmoplantar Investigator's Global Assessment (ppIGA) 0/1 and all secondary endpoints of this study were met, demonstrating superiority of secukinumab to placebo at week 16 (2). An interim analysis at week 80 established the

continuation improvement of palmoplantar disease for all efficacy parameters. The effect was sustained through 2.5 years with 59.2% and 52.5% of subjects in secukinumab 300 and 150 mg groups, respectively [multiple imputation (MI)] achieving clear or almost clear palms and soles (ppIGA 0/1). Consistent with this observation, the mean palmoplantar Psoriasis Area and Severity Index % change from baseline reached -74.7% and -61.6% for secukinumab 300 and 150 mg, respectively, at 2.5 years (MI). The Dermatology Life Quality Index 0/1 response, was achieved in 45.5% vs. 23.9% of subjects for secukinumab 300 and 150 mg groups respectively (LOCF). Pain and function of palms and soles was markedly improved with secukinumab; as reflected by the Palmoplantar Quality of Life Instrument overall scores with 16.7% and 17.9% subjects experiencing no difficulty in hand and feet functionality in secukinumab 300 mg and 150 mg groups respectively (LOCF). The safety profile was consistent with that seen in secukinumab phase 3 trials. The most common adverse events across all treatment arms were nasopharyngitis, upper respiratory tract infection and headache.

Conclusions: GESTURE, the largest and longest duration randomised controlled trial to date, revealed that secukinumab provides a novel treatment option for the challenging and infrequently studied ppPsO population by providing a strong and sustained response through 2.5 years.

References:

1. Kumar B, et al. *Acta Dermatol Venereol.* 2002; 82:192-5.
 2. Gottlieb A, et al. *J Am Acad Dermatol.* 2017; 76:70-80.
- This investigation was sponsored by Novartis Pharma AG, Basel, Switzerland.

P116

SECUKINUMAB SHOWS HIGH AND SUSTAINED EFFICACY IN NAIL PSORIASIS: 2.5-YEAR TRANSFIGURE STUDY RESULTS

Kristian Reich¹, Petr Arenberger², Ulrich Mrowietz³, Sasha Jazayeri⁴, Matthias Augustin⁵, Anne Parneix-Spake⁶, Pascaline Regnault⁷, Ruquan You⁸, Jennifer Frueh⁹

¹Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany, ²Department of Dermatology, Charles University, 3rd Faculty of Medicine, Prague, Czech Republic, ³Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁴Alliance Dermatology and MOHS Center, Phoenix, USA, ⁵Universität Hamburg, Hamburg, Germany, ⁶Novartis Pharmaceuticals Corporation, East Hanover, USA, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸China Novartis Institutes for BioMedical Research, Shanghai, China

Introduction: Nail psoriasis is associated with decreased finger mobility, functional impairment, pain and reduced quality of life (QoL) and is often challenging to treat. It correlates with more severe psoriatic disease and is an important predictor of psoriatic arthritis (PsA). Nails are affected in up to 50% of psoriasis patients, with a lifetime incidence as high as 90%¹. Secukinumab, a fully human monoclonal antibody that selectively neutralises IL-17A, has shown long lasting efficacy and safety in the complete spectrum of psoriasis manifestations, including nails, scalp, palms and soles and psoriatic arthritis.

Objectives: Here, we report the long-term follow-up efficacy and safety results from the TRANSFIGURE study, the first robust (2.5-year) data reported in subjects with nail psoriasis treated with secukinumab.

Methods: TRANSFIGURE is a double blind, randomised, placebo-controlled, parallel group, multi-centre phase 3b study, to investigate safety and efficacy of secukinumab 150 and 300 mg s.c. in moderate to severe nail psoriasis, involving 198 subjects.

Results: As previously reported, at week 16 the primary endpoint NPSI (Nail Psoriasis Severity Index) and all secondary endpoints of this study was met, demonstrating superiority of secukinumab to placebo after 16 weeks placebo-controlled treat-

ment². An interim analysis at week 80 demonstrated the continuation of improvement in nail psoriasis for all efficacy parameters. The effect was sustained through 2.5 years with a large mean NAPSI improvement from baseline (BL) of -73.3% and -63.6% with secukinumab 300 and 150 mg, respectively (as observed). Secukinumab demonstrated sustained reductions (improvements) in total mean NAPPA (Nail Assessment in Psoriasis and Psoriatic Arthritis) QoL scores from BL to 2.5 years by -52.4% and -18.1%, and 70.2% and 71.0% of subjects achieved a weighted NAPPA-PBI (Patient Benefit Index) global score of ≥ 2 (at least moderate benefits) with secukinumab 300 and 150 mg, respectively (LOCF). Subjects showed considerable improvements in EQ-5D (EuroQOL 5-Dimension Health Status Questionnaire) compared with BL reporting decreased pain and discomfort. The safety profile was consistent with that observed in previous phase 3 trials of psoriasis and PsA.

Conclusions: TRANSFIGURE is the first large, randomised controlled trial to report long-term results in subjects with nail psoriasis. Secukinumab demonstrated strong sustainability of clinically meaningful efficacy, large QoL improvement and a favourable safety profile up to 2.5 years in this challenging form of psoriasis. This investigation was sponsored by Novartis Pharma AG, Basel, Switzerland.

References:

Baran R. *Dermatology*. 2010; 221 Suppl 1:1-5.
Reich K. *Ann Rheum Dis*. 2016;75:603.

PI117

THE OBESITY AND PREVALENCE PSORIATIC ARTHRITIS IN PATIENTS WITH PLAQUE PSORIASIS: DERMATOLOGICAL REAL-SETTING DATA

Maria Chamurlieva, *Tatiana Korotkova*

N.A.Nasonova Research Institute of Rheumatology

Background: Psoriasis (PsO) is a chronic inflammatory disease, which can be associated with the obesity. A link between body mass index (BMI) and psoriatic arthritis (PsA) has been found recently. But there is limited data about this association in Russian population and from real-world data.

Objective: To study the incidence of PsA in PsO patients (pts) with/without obesity.

Methods: 103 pts (male-47/female-56) with different forms of plaque PsO, mean age 44 ± 13.69 years (yrs.), mean PsO duration 10.7 ± 10.2 yrs., mean PASI 15.39 ± 12.51 were included. 61 out of 103 pts with PsO (59.2%) had psoriatic arthritis (PsA) by CASPAR criteria. In all pts BMI was calculated. If the BMI was more than 30 it was regarded as obesity. $M \pm m$, %, t-test were performed. All $p < 0.05$ were considered to indicate statistical significance.

Results: The overweight in both groups of pts with PsO and PsA was not significantly different: in 30 pts without PsA and in 48 with PsA, 71.4% and 78.7% respectively. However, there was a significant difference in the frequency of PsA in the group of pts with a BMI = 30-35 (obesity 1 degree). Thus, it was more than 4 times higher the pts with PsA, compared with pts without PsA - 19 and 4 pts (31.2% vs. 9.5%) respectively ($p = 0.06$).

Conclusion: There is a higher incidence of PsA in PsO pts with obesity. It should be taken into account during choice of treatment and evaluation of efficiency of therapy in real-world dermatological setting. Russian population - based studies are needed.

PI118

DIAGNOSIS OF PSORIATIC ARTHRITIS IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS TREATED WITH SECUKINUMAB VS. OTHER TREATMENTS IN THE PURE REGISTRY: INDICATION OF SELECTION PREFERENCES AND UNDERDIAGNOSIS

Kim Papp¹, *Melinda Gooderham*², *Jennifer Beecker*³, *Charles Lyn-de*⁴, *Isabelle Delorme*⁵, *Ignacio Dei-Cas*⁶, *Emmanouil Rampakakis*⁷, *Lenka Rihakova*⁸, *Shamiza Hussein*⁸, *Antonio Vieira*⁸

¹K Papp Clinical Research and Probit Medical Research, Waterloo, ON,

²SKiN Center for Dermatology, Queen's University and Probit Medical Research, Peterborough, ON, ³University of Ottawa, Division of Dermatology, Ottawa, ON, ⁴Lynde Institute for Dermatology, University of Toronto

and Probit Medical Research, Markham, ON, ⁵Dr. Isabelle Delorme Inc, Drummondville, QC, Canada, ⁶Facultad de Medicina de la Universidad de

Buenos Aires, Buenos Aires, Argentina, ⁷JSS Medical, Saint-Laurent, QC, ⁸Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

Introduction: Secukinumab (SEC) is a fully human monoclonal antibody that selectively neutralizes IL-17A, a key cytokine involved in the development of psoriasis (PsO). SEC has shown long lasting efficacy and safety in the complete spectrum of PsO manifestations, including nails, scalp, palms and soles and psoriatic arthritis (PsA). PURE is an international registry of adult patients (pts) from Canada and Latin America with moderate to severe PsO treated with SEC vs other approved therapies (other Tx).

Objectives: To describe and compare the baseline demographic, disease, and clinical characteristics - specifically, the history of a PsA diagnosis among PsO pts treated with SEC vs other Tx.

Methods: Approximately 2,500 adult pts (1:1 ratio, SEC: other Tx) will be recruited. A decision regarding treatment must have been reached prior to enrollment. The independent-samples and Chi-square tests were used for continuous and categorical variables, respectively, for treatment group comparison.

Results: As of Nov 27, 2017, 1032 pts (397 SEC vs 635 other Tx) had been enrolled. Mean age (50.5 vs 49.4 years), time since diagnosis (18.5 vs 16.9 years), duration since symptom onset (20.5 vs 19 years), and race (78.6% vs 83.8% Caucasian) were comparable between groups. The percentage of females was lower in the SEC group (38.0%) vs other Tx (45.5%; $p = 0.037$). At baseline, the majority of SEC-treated pts (66.2%) were employed, and 23.7% vs 34.8% vs 34.3% had public vs private vs combined coverage, respectively. There was no difference between cohorts. A higher proportion of SEC pts had a history of PsA (23.2% vs 15.0%; $p = 0.001$) or diabetes (18.1% vs 13.4%; $p = 0.072$) compared to pts on other Tx. About 87.9% pts with PsA history and 34.1% pts without had a Psoriasis Epidemiology Screening Tool (PEST) score ≥ 3 at baseline; however, the diagnosis of PsA in these pts needs to be confirmed. In terms of prior PsO treatments, 52.4% vs 29.9% ($p < 0.001$) of SEC vs other Tx pts had been previously treated with methotrexate, and 50.6% vs 18.0% ($p < 0.001$) with a biologic. Prior to enrollment, 4.7%, 13.2% and 4.7% pts in the other Tx group received anti-IL-12/23, anti-TNF- α , and anti-IL-17A, respectively. Pts treated with SEC had a higher historical Psoriasis Area and Severity Index (PASI) score (16.5 vs 14.2; $p = 0.005$), baseline PASI (13.6 vs 12.0; $p = 0.001$) and Investigator's Global Assessment score (severe disease [score = 4]: 25.4% vs 20.1%) at enrollment compared to pts on other Tx.

Conclusions: Pts with moderate to severe PsO selected for treatment with SEC were more likely to have been previously exposed to another biologic, have comorbid PsA and had more severe skin disease, compared to pts treated with other Tx. A significant proportion of PsO pts may have their PsA undiagnosed in routine clinical care.

References:

Langley R, et al. *NEJM* 2014;371:326.

Armstrong AW, et al. *J Clin Aesthet Dermatol* 2016; S12-S16

McInnes IB, et al. *Lancet* 2015;386:1137 Mease PJ, et a

PI119

EFFICACY AND SAFETY RESULTS OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 56 WEEKS

Wolf Henning Boehncke¹, *Alice Gottlieb*², *Atul Deodhar*³, *Bin*

Dong⁴, Yuhua Wang⁴, Yanli Zhuang⁴, William Barchuk⁵, Xie L. Xu⁵, Elizabeth Hsia⁴

¹Division of Dermatology and Venereology, Geneva University Hospital, and Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland, ²Department of Dermatology, New York Medical College at Metropolitan Hospital, New York, NY, ³Oregon Health & Science University, Portland, OR, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, San Diego, CA, USA

Introduction/Objective: To evaluate the efficacy, safety & tolerability of guselkumab (GUS) in patients (pts) w/ PsA.

Methods: In this double-blind, PBO-controlled study, pts w/ active PsA & $\geq 3\%$ BSA of PsO despite treatment were randomized 2:1 to SC GUS 100mg or PBO at wks 0, 4, & q8w thereafter through wk44. At wk16, pts w/ $< 5\%$ improvement from baseline (BL) in swollen & tender joint counts were eligible for early escape (EE) to open-label ustekinumab. At wk24, PBO pts crossed-over to GUS 100mg (PBO to GUS). The primary endpoint was ACR 20 at wk24. Major secondary endpoints were PASI 75 & ACR 50 responses, change from BL in HAQ-DI, & improvement in enthesitis (Leeds enthesitis index [LEI]) & dactylitis score (by a 0–3 scoring system) at wk24; & ACR 20 response at wk16. Through wk24, efficacy analyses were performed in a modified Intent-to-Treat (mITT) population. Pts who met treatment failure criteria, EE or had missing data at wk24 were considered non-responders for ACR/MDA endpoints at wk24. Efficacy post wk24 was evaluated in pts who did not EE & continued treatment at wk24 based on observed data.

Results: Of 149 pts (PBO:49, GUS:100), BL demographics & ACR component measures were generally similar between the 2 groups. 4 PBO & 9 GUS pts were previously exposed to anti-TNF α agents. At wk24, significantly more GUS pts achieved ACR 20 (58.0% vs 18.4%, $p < 0.001$), PASI 75 (78.6% vs 12.5%, $p < 0.001$), & ACR 50 (34.0% vs 10.2%, $p = 0.002$) responses vs PBO. At wk24, mean decrease in HAQ-DI score from BL (-0.42 vs. -0.06, $p < 0.001$), & median percent improvement in enthesitis (100% vs 33.33%, $p = 0.009$) & dactylitis (100% vs 33.33%, $p < 0.001$) scores (among pts w/ BL enthesitis and dactylitis) were significantly greater in GUS group vs. PBO. Significantly more GUS pts achieved ACR 20 at wk16 (60.0% vs 16.3%, $p < 0.001$) and MDA at wk24 (23.0% vs. 2.0%, $p = 0.001$) vs. PBO. Post wk24, efficacy improved in PBO to GUS crossover pts as expected and were well-maintained in GUS pts through wk56.

Through wk24, the frequencies of AEs & infections were comparable (AEs: PBO 32.7%; GUS 36.0%; infections: PBO: 20.4%; GUS: 16.0%). Post wk24, there was no disproportional increase in AE frequency or infections among GUS pts w/ longer exposure. Through wk56, there was 1 malignancy (basal cell carcinoma), 6 SAEs (myocardial infarction, osteoarthritis, pupils unequal, radius fracture, pneumonia, ulcerative keratitis), 2 pts discontinued treatment due to AEs, 1 grade 3 neutropenia, & 6 pts were positive for antibodies to GUS. No deaths occurred through wk56.

Conclusions: GUS demonstrated significant improvement on joint symptoms, physical function, PsO, enthesitis, dactylitis & quality of life; efficacy was well-maintained through wk56. GUS was well tolerated in this population after ~1 year of exposure.

Data has been previously presented at EULAR 2017 & ACR 2017

P120

TILDRAKIZUMAB EFFICACY OVER TIME BY WEEK 28 RESPONSE LEVELS IN TWO PHASE 3 CLINICAL TRIALS IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS

Andrew Blauvelt¹, Howard Sofen³, Kim Papp³, Melinda Gooderham⁴, Yang Zhao⁵, Simon Lowry⁵, Jeff Parno⁵, Qing Li⁶, Carmen La Rosa⁶, Kristian Reich⁷

¹Oregon Medical Research Center, Portland, OR, ²Department of Medicine (Dermatology) UCLA, Los Angeles, CA, USA, ³Probit Medical Research,

Waterloo, ON, ⁴Skin Centre for Dermatology, Peterborough, ON, Canada, ⁵Sun Pharmaceuticals, Princeton, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ, USA, ⁷SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany

Introduction: Tildrakizumab (TIL), a humanized, IgG1/ κ monoclonal antibody for IL-23p19, recently demonstrated its efficacy in subjects with chronic plaque psoriasis in two, phase 3 clinical studies¹.

Objective: In this analysis, we examined efficacy from baseline to week 52 among TIL patients achieving various Psoriasis Area and Severity Index (PASI) responses at week 28.

Methods: reSURFACE 1 (NCT01722331) and reSURFACE 2 (NCT01729754) were double-blind, randomized controlled studies in subjects with moderate-to-severe chronic plaque psoriasis. Part 1 (0–12 weeks) was placebo controlled; Part 2 (12–28 weeks) re-randomized placebo patients to TIL; Part 3 (28–64 weeks, reSURFACE 1; 28–52 weeks, reSURFACE 2) re-randomized patients with \geq PASI 50 to continue or increase TIL dose or to placebo based on their PASI response at week 28. In this post-hoc pooled analysis, patients consistently on TIL 100 mg and 200 mg from baseline to week 52 were classified in 5 mutually exclusive groups based on their week-28 PASI response: PASI < 50 , PASI 50–74, PASI 75–89, PASI 90–99, and PASI 100. Baseline characteristics and % PASI improvement from baseline up to week 52 (observed data) were examined for each group.

Results: This analysis included 575 (TIL 100 mg) and 581 (TIL 200 mg) patients; the proportions of patients with week-28 PASI 75/90/100 responses were 77%/54%/23% (TIL 100 mg) and 78%/58%/29% (TIL 200 mg). At week 28, 133 (23.1%), 175 (30.4%), 137 (23.8%), 82 (14.3%), and 48 (8.3%) TIL 100 mg patients and 170 (29.3%), 169 (29.1%), 114 (19.6%), 105 (18.1%), and 23 (4.0%) TIL 200mg achieved PASI 100, PASI 90–99, PASI 75–89, PASI 50–74, and PASI < 50 , respectively. On average, PASI 100 patients were younger, lighter, and had shorter disease duration at baseline compared to other response groups. For TIL 100 mg, % PASI improvement was highest for PASI 100 and least for PASI < 50 patients on all visits up to week 28 (week 4: 53%, 46%, 38%, 30%, and 16%; week 28: 100%, 95%, 83%, 64%, and 33% for PASI 100, PASI 90–99, PASI 75–89, PASI 50–74, and PASI < 50 categories, respectively). Among patients achieving PASI > 50 at week 28 and continued up to 52 weeks, % PASI improvement maintained or improved from week 28 to week 52. Similar results were observed for TIL 200 mg as well as a subgroup analysis with bio-naïve and bio-experienced patients respectively.

Conclusions: The majority of TIL 100 and 200 mg patients achieved PASI > 50 response at week 28, and PASI improvement was maintained from week 28 to week 52. Among patients achieving PASI > 90 at week 28, TIL 100 and 200 mg were associated with a rapid PASI improvement by week 4.

Reference:

1. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. *Lancet*. 2017;390(10091):276-288.

This abstract was presented at 2018 Annual Meeting of American Academy of Dermatology. Note: This abstract was presented at 2018 Annual Meeting of American Academy of Dermatology.

P122

POTENTIAL DISCONNECT: CO-MANAGEMENT OF PATIENTS WITH PSORIATIC ARTHRITIS BETWEEN RHEUMATOLOGISTS AND DERMATOLOGISTS

Lynn Price, Jennifer Robinson, Gianna Melendez
Spherix Global Insights

Introduction: On average, the majority of psoriasis (PSO) patients are diagnosed a year prior to a psoriatic arthritis (PsA) diagnosis, making the referral patterns and co-management between derma-

tologists and rheumatologists an important aspect to understanding the management of these diseases. Dermatologists represent an important referral-base for rheumatologists, accounting for over one-quarter of all new PsA patients. However, there are discrepancies between the specialists regarding the timing in which these referrals take place.

Objectives: One objective of the study was to gain further insight into rheumatologist and dermatologist co-management of patients with PsA.

Methods: An independent market analytics firm collaborated with US rheumatologists ($n = 101$) and US dermatologists ($n = 101$) to conduct analysis of both the PsA and PSO markets. Data were collected via an online survey fielded in November/December 2017 and included patient demographics, as well as physician demographics, and attitudinal survey responses.

Results: Rheumatologists indicate that 51 percent of referrals result from primary care physicians, 28 percent result from a dermatologist, and 13 percent are self-referred. The majority (73%) of PsA patients under the care of collaborating rheumatologists had previously been diagnosed with PSO prior to PsA. Dermatologists state that one-quarter of their patients with severe PSO also have PsA, with more than one-third of severe PSO patients also being co-managed with a rheumatologist. The majority of rheumatologists believe that dermatologists refer patients at the first sign of joint involvement and do not attempt to treat joint pain; however, 31 percent of dermatologists report they do not refer PSO patients to rheumatologists until patients have failed biologics or are not improving on their current systemic regimen, while an additional 35 percent report they refer only severe arthritis/patients with worsening disease. Furthermore, only 35 percent of dermatologists agree that they refer their PSO patients to a rheumatologist at the first sign of joint involvement.

At the time of dermatologist referral, rheumatologists state that two-thirds of referred patients are biologic/apremilast naïve, with only 6 percent having controlled PSO and joint pain. However, dermatologists state that 40 percent the patients that they referred to rheumatologists were treated with biologics and 15 percent of said referred patients were treated with apremilast. Indeed, 76 percent of dermatologists agree with the statement, “I believe that starting my PSO patients earlier on biologic therapy will slow the development and progression of the arthritic component of the disease (PsA),” while 57 percent of dermatologists agree “I prefer to use biologics that are indicated in both PSO and PsA.”

Conclusion: With many patients diagnosed with both PSO and PsA, co-management between dermatologists and rheumatologists is common. While rheumatologists appear to be under the impression that they are receiving the majority of dermatologist-treated patients with PsA at the first sign of joint involvement, dermatologists largely report that they are managing and treating PsA patients. Furthermore, most dermatologists believe early aggressive use of biologic treatments will mitigate the development and/or progression of joint involvement, implying their willingness to manage their patients with PsA, particularly at early stages.

P123

THE USE OF TUMOR NECROSIS FACTOR INHIBITORS (TNF) IN THE SECOND-LINE BIOLOGIC/SMALL MOLECULE SETTING: A CROSS-SPECIALTY COMPARISON

Lynn Price, Jennifer Robinson, Gianna Melendez
Spherix Global Insights

TNF therapy has been the standard of care for adult patients diagnosed with autoimmune conditions, resulting in familiarity, comfort, and satisfaction among physicians. TNFs are typically used as a first-line biologic/small molecule in the treatment of psoriasis (PSO) and psoriatic arthritis (PsA). However, the adoption of agents with alternate mechanisms of action (AMOA) has

increased in recent years across indications and the practice of sequential TNF prescribing after an initial TNF is less common. Though TNFs are still the preferred first-line agent, there are discrepancies between specialists on the use of AMOA agents in the second-line setting. This research sought to understand the extent to which AMOA agents are prescribed after an initial TNF, and how this varies across PSO and PsA.

An independent market analytics firm collaborated with US dermatologists ($n = 201$) and US rheumatologists ($n = 200$) to conduct a retrospective chart review of patients diagnosed with PSO ($n = 950$) and PsA ($n = 1,008$) who had switched from one biologic/apremilast to another agent in the prior 12 weeks. Physicians were able to submit up to 7 patient charts. PSO data was collected in September 2017 and PsA data was collected in April 2017.

Analysis of patients recently switched from one biologic/apremilast to a different brand revealed the majority of patients were treated with a TNF in the first-line biologic/small molecule setting, though this varies by indication. Rheumatologists prescribe first-line TNFs significantly more than dermatologists. 83% of PsA patients are prescribed TNFs first-line compared to just 69% of PSO patients. Furthermore, rheumatologists are significantly more likely to practice TNF-sequencing than dermatologists. Indeed, 44% of PsA patients treated with a first-line TNF were prescribed a second TNF, compared to 6% of PSO patients. Additionally, certain TNF brands have experienced recent declines in first line use, though this varies by indication as well. For rheumatologists, use of first-line etanercept has declined, 38% of PsA patients were initiated on etanercept at least 24 months prior to the study, compared to just 28% initiated on etanercept within 12 months of the study. For dermatologists, there were significantly more PSO patients initiated on etanercept in the first-line setting 24 months or more prior to the study compared to those initiated within 12 months of the study, (45% vs 31%.) This pattern also held true for adalimumab, where 42% of first-line PSO patients initiated more than 24 months prior to the study were prescribed adalimumab, a figure that drops to just 27% for patients initiated within 12 months.

Though the position of TNFs as first-line agents remains dominant, the treating specialist and indication influence how widespread and continuous TNF use is. Specifically, dermatologists are less likely to prescribe TNFs as first-line agents and are also significantly less likely to partake in the sequencing of TNFs in the first- and second-line setting than rheumatologists. The introduction of several agents in PSO reporting substantially higher rates of skin clearance compared to TNFs could potentially be the source of increased switching to AMOAs compared to other specialties; whereas superior efficacy of AMOA agents over TNFs in PsA may be less apparent.

P124

IMPACT OF GUSELKUMAB VERSUS PLACEBO AND ADALIMUMAB ON PATIENT REPORTED OUTCOMES IN PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS IN VOYAGE 2

Luis Puig¹, Chenglong Han², Ron Vender³, Michael Song², Yin You², Yaung-Kaung Shen², Peter Foley⁴

¹Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona Medical School, Barcelona, Spain, ²Janssen Research & Development, LLC, Spring House, PA, USA, ³McMaster University, Hamilton, ON, Canada, ⁴University of Melbourne, St. Vincent's Hospital, Melbourne and Skin & Cancer Foundation Inc., Carlton, Victoria, Australia

Introduction/Objective: VOYAGE 2 is a phase 3 double-blind, placebo/active comparator-controlled trial comparing guselkumab (GUS) with placebo (PBO) and adalimumab (ADA) in patients (pts) with moderate-to-severe PsO. The impact of treatment on patient-reported outcomes (PROs) was evaluated.

Methods: Pts were randomized to GUS 100mg (wks 0 & 4, then

q8wks), ADA (80 mg wk 0, 40 mg wk 1, then 40 mg q2 wks), or PBO (wks 0, 4, & 12, then GUS 100 mg wks 16 & 20). We evaluated PROs using the Work Limitations Questionnaire [WLQ; work productivity], the Hospital Anxiety & Depression Scale [HADS], and the Medical Outcomes Study 36-Item Short Form (SF-36; health related quality of life) at wk16 (GUS vs PBO) and wk24 (GUS vs ADA) in pts with and without PsA.

Results: In all, 18% of pts reported a history of PsA. At wk16, GUS pts had numerically greater improvements vs PBO in work productivity, anxiety and depression, and SF-36 PCS & MCS scores regardless of PsA status. The least square (LS) mean differences (95% CI; adjusted for baseline value) for GUS vs PBO for all PROs were generally similar between pts with and without PsA. At wk24, GUS pts had numerically greater improvements vs ADA in all PROs regardless of PsA status. The LS mean differences for GUS vs ADA were generally greater for pts with PsA vs pts without PsA (Table).

Conclusions: GUS showed better improvements in all PROs vs PBO at wk16 and vs ADA at wk24. Improvements vs PBO were similar regardless of PsA status, while improvements vs ADA were greater for pts with PsA.

Table: Summary of Change from Baseline in WLQ, HADS and SF-36 Scores from VOYAGE 2

| | Week 16 GUS vs PBO | | | Week 24 GUS vs ADA | | | | |
|--------------------------|-------------------------------------|-------------------------------------|---------------------------------|-------------------------------------|-------------------------------------|---------|--------------------------------|--------|
| | w/ PSA | w/out PSA | | w/ PSA | w/out PSA | | | |
| | N, LSMean Diff (95% CI) | N, LSMean Diff (95% CI) | | N, LSMean Diff (95% CI) | N, LSMean Diff (95% CI) | | | |
| | | p-value | p-value | p-value | p-value | p-value | | |
| WLQ Physical Demands | 86, -7.1 (-13.21, -0.92) | 0.0249 | 446, -7.7 (-10.56, -4.88) | <0.0001 | 79, -1.6 (-10.58, 7.29) | 0.7152 | 445, -2.6 (-5.39, 0.28) | 0.0769 |
| WLQ Time Management | 85, -6.6 (-15.35, 2.06) | 0.1326 | 419, -7.0 (-10.31, -3.79) | <0.0001 | 79, -4.3 (-14.40, 5.81) | 0.3996 | 420, -0.6 (-3.46, 2.30) | 0.6931 |
| WLQ Mental-Interpersonal | 83, -3.8 (-11.03, 3.35) | 0.2913 | 439, -4.9 (-7.54, -2.35) | 0.0002 | 78, -11.4 (-19.37, -3.34) | 0.0061 | 436, -1.5 (-4.16, 1.11) | 0.2569 |
| WLQ Ouput Demands | 84, -7.9 (-14.51, -1.21) | 0.0211 | 440, -3.5 (-6.11, -0.88) | 0.0089 | 79, -14.7 (-24.29, -5.17) | 0.0030 | 437, -1.2 (-3.94, 1.62) | 0.4136 |
| Anxiety Score | 135, -1.2 (-2.45, 0.04) | 0.0584 | 608, -1.6 (-2.05, -1.07) | <0.0001 | 133, -2.1 (-3.33, -0.83) | 0.0012 | 608, -0.8 (-1.29, -0.28) | 0.0025 |
| Depression Score | 135, -1.2 (-2.55, 0.06) | 0.0611 | 608, -1.5 (-1.96, -0.98) | <0.0001 | 133, -1.5 (-2.85, -0.09) | 0.0374 | 608, -0.4 (-0.91, 0.10) | 0.1158 |
| SF-36 Physical Score | 135, 5.7 (2.94, 8.43) | <0.0001 | 607, 4.4 (3.31, 5.39) | <0.0001 | 132, 2.9 (0.21, 5.57) | 0.0346 | 608, 1.0 (-0.10, 2.04) | 0.0753 |
| SF-36 Mental Score | 135, 4.5 (1.61, 7.48) | 0.0026 | 607, 4.8 (3.53, 6.15) | <0.0001 | 132, 3.2 (-0.12, 6.53) | 0.0591 | 608, 1.8 (0.45, 3.15) | 0.0092 |

N is the sample size across two groups.

P125

THE DERMATOLOGY LIFE QUALITY INDEX IN RUSSIAN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS.

Nadezhda Batkaeva, Edgem Batkaev, Muslimat Gitinova
Peoples' Friendship University of Russia (RUDN University)

Introduction: The most severe form of psoriasis is psoriatic arthritis (PsA), which belongs to the seronegative spondyloarthritis group, characterized by chronic inflammation of the joints, spine, entheses. The frequency of PsA in the population is 0.06–1.4%. PsA is comparable to rheumatoid arthritis (RA) in terms of progression, disability and quality of life (QOL) in patients.

Objectives: Compare the quality of life index of patients with severe forms of psoriasis (PsO) with psoriatic arthritis patients' index.

Methods: 120 (100%) patients suffering from PsO and PsA (Male-87/female - 33) were analyzed. 70 (54.2%) patients were diagnosed PsO, 50 (41.7%) were diagnosed PsA. The average age of patients with skin manifestations PsO was 54.0±14.2 years (n = 70). The average age of patients with PsA was 49.1±15.9 years

(n = 50). The group of patients with PsA was older than the group PsO patients by age. PASI > 10. The quality of life was assessed using the Dermatology Life Quality Index (DLQI) questionnaire. The results were evaluated: from 0 to 1 score - cutaneous disease does not affect the patient's life, from 2 to 5 scores - the disease has a minor effect on the patient's life, from 6 to 10 scores - the disease has a moderate effect on the patient's life, from 11 to 20 scores - the disease has a very strong effect on the patient's life, from 21 to 30 scores - the disease has an extremely strong effect on the patient's life. Statistical processing of the data was carried out using the Excel analysis package. All $p < 0.05$ were considered to indicate statistical significance.

Results: 120 (100%) patients suffering from PsO were taken for analysis. The duration of PsO was: for more than 15 years - 25 people (35.7%), 10–15 years - 18 people (25.7%); 3–10 years - 15 people (21.4%), 1–3 years - 12 people (17.1%). The duration of PsA was: for more than 15 years - 5 people (10.0%), 10–15 years - 7 people (14.0%); 3–10 years - 20 people (40.0%), 1–3 years - 18 people (36.0%). Heredity was aggravated in 35 (29.1%) out of 120 patients. Comorbidity was presented in 112 (93.3%) out of 120 patients. Gastrointestinal and liver diseases were found in 48 (42.8%) out of 120 patients. Type 2 diabetes was observed in 45 (40.1%) out of 120 patients, cardiovascular diseases - in 100 (89.2%) out of 120 patients, diseases of the nervous system - in 59 (52.6%) out of 120 patients, and diseases of the urinary system - in 20 (17.8%) out of 120 patients.

The total score DLQI in the psoriasis group was 15.8±5.2. The score DLQI in PsO patients was 12.5±3.4 and in PsA patients was 20.4±3.7. The total score DLQI in PsO patients with comorbidity was 16.1±5.3.

Conclusions: The total score DLQI was significantly higher in patients with PsA compare to PsO patients. This result revealed the existence of an inferior quality of life for the PsO patients with comorbidity disease, compared with pts without comorbidity disease. The score of DLQI is affected the development and progress of the psoriasis and comorbidity pathology. Then higher DLQI value, the more it affects experience considerable physical and/or psychological discomfort, difficulties in social and professional adaptation, which subsequently cause significant distress and even social phobia. All these conditions psoriasis are interrelated by genetic and immunopathogenetic mechanisms. Thus, patients with psoriasis require an integrated approach and dynamic observation by dermatologists and doctors of related specialties.

P126

EFFECTS OF MINDFULNESS-BASED COGNITIVE THERAPY ON SELF-REPORTED PSORIASIS AND PSYCHOLOGICAL SYMPTOMS

Alan Maddock, David Hevey

School of Psychology, Trinity College Dublin

Introduction: Psoriasis can have a profound impact on a patient's life, with the prevalence of anxiety, depression, poor wellbeing and quality of life generally found to be high in psoriasis populations. Mindfulness based interventions have been shown to have positive impacts on anxiety, depression, wellbeing and quality of life in various populations.

Objectives: The aim of the present study was to investigate the effect of mindfulness-based cognitive therapy (MBCT) on psoriasis symptoms and psychological symptoms associated with psoriasis including anxiety, depression, reduced wellbeing and QoL. The study also aimed to investigate if MBCT significantly impacted the potential mediating variables of a new theory of mindfulness mechanisms the 'Clinically Modified Buddhist Psychological Model (CBPM)', these variables being acceptance, mindfulness, self-compassion, aversion, non-attachment, attention, rumination and worry.

Methods: 101 participants were randomly allocated to a treatment arm (MBCT) or a TAU arm. Participants were measured pre, post-treatment and after a 3-month follow up period. Data were analysed using intention-to-treat analysis and the ANCOVA method with baseline scores entered as covariates.

Results: There was a significant group×time (pre vs. post) interaction on all variables except QoL, indicating a significant reduction of each variable except QoL over time in the MBCT group, but not in the control group. When baseline variables were controlled for, the participants in the MBCT group achieved small statistically significant changes across all variables post intervention versus the TAU group.

Conclusions: The results suggest that MBCT may be a useful adjunct therapy for those suffering from psoriasis and the associated psychological symptoms relating to the condition. The results also indicate that each of the mechanisms outlined in the CBPM change significantly for patients who engage in the intervention.

P127

A MIXED METHODS STUDY EXPLORING THE IMPACT OF MINDFULNESS ON PSORIASIS, ANXIETY, DEPRESSION AND QOL

Alan Maddock, David Hevey

School of Psychology, Trinity College Dublin

Introduction: Psoriasis is a common condition with recognised psychological comorbidity. Psoriasis can have a profound impact on a patient's life, with the prevalence of anxiety, depression, poor wellbeing and quality of life generally found to be high in psoriasis populations. Based on Buddhist psychology, mindfulness based interventions have been shown to have positive impacts on anxiety, depression, wellbeing and quality of life in various populations.

Methods: Mixed methods explored the impact of a mindfulness based cognitive therapy (MBCT) intervention on 10 psoriasis patients using a Buddhist Psychological Model (BPM) as a theoretical framework to understand changes in these variables. Quantitative measures of acceptance, attention regulation, attachment, aversion, self-compassion, mindfulness, rumination, worry, wellbeing, anxiety, depression and psoriasis symptoms were completed pre and post intervention, and participants were interviewed about their experiences of MBCT.

Results: Statistically significant changes in attention, mindfulness, attachment, aversion, rumination, quality of life, anxiety and psoriasis were found. The qualitative data provided support for the BPM as a theoretical lens with which to understand the way in which mindfulness impacts on patient quality of life, anxiety and psoriasis symptoms.

Conclusions: This study gives support to the promising potential of mindfulness interventions being implemented by mental health care professionals with psoriasis patients.

P128

A LINK BETWEEN QUALITY OF PATIENT-PHYSICIAN COMMUNICATION AND PATIENT HEALTHCARE NEEDS IN PSA

A-M Orbai¹, L Coates², VF Azevedo³, A Garg⁴, A Majhoo⁵, CEM Griffiths⁶, P Young⁷, JC Cappelleri⁸, J Moser⁹, L Fallon¹⁰

¹Johns Hopkins University School of Medicine, Baltimore, MD, USA,

²University of Oxford, Oxford, UK, ³Universidade Federal do Paraná,

Curitiba, Brazil, ⁴Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, ⁵Shores Rheumatology, MI, USA,

⁶University of Manchester, Manchester, UK, ⁷Pfizer Inc, Collegeville, PA,

⁸Pfizer Inc, Groton, CT, ⁹The Harris Poll, Rochester, NY, USA, ¹⁰Pfizer

Canada, Montréal, QC, Canada

Introduction: Patient(pt)-physician(HCP) communication may influence symptom reporting and disease control.

Objectives: To evaluate psoriatic arthritis (PsA) symptoms, life

impact and treatment satisfaction in pts who report good communication with their HCP vs suboptimal communication.

Methods: An online pt-based survey was conducted in the US from 2 Nov–1 Dec 2017. Pts had reported having PsA for > 1 year, taken ≥1 synthetic(s) or biologic(b) DMARD for PsA. Pts reported overall health, PsA severity/symptoms/life impact, treatment satisfaction and communication experience. We evaluated differences by pt-HCP communication status.

Results: Overall, 301 pts with PsA responded, mean age 45 years, 61% female, 89% self-reported moderate/severe PsA. Current PsA treatments included bDMARD (52%), sDMARD (25%), combination b/sDMARD (15%). Overall, 256 (85%) of PsA pts were managed by a rheumatologist and 15% by a dermatologist. Of the 256, > 40% reported suboptimal pt-HCP communication. Pts in the suboptimal vs good communication subgroups were typically younger, more likely to be Hispanic and reported greater life impact and lower satisfaction with pt-HCP communication (Table).

Table. Pts with PsA managed by rheumatologist (n = 256)

| | Agree n = 105 (41%) % | Disagree n = 151 (59%) % | Agree n = 118 (46%) % | Disagree n = 138 (54%) % |
|---------------------------------------|-----------------------------|--------------------------------|-----------------------------|--------------------------------|
| Mean age (years) | 41.9 | 46.8* | 41.6 | 47.5* |
| White | 66 | 73 | 58 | 80* |
| Hispanic | 20 | 15 | 26* | 9 |
| Black | 10 | 7 | 11 | 7 |
| Symptoms in past 12 months | 85 | 90 | 86 | |
| Joint pain | 83 | 84 | 84 | 89 |
| Skin/nail symptoms | 74 | 79 | 72 | 83 |
| Stiffness | 70 | 72 | 75 | 82 |
| Joint swelling | | | | 68 |
| Moderate PsA | 70* | 55 | 58 | 64 |
| Severe PsA | 23 | 32 | 33 | 25 |
| Reported impact on | 76* | 59 | 78* | 56 |
| -emotional well being | 69* | 56 | 69* | 54 |
| -work productivity | 67* | 48 | 66* | 46 |
| -romance/intimacy | 40* | 24 | 42* | 21 |
| -decision to start family | 35* | 17 | 36* | 15 |
| -education | | | | |
| Very satisfied with HCP communication | 43 | 75* | 52 | 71* |
| Very satisfied with treatment | 29 | 45* | 36 | 40 |
| Stopped taking treatment | 22* | 8 | 19* | 9 |

*p < 0.05

Conclusions: Pts who reported suboptimal communication with their HCP may have greater healthcare needs for their PsA vs other pts.

P129

PSORIASIS PATIENTS POINT OF VIEW: WHAT ARE WE MISSING WHEN MANAGING THEM?

Elena Popa¹, Alexandra Brahas², Caius Solovan¹

¹Department of Dermatology and Venereology, Clinical Emergency City Hospital Timisoara; University of Medicine and Pharmacy "Victor Babes" Timisoara, Romania, ²University of Medicine and Pharmacy "Victor Babes" Timisoara, Romania

Introduction: Psoriasis is a skin disease that can occur at any time and it is most common in the age group 50–69. The reported prevalence of Psoriasis in countries ranges between 0.09% and 11.4%, making it a serious global problem.

Psoriasis affects the quality of life and it is associated with many comorbidities such as depression, diabetes, cardiovascular disease and psoriatic arthritis.

To evaluate the severity and the efficiency of the treatment applied to patients with Psoriasis, in practice it is used PASI (Psoriasis Area and Severity Index). The value may vary, for example, in this study, PASI 75 represents the percentage (or number) of patients that have achieved a 75% or more reduction in their PASI score in 12 weeks from baseline.

Objectives: Aim of this study is to gain a better perspective on the Psoriasis patient's point of view when seeking a physician's

help, therefore, to try and minimize the gaps that exist when managing them.

Methods: This study was based on a custom questionnaire which included 14 questions for each patient. The responses were gathered from 20 patients (and it is still ongoing) diagnosed in our Department of Dermatology and Venereology Timisoara, each in different stages of disease. All the answers are confidential and anonymous. An informed consent was signed prior to any taken actions. To achieve meaningful results, we asked patients to be honest and to present the situation in a real way. The most important question on the questionnaire was "Which of the three options represents the PASI score you would like to achieve? 50/75/90?". In addition to this question, we provided the patients with three pictures each of them showing a different PASI score, so they can choose the proper answer much easier.

Results: 80% of the patients chose PASI 90, 15% chose PASI 75 and only 5% chose PASI 50.

In addition to this, the gender distribution showed us that 100% of the female patients chose PASI 90, proving how important appearance is for them, and how much of a weight it is for them to have disease that is in the limelight. On the other hand, the male patients were divided into three groups. 69% said that the efficiency of the therapy is very good, choosing PASI 90. Only 23% of male patients consider PASI 75 satisfying and the last 8% represents PASI 50.

Conclusions: Psoriasis is a chronic inflammatory disease, which is intensively studied at the cellular and molecular level. What is considered a good response to a treatment is sometimes different from the perception of a patient vs. a physician, therefore we must always keep a balance between aiming high (and maybe risking to over-treat some patients) and meeting the patient's expectations.

P130

THE IMPACT OF PSORIASIS AND PSORIATIC ARTHRITIS ON QUALITY OF LIFE AND CAREER IN SCANDINAVIA

Albert Duvetorp¹, Mikkel Østergaard², Lone Skov³, Oliver Seifert⁴, Kåre Steinar Tveit⁵, Kjersti Danielsen⁶, Lars Iversen⁷

¹Skånes Universitetssjukhus, Malmö, Sweden; ²Linköping University, Linköping, Sweden; ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, University of Copenhagen Copenhagen; ⁴Herlev and Gentofte Hospital, University of Copenhagen, Denmark; ⁵Linköping University, Linköping, Sweden; ⁶Ryhov Hospital, Jönköping, Sweden; ⁷Haukeland University Hospital, Bergen, Norway; ⁸UiT The Arctic University of Norway; University Hospital of North Norway, Tromsø, Norway; ⁹Aarhus University Hospital, Aarhus, Denmark

Introduction: Patients' perspectives on the effects of psoriasis (PsO) and psoriatic arthritis (PsA) on health-related quality of life (HRQoL) are important in establishing better approaches to their care and treatment.

Objectives: To better understand the impact of PsO and PsA on daily life, education and work in Scandinavian countries.

Methods: The NORdic PATient survey of Psoriasis and Psoriatic arthritis (NORPAPP) was an on-line survey carried out in Nov/Dec 2015 using YouGov panels in Sweden, Denmark, and Norway. Adults (18–74 years old), with physician-diagnosed PsO or PsA ($n = 1221$), answered questions about the impact of disease on 10 aspects of daily activity/mood and on work/education; 5-point Likert scale responses were dichotomised into "no/minor impact" (1–3 or "don't know") and "strong impact" (4–5).

Results: For the 10 aspects of activity/mood a "strong impact" was reported for ≥ 4 , 1–3 or 0 aspects by 22.8%, 24.2%, and 61.9% of respondents with PsO alone and 44.5%, 63.0%, and 27.0% of those with PsA±PsO. The most commonly reported strong impacts were limitations on dress (22.6%), sleep disorders (16.3%) and depression and/or anxiety (16.2%) for respondents with PsO alone; and, daily routine (45.1%), leisure/sports (44.0%), sleeping disorders

(44.5%), and limitations on clothing (41.8%) for respondents with PsA±PsO. Regarding the impacts on work/career or education since development of symptoms, 6.4% of respondents with PsO alone and 30.3% of those with PsA±PsO reported a strong negative impact. Of the 82.2% of respondents who were working or studying, frequency of absences in the previous 12 months were significantly higher (Bonferroni corrected z-tests, total $\alpha = 0.05$) among those who: had PsA±PsO vs PsO alone; perceived their symptoms to be severe vs non-severe; used systemic vs only topical treatments; were aged 18–44 years vs 45–74; were members of patient groups vs non-members; saw a dermatologist or rheumatologist at least annually vs those who did not.

Conclusion: PsO has a profound impact on the HRQoL and career/education of individuals with these conditions in Scandinavia. The impact is greater among individuals with PsA±PsO.

P131

QUALITY OF LIFE OF PATIENTS WITH PSORIASIS IN KHARTOUM DERMATOLOGY HOSPITAL, DECEMBER 2017

Hind Madani

University of Khartoum- faculty of medicine

Introduction: Psoriasis is a common chronic non-contagious skin disease, affecting 1–3% of the world population. Defects in the immune regulation and the control of inflammation are thought to play major roles. Quality of life (QOL) is increasingly recognized as an important outcome measure in dermatology. Psoriasis although it doesn't affect the survival it has a great impact on quality of life of patients, and has a strong effect on social relations, psychological status, daily activities and thought to be associated with depression.

Objectives: The aim of this study was to determine the impact of psoriasis on the quality of life (QOL) of the patients in Khartoum dermatology hospital, 2017.

Methods: Descriptive case series study, hospital based survey conducted among 70 participants from psoriasis patients aged above 18 years in Khartoum dermatology hospital, through self-administered standard questionnaire, which was developed after extensive literature reviewing, comprised of Socio-demographic data, psoriasis life stress inventory (PLSI), psoriasis disability index (PDI) and depression assessment.

Results: 64.3% of the participants have a high psoriasis-related stress (PLSI) and 35.7% have a low psoriasis-related stress. 21.4% of the participants have a very large disability in daily activities (PDI), 37.1% have a large disability, 24.3% have a moderate disability, 14.3% have a mild disability and 2.9% have no disability at all. 7.1% of the participants have a moderately severe depression, 15.7% have a moderate depression, 35.7% have a mild depression, 41.4% have none or minimal depression and none of the participants has a severe depression.

Conclusion: the study concluded that psoriasis has impacts on the quality of life, causing high stress and high disability in daily activities with variable degrees of depression.

Key words: psoriasis, QOL, PLSI, PDI, depression.

References:

1. El-Moselhy EA, Atlam SA, Mohammed AS, Hassan HM, Ebrahim AM (2015) Psychosocial Impact and Quality of Life among Adult Egyptian with Psoriasis. *Dermatol Case Rep* 1: 104.
2. Abbas Darjani N. Quality of Life in Psoriatic Patients: A Study Using the Short Form-36 [Internet]. *PubMed Central (PMC)*. 2017 [cited 30 March 2017]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192777/>
3. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. *Br J Dermatol* 1995;132:236–44. *CrossRef PubMed Web of Science Google Scholar*
4. Tang M, Chang C, Chan L, Heng A. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. 2018
5. Langley R. Psoriasis: epidemiology, clinical features, and quality of life. *Annals of the Rheumatic Diseases*. 2005;64(suppl_2):ii18–ii23.

P132

MIRIKIZUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED DISEASE SEVERITY AND GENERAL HEALTH STATUS IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS

Melinda Gooderham¹, Paul Klekotka², Emily Edson Heredia², Joanne Li², Baojin Zhu², Jiaying Guo², Jerry Bage³

¹SKiN Centre for Dermatology, ²Eli Lilly & Company, ³Windsor Dermatology

Introduction: In a randomized, placebo-controlled, phase 2 trial (NCT02899988), mirikizumab met its primary efficacy endpoint at Week 16.1

Objective: To determine if mirikizumab improves patient-reported disease severity and general health status in psoriasis patients at Week 16.

Methods: Adults with moderate-to-severe psoriasis were randomized 1:1:1:1 to receive placebo ($n = 52$), mirikizumab 30 mg ($n = 51$), 100 mg ($n = 51$), or 300 mg ($n = 51$) at Weeks 0 and 8. At baseline and Weeks 2, 4, 8, 12, and 16, patients completed the Patient Global Assessment of psoriasis (PtGA) (0 = clear, 5 = severe). At baseline and Week 16, patients completed the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36; [range 0–100]) which measures 8 general health status domains that can be scored as mental component and physical component summaries. For continuous measures, comparisons were made by a mixed-effects for repeated measures model (PtGA) or an analysis of covariance model (SF-36). Comparisons of categorical efficacy variables were conducted by logistic regression analysis with non-responder imputation (NRI).

Results: At Week 16, mirikizumab-treated patients reported greater improvements in psoriasis severity and aspects of physical functioning versus placebo (Table).

Conclusion: Mirikizumab treatment at various doses significantly improved psoriatic disease severity and physical health status.

Reference:

1. Reich K et al. Programme and abstracts of Psoriasis from Gene to Clinic; Nov. 30-Dec. 2, 2017; Abstract FC31.
Table. Patient-Reported Outcomes (Week 16)

| | Mirikizumab | | | |
|---|---------------------|-------------------|--------------------|--------------------|
| | Placebo $n = 51$ | 30 mg $n = 48$ | 100 mg $n = 51$ | 300 mg $n = 51$ |
| PtGA, least squares mean(SE) | 0.4 (0.16) | 2.2 (0.16)*** | 2.9 (0.16)*** | 2.8 (0.16)*** |
| Change from Baseline in SF-36 Domains, LSM (SE) | | | | |
| Physical functioning | 2.8 (1.9) | 7.2 (2.0) | 8.2 (1.9)* | 7.2 (2.0) |
| Role-physical | 1.2 (2.4) | 11.4 (2.5)** | 11.5 (2.5)** | 12.3 (2.5)** |
| Bodily pain | 5.7 (2.8) | 17.6 (2.9)** | 19.2 (2.9)*** | 18.9 (2.9)** |
| General health | 1.4 (1.9) | 5.8 (2.0) | 3.2 (1.9) | 5.4 (1.9) |
| Vitality | 1.0 (2.0) | 6.9 (2.1)* | 4.7 (2.0) | 6.2 (2.0) |
| Social functioning | -0.2 (2.4) | 10.5 (2.4)** | 13.4 (2.4)*** | 8.2 (2.4)* |
| Role-emotional | 1.3 (2.0) | 5.2 (2.1) | 6.1 (2.0) | 6.0 (2.0) |
| Mental health | 1.7 (1.8) | 5.5 (1.8) | 6.6 (1.8) | 3.2 (1.8) |
| ≥2.5 point improvement in SF-36 | 36.5 | 37.3 | 45.1 | 33.3 |
| MCS, % (NRI) | | | | |
| ≥2.5 point improvement in SF-36 | 42.3 | 52.9 | 56.9 | 62.7* |
| PCS, % (NRI) | | | | |

MCS, mental component summary; PtGA, Patient Global Assessment; PCS, physical component summary; SE, standard error; SF-36, 36-Item Short Form Health Survey.

* $p < .05$ vs placebo; ** $p < .01$ vs placebo; *** $p < .001$ vs placebo.

P133

EFFECT OF TILDRAKIZUMAB ON PERSONAL RELATIONSHIPS IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS

Kim Papp¹, Alexa Kimball², Andrew Blauvelt³, Kristian Reich⁴, Melinda Gooderham⁵, Stephen Tyring⁶, Rodney Sinclair⁷, Diamant Thaci⁸, Yang Zhao⁹, Nicole Cichanowitz¹⁰, Qing Li¹⁰, Carmen La Rosa¹⁰

¹K Papp Clinical Research and Probiy Medical Research, Waterloo, Ontario, Canada, ²Harvard Medical School, Boston, MA, ³Oregon Medical Research Center, Portland, OR, USA, ⁴SciDerm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, ⁵SKiN Centre for Dermatology and Probiy Medical Research, Peterborough, and Queen's University, Kingston, Ontario, Canada, ⁶Department of Dermatology, University of Texas, Houston, TX, USA, ⁷University of Melbourne, Melbourne, VIC,

Australia, ⁸University of Lübeck, Lübeck, Germany, ⁹Sun Pharmaceutical Industries, Inc., Princeton, NJ, ¹⁰Merck & Co., Inc., Kenilworth, NJ, USA

Introduction: The negative impact of psoriasis extends beyond the patient, affecting his/her social interactions and the quality of life of cohabitants. Furthermore, patients with psoriasis often experience sexual difficulties because of their disease.

Objective: This analysis examined the effect of treatment with tildrakizumab (TIL) on personal relationships of patients with moderate-to-severe chronic plaque psoriasis.

Methods: Patients in two phase 3 trials reSURFACE 1 (NCT01722331) and reSURFACE 2 (NCT01729754) were randomized to subcutaneous TIL 200 mg, 100 mg, or placebo (PBO) and received treatment at weeks 0 and 4. PBO patients were re-randomized at week 12 to either TIL 200 mg or 100 mg. Etanercept (ETN) 50 mg (semiweekly until week 12 then weekly until week 28) was also a treatment arm in reSURFACE 2. Data on personal relationships were collected at weeks 12 and 28 from the Dermatology Life Quality Index (DLQI) questionnaire question 8 (Q8) "Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives" and question 9 (Q9) "Over the last week, how much has your skin caused any sexual difficulties". Each question was scored on a scale of 0 (not affected at all) to 3 (very much affected). The data were pooled from reSURFACE 1 and 2.

Results: In all, 1,820 patients had DLQI data. All patients reported a negative effect for Q8 and Q9 at baseline. At week 12, the proportion of patients with no negative effect (score of 0) on personal relationships (Q8 and Q9) was higher for TIL 200 mg, TIL 100 mg, and ETN than for PBO (76%, 72%, and 64% vs. 39%, respectively). A similar trend was observed for individual questions Q8 and Q9. At week 28, more patients on TIL 200 mg and TIL 100 mg reported no negative effect on personal relationships than those on ETN (85% and 77% vs. 66%; respectively). More patients on TIL 200 mg and TIL 100 mg reported no negative effect than those on ETN for Q8 (89% and 81% vs. 70%; respectively) and for Q9 (89% and 84% vs. 75%, respectively).

Conclusions: TIL had a beneficial effect on psoriasis-related personal relationship problems and sexual difficulties, compared to placebo and ETN.

This abstract was presented at 2018 Annual Meeting of American Academy of Dermatology.

P134

PRURITUS SEVERITY ASSESSMENT AND CORRELATION WITH BASELINE CHARACTERISTICS OF PATIENTS WITH PSORIASIS VULGARIS: AN EXPLORATORY ANALYSIS OF THE PHASE IIIB, PSORITUS STUDY

Sonja Ständer¹, Sabine Steinke¹, Matthias Augustin², Dieter Metzger¹, Karin Loser¹, Daniel Baeumer³, Thomas Luger⁴

¹Department of Dermatology and Competence Center Chronic Pruritus and ⁴Department of Dermatology, University hospital Münster, Münster, ²Institute for Health Services Research in Dermatology and Nursing, Hamburg, and ³Novartis Pharma, Nuernberg, Germany

Introduction: Chronic pruritus lasts for at least 6 weeks and is a most common symptom in patients with psoriasis. Pruritus is a highly prevalent and troublesome symptom and has a negative impact upon patients' health-related quality of life (QoL). The ItchyQoL is a pruritus-specific QoL questionnaire that can be applied to patients with pruritus independent of the underlying disease.

Objective: To assess the impact of pruritus on QoL in patients with psoriasis by an exploratory analysis of baseline characteristics of subjects from the PSORITUS study.

Methods: PSORITUS was an exploratory, randomized, double-blind, placebo-controlled 16-week drug withdrawal study with a 16-week open-label run-in phase, to assess the kinetics of psoriasis symptoms, pruritus intensity, and lesional biomarkers. Subjects

≥18 years of age with chronic moderate-to-severe psoriasis at least 6 months prior to baseline, with a Psoriasis Area and Severity Index (PASI) score > 10 at baseline, and pruritus intensity ≥30 on a 100-point Visual Analogue Scale (VAS, the worst itching within a recall period of 24 hours), were included. In an exploratory baseline analysis, correlation coefficients were calculated between ItchyQoL outputs and individual baseline characteristics based on Spearman's (r) and Kendall rank correlations (t). A multiple linear regression model was performed to assess the effect of exploratory variables correlating with the ItchyQoL score and achieving statistical significance (p -value < 0.05).

Results: The study included 130 subjects with psoriasis. The subjects had a mean age of 46.8 years (standard deviation [SD], 12.30) and majority (71.5%) were in the age group of 35–64 years. The mean (SD) time since first diagnosis of psoriasis and psoriatic arthritis (PsA) was 19.5 (13.81) and 17.2 (18.30) years, respectively; 13.8% of subjects had PsA. The mean (SD) baseline PASI, patient benefit index (PBI), and ItchyQoL score was 23.9 (10.85), 84.2 (24.17), and 78.7 (17.42) respectively, indicating severe disease activity and pruritus. The baseline ItchyQoL score showed moderate correlation with baseline VAS scores for average and worst pruritus (r: 0.542 [95% CI: 0.41, 0.65] and 0.547 [95% CI: 0.41, 0.66]; t: 0.381 [95% CI: 0.22, 0.52] and 0.383, 95% CI: 0.23, 0.52) and a strong correlation with baseline dermatology life quality index (DLQI) scores (r: 0.803 [95% CI: 0.73, 0.86]; t: 0.622 [95% CI: 0.50, 0.72]). Furthermore the multiple linear regression analysis showed substantial dependency of QoL measured by ItchyQoL for VAS (average pruritus last 24 h), duration of psoriasis and health-related patient needs as measured by patient benefit index.

Conclusions: ItchyQoL assessment demonstrated that subjects with psoriasis are highly burdened by pruritus and show severely impaired quality of life. The correlation between pruritus intensity, ItchyQoL- and DLQI questionnaire results suggests the need for routine assessment of pruritus in clinical practice.

P135

QUALITY OF LIFE AND PSYCHOSOCIAL IMPLICATIONS IN PATIENTS WITH PSORIASIS

Anargyros Kouris¹, Eftychia Platsidaki¹, Alexandros Katoulis², Vasiliki Markanton¹, Christos Christodoulou², Evangelos Balaskas¹, Georgios Kontochristopoulos¹

¹Andreas Sygros Skin Hospital, ²Attikon University Hospital, Athens, Greece

Introduction: Psoriasis is a common, long-term skin disease that affects approximately 1.5–3% of the population. The burden of living with psoriasis is equivalent to or greater than that seen in other long-term conditions, such as cardiac failure and chronic lung disease. The stigma provoked by the disease, often lead to the discontinuation of daily activities and social withdrawal. Nevertheless, these effects of psoriasis are seldom recognized and often undertreated.

Objectives: The aim of the study is to evaluate the quality of life, anxiety and depression, self-esteem and loneliness in patients with psoriasis.

Methods: Ninety-eight patients with psoriasis were enrolled in the study. The quality of life, depression and anxiety, loneliness and self-esteem of the patient were assessed using the Dermatology Life Quality Index, Hospital Anxiety and Depression Scale, the UCLA loneliness Scale (UCLA-Version 3) and Rosenberg's Self-esteem Scale, respectively.

Results: The Dermatology Quality of Life Index score among psoriasis patients was 13.52±4.58. They had statistically significantly higher scores according to the Hospital Anxiety and Depression Scale-anxiety subscale ($p=0.031$)-compared with healthy volunteers. Moreover, a statistically significant difference was found between the two groups concerning the UCLA-scale ($p=0.032$) and RSES-scale ($p<0.0001$). Female patients presented with lower self-esteem than male patients.

P136

SWEDISH PSORIATIC PATIENTS' PERSPECTIVE OF THEIR DISEASE. RESULTS FROM AN OBSERVATIONAL PATIENT SURVEY

Charlotta Enerbäck¹, Sofie Fors², Anna-Karin Dahlborn²

¹Department of Dermatology, Linköping University Hospital, Linköping, Sweden, ²Novartis

Introduction: A global patient survey was adapted and implemented in Sweden, in order to explore and understand the patients' view on their disease, as well as the personal and emotional impact of their psoriasis. The focus of the survey was the patient's perception of the possibility to achieve clear skin, and how having clear skin could affect their quality of life. A publication based on earlier data is under review.

Methods: The Swedish "Clear about Psoriasis" survey was conducted from June 16 2017 to August 8 2017. Recruitment was made via online panels and patient organizations. Validated methods were used to assess severity of disease and health-related quality of life. The survey consisted of multiple-choice questions, no definition of clear skin was given, and spontaneous feelings/perceptions were reported. Respondents (≥18 years old) were required to have current plaque psoriasis, for which they had received a medical diagnosis and should not have participated in an online survey about psoriasis in the preceding four weeks. The analysis included only patients with moderate-to-severe plaque psoriasis, defined as a Psoriasis Area Severity Index (PASI) score ≥10, or a PASI score 5.0–9.9 with plaques in visible and/or in sensitive areas, such as the face and genitals.

Results: In total, 54 patient responses were completed and analyzed. Mean age was 45 years and 80% were female. The average self-assessed PASI score was 16.0, 26% had PASI 5.0–9.9, 74% PASI > 10 and 54% reported to have psoriatic arthritis. Current treatment allowed 44% of patients to achieve clear or almost clear skin. Clear or almost clear skin was believed to be achievable by 30% of the patients. Of patients reaching clear or almost clear skin, 71% had talked to their physician about their aim for clear skin. Among patients who have not achieved clear or almost clear skin, 47% had spoken to their physician about their aim. 57% of the patients were satisfied with their current treatment. The most important reasons for treatment satisfaction were less itching (81%), and the achievement of less pain and soreness (55%). Not achieving clear skin was the major reason for dissatisfaction. Discrimination or humiliation has been experienced by 98%. About 69% have been asked if they are contagious. Relationships were affected and 52% avoided to have sex. Worklife was affected by 65% of the respondents. For 58% of patients it took more than 5 years to get a treatment that resulted in clear or almost clear skin. During the last 6 months, 24% of employed patients had taken at least one day off work due to their disease whilst 5% took more than 14 days.

Conclusions: This survey shows that a majority of patients do not believe achieving clear or almost clear skin is possible and they are not comfortable to talk to their physician about it. Furthermore, patients encounter a stigmatizing environment. Better treatment as well as improved patient information is needed.

Novartis is grateful to Psoriasisförbundet for facilitating the survey.

P137

IXEKIZUMAB PROVIDES GREATER CUMULATIVE BENEFITS VERSUS USTEKINUMAB OVER 24 WEEKS FOR PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS IN A RANDOMIZED, DOUBLE-BLIND PHASE 3B CLINICAL TRIAL

Andrew Blauvelt¹, Mark Lomaga², Russel Burge³, Baojin Zhu³, Carsten Henneges³, Wei Shen³, David Shrom³, Martin Dossentbach³, Andreas Pinter⁴

¹Oregon Medical Research Center, ²DermEdge Research, ³Eli Lilly and Company, ⁴University Hospital Frankfurt

Introduction: Ixekizumab, a high-affinity monoclonal antibody that selectively targets IL-17A, was shown to be superior to ustekinumab, an IL-12/23 inhibitor, with respect to skin clearance and quality of life up to 24 wks in patients with moderate-to-severe psoriasis in IXORA-S1.

Objectives: The objective of this analysis was to compare the cumulative benefits of ixekizumab versus ustekinumab at 12 and 24 weeks of treatment in IXORA-S, with respect to skin clearance, itching, health-related quality of life (HRQoL), and pain.

Methods: In the IXORA-S trial, patients were randomized (1:1) to receive either IXE (160-mg starting dose, then 80-mg every 2 wks for 12 wks followed by 80-mg every 4 wks; $n = 136$) or UST (45-mg/90-mg weight-based dosing per label; $n = 166$) through 52 wks. Data at week 12 and week 24 were used in this post-hoc analysis. At wks 2, 4, and every 4 wks thereafter, clinical benefits were measured using percentage improvements in Psoriasis Area and Severity Index (PASI 75/90/100); the Itch Numeric Rating Scale (NRS; 0 = no itch, 10 = worst itch imaginable); and Skin Pain VAS (0 = no pain, 100 = maximum pain). Health-related quality of life (HRQoL) benefit was measured at wks 2, 4, 12, and 24 using the Dermatology Life Quality Index (DLQI) [DLQI score = 0.1 indicates no effect on patient's life]. Total benefits - PASI 75/90/100; itch NRS = 0; DLQI = 0.1; Pain VAS 0 - were used to determine the area-under-the-curve (AUC) of responders for each outcome at 12 and 24 weeks. Missing values were imputed using non-responder imputation (NRI). AUC results, capturing the rapid and sustained treatment response, were normalized as a percentage of maximum possible (0–100%) AUC. The clinical benefit ratios between IXE vs UST were calculated for each outcome to show relative cumulative benefit.

Results: At 12 wks, the normalized cumulative clinical benefit with IXE vs UST, respectively, was 58.2% and 32.9% (PASI75); 36.7% and 15.6% (PASI90); 14.2% and 4.0% (PASI100); 25.3% and 14.3% (itch); 36.0% and 23.7% (pain); and 44.9% and 25.2% (DLQI). Cumulative clinical benefits at week 24 for IXE and UST, respectively, were 74.3% and 54.3% (PASI75), 58.1% and 32.3% (PASI90), 29.0% and 12.2% (PASI100); 33.5% and 22.1% (itch); 42.7% and 30.6% (pain); and 54.3% and 37.0% (DLQI). At 12 wks, clinical benefit ratios (IXE/UST) for PASI 75/90/100 were 1.77, 2.36, and 3.52; 1.51 for pain; and 1.78 for both itch and DLQI. At 24 wks, the ratios were 1.37, 1.80, 2.38 (PASI 75/90/100), 1.52 (itch), 1.39 (pain) and 1.47 (DLQI).

Conclusions: Cumulative benefits measured by PASI, itch, pain, and DLQI responders were greater for IXE vs. UST following 12 and 24 wks of treatment. Long-term cumulative benefits will be addressed upon publication of Week 52 results from the IXORA-S trial.

Reference:

Reich K, et al. *Br J Dermatol*. 2017;177(4):1014-1023.

Previously presented at AAD, San Diego, CA; February 16 – 20, 2018.

P138

COACH@HOME: A SUPPORT PROGRAM FOR PATIENTS TREATED WITH CERTOLIZUMAB PEGOL

Nicolai Böhme¹, Ann-Dörthe Holst², Friedrich Dybowski³, Christoph Volberg⁴, Hans-Georg Pott⁵, Udo Lendl⁶

¹Healthcare at Home Deutschland GmbH, Weinheim, ²Rheumapraxis, Ludwigslust, ³Rheumapraxis Ruhr, Herne, ⁴Rheumatologie in Neuss, Neuss, ⁵Rheumatologikum Hannover, Hannover, ⁶UCB Pharma GmbH, Monheim am Rhein, Germany

Introduction: Coach@home (c@h) is a German support program for certolizumab pegol (CZP)-treated patients (pts) with rheumatic diseases, including psoriatic arthritis (PsA). Eight coaching calls are offered over one year, scheduled around critical milestones on the therapeutic journey. These are made by trained nurses, who offer support and information about both the pt's disease and its treatment with CZP.

Objectives: To assess the baseline characteristics of PsA pts subscribed to c@h, and the level of pt satisfaction with the program across indications (Sep 2017 data cut).

Methods: c@h was launched in Jun 2014, and is available to pts who are prescribed CZP according to the local product label. Pts must be CZP-naïve when subscribed to the program, and pt consent is required prior to subscription by the treating physician. There are no additional criteria for enrolment, although the program must be recommended to the pt by the treating physician. Pt satisfaction across indications (PsA, rheumatoid arthritis and axial spondyloarthritis) was measured at program completion or discontinuation using the net promoter score (NPS), which has previously been used for this purpose.¹ The NPS is derived by asking pts to state the likelihood that they would recommend c@h to others (on a 0–10 scale). Rankings of 9–10 are considered 'promoters', 7–8 'passives', and 0–6 'detractors'. Subtracting the percentage of detractors from that of promoters yields the NPS.

Results: A cumulative total of 136 PsA pts had been registered to c@h by Sep 2017. Mean age at baseline was 52 years; the majority were female (69%). Prior biological DMARD exposure was 24%. The most common topics discussed on calls were treatment adherence (290 calls), CZP maintenance dose (284 calls) and syringe disposal (201 calls). The average length per call was 15.7 min (SD: 5.33) at the end of Week 0 (total: 135 calls), and 14.6 min (SD: 6.59) at the end of Week 52 (45 calls).

Across indications, a cumulative total of 272/655 pts had either completed the coaching period ($n = 70$) or discontinued ($n = 202$) by 28 Sep 2017, of whom 106 rated the program. Of these, 87.5% gave promoter scores, 10.4% passive, and 3.8% detractor, yielding an NPS of 83.7. The program was still ongoing at the time of this data cut.

Conclusions: c@h offers support and guidance to CZP-treated pts in Germany. Feedback from pts willing to provide a rating (39%) indicates a high level of satisfaction with the program.

References:

1. Hamilton DF. *Bone Joint J* 2014;96-B(5):622–8.

Acknowledgements: c@h is performed by Healthcare@home Deutschland GmbH, funded by UCB Pharma, led by Elke Zeise and managed by Karen Thiel and Manh Dan Nguyen. We thank the patients and their caregivers in addition to the investigators and their teams who contributed to this program. Editorial services were provided by Costello Medical.

P139

A COMPREHENSIVE SURVEY ASSESSING THE FAMILY PLANNING NEEDS OF WOMEN WITH PSORIASIS

Mark Lebwohl¹, Abby S Van Voorhees², Michael Siegel³, Lindsey Shankle³, Lisa Pisenti⁴, Mohamed Yassine⁴

¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Eastern Virginia Medical School, Norfolk, VA, ³National Psoriasis Foundation, Portland, OR, ⁴UCB Pharma, Smyrna, GA, USA

Introduction: Psoriasis (PS) in women often overlaps with their peak reproductive years. Data on the family planning (FP) experience of patients (pts) are therefore needed to optimize PS management.

Objectives: To report the results of a survey evaluating the FP needs of women with PS.

Methods: Women of childbearing potential (WoCP; aged 18–45) diagnosed with PS (including pts with psoriatic arthritis), were recruited to complete a 96-question web-based survey on SurveyGizmo®. The survey included questions on pts' experience, concerns and educational needs, and was disseminated using e-blasts (the National Psoriasis Foundation, Advance E-News, and TalkPsoriasis.org mailing lists) and social media (Facebook and Twitter). Responses were collected Dec 2017–Feb 2018.

Results: Of 141 pts completing the survey, 91 (65%) were planning to conceive (PTC), and 66 (47%) had experienced pregnancy (EP) within the last 5 years. Prescribed systemic medications were

being used by 40% of pts PTC and 12% of pts who had EP. Only 41% pts who had EP informed the healthcare provider (HCP) treating their PS of their pregnancy right away, while 21% did not notify them at all.

While PTC, most pts who had not EP (88%), sought FP advice from the internet; only 21% had consulted the HCP treating their PS, compared to 55% of pts who had EP. Of the 96 pts who discussed FP with the HCP treating their PS, just 7% said this was initiated by the HCP. Pts PTC were most influenced by their personal network (e.g. family), but of pts who had EP, 41% said the HCP treating their PS was one of the most influential types of support in their FP decisions. Pts reported wanting information on the impact of PS and treatments on their baby, the heritability of PS, and flare management during pregnancy. During pregnancy, 65% pts who had EP stopped treatment (of any type), 79% of whom did so out of fear of harming their baby. In 40% cases where pts had stopped all and any treatment for PSO, the decision was initiated by the pt, and in 47%, by their PS treatment provider. Of pts who stopped treatment, 44% experienced a worsening in the severity of their PS, yet most pts do/did not have a plan for flare management during pregnancy (PTC: 69%; EP: 65%). Many pts stopping all treatment had not been advised on restarting treatment post-partum (PTC: 42%; EP: 23%).

Conclusions: Many WoCP with PS take systemic medications but many do not discuss FP with their PS treatment provider, and if they do, the discussion is rarely initiated by the HCP. PS treatment providers should prioritize discussing FP, and plan treatment around and during pregnancy. The educational needs of WoCP with PS include the impact of treatment on their baby, flare management during pregnancy, and restarting treatment post-partum. **Acknowledgements:** This study was funded by UCB Pharma. The survey was conducted by the National Psoriasis Foundation. We thank the patients who contributed to this study. Editorial services were provided by Costello Medical.

P140

THE PSYCHOSOCIAL IMPACT OF PSORIASIS: DIFFERENTIAL EXPERIENCES OF MEN AND WOMEN IN EARLY ADULTHOOD

Caitriona Ryan¹, Carl Vandelaar², Duncan Munro³, Alvaro Arjona¹
¹Blackrock Clinic, Dublin, Ireland and University College, Dublin, Ireland,
²UCB Pharma, Brussels, Belgium, ³Cello Health, London, UK

Introduction: Plaque psoriasis (PSO) can have a profound impact on patients' (pts') psychosocial wellbeing, leading to self-consciousness, embarrassment, depression, social isolation and stigmatization. However, little is known of how the impact of disease differs between genders.

Objective: To evaluate differences in the psychosocial impact of PSO on quality of life in men and women in early adulthood.

Methods: Pts aged ≥18 in the US, Canada, France, Germany and Italy without a diagnosis of psoriatic arthritis were invited to complete a postal survey (Oct 2016–Jan 2017), in the ratio 3:1 as being treated with advanced therapy (biologic/apremilast), or eligible for but not yet receiving advanced therapy. Answers were given on 5- or 7-point Likert Scale. Percentages shown are proportions of pts responding using either of the two responses indicating greatest impact of disease. Data are presented for pts in early adulthood (18–45 years),[1] stratified by gender.

Results: 63 women and 73 men completed the survey; mean age was 35 and 36 years, respectively, mean age at diagnosis was 28 for both genders. Disease distribution was similar between genders, although women reported more severe disease affecting their arms and males reported more severe scalp disease. Whilst physical impacts of disease were similar (≤2 pts reported severe problems with walking, washing/dressing, carrying out housework/family/leisure activities or daily work), a higher proportion of women (14% vs 4%) reported severe/extreme pain or discomfort. Both

genders were more concerned by appearance (women: 73%, men: 63%) than pain (women: 43%, men: 34%).

A higher proportion of women than men were concerned by their appearance (73% vs 63%), reported a greater impact on their choice of clothing (37% vs 21%), and always/usually tried to cover their skin (27% vs 16%). Similarly, psychosocial effects of disease tended to be greater in women: 16% women vs 8% men reported severe/extreme anxiety or depression; 29% women vs 18% men suffered sexually/in achieving intimacy. Similar proportions had suffered at work (women: 11%, men: 16%), while a higher proportion of women (6%) than men (3%) struggled to live their lives as they did prior to their diagnosis. These findings have been corroborated by ethnography studies.

Conclusion: Despite similar clinical manifestations of PSO, women in early adulthood tended to report a greater impact of their disease on their lives, both physically, in terms of pain, and psychosocially, in terms of effects on relationships and impact on their daily lives. Physician awareness of such gender differences in the impact of the disease on patients' lives would encourage a more holistic approach to discussing treatment options with their patients.

Reference:

1. A Conception of Adult Development. Daniel J. Levinson. 1986. American Psychologist vol. 41, No. 1, 3-13

P141

CERTOLIZUMAB PEGOL IMPROVES PATIENT-REPORTED OUTCOMES IN CHRONIC PLAQUE PSORIASIS OVER 1 YEAR

Diamant Thaci¹, Alice B Gottlieb², Kristian Reich³, Jerry Bagel⁴, Luke Peterson⁵, Oana Purcaru⁶, Jolanta Węglowska⁷

¹University Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany, ²Department of Dermatology, New York Medical College at Metropolitan Hospital, NY, NY, ³SCIderm Research Institute, Hamburg, and Dermatologikum Berlin, Germany, ⁴Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, ⁵UCB Pharma, Raleigh, NC, USA, ⁶UCB Pharma, Brussels, Belgium, ⁷Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław, Poland

Introduction: Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-TNF biologic. Here we present patient (pt)-reported quality of life (QoL), work productivity and social activities over 48 weeks of CZP treatment.

Materials/Methods: Data were pooled from CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272) phase 3 trials of adults with PSO ≥6 months (psoriasis area and severity index [PASI] ≥12, affected body surface area [BSA] ≥10%, physician's global assessment [PGA] ≥3/5). Pts were randomized to CZP 400 mg every 2 weeks (Q2W), CZP 200 mg Q2W (following 400 mg loading dose at Weeks 0, 2, 4), or placebo (PBO) Q2W for 16 weeks. Week 16 CZP-treated PASI 50 responders continued initial blinded treatment to Week 48 (PBO-treated PASI 50 responders are not included). PASI 50 non-responders at Weeks 32, 40 and 48 were discontinued.

Mean change from baseline (CFB) in Dermatology Life Quality Index (DLQI), rates for DLQI minimally clinically important difference (MCID; ≥4-point improvement) and DLQI remission (score of 0/1), and CFB in Work Productivity and Activity Impairment (WPAI) PSO-specific at Weeks 16 and 48 were assessed. Negative CFB for DLQI and WPAI signifies improvement. CFB DLQI analyses used last observation carried forward (LOCF) imputation for missing data, DLQI MCID and remission analyses used non-responder imputation, WPAI analyses used last observation carried forward imputation at Week 16 and observed data at Week 48.

Results: At Week 16, CZP pts showed greater improvements in DLQI vs PBO, and higher proportions achieved DLQI MCID and DLQI remission (Table). Improvements were maintained to Week 48 in CZP-treated pts who continued treatment (Table). Improve-

ments in work productivity and reductions in activity impairment were seen with both CZP doses vs PBO; and were maintained to Week 48 in patients remaining in the trial. (Table).

Conclusions: Treatment with CZP was associated with improvements in QoL, work productivity and social activities vs PBO at Week 16, which was maintained to Week 48 in patients remaining in the trials.

Table. Improvements in DLQI and WPAI at Weeks 16 and 48

| | PBO (n = 100) | CZP 400 mg Q2W (n = 175) | CZP 200 mg Q2W (n = 186) |
|--|------------------|-----------------------------|-----------------------------|
| Week 16 | Week 16 | Week 16 | Week 48 |
| DLQI | | | |
| Mean CFB (SD) | -3.1 (6.7) | -9.8 (7.0) | -10.3 (7.5) |
| MCID, n (%) | 41 (41.0) | 135 (77.5) | 121 (69.1) |
| DLQI 0/1, n (%) | 7 (7.0) | 84 (48.0) | 90 (51.4) |
| WPAI Domains, mean change from baseline (SD) | | | |
| Absenteeism | 2.9 (22.1) | 4.7 (22.7) | -0.1 (17.5) |
| Presenteeism | 0.7 (21.8) | -12.9 (25.2) | 0.7 (21.7) |
| Work productivity loss | 4.8 (28.5) | -9.0 (32.7) | -16.4 (28.9) |
| Activity impairment | -1.5 (25.3) | -23.9 (28.3) | -28.6 (28.9) |

P142

TRANSLATING WHO RESOLUTION INTO THE PUBLIC: THE GERMAN PROGRAM AGAINST STIGMATIZATION OF PEOPLE WITH CHRONIC VISIBLE SKIN DISEASES

Matthias Augustin¹, Claudia Luck-Sikorski², Rachel Sommer¹, Janine Topp¹, Ines Schaefer¹, Marc Radtke¹, Sophie Schlette³, Nata-scha Weinberger⁴, Regina Spreckelsen⁵, Anja Hilbert⁶, Alexander Zink⁷, Dagmar Wilsmann-Theis⁸, Eckardt Breitbart⁹, Ulrich Mrowietz¹⁰

¹University Medical Center Hamburg-Eppendorf, ²University Gera, ³BVDD, ⁴University of Leipzig, ⁵University Hospital Kiel, ⁶University Medical Center Leipzig, ⁷University Munich, ⁸University Bonn, ⁹Dermatology Breitbart, ¹⁰University Kiel

Introduction: The WHO resolution 2014 raised fundamental demands for the health care system to increase the awareness for patients with chronic skin diseases such as psoriasis, including its fight against stigmatization. Single member states were encouraged to take action on all levels, including public awareness campaigns. After a period of refusal, the German ministry of health approved a project submitted by German dermatologists, patient groups and further experts to develop interventions against stigmatization.

Objectives- Aim of investigation: The project aims to develop and evaluate public interventions against stigmatization of people with visible skin diseases.

Methods: The project consist of three phases. Within a one-year period current research will be processed through a systematic literature search; recommendations for intervention formats will be derived. The consecutive 18 months involve the development of defined intervention formats. The interventions are supposed to focus on locations of stigma and encounters of stigmatizing with stigmatized persons.

Results: The application has been approved and is funded by the German ministry of health for a period of three years throughout the years 2018 to 2021. The project group consists of 25 dermatology-, science- and patient-experts who work in operative groups in order to develop the content and the intervention format. In doing so, different levels of the stigmatization process, namely stereotypes, prejudice, discrimination are considered as important aspects and will be accounted for in the development of the intervention. First results of the literature review imply that people with visible skin disease such as psoriasis are affected by stigmatization in several dimensions and strategies for reducing the stigma are required.

Conclusion: Following the WHO resolution, this project is an example for successful project initiation of an interdisciplinary team to develop and implement an intervention against stigmatization.

First outcomes will be a comprehensive review of papers derived from the systematic literature search in May 2018.

P143

THE GLOBAL RESEARCH ON THE IMPACT OF DERMATOLOGICAL DISEASES (GRIDD)

Matthias Augustin¹, Nirohshah Suthakharan¹, Christine Janus², Jennifer Austin², Christine Bundy³, Rachael Pattinson³

¹University Medical Center Hamburg, Institute for Health Services Research in Dermatology and Nursing (IVDP), ²International Alliance of Dermatology Patient Organisations – IADPO, ³University of Cardiff

Introduction: The Global Research on the Impact of Dermatological Diseases (GRIDD) project will be the first global patient-initiated and patient-led impact research study in dermatology. By including the patient perspective stringently into the burden metrics, this will be the first program to systematically challenge the current Global Burden of Disease concept, which markedly underestimates the patient burden of skin diseases.

Objective: The objective of the GRIDD research project is to develop a comprehensive measure of the impact of living with skin diseases instruments by country, regionally and worldwide. The global instrument, developed with patient organisations, will capture patient experiences, including the extent of disease impact and burden for patients and their families, for generic (i.e. all dermatological diseases) and specific dermatological disease including psoriasis assessment worldwide.

Materials + Methods: Development of the comprehensive measure of impact of disease will be based on a novel methodology with several phases. Phase 1 will systematically review existing measures of the life impact of skin diseases and conduct a patient-centered item identification exercise. Phase 2 will be informed by Phase 1 data and will focus on instrument development: develop the wording for items (i.e. impact categories) and appropriate item scaling. This measure will describe the impact on life which may include economic; psychological and social impacts. Phase 3 describes the acquisition of real world data to further test the validity and acceptability of the new measure. Lastly, phase 4 and 5 include dissemination and launch of data, the new measure and an implementation strategy to increase uptake of the measure.

Results: GRIDD has assembled a scientific advisory board representing different regions worldwide. Currently, we are collaborating with over 100 patient associations in 32 countries worldwide, with more than 26 disease areas. Industry funding has been secured from five different companies for the first phase and a portion of phase 2. The GRIDD research team, including researcher from the University Medical Center in Hamburg and University of Cardiff, met in 2017 to start phases 1 and 2. The systematic literature review on “Existing patient-centred outcome measures currently used in dermatology” is currently underway.

Conclusion: This novel patient-centric methodology will complement existing concepts of evaluating patient perspective in dermatology. GRIDD will provide an extended patient view for better decision making in dermatology on a global and country level. It supports local, regional and international attempts to create awareness, better position psoriasis and other skin diseases and encourage decision-makers and stakeholders to include dermatological diseases in their policies.

P144

TREATMENT OF NAIL PSORIASIS WITH DIFFERENT PULSE DURATIONS OF PULSED DYE LASER

Mohamad Goldust¹, Homan Alipour²

¹Mazandaran University of Medical Sciences, ²Tabriz University of Medical Sciences

Background: There are different treatment modalities for nail psoriasis but the treatment of choice is still controversial. Laser

therapy opened new windows for treatment of nail psoriasis (1,2). **Objective:** The aim of this study was to evaluate the efficacy of different pulse durations in the treatment of nail psoriasis with the 595-nm PDL to determine the optimal pulse duration.

Methods: In this clinical trial study, 120 patients with bilateral fingernail psoriasis were evaluated. PDL was applied on the proximal and lateral nailfolds based on random assignment. 240 nails were treated with 6-millisecond pulse duration and 9 J/cm(2) whereas 240 nails were treated with 0.45-millisecond pulse duration and 6 J/cm(2). Nail Psoriasis Severity Index (NAPSI) was used to assess the clinical outcome from pretreatment and posttreatment photographs.

Results: After 6 months of first treatment, there was a significant reduction in overall NAPSI, nail matrix NAPSI, and nail bed NAPSI scores from baseline in both groups; however, no significant difference was found between the two pulse duration groups. Side effects were mild including transient petechiae and hyperpigmentation.

Conclusion: PDL was found to be an effective and well-tolerated option in the treatment of nail psoriasis. This study demonstrated that both the longer 6-millisecond and shorter 0.45-millisecond pulses of PDL (595 nm) have been clinically proven to be effective for the treatment of nail matrix and nail bed psoriasis.

References:

1. Al-Mutairi N, Nour T, Al-Rqobah D. Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab. *Expert Opin Biol Ther* 2013;13(5):625-629.
2. Radtke MA, Beikert FC, Augustin M. Nail psoriasis - a treatment challenge. *J Dtsch Dermatol Ges* 2013;11(3):203-219.

P145

NEUTROPENIA IN A PSORIASIS PATIENT: SECUKINUMAB OR MICRONUTRIENT DEFICIENCY?

Maruska Marovt, Katarina Trcko, Pij B. Marko
University Medical Centre Maribor, Maribor, Slovenia

We report a case of severe neutropenia in a psoriasis patient, which developed three months after discontinuation of secukinumab. She had gastric bypass surgery a few years ago and was intermittently treated due to iron deficiency anemia. According to the suggested approach to the adult with unexplained neutropenia (1) a range of diagnostic tests were performed and no abnormalities were noticed. Neutropenia still persists, however the patient hasn't had any complications. Neutropenia was reported infrequently in subjects with moderate to severe psoriasis receiving secukinumab in a pooled analysis of 10 phase II and III clinical studies (2). Most were grades 1 or 2. Grade 3 neutropenia was uncommon and not associated with serious infections, and no grade 4 neutropenia was recorded. Deficiencies of dietary vitamins and minerals typically cause neutropenia in association with other cytopenias. Patients who have undergone bariatric surgery require lifelong vitamin and mineral supplementation. Severe neutropenia in our patient could be due to combination of secukinumab and micronutrient deficiency, however exact etiology remains unclear.

Berliner N (2018). Approach to the adult with unexplained neutropenia. In Newburger P (Ed.), *UpToDate*. Retrieved February 19, 2018, from <https://www.uptodate.com/contents/approach-to-the-adult-with-unexplained-neutropenia>

Van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. *J Am Acad Dermatol* 2016 Jul;75(1):83-98.e4.

P146

ESTABLISHMENT OF A PSORIATIC SKIN MODEL FOR A-IRRADIATION

Julia Wiedemann¹, Valeria Grünebaum¹, Claudius Witzler¹, Maximilian Dornhecker¹, Sylvie Lerchl, Claudia Fournier^{1,2}

¹GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany,

²University of Applied Sciences, Darmstadt, Germany

Introduction: Psoriasis is on the indication list for therapy in radon galleries (1). Radon is a radioactive noble gas evaporating from rocks. It is absorbed through skin or lung epithelium during inhalation. Radon decays in the tissue under emission of α -particles. The estimated dose received during a radon therapy is in the order of 1.2 mSv which corresponds to the annual background irradiation caused by radon. Chronic inflammatory diseases such as rheumatoid arthritis are treated with radon and pain reduction and improvement of mobility are reported (2). Positive effects are also reported for psoriasis, but sparsely documented. However, for both diseases the mechanisms underlying the clinical benefit are unknown.

Objectives: To investigate effects of radon treatment we have established a cellular model for psoriasis which can be used for irradiation with α -particles. The requirements in using α -particles are specific due to their short range.

Methods: Special rings strung with a 2 μ m oxygen plasma treated boPET foil are used to facilitate α -irradiation and growth of NHEK (normal human epidermal keratinocytes). Cells were cultured in rings or culture dishes for 24 hours and induced with IL-17, IL-22 and TNF- α . Supernatants and cells for protein and mRNA extraction were collected 24 hours after induction. ELISA, qPCR and Western Blot analysis was performed.

Results: We could show that it is possible to culture primary keratinocytes on plasma treated boPET foil with a similar morphology to cells cultured in cell culture dishes. Furthermore, the selected cytokines are able to significantly induce psoriasis-related markers like IL-19 and BDEF2 on mRNA level and the release of the cytokine IL-6. Testing if culturing of NHEK on the treated boPET foil alone has an inflammatory effect revealed no significant differences in the expression or release of markers compared to cells cultured in cell culture dishes.

Conclusion: We conclude that the plasma treated boPET foil is a promising tool for a setup, which enables α -irradiation of monolayer cell cultures. The induction of a psoriasis-like phenotype with cytokines leads to an enhancement of relevant markers.

References:

- Gasteiner Kur- Reha- und Heilstollen-Betriebsges.m.b.H. www.gasteiner-heilstollen.com
Cucu et al; *Front Immunol*. 2017; 8: 882.; doi: 10.3389/fimmu.2017.00882
This work is supported by the Forschungsinstitut Bad Gastein (FOI-15/08-031WIE), EURADON, the Radon Gallery of Bad Gastein and GREWIS (02NUK017A)

P147

THE HISTORY OF PSORIASIS

Selma Poparic

Dermatology Department University Clinical Center of Sarajevo

Many ancient texts, including the Bible, mention people afflicted with diseases and symptoms very much like psoriasis. Ancient Egyptians wrote about a salve made with various herbs that would be spread on the skin, after which the afflicted person would be instructed to sit in the sun to bring relief to symptoms that seem to point to psoriasis. The Arabian physicians perhaps first distinguished psoriasis from other skin diseases already in the 8th century A.D., but the first written description of psoriasis appears during the Roman Empire in the 1st century AD in the books of A. Cornelius Celsus »De re medica libri octo«. Galen (131–201 AD) of Pergamon, physician of some Roman emperors, was the first who used the term psoriasis, but only for an itchy, scaly eruption of the eyelids and scrotum, that was probably seborrheic dermatitis. Unfortunately, little was known about the origin of the disease for hundreds of years, in the darkness of the Middle Age - a period of stagnation, and many psoriasis sufferers were thought at the time to have leprosy. Because so little was known about contraction

and treatment, psoriasis patients were often separated from the general population for fear of them contaminating others. People with psoriasis – thousands in medieval Europe – were forced to warn others of their arrival by ringing a clapper.

It wasn't until the early 1800's that psoriasis was determined to be a condition separate from leprosy. In the cultural movement of Renaissance some authors mentioned the diseases psora and lepra in their books. In the 18th century hospitals or dispensaries were opened only for treatment of skin or venereal diseases giving to the physicians the opportunity to study more cases of skin diseases and psoriasis as well, while the end of the 19th century psoriatic micro morphology was already described. In 20th century many authors studied the genetic alteration, and today there is undisputed evidence that the disease is multifactorial.

Psoriasis, as a common disease, has a significant socio-economic impact on the individual and on the society. Last decades numerous immunological researches accumulate evidence of presence of alteration of the innate and adaptive immune response in psoriatic patients. This imply a primary dysregulation of the immune system and permits a better understanding and new insight in the pathogenesis and as well new possibilities in the management of psoriasis. This article shows a retrospective view of development of our knowledge on psoriasis through history.

P148

COMORBIDITIES AND TREATMENTS IN PATIENTS WITH INVERSE PSORIASIS

Mia Schneeweiss, Joseph Merola

Brigham and Women's Hospital

Introduction: Inverse (intertriginous) psoriasis is an underdiagnosed, often untreated phenotype of psoriasis (PsO) with a high burden of illness. Inverse PsO may occur in up to 23% of subjects with psoriasis, higher than previously reported.

Objectives: To characterize the frequency of inverse PsO and patient characteristics and their treatment in a large commercial insurance claims database.

Methods: We used longitudinal claims data from commercially insured patients in the US between 10/2015 and 12/2016 to identify adults with a diagnosis of flexural psoriasis (ICD-10-CM: L40.8, "other psoriasis" which is "recommended to be used for flexural PsO") associated with an outpatient or inpatient encounter. A 180-day enrollment period was required before the first diagnosis of AD. Among those diagnosed we computed the risk of initiating immunomodulating medications during the following 6 months. All analyses were conducted using the Aetion Evidence Platform.

Results: Of 1.5million patients with at least one code for PsO, after excluding patients with concomitant other autoimmune conditions, we identified 5,310 patients with an ICD-10 code of L40.8 used for inverse PsO (4/1,000) with a median age of 52 years and an equal gender distribution. Half of the patients were 41–60 years old.

Of those, 0.3% generalized pustular, 0.5% guttate, and 0.2% pustulosis palmaris et plantaris. Prevalent comorbidities included depression (7%), anxiety (6.5%), and cardiovascular conditions (5%). 20% received antidepressants. Within 180 days after the diagnosis of flexural PsO, 81% were using high-potency topical corticosteroids, 66% phototherapy, 8.6% calcipotriene, 5.6% ustekinumab, 7.2% methotrexate, 7.3% adalimumab, 3.3% etanercept, 1.3% acitretin, 0.8% infliximab, 0.9% Cyclosporine, 0.1% Sulfasalazine, 0.02% topical tacrolimus, 0.5% topical pimecrolimus.

In patients 60+, 83% used high-potency topical corticosteroids, 7.8% phototherapy, 8.8% calcipotriene, 3.1% ustekinumab, 6.9% methotrexate, 4.8% adalimumab, 2.9% etanercept, 1.5% acitretin, 0.5% infliximab, 0.9% Cyclosporine, 0.6% topical pimecrolimus.

Limitations: Although the ICD-10-CM code L40.8 is recommended for flexural PsO, its sensitivity/specificity for validating cases

of flexural PsO has not been established, it may not encompass all aspects of inverse/intertriginous disease and the code may be highly underutilized.

Conclusions: Using the code ICD-10-CM L40.8, which is recommended to be used for inverse "flexural" PsO leads to lower prevalence estimates of inverse PsO than previously reported; this underscores the known underreporting and underdiagnosis of this condition. Among those patients diagnosed and coded, most received topical corticosteroids and/or phototherapy, others received calcipotriene, ustekinumab, methotrexate, adalimumab, etanercept, and acitretin. Further work is needed to understand how best to capture inverse (intertriginous) / flexural psoriasis for clinical research work.

P150

DEVELOPMENT OF THE "PSO SLEEPY-Q" AND THE "PSA SLEEPY-Q": TWO QUESTIONNAIRES TO CHARACTERIZE SLEEP IN PATIENTS WITH PSORIATIC DISEASE

Lourdes Perez-Chada

Harvard Medical School - Brigham and Women's Hospital

Introduction: Substantial evidence suggests that psoriasis (PsO) and psoriatic arthritis (PsA) are independently associated with sleep disturbance, which may result in serious health consequences including cardiovascular events and mortality. However, the validity of the sleep measures used in these studies is unknown as they have not been validated in patients with psoriatic disease or included psoriatic patients during their development process. There is a need for validated disease-specific Patient-Reported Outcome Measures (PROMs) to accurately characterize sleep in this population and to measure the effect of psoriatic therapies on sleep disturbance.

Objectives: This study aimed to develop and establish the content validity of 2 new sleep PROMs: the "PsO Sleepy-Q" and the "PsA Sleepy-Q".

Methods: Following FDA PROM-development guidance, our study: (i) hypothesized a conceptual framework and identified domains through literature review and patient semi-structured interviews using a saturation model ($n=30$); (ii) rated domains for importance by patients ($n=42$) and an international expert panel including dermatologists, rheumatologists and sleep experts ($n=45$); (iii) selected final domains based of the patients' preference; (iv) generated item pools and the preliminary versions of the instruments.

Results: Psoriatic patients reported that sleep maintenance, adequacy, quantity and quality were the most important aspects of disordered sleep. Regarding causes of disturbed sleep: itch, skin and joint pain, stiffness, taking care of psoriatic lesions before bedtime, worsening of psoriatic symptoms at night, feeling uncomfortable in bed due to PsA and sleep apnea were the most outstanding factors selected. Finally, patients reported that disturbed sleep may increase psoriatic signs and symptoms as well as fatigue, cognitive impairment and psychological stress. Overall, patients with PsA expressed a higher burden of sleep disturbance compared to patients with PsO. Preliminary versions of the "PsO Sleepy-Q" and "PsA Sleepy-Q" including 18 and 24 items, respectively, were created. These questionnaires intend to measure the degree of sleep disturbance, the potential causes of sleep disturbance and the impairment related to sleep disturbance.

Conclusion: This study establishes the content validity of the "PsO Sleepy-Q" and "PsA Sleepy-Q", two patient-derived PROMs to characterize sleep in patients with psoriatic disease in research and clinical settings. These questionnaires will undergo cognitive debriefing and further psychometric testing to define the final instrument forms.

P151**UNSTABLE FORMS OF PSORIASIS – INDICATOR OF AN INTERMEDIATE STATE OF SYSTEMIC DISEASE***Florentina-Silvia Delli**State Hospital for Skin and Venereal Diseases - Hippokratia General Hospital, Thessaloniki, Greece*

Introduction: Erythrodermic psoriasis, inverse psoriasis and generalized pustular psoriasis are considered three particular clinical forms of psoriasis.

Objectives: We present two clinical cases in which it is discussed the possibility of considering these clinical pictures as a manifestation of the immunological switch of psoriasis from an organ-target (skin or joint) disease, to a systemic form of psoriasis.

Methods: A 22-year-old-man with erythrodermic psoriasis and a history of inverse psoriasis since childhood was successfully treated with 60 mg acitretin, until the diagnosis of psoriatic arthritis at the age of 26. The presence of arthritis determined us to change the therapy. Secukinumab at the classic therapeutic scheme is keeping the patient's skin clean of psoriatic lesions, except from the armpits, and without any arthritic symptoms. A 75-year-old-woman with psoriatic arthritis and hyperkeratotic palms and soles non-specific lesions, under infliximab therapy presented generalized pustular psoriasis. After 3 months of acitretin 40mg and etanercept at the classic dose, the patient remains free of any symptoms.

Conclusions: The majority of psoriasis studies focus on chronic plaque psoriasis. We sustain the opinion that the above unstable forms of psoriasis, usually impossible to diagnose by other specialities than Dermatology, should be consider the main step in multidisciplinary approach of psoriasis as a systemic disease.

References:

1. Kivelevitch D et al. Pharmacotherapeutic approaches for treating psoriasis in difficult-to treat areas. *Expert Opin Pharmacother* 2018 April; 19(6): 561-575
2. Sano S et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicentre, open-label study. *JDermatol* 2018 May; 45(5): 529-539
3. Cafaro G, McInnes IB. Psoriatic arthritis: tissue-directed inflammation? *Clin Rheumatol* 2018 Apr; 37(4): 859-868.

P152**COULD BIOLOGICAL AGENTS FOSTER SUICIDE THROUGH ITS POTENTIAL ANTIDEPRESSANT MECHANISM? A PSYCHODERMATOLOGICAL APPROACH***Estela M Malatesta**Dermatologist and Psychiatrist, Doctor. Arturo Ameghino Mental Health Centre, Buenos Aires, Argentina. President of ADEPSI, Academy of Dermatology and Psychiatry*

Introduction: Depression and Psoriasis are associated in up to 60% of the cases, with an increased risk of attempted and completed suicide in patients with severe forms of the disease. Bipolar Disorder is a biological condition that affects between 2 and 5% of the population, being an important cause of disability in the world. In spite of this, Bipolar Disorder is often underdiagnosed as Unipolar Depression, which increases the possibility of prescribing errors, as it occurs when administering only antidepressant agents without accompanying them with mood stabilizers, fostering the appearance of episodes of inverse polarity (SWITCHING) which, in turn, raises the risk of suicide.

Objectives: The "Cytokine Hypothesis" as a cause of depression suggests the association between the immune system and depression through the induction of the indolamine 2, 3- dioxygenase enzyme. The objectives of the poster are:

- To raise the need for new studies to confirm this hypothesis as well as the antidepressant effect of biological agents and their potential ability to cause a shift into mania.

- To deepen the criteria for patient selection for both scientific and therapeutic protocols.

Methods: This poster reviews the literature for evidence that while biological agents could improve the mood of patients with psoriasis treated with these drugs, this same favourable antidepressant effect on humor may trigger a switch of mood into mania, favouring attempted and completed suicide in undiagnosed bipolar patients treated for psoriasis with IL17-TNF alpha cytokine blockers.

Results: Evidence gathered so far suggests that common inflammatory processes could underpin both bipolar and psoriasis. The current literature is lacking of longitudinal and mechanistic studies, as well as comparison studies to explore the magnitude of this relation.

Conclusion: Considering both bipolar disorder and psoriasis as a multi-system disorder should help us understand the common physiopathology of this comorbidity so as not to see them as separated disorders. Consequently, it is vital to emphasize the importance of the initial psychiatric evaluation for a correct psychiatric/ clinical diagnosis for patients with Psoriasis to be both admitted to a strict control protocol and treated with biological agents.

P153**TREATING THE PAIN, NOT THE PROBLEM? RESULTS FROM A SWEDISH ONLINE SURVEY ON PSORIATIC ARTHRITIS AND PSORIASIS WITH JOINT PAIN***T Norgren, B Bohannan**Psoriasisförbundet, Stockholm, Sweden*

Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis, that can cause pain, swelling and, if untreated, severe joint destruction and disability. The knowledge about PsA among both the public and healthcare providers is limited, leading to both underdiagnosis and undertreatment. To raise awareness of PsA and gather relevant data, the Swedish Psoriasis Association (Psoriasisförbundet) and the Swedish Rheumatism Association (Reumatikerförbundet) initiated an educational awareness campaign on a well-visited online health information platform, which also featured a survey on healthcare experiences and Quality of Life.

Objectives: The purpose of the survey was to identify gaps or discrepancies in the healthcare provided for individuals diagnosed with PsA and for individuals with psoriasis and joint pain consistent with a PsA diagnosis, as well as understanding the impact on QoL for both groups.

Methods: The survey consisted of two questionnaires, one for individuals diagnosed with PsA, group A, and one for individuals diagnosed with psoriasis who have joint pain consistent with a PsA diagnosis (using CASPAR criteria as reference), group B. The survey was open from April 6 2017 to March 31 2018. The total number of respondents in group A was 5 201, and in group B 11 272. It was not mandatory to answer all questions in the survey. One section of the survey focussed on prescribed medication, to specifically identify discrepancies in the treatment of the diagnosed (A) and undiagnosed (B) groups. Limitations: self-reported diagnosis, possible to take survey multiple times using different devices.

Results: In response to the question "Which medication has been prescribed for your joint pain during the past year?" 23.91% of group B (214 of 895) answered that they had been prescribed opioid pain medication for their joint pain. In group A only 4.61% of the respondents (73 out of 1 582) were prescribed opioid pain medication for their PsA.

Conclusions: The results show a large discrepancy between the groups in the prescription of opioid pain medication. The results suggest that individuals with psoriasis that have joint pain consistent with a PsA diagnosis are being over-prescribed potentially addictive pain medication rather than receiving treatment for their underlying condition or inflammatory symptoms apart from pain.

As early diagnosis and effective treatment is vital to slow down disease progression, individuals with psoriasis as well as healthcare providers need to be educated on symptoms and diagnosis criteria of PsA to prevent undertreatment or treatment that may even be harmful.

Disclosure: Project platform and consultancy services were provided by health portal company Netdoktor. The project received funding from Novartis.

P154

AN INTERNATIONAL DELPHI SURVEY TO DEFINE SCREENING FOR PSORIATIC ARTHRITIS AND MEASUREMENT OF PSORIATIC ARTHRITIS SYMPTOMS IN PSORIASIS CLINICAL TRIALS

Lourdes Perez Chada

Harvard Medical School-Brigham and Women's Hospital

Introduction: The International Dermatology Outcome Measures (IDEOM) group was established to standardize patient-centered outcome measures to improve the assessment of treatment response and disease course in dermatology. To define the measurement set for psoriasis, IDEOM has initially defined a set of domains to be measured in all psoriasis clinical trials representing a "Core Domain Set". "Psoriatic arthritis (PsA) Symptoms" is part of this set. *Objectives:* To achieve consensus on whether patients enrolling in a psoriasis clinical trial should first be screened for PsA and then with which measure their PsA symptoms should be assessed. *Methods:* Following the OMERACT (Outcome Measures in Rheumatology) Filter 2.0, the COSMIN guidelines, and based upon the feedback from a consensus meeting held at the IDEOM 2017 Annual Meeting, we conducted an international, multidisciplinary and multi-stakeholder on-line Delphi survey. The survey was organized into 3 parts in which participants were asked to (1) vote on the role of PsA screening in psoriasis trials, (2) vote on the quality (measurement properties) of 4 patient-reported instruments: Patient Global (PG)-arthritis associated to a pain assessment tool, PG-Psoriatic Arthritis (PG-PsA) associated to a pain assessment tool, Routine Assessment of Patient Index Data-3 (RAPID3), and Psoriatic Arthritis Impact of Disease 9 (PsAID9), and (3) rank these instruments in order of importance. Additionally, respondents were invited to provide feedback on the survey. *Results:* A total of $n = 293$, $n = 233$ and $n = 218$ subjects completed the PsA screening, instrument quality assessment, and ranking sections of the survey, respectively. The group was comprised of rheumatologists (44.5%), dermatologists (26%), patients (7.5%), industry partners (8.9%), dermatologist-rheumatologists (5.1%), and patient association representatives (3.4%). Results showed that 90% of participants agreed that all patients enrolling in a psoriasis trial should be screened for PsA. Regarding the quality of the instruments, only the PsAID9 reached the pre-specified endpoint of $> 70\%$ with agreement that the instrument has good-to-excellent validity, feasibility, reliability and responsiveness; $< 15\%$ agreed that the quality of the instrument is poor or that there is not enough information to make an informed decision. In the ranking exercise, PsAID9 was the first choice (voted by 48% of respondents) and RAPID3 represented an acceptable alternative second choice (voted by 33% of respondents).

Conclusion: In this Delphi study, most participants agreed that all psoriasis trial participants should be screened for PsA. Regarding the measurement set for "PsA Symptoms", PsAID9 was selected

as the most appropriate measure, while RAPID3 could be an acceptable alternative to PsAID9. This will be followed by a workshop at the IDEOM and GRAPPA 2018 annual meetings to review discussion points as well as any need for a second Delphi round.

P155

THE IMPACT OF A DIAGNOSIS ON THE PATIENTS' PERCEPTION OF TREATMENT AND CARE. RESULTS FROM AN ONLINE SURVEY ON PSORIATIC ARTHRITIS AND PSORIASIS WITH JOINT PAIN

T Norgren, B Bohannan

Psoriasisförbundet, Stockholm, Sweden

Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory joint disease that, if untreated, can cause joint destruction and disability. The knowledge about PsA among both public and healthcare providers is limited, leading to underdiagnosis and undertreatment. To raise awareness of PsA and gather relevant data, the Swedish Psoriasis Association and the Swedish Rheumatism Association initiated a web-based educational campaign which also featured a survey on healthcare experiences and Quality of Life.

Objectives: The purpose of the survey was to identify the gaps in the healthcare provided for individuals diagnosed with PsA and individuals with psoriasis and joint pain consistent with a PsA diagnosis, as well as understanding the impact on QoL for both groups.

Method: The survey consisted of two questionnaires, one for individuals diagnosed with PsA, group A, and one for individuals diagnosed with psoriasis who have joint pain consistent with a PsA diagnosis (using CASPAR criteria), group B. The survey was open from April 6 2017 to March 31 2018. One section of the survey focussed on time to diagnosis and perception of healthcare. Limitations: self-reported diagnosis, possible to take survey multiple times using different devices.

Results: Both groups had seen multiple doctors for their joint pain. In group A 60% ($n = 1\ 132$) had seen > 4 doctors, with 11% reporting having seen > 10 . In group B 52.5% ($n = 824$) had seen > 4 doctors, with 8% having seen > 10 . In group A nearly 51% ($n = 1\ 211$) reported having had joint pain/symptoms for at least 1 year before receiving a diagnosis, with 12% waiting > 10 years. In group B 91% ($n = 1\ 872$) reported having had joint pain/symptoms for at least 1 year, with 35% at > 10 years.

Perception of healthcare differed greatly between the groups. In group A over half ($n = 1\ 273$) reported that their perception of healthcare improved or improved greatly after receiving their PsA diagnosis. In group B nearly 78% ($n = 1\ 227$) reported being dissatisfied or very dissatisfied with the care they receive. *Conclusions:* The results show that the group with a PsA diagnosis have a much more positive perception of the treatment and care they receive than the group without a diagnosis. Interestingly, in another part of the survey group B reported their psoriasis having a low to medium impact on their lives, indicating that their psoriasis may be mild enough to be treated in a primary care setting only. In the past few years there have been extensive efforts put into educating Swedish dermatologists on recognizing early signs of PsA, but steps should also be taken to raise awareness of psoriasis-associated joint pain among general practitioners to ensure timely referral to specialist care.

Disclosure: Project platform and consultancy services were provided by health portal company Netdoktor. The project received funding from Novartis.

Index

- A**
- Abdallah, Florence 41
 Abell, Jill 46
 Abramovits, William 25
 Abrams, Ken 15, 17
 Adam, Abdulfatah 7, 34
 Adam, David 21
 Adams, David 16
 Alenius, Gerd-Marie 37
 Aletaha, Daniel 23
 Alikhan, Ali 14
 Alipour, Homan 58
 Altemeyer, Evelyn 11
 Andersen, Anne-Marie Nybo 7, 34
 Arakawa, Akiko 43
 Arakawa, Yukiyasu 43
 Arenberger, Petr 47
 Arendt, Catherine 21, 24, 26, 27
 Arikani, Dilek 19, 25
 Arjona, Alvaro 57
 Armstrong, April 22
 Asquith, Darren L 19
 Augustin, Matthias 13, 28, 32, 35, 36, 38, 47, 54, 58
 Austin, Jennifer 58
 Azevedo, VF 52
 Azimi, Seyyede Zeinab 6, 44
- B**
- Bachelez, Hervé 28
 Bachhuber, Teresa 11
 Baumer, Daniel 54
 Bagel, Jerry 14, 21, 30, 54, 57
 Balaskas, Evangelos 55
 Balsa, Alejandro 15
 Bang, Chul Hwan 34
 Bao, Weibin 11
 Baran, Wojciech 29
 Barat, Tara 6
 Barcluk, William 49
 Barker, Jonathan 34
 Batkaeva, Nadezhda 45, 51
 Batkaev, Edgem 45, 51
 Beecker, Jennifer 48
 Behrens, Frank 26
 Benichou, Olivier 23
 Berianu, Florentina 5
 Bessette, Louis 15, 16
 Bircan, Ebru 8
 Birt, Julie 46
 Bissonnette, Robert 20
 Blauvelt, Andrew 21, 22, 24, 26, 27, 28, 31, 46, 49, 54, 55
 Bleakman, Alison Potts 11
 Blegvad, Christoffer 7, 34
 Boehncke, Wolf Henning 20, 48
 Boehnlein, Marion 24
 Boettcher, E 17
 Bogunia-Kubik, Katarzyna 36
 Bohannan, B 61, 62
 Böhme, Nicolai 56
 Bomas, Stefanie 13
 Botev, Ivan 35
 Brahas, Alexandra 52
 Breitbart, Eckardt 58
 Brysch, Wolfgang 17
 Bukhalo, Michael 30
 Bulic, Suzana Ozanic 7
 Bundy, Christine 13, 58
 Burge, Daniel 21, 27
 Burge, Russel 11, 55
 Burmester, Gerd R. 19
 Butrym, Aleksandra 9
- C**
- Cagalj, Adela Markota 39
 Camez, Anne 30
 Cappelleri, JC 52
 Carija, Antoanela 39
 Castillo, Inmaculada Lopez 6
 Castillo, Veronica Lopez 6
 Cather, Jennifer Clay 11
 Chada, Lourdes Perez 62
- Chamurlieva, Maria 48
 Chandran, Vinod 14, 23
 Chan, Henry 5
 Chaouche-Teyara, Kamel 12
 Chaparro, Elena 9
 Chow, Andrew 15
 Christodoulou, Christos 55
 Cichanowitz, Nicole 22, 24, 28, 29, 54
 Cirulli, Joshua 14
 Coates, Laura C 16, 19, 21, 52
 Colombel, Jean-Frederic 18
 Combe, Bernard 15
 Cordey, Myriam 13
 Crespo, Alejandra 9
 Cristodor, Patricia 39
 Crowley, Jeffrey 20, 25, 28, 29, 30, 31
- D**
- Dadras, Mohamad Shahidi 6
 Dahlborn, Anna-Karin 55
 Dalkilić, Ediz 20
 Danielsen, Kjersti 12, 33, 53
 Davenport, Eric K. 14
 Dei-Cas, Ignacio 48
 Delli, Florentina-Silvia 32, 61
 Delorme, Isabelle 48
 Dencheva, Iveta 35
 Deodhar, Atul 11, 18, 48
 Dietrich, Cecilia 18
 Dong, Bin 48
 Dornhecker, Maximilian 59
 Dossenbach, Martin 55
 Duffin, Kristina Callis 14
 Dungee, Danielle 46
 Dutz, Jan 42
 Duvetorp, Albert 12, 33, 53
 Dybowski, Friedrich 56
- E**
- Efthimiadis, Konstantinos 32
 Ehrström, Marcus 44
 Eidsmo, Liv 44
 Elewski, Boni 24, 26, 31
 Ellis, Charles 30
 Enerbäck, Charlotta 55
 Erickson, Janelle 23
 Eyerich, Kilian 13
- F**
- Fakharzadeh, Steve 46
 Fallon, L 52
 Feagan, Brian G 18
 Fekkas, Nikolaos 40
 Feldman, Steven 46
 Ferris, Laura 29
 Flack, Mary 28, 30
 Fleischer, Alan 25
 Fleischmann, Roy 23
 Foley, Peter 22, 28, 50
 Forman, Seth 14
 Fors, Sofie 55
 Fotiadou, Christina 40
 Fournier, Claudia 59
 Fox, Todd 18
 Franck, Johan 8
 Frankel, Ellen H. 30
 Frueh, Jennifer 47
 Fung, Japio 5
- G**
- Gaille, Corine 19, 21
 Galinski, Adrian 43
 Gallo, Gaia 16
 Ganz, Fabiana 20, 23
 Garg, A 52
 Geale, Kirk 9
 Geng, Ziqian 25, 26, 28, 30
 Ghitulescu, Persa 39
 Ghoreishi, Mehran 42
 Giannoukos, Anastasios 40
 Gisoni, Paolo 25
 Gitinova, Muslimat 51
 Gladman, Dafna 11, 14, 23
- Glukhova, Svetlana 10, 45
 Godzenko, Alla 38
 Gold, Linda Stein 14
 Goldust, Mohamad 10, 58
 Gómez, Natalie Núñez 13
 Gonzalez, Daniela 9
 Gooderham, Melinda 22, 24, 31, 48, 49, 54
 Gordon, Kenneth 19, 22, 28, 29, 30, 31
 Gossec, Laure 21
 Gottlieb, Alice 11, 24, 26, 27, 46, 47, 48, 57
 Greggio, Chiara 14
 Grendár, Marián 12
 Griffiths, Christopher EM 13, 20, 46, 52
 Groegel, Kathrin 13
 Groot, Jonathan 34
 Grünebaum, Valeria 59
 Gual, Adria 18
 Gubar, Elena 10, 38, 45
 Guerette, Benoit 14
 Guillet, Gérard 26
 Gulati, Kunal 34
 Gulliver, Susanne 27
 Gulliver, Wayne 27
 Guo, Dianlin 25
 Guo, Jiaying 54
 Gupta, Ayan Das 18
 Gupta, Samar 42
 Gu, Yihua 28, 30
- H**
- Han, Chenglong 50
 Han, Ju Hee 34
 Han, Kyung Do 34
 Haraoui, Boulos 16
 Haraoui, Boulos 15
 Heijde, D van der 17
 Helliwell, Philip 23
 Henneges, Carsten 44, 55
 Henriksson, Martin 9
 Heredia, Emily Edson 54
 Hevey, David 51, 52
 Hilbert, Anja 58
 Hoffer, Elena 44
 Hojnik, Maja 20
 Holst, Ann-Dörthe 56
 Hong, Chih-ho 29
 Hong, H. Chih-Ho 29
 Hoops, Timothy 46
 Horváth, Rudolf 20
 Hsia, Elizabeth 49
 Husni, M. Elaine 16
 Hussain, Samina 11
 Hussein, Shamiza 48
- I**
- Ignatov, Borislav 44
 Inal, Ali 43
 Iversen, Lars 12, 33, 53
 Ivic, Neira Puizina 39
 Iwaszko, Milena 36
- J**
- Jackson, J. Mark 14
 James, Edd 43
 Janus, Christine 58
 Jazayeri, Sasha 47
 Jiang, Gigi 29
 Jokinen, Jussi 9
 Jukic, Zlatica 8
 Juneblad, Kristina 37
- K**
- Kaiser, Astrid 17
 Kanehisa, Fuminao 39
 Kappelman, Michael 46
 Kasumagić-Halilović, Emina 41
 Katoh, Norito 39
 Katoulis, Alexandros 55
 Kaura, Satyin 14
 Kavanagh, Sarah 21
 Kavanaugh, Arthur 46
- Kazemnejad, Ehsan 6, 44
 Kellet, Cristian Vera 42
 Kerdel, Francisco 25
 Kerkhof, P. van de 46
 Kerr, Lisa 16
 Keskin, Esra Dilek 43
 Keskin, Goksal 43
 Khosravi-Hafshejani, Touraj 42
 Khraishi, Majed 14, 15, 16
 Kiedrowski, Ralph von 32
 Kimball, Alexa 54
 Kirkham, Bruce 15
 Kishimoto, Mitsumasha 16
 Klekotka, Paul 54
 Kleyn, C. Elise 13
 Kontochristopoulos, Georgios 55
 Koo, John 31
 Korge, Bernhard 13
 Korman, Lucyna 36
 Korman, Neil 14
 Korotaeva, Tatiana 10, 38, 45, 48
 Koscielnny, Volker 13
 Kosel, David 17
 Kouris, Anargyros 55
 Kozłowski, Mikołaj 36
 Kreimer, Jennifer 9
 Kriegel, Martin 5
 Krnic, Andrea 8
 Kubanov, Alexey 47
 Kuehn, Vera 25
 Kühl, Laura 32
 Kupper, Hartmut 25
 Kvien, Tore Kristian 21
- L**
- Lacour, Jean-Philippe 30
 Lajevardi, Vahideh 6
 Landells, Ian 20
 Landewé, R 17
 Langenbruch, Anna 38
 Langley, G. 30
 Langley, Richard 11, 21
 Lau, Winnie L. 19
 Lazaridou, Elizabeth 40
 Lebowitz, Mark 14, 21, 28, 56
 Lee, Edward 37
 Lee, Ji Hyun 34
 Lee, Jun Young 34
 Lendl, Udo 56
 Leonardi, Craig 24, 26, 27, 28, 30, 46
 Lerchl, Sylvie 59
 Lespessailles, Eric 16, 23
 Levi, Eugenia 14
 Ligozio, Gregory 15
 Li, Joanne 54
 Lima, Sónia A. L. 20
 Lin, Chen-Yen 11, 46
 Li, Qing 22, 24, 28, 29, 49, 54
 Li, Shu 22
 Liubiankova, Veranika 6
 Lockshin, Benjamin 14
 Loginova, Elena 10, 45
 Lomaga, Mark 55
 Lonne-Rahm, Sol-Britt 8
 Lopez-Rodriguez, Dalila Alejandra 8, 35
 Loser, Karin 54
 Lowry, Simon 24, 31, 49
 Lubrano, Ennio 20
 Luck-Sikorski, Claudia 58
 Luger, Thomas 54
 Lynde, Charles 48
- M**
- Macias-Garcia, Karla Del Rocio 8
 Madani, Hind 53
 Maddock, Alan 51, 52
 Mahesh, Seema 38
 Majhoo, A 52
 Makarava, Sviatlana 6
 Malatesta, Estela M 61
 Mallappa, Mahesh 38
 Markanton, Vasiliki 55
 Marko, Pij B. 59
 Marovt, Maruska 59

- Martini, Elisa 44
 Martinka, Magdalena 42
 Martin, Ruvie 15
 Mason, Kayleigh 33
 Masuda, Koji 39
 Maya, Juan J. 5
 Mazur, Grzegorz 9
 McGonagle, Dennis 19
 McInnes, Iain B 18
 McKenzie, Robert 34
 Mease, Philip J 14, 15, 17, 19, 21
 Meeuwis, Kim 11
 Mehta, Nehal N. 14, 46
 Melendez, Gianna 33, 49, 50
 Mendelsohn, Alan 24, 28, 29, 30, 31
 Menter, Alan 28, 29, 31
 Mentz, Hannah 13
 Merola, Joseph F 16, 46, 60
 Metzke, Dieter 54
 Milutinovic, M. 46
 Miteva, Lyubka 35
 Morita, Akimichi 46
 Moser, J 52
 Mpofu, Shephard 17, 19
 Mrowietz, Ulrich 44, 47, 58
 Muhović, Jasmina 5, 41
 Muñoz-Elías, Ernesto J 22
 Munro, Duncan 57
 Muser, Erik 46
- N**
 Nash, Peter 14, 15, 21
 Nasonov, Eugeny 10
 Navarra, S 17
 Nica, Radu Dumitru 44
 Nielsen, Tilde Elkjær Tind 34
 Ni, Michael 5
 Nora, Kogan 9
 Nordlind, Klas 8
 Norgren, T 61, 62
- O**
 Ohtsuki, Mamitaro 28
 Okada, Masato 20
 Olmez, Umit 43
 Orasan, Remus Ioan 44
 Orbai, A-M 52
 Orsenigo, Roberto 12
 Østergaard, Mikkel 12, 33, 53
 Ott, Elyssa 29
 Ovčina-Kurtović, Nermina 41
- P**
 Padulles, Laura 18
 Panaccione, Remo 19
 Pang, Herbert 5
 Papanastasiou, P. 46
 Papatthemeli, Despina 40
 Papp, Kim A. 20, 22, 28, 29, 44, 48, 49, 54
 Pariser, David 24, 29, 30
 Park, So Young 16
 Park, Yong Gyu 34
 Park, Young Min 34
 Parneix-Spake, Anne 47
 Parno, Jeff 24, 29, 30, 49
 Parno, Jeffrey 29, 31
 Patrk, Ivana 8
 Pattinson, Rachael 58
 Paul, Carle 11
 Pavlova, Viktoria 15
 Péč, Juraj 12
 Péčová, Tatiana 12
 Perez-Chada, Lourdes 60
 Perkins, Megan Leone 46
 Peterson, Luke 24, 26, 27, 57
 Philipp, Sandra 21, 30
 Pinter, Andreas 55
 Pisenti, Lisa 21, 37, 56
 Platsidaki, Eftychia 55
 Polic, Melita Vuksic 8
 Politou, Maria 40
 Polzer, Paula 44
 Pompou, Maria 40
 Popa, Elena 39, 52
 Poparic, Selma 7, 59
 Porter, Brian 18
 Pott, Hans-Georg 56
 Poulin, Yves 24, 26, 27, 28, 30
 Price, Lynn 33, 49, 50
 Pricop, Luminita 15, 17, 18, 21
 Prinz, Jörg 43
 Puig, Lluís 11, 14, 28, 50
 Purcaru, Oana 57
- Q**
 Quebe-Fehling, Erhard 19
 Quinn, Sean 46
- R**
 Radtke, Marc Alexander 13, 20, 32, 38, 58
 Rahman, P 17
 Rampakakis, Emmanouil 48
 Randazzo, Bruce 20, 22
 Randell, Shane 27
 Rasouliyan, Lawrence 19, 21
 Readie, A 17
 Rech, Jürgen 15
 Reeves, Emma 43
 Regnault, Pascaline 47
 Reich, Kristian 11, 13, 18, 21, 22, 24, 26, 27, 29, 31, 46, 47, 49, 54, 57
 Remple, Valencia 15, 16
 Rich, Pheobe A. 26
 Rigopoulos, Dimitrios 40
 Rihakova, Lenka 48
 Rissler, Michael 12
 Robinson, Jennifer 33, 49, 50
 Rodriguez, Pedro 6
 Rokni, Ghasem Rahmatpour 10
 Roller, Robert 21
 Rosa, Carmen La 22, 24, 28, 29, 49, 54
 Rosana, Veira 9
 Rosenbaum, James 19
 Rozzo, Stephen 24, 29, 30, 31
 Rubel, Diana 20
 Rustenbach, Stephan Jeff 32
 Ryan, Caitriona 11, 57
- S**
 Safi, Jorge 11
 Saure, Daniel 34
 Schaefer, Ines 58
 Scherer, Joseph 30
 Schett, Georg 19
 Schlette, Sophie 58
 Schmitt-Egenolf, Marcus 9
 Schneeweiss, Mia 60
 Schreiber, Stefan 18
 Schulz, Petra 17
 Schumann, Sara 17
 Schwichtenberg, Uwe 13
 Seifert, Oliver 12, 33, 53
 Séréal, Irène Gallais 44
 Servin, Ofelia Reyes 25, 26
 Shah, Viraj 38
 Shankle, Lindsey 56
 Sheahan, Anna 37
 Shen, Wei 55
 Shen, Yaung-Kaung 20, 21, 22, 50
 Shen, Zhu 42
 Shrom, David 55
 Shuler, Catherine 23, 46
 Sieder, Christian 12
 Siegel, Michael 56
 Sinclair, Rodney 22, 54
 Singhal, A 17
 Singh, Rakesh 25
 Skov, Lone 7, 12, 33, 34, 53
 Smolen, Josef S. 21, 23
 Sofen, Howard 24, 28, 29, 49
 Sokolik, Renata 9, 36
 Solovan, Caius 39, 52
 Sommer, Rachel 58
 Song, Michael 20, 21, 22, 50
 Sorbe, Christina 32
 Spreckelsen, Regina 58
 Srivastava, Bhaskar 46
 Stähle, Mona 13
 Ständer, Sonja 54
 Steinke, Sabine 54
 Stewart, Jacqueline 15
 Stokkeland, Knut 8
 Strober, Bruce 11, 20, 21, 24, 28
 Sturgill-Koszycki, Sheila 28
 Sullivan, John 47
 Suruki, Robert 37
 Suthakharan, Nirohshah 36, 58
 Svanström, Caroline 8
 Świerkot, Jerzy 36
 Szepietowski, Jacek 11
- T**
 Tahir, H 17
 Tarzynski-Potempa, Rita 19
 Teng, Lichen 14
 Thači, Diamant 16, 20, 22, 24, 26, 27, 46, 54, 57
 Thompson, Elizabeth H.Z. 28, 30
 Topp, Janine 58
 Trakatelli, Myrto 40
 Trecko, Katarina 59
 Tsai, T. 46
 Tveit, Kåre Steinar 12, 33, 53
 Tying, Stephen 21, 22, 29, 30, 31, 54
- V**
 Valdes, Joaquin M. 28
 Vandello, Carl 57
 Vaya, Jose Maria Ricart 6
 Vender, Ron 50
 Vender, Ronald 34
 Vieira, Antonio 48
 Vithoulkas, George 38
 Volberg, Christoph 56
 Vollmer, Sigrid 43
 Voorhees, Abby S Van 56
 Vorčáková, Karolína 12
 Vukadin, Renata 8
 Vural, Secil 43
 Wang, Hailun 5
 Wang, Yinpeng 5
 Wang, Yuhua 49
 Warren, Richard 11
 Wasfi, Yasmine 20, 21, 22
 Wasilewski, Alicja 42
 Weaver, Jerry 14
 Węglowska, Jolanta 57
 Weinberger, Natascha 58
 Wiedemann, Julia 59
 Wiland, Piotr 9, 36
 Wilhelm, Stefan 34, 44
 Wilsman-Theis, Dagmar 58
 Witzler, Claudius 59
 Wu, Jashin J. 25, 30
- X**
 Xu, Xie L. 49
- Y**
 Yamauchi, Paul 24
 Yan, Kang 5
 Yao, Xiaoxin 5
 Yassine, Mohamed 21, 37, 56
 Young, P 52
 Youn, Sang Woong 20
 You, R. 46
 You, Ruquan 47
 You, Yin 20, 21, 50
- Z**
 Zachariae, Claus 7
 Zander, Nicole 38
 Zargari, Omid 6, 44
 Zhang, Ying 23
 Zhao, Yang 31, 49, 54
 Zhou, Xiaolei 14
 Zhuang, Yanli 49
 Zhu, Baojin 54, 55
 Zhu, X 17
 Zink, Alexander 58
 Zitti, Beatrice 44

